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Abstract 
 
Infection with Coxiella burnetii in humans is associated with severe disease, known as Q fever. 
Acute infection, that can be sub-clinical in nature, can lead to the development of a chronic 
life-threatening cardiac condition. The largest reported human outbreak of Q fever recently 
occurred in the Netherlands between 2007 and 2010. This outbreak gave rise to over 4,000 
reported human cases and efforts such as the culling of 50,000 pregnant goats in an attempt 
to control the outbreak. While an effective vaccine exists for protection against infection, it has 
an unsatisfactory safety profile that has led to it being licenced in only a single country and in a 
defined group at risk of occupational exposure to infection. In addition, this vaccine involves 
culturing the organisms at high levels of biological containment; this makes the vaccine 
expensive to produce and presents a challenge in attaining reproducible batch-to-batch 
variation.  
In this work, two species of laboratory animals were infected by the aerosol route to closely 
mimic the likely natural route of infection in humans. The species investigated were guinea 
pigs (Dunkin Hartley strain) and mice (BALB/c and A/J strains). The infection in guinea pigs 
more closely mimicked human acute disease than that in the two different strains of mice: In 
terms of a more acute febrile response and greater clearance of the organism from the tissues. 
After clinical recovery from disease, the antibodies from the guinea pigs’ sera were used to 
isolate immune-reactive proteins found in axenically-grown C. burnetii organisms. Isolation of 
protein was achieved by picking spots from 2D-PAGE gels corresponding to reactive spots on 
parallel Western blots as well as immunoprecipitation (pull down) of bacterial protein extracts, 
a method not previously applied to this type of analysis. These isolated proteins were then 
identified using nanoLC-electrospray ionisation tandem mass-spectrometry (Q Exactive™ 
instrument). 
More than 100 proteins were identified, 71 of which had not been previously described in the 
literature. The identified proteins were considered for their suitability for inclusion in a future 
subunit vaccine to protect against Q fever. The most promising candidates were an OmpA-like 
surface protein similar to a molecule that has already been described as an invasin, two 
surface-exposed components of the bacterial type IV secretion system (DotA and IcmX), and 
two hypothetical proteins that warrant further study.  
  
iv 
 
Table of Contents 
 
Copyright ........................................................................................................................................ ii 
Abstract ......................................................................................................................................... iii 
Table of Contents .......................................................................................................................... iv 
List of Tables ............................................................................................................................... viii 
List of Figures ................................................................................................................................ xi 
Abbreviations ............................................................................................................................ xviii 
Acknowledgements ...................................................................................................................... xx 
Dedication ................................................................................................................................... xxi 
Declaration ................................................................................................................................. xxii 
1 Introduction ........................................................................................................................ 23 
1.1 History ......................................................................................................................... 23 
1.2 The organism ............................................................................................................... 24 
1.3 The disease .................................................................................................................. 26 
1.4 Epidemiology ............................................................................................................... 28 
1.5 Immunity ..................................................................................................................... 30 
1.6 Vaccines ...................................................................................................................... 33 
1.7 Towards a second-generation vaccine ........................................................................ 34 
1.8 Aims ............................................................................................................................. 37 
1.9 Roadmap ..................................................................................................................... 38 
2 In vivo Experiments ............................................................................................................. 39 
2.1 Introduction ................................................................................................................ 39 
2.1.1 Mouse models of acute Q fever .......................................................................... 39 
2.1.2 Guinea pig models of acute Q fever ................................................................... 40 
2.1.3 In vitro enumeration of Coxiella burnetii organisms .......................................... 41 
2.1.4 Aims ..................................................................................................................... 44 
v 
 
2.2 Materials and Methods ............................................................................................... 45 
2.2.1 Real-time quantitative PCR assay ....................................................................... 45 
2.2.2 Virulence assessment of Coxiella burnetii stocks ............................................... 50 
2.2.3 Aerosol infection of guinea pigs and two strains of mouse ................................ 51 
2.3 Results ......................................................................................................................... 55 
2.3.1 Real-time quantitative PCR assay ....................................................................... 55 
2.3.2 Virulence assessment of Coxiella burnetii stocks ............................................... 63 
2.3.3 Aerosol infection of guinea pigs and two strains of mouse ................................ 68 
2.4 Summary of Results .................................................................................................... 79 
2.4.1 Virulence assessment of Coxiella burnetii stocks ............................................... 79 
2.4.2 Aerosol infection of guinea pigs and two strains of mouse ................................ 80 
2.5 Outcomes .................................................................................................................... 82 
3 Protein Isolation .................................................................................................................. 83 
3.1 Introduction ................................................................................................................ 83 
3.1.1 Aims ..................................................................................................................... 86 
3.2 Materials and Methods ............................................................................................... 87 
3.2.1 Growth of C. burnetii ........................................................................................... 87 
3.2.2 Extraction of proteins from ACCM-2 grown C. burnetii ...................................... 90 
3.2.3 One dimensional protein separation and detection ........................................... 91 
3.2.4 Two-dimensional protein separation and immune-reactive protein isolation .. 94 
3.2.5 Immunoprecipitation of immune-reactive proteins ........................................... 99 
3.3 Results ....................................................................................................................... 103 
3.3.1 Growth of C. burnetii ......................................................................................... 103 
3.3.2 One dimensional protein separation ................................................................ 107 
3.3.3 Two-dimensional protein separation and immune-reactive protein isolation 109 
3.3.4 Immunoprecipitation of immune-reactive proteins ......................................... 116 
3.4 Summary of Results .................................................................................................. 121 
3.5 Outcomes .................................................................................................................. 123 
vi 
 
4 Protein Identification ........................................................................................................ 124 
4.1 Introduction .............................................................................................................. 124 
4.1.1 Aims ................................................................................................................... 127 
4.2 Materials and Methods ............................................................................................. 128 
4.2.1 In gel tryptic digestion of proteins .................................................................... 128 
4.2.2 Mass spectrometry analysis .............................................................................. 129 
4.2.3 Database searching and protein identification ................................................. 130 
4.2.4 Organisation of identified proteins ................................................................... 131 
4.2.5 Protein functional characterisation .................................................................. 131 
4.3 Results ....................................................................................................................... 133 
4.3.1 Protein identification ........................................................................................ 133 
4.3.2 Functional grouping of proteins ........................................................................ 138 
4.3.3 Further characterisation of unpublished proteins ............................................ 140 
4.4 Summary of Results .................................................................................................. 141 
4.5 Outcomes .................................................................................................................. 142 
5 Critical Discussion & Reflection ......................................................................................... 143 
5.1 Summary ................................................................................................................... 149 
5.2 Further work ............................................................................................................. 150 
5.2.1 Towards a robust anti-LPS response ................................................................. 150 
5.2.2 Neutralizing antibodies ..................................................................................... 150 
5.2.3 Cell-mediated immunity ................................................................................... 151 
5.3 Related professional activities .................................................................................. 152 
5.4 Critical Reflection ...................................................................................................... 154 
5.4.1 Description ........................................................................................................ 154 
5.4.2 Feelings ............................................................................................................. 154 
5.4.3 Evaluation ......................................................................................................... 154 
5.4.4 Analysis ............................................................................................................. 155 
5.4.5 Conclusions ....................................................................................................... 155 
vii 
 
5.4.6  Action plan ........................................................................................................ 155 
Bibliography .............................................................................................................................. 156 
Appendix One –Formulations and Stock Solutions ................................................................... 167 
Appendix Two – Ethical Statement ........................................................................................... 169 
Appendix Three – Comprehensive listing of 2D‐PAGE picked protein spots ............................ 170 
Appendix Four – Poster (American Rickettsiology Society) ...................................................... 203 
Appendix Five – Review Article (Comparative Medicine) ......................................................... 205 
Appendix Six – Research Article (Coxiella antibiotics) .............................................................. 214 
Appendix Seven – Research Ethics Review Form (UPR16) ....................................................... 224 
 
  	
viii 
 
List of Tables 
 
Table 2.1 - C. burnetii nucleotide sequences used to produce nucleotide alignments of the icd gene and 
generate consensus sequence for qPCR primer and probe design. ............................................................ 45 
Table 2.2 - All qPCR targets that were designed into the pCox quantitative control plasmid synthetic 
insert. The icd1, icd2 and icd3 (icd – isocitrate dehydrogenase gene) targets were designed and validated 
within this project. Other targets were added to allow future utility of the control plasmid for 
quantitation (sod – superoxide dismutase gene, and 16s RNA) and for more sensitive detection of the 
variable/multi-copy target is1111 (an insertion sequence present in a variable number of copies in C. 
burnetii isolates). ........................................................................................................................................ 46 
Table 2.3 - Reaction constituents of restriction endonuclease reaction for linearisation of the pCox 
plasmid. ...................................................................................................................................................... 47 
Table 2.4 - Real-time PCR master-mix for icd assay (TaqMan chemistry). ................................................. 49 
Table 2.5 – Virulence assessment experiment: Guinea pig identities, group allocations and challenge 
material used during the virulence assessment experiment. Individual animal identities are of the form 
Vx-y; V=virulence assessment, x=group identifier; y=individual animal identifier. Eg. V2-3 is individual 3, 
in group 2 of the virulence experiment. ..................................................................................................... 50 
Table 2.6 – Aerosol Infection Experiment: Guinea pig and mouse identities with group allocations used 
during the aerosol infection experiment. Individual animal identities are of the form Ax-y; A=aerosol 
infection experiment, x=group identifier; y=individual animal identifier. Eg. A2-6 is individual 6, in group 2 
of the aerosol exposure experiment. .......................................................................................................... 52 
Table 2.7 - Biaera (AeroMP) parameters for the aerosol exposure of animals to C. burnetii. Showing the 
nebulisation parameters, the flow rate and collection medium used in the aerosol sampler, and the 
exposure time. ............................................................................................................................................ 53 
Table 2.8 – Quantification of DNA present used to make standard pCox plasmid for real-time PCR assay. 
Ultraviolet spectrophotometry was used to quantify linearised and purified pCox plasmid. The ratio of 
absorbance at 260 nm and 280 nm is used to assess the purity of DNA. A reading of 1.80 at 260/280 nm 
is generally accepted as pure. The ratio of absorbance at 260 nm and 230 nm is used as a secondary 
measure of purity. An acceptable reading at 260/230 is usually 2.00-2.20. If the readings are 
substantially lower, it is an indication of contaminants such as proteins present in the sample. ............. 59 
Table 2.9 – Real-time PCR assessment of relative sensitivity of the three primer/probe sets. The mean 
cycle at which fluorescent signal crosses the threshold (Ct) and standard deviation (SD) for seven 
concentrations of pCox plasmid for all three primer probe sets. This shows that the icd2 assay is 
consistently more sensitive than the icd1 and icd3 assays, as evidenced by the small Ct values for a given 
target DNA concentration. ......................................................................................................................... 61 
Table 2.10 – Limit of detection determination of the icd2 real-time PCR assay. The regression table from 
Probit analysis shows that the regression, and thus the analysis, is valid. ................................................ 61 
ix 
 
Table 2.11 – Limit of detection determination of the icd2 real-time PCR assay. Goodness of fit output 
from Probit analysis shows that the chosen distribution (Normal) is a good fit for the dataset being 
analysed. .................................................................................................................................................... 61 
Table 2.12 – Amplification efficiency determination of the icd2 real-time PCR assay. MiniTab linear 
regression output for the Quantity (Copies/µl) vs. Ct value. The ANOVA shows that the regression is 
highly significant (P < 0.05) with strong correlation (R
2
 values close to 100 %). Therefore, the use of the 
calculated slope value from the regression to calculate the PCR efficiency of the assay is supported. The 
calculated value for the sloper (-3.281) used in the efficiency calculations is highlighted in bold in the 
table. .......................................................................................................................................................... 62 
Table 2.13 – Virulence Assessment Experiment: Weights of animals, spleens and spleens as a percentage 
of necropsy bodyweight for all animals by group suggesting that the spleen weights (and thus 
splenomegaly) are higher in the Group 2 animals. .................................................................................... 64 
Table 2.14 - Virulence Assessment Experiment: Statistical analysis using t-test (assuming equal variances) 
of spleen weight as a percentage of bodyweight at necropsy. Showing that the observed greater spleen 
weight in Group 2 (egg yolk sack homogenate) is not significant (p>0.05) and therefore no difference in 
splenomegaly was observed in the experiment. ........................................................................................ 65 
Table 2.15 - qPCR titres of the bacterial culture material in the Collison nebuliser (generator 1 - Cnebuliser) 
samples taken prior to challenge of each group as well as the impinger samples (Cimpinger) and the derived 
Caero concentrations in copies/ml (derived from Cimpinger x 20 ml (the sample volume)/l/min (sample flow) x 
10 min(sampling time)/1000). ................................................................................................................... 68 
Table 2.16 – Volume of infectious aerosol inspired by the animals in each group and the calculated 
inhaled dose (copies) of C. burnetii calculated from Caero x Inspired volume. The inhaled dose is an 
estimate of the number of organisms to which each animal was exposed. .............................................. 69 
Table 2.17 – Aerosol Infection Experiment: Analysis of Covariance (ANCOVA) on guinea pig weight data. 
Demonstrating that the observed slower rate of weight gain in the animals exposed to C. burnetii versus 
the unexposed animals is statistically significant (P < 0.05). ..................................................................... 73 
Table 2.18 - Aerosol Infection Experiment: Analysis of Covariance (ANCOVA) on BALB/c mouse weight 
data. Demonstrating that the observed slower rate of weight gain in the animals exposed to C. burnetii 
versus the unexposed animals is statistically significant (P<0.05) ............................................................. 75 
Table 2.19 - Aerosol Infection Experiment: Analysis of covariance (ANCOVA) on A/J mouse weight data. 
Demonstrating that the observed slower rate of weight gain in the animals exposed to C. burnetii versus 
the unexposed animals is not statistically significant (P < 0.05) ................................................................ 76 
Table 2.20 - Aerosol Infection Experiment: Bacterial load measurements in the three mice (A/J) found at 
necropsy to have detectable C. burnetii in their blood. .............................................................................. 76 
Table 3.1 – For first dimension separation of C. burnetii proteins by isoelectric point the IPG Strip running 
conditions here were used for focussing the 7 cm Immobiline DryStrips on the Ettan IPGPhor II Isoelectric 
focussing instrument. Temperature was held at 20 °C and current was capped at 50 µA/strip. ............... 97 
x 
 
Table 4.1 - NanoLC parameters used to feed the electrospray ionisation (ESI) component of the tandem 
mass spectrometer. Buffer A (default) consisted of 0.1 % (v/v) aqueous formic acid and buffer B of 0.1 % 
(v/v) formic acid in acetonitrile. ............................................................................................................... 130 
Table 4.2 - Tools used to predict subcellular localisation and functionality of identified C. burnetii 
proteins. ................................................................................................................................................... 132 
Table 4.3 - Proteins identified by both 2D-PAGE spot picks and immunoprecipitation methods that have 
previously been reported in the literature. ............................................................................................... 133 
Table 4.4 - Proteins identified by immunoprecipitation method (and not seen in 2D-PAGE spots) that have 
previously been reported in the literature. ............................................................................................... 134 
Table 4.5 – Novel proteins identified by 2D-PAGE spot picks and by immunoprecipitation methods that 
have not been previously reported as immunoreactive in the literature; the calculated molecular weight 
(MW) in Daltons (Da) and the estimated average isoelectric point (pI) are shown for each protein. ..... 135 
Table 4.6 – Novel proteins identified by immunoprecipitation method that have not been previously 
reported as immunoreactive in the literature; the calculated molecular weight (MW) in Daltons and the 
estimated average isoelectric point (pI) are shown for each. .................................................................. 137 
Table 4.7 – Novel identified proteins (previously unpublished) that have predicted notable features 
and/or non-cytoplasmic locations. Predictions of transmembrane regions using TMHMM2.0, lipoproteins 
using Lipo and LipoP, secretion using SecretomeP2.0, signal peptides using SignalP4.1 and beta-barrel 
outer membrane regions using BOMP. Of particular interest for possible antibody-mediated vaccine 
targets are CBU_0091, CBU_1648, and CBU_1652 as inhibition of those features has been shown in the 
literature to inhibit bacteria replication. The two hypothetical proteins are also worthy of future study 
due to their, as yet, unknown functions. .................................................................................................. 140 
  
xi 
 
List of Figures 
 
Figure 1.1 - Diagram of a Gram-negative bacterial cell envelope. The cytoplasm (inside) of the organism 
is situated at the bottom of the figure. The components of each layer of are listed on the right of the 
figure. The lipopolysaccharide (LPS) that is particularly important in C. burnetii consists of the Lipid A and 
the “O” antigen side chains embedded in and protruding from the Outer Membrane. Diagram from B. D. 
Davis (1990a). ............................................................................................................................................ 24 
Figure 1.2 - The putative developmental cycle of C. burnetii in eukaryotic cells. (1) The small cell variant 
(SCV) enters the cell and is transported to the endosome which becomes acidified (2). The SCV develop 
into the large cell variant (LCV) which begins to replicate. After the lysosome fuses with the endosome to 
form the phagolysosome (3) the LCV continue to replicate by binary fission. As bacterial numbers 
increase the LCV mature into the SCV (4) and are released from the cell (5). Diagram adapted from 
Arricau-Bouvery and Rodolakis (2005). ...................................................................................................... 26 
Figure 1.3 - Transmission cycle for infection of hosts by C. burnetii. Ixodid ticks act as a reservoir 
maintaining and spreading the microorganism through transovarial transmission. Ticks (Ixodid & 
Argasid) maintain the wildlife cycle throughout the world and spread the infection to wild and 
domesticated animals by feeding. Humans generally acquire the infection by inhalation of aerosols from 
domesticated animals during parturition through exposure to placental tissues, birth fluids, faeces, urine, 
and contaminated dust and bedding materials. However, infection via contact with contaminated food 
has been described. Diagram from Weiss, Williams, and Thompson (1991) ............................................. 29 
Figure 1.4 - Immune response to C. burnetii infection. Macrophages and dendritic cells (DC), once 
infected, present bacterial antigens to T lymphocytes. The production of interferon-γ (IFN-γ) by T 
lymphocytes and tumour necrosis factor (TNF) by various immune cells induce apoptosis (genetically-
directed cell death) of infected macrophages and killing of C. burnetii. Diagram adapted from Capo and 
Mege (2012) ............................................................................................................................................... 30 
Figure 2.1 - The small animal configuration of the AeroMP-Henderson. The compressor, vacuum pump 
and AeroMP control unit are sited outside of the containment isolator. The required flow and electrical 
connections pass through the service panel into the flexible film isolator to connect to delivery system. 
Conditioned airflow from the AeroMP control unit enters the isolator through a single HEPA filter where 
it is mixed in the piccolo with the challenge aerosol from a Collison nebuliser. The challenge aerosol flows 
into the exposure chamber/sow. A sample of aerosol is collected via an impinger before returning to the 
AeroMP control unit through two HEPA filters. This airflow circuit allows the control of the relative 
pressure of the sow compared to the isolator. ........................................................................................... 53 
Figure 2.2 - Nucleotide alignment of part of the icd gene of four strains of C. burnetii (Q212, Q194, 
Dugway, RSA331, and the type strain RSA493 – Nine Mile) showing the positions of the three 
primer/probe sets (coloured in the consensus sequence) designed for the real-time quantitative PCR 
xii 
 
assay (forward (fwd) primers in blue, probe oligonucleotides (prb) in red, and reverse (rev) primers in 
green). Mismatches from the consensus sequence are illustrated by a contrasting background colour. .. 56 
Figure 2.3 - Annotated sequence of the pCox insert fragment synthesized by Geneart. Red block arrows 
(top of the figure) indicate the location of the 16s primer and probe set, green block arrows indicate the 
three icd gene in-house designed primer and probe sets (labelled accordingly), the pale blue block arrows 
indicate the IS1111 primer and probe set and the purple/pink block arrows (bottom of the figure) 
indicate the SOD in-house primer and probe set. ....................................................................................... 58 
Figure 2.4 - Kpn I Restriction digest of plasmid pCox, after 2 hours. Electrophoresed on a 1.0 % (w/v) 
Agarose gel. Lanes 1 and 13; NEB 1 kb MW marker (#N3232), Lanes 2 – 11; 10 restriction reactions. Lane 
12; Negative (undigested) control – showing uncut plasmid in supercoiled state. White box indicates the 
plasmid bands between 3 and 4 kb. The molecular weights (Lanes 1 and 13), in kilobases, of the MW 
marker starting from the bottom (smallest) are; 0.5, 1.0, 1.5, 2.0, 3.0 (bright), 4.0, 5.0, 6.0, 8.0. ............ 59 
Figure 2.5- Real-time PCR Amplification slopes of the three icd primer/probe sets. The steepest and 
highest slopes are icd2, the next steepest/highest are icd3, and the shallowest/lowest are icd1. The pairs 
of lines for each primer/probe set are for the decimal dilutions of pCox plasmid (1 x 10
7
 down to 1 x 10
1
 
copies/µl). This illustrates that the icd2 primer/probe set amplifies the target with greater efficiency than 
either icd3 or icd1. ...................................................................................................................................... 60 
Figure 2.6 - Amplification efficiency determination of the icd2 real-time PCR assay. The regression 
analysis fitted line plot of the quantity (copies/µl) vs. the output Ct value from the assay. This figure 
shows a close relationship between the input and output values of the assay and the calculated 
regression line. ........................................................................................................................................... 62 
Figure 2.7 – Virulence Assessment Experiment: Group mean guinea pig bodyweight change as a 
percentage of the average baseline weights for each group. This shows that the animals that received 
the yolk sac homogenate material, by intraperitoneal injection (ip), lost substantially more weight than 
those that received the spleen homogenate. Error bars ±1 Standard Error of the mean - black arrows 
signify the euthanasia points of animals V2-3, V2-1, and V2-2 respectively. ............................................. 65 
Figure 2.8 - Virulence Assessment Experiment: Group mean guinea pig temperature for each group. Error 
bars ±1 Standard Error of the mean – black arrows signify the euthanasia points of animals V2-3, V2-1, 
and V2-2 respectively. Fever was defined as the average of the 32 pre-inoculation temperatures added to 
double the standard deviation (38.8 °C). This shows that the animals that were inoculated with yolk sac 
homogenate by intraperitoneal injection (ip) had a higher and more sharply defined fever ‘spike’ than 
those that received spleen homogenate. ................................................................................................... 66 
Figure 2.9 - Virulence Assessment Experiment: Blood bacterial load of C. burnetii as determined by real-
time qPCR. Three different blood sampling tubes; EDTA or Heparin as anticoagulant or separated serum, 
were used to assess which would give the best recovery of organisms for future work. Figure shows that 
no Coxiella DNA was detected in the blood of in any of the group 1 (spleen homogenate) animals or in 
V2-4 (the surviving animal from group 2 – yolk sack homogenate) and that EDTA as anticoagulant gave 
xiii 
 
recovery approximately one order of magnitude higher than either heparin anticoagulant or separated 
serum collection tubes................................................................................................................................ 67 
Figure 2.10 - Virulence Assessment Experiment: Bacterial load of C. burnetii as determined by qPCR in the 
spleen of animals at necropsy. The spleens of group 1 (spleen homogenate) animals V1-2 and V1-4 
contained low levels of C. burnetii relative to the spleens of group 2 (yolk sack homogenate). Animals V1-
1, V1-3, V2-4 (only survivor in group 2) had no detectable C. burnetii DNA present in their spleens. ....... 67 
Figure 2.11 - Aerosol Infection Experiment: Guinea pig temperature measurements collected via 
subcutaneous implant post-challenge with C. burnetii aerosol. Fever was defined as the mean pre-
challenge temperature measurements of all seven animals plus double the standard deviation. Shows 
exposed guinea pigs demonstrated a fever from day 9 lasting approximately 3 days relative to the 
unexposed animal. Error bars ±1 SEM. ....................................................................................................... 70 
Figure 2.12 – Aerosol Infection Experiment: Mouse (BALB/c strain) temperature measurements collected 
via subcutaneous implant post-challenge with C. burnetii aerosol. Fever was defined as the mean pre-
challenge temperature measurements of all seven animals plus double the standard deviation. No clear 
fever can be seen in the exposed mice relative to the unexposed. Error bars ±1 SEM. .............................. 71 
Figure 2.13 – Aerosol Infection Experiment: Mouse (A/J strain) temperature measurements collected via 
subcutaneous implant post-challenge with C. burnetii aerosol. Fever was defined as the mean pre-
challenge temperature measurements of all seven animals plus double the standard deviation. No clear 
fever can be seen in the exposed mice relative to the unexposed. Error bars ±1 SEM. .............................. 72 
Figure 2.14 - Aerosol Infection Experiment: Guinea pig weight change post-challenge with C. burnetii 
aerosol. The linear regression line equations, R
2
-values and P-values are shown for each data set 
(MiniTab v16). Graph indicates that exposed guinea pigs gained weight at a slower rate relative to 
unexposed. Exposed guinea pigs failed to gain any weight from approximately day 8 until day 9, broadly 
coinciding with the observations of fever in Figure 2.11. Error bars ±1 SEM. ............................................ 73 
Figure 2.15 - Aerosol Infection Experiment: Mouse (BALB/c strain) weight change post-exposure with C. 
burnetii aerosol. The linear regression line equations, R
2
-values and P-values are shown for each data set 
(MiniTab v16). Graph indicates there may be a small difference in weight gain between exposed and 
unexposed mice, the exposed mice gaining weight at a lower rate. Error bars ±1 SEM. ........................... 74 
Figure 2.16 - Aerosol Infection Experiment: Mouse (A/J strain) weight change post-exposure with C. 
burnetii aerosol. The linear regression line equations, R2-values and P-values are shown for each data set 
(MiniTab v16). *It should be noted that the P-value for the regression of the unexposed A/J mice did not 
reach significance, likely due to the deviation from the predicted lines between days 6 and 10. Graph 
indicates there may be a small difference in weight gain between exposed and unexposed mice, the 
exposed mice gaining weight at a lower rate – this was not found to be statistically significant. Error bars 
±1 SEM........................................................................................................................................................ 75 
Figure 2.17 - Aerosol Infection Experiment: C. burnetii bacterial loads (measured by qPCR) in guinea pig 
tissues at 15 and 21 days post-exposure. Black bars indicate the animals autopsied (PM) at day 15 (d+15) 
post-exposure (p.e.), white bars those autopsied at day 21 post-exposure. Figure shows that by day 21 
xiv 
 
guinea pigs have cleared the infection from all tissues other than lung, consistent with an acute 
infection. Error bars +1 SEM. ...................................................................................................................... 77 
Figure 2.18 - Aerosol Infection Experiment: Aerosol Infection Experiment: C. burnetii bacterial loads 
(measured by qPCR) in mouse (BALB/c) tissues at 15 and 21 days post-exposure. Black bars indicate the 
animals necropsied (PM) at day 15 (d+15) post-exposure (p.e.), white bars those necropsied at day 21 
post-exposure. Figure shows that mice had not cleared the infection by day 21 relative to day 15 (levels 
in kidney and testes had actually increased), consistent with chronic infection of the mice. Error bars +1 
SEM. ........................................................................................................................................................... 78 
Figure 2.19 - Aerosol Infection Experiment: C. burnetii bacterial loads (measured by qPCR) in mouse (A/J) 
tissues at 15 and 21 days post-exposure. Black bars indicate the animals necropsied (PM) at day 15 
(d+15) post-exposure (p.e.), white bars those necropsied at day 21 post-exposure. Figure shows that mice 
had not cleared the infection by day 21 relative to day 15, consistent with chronic infection of the mice 
Error bars +1 SEM. ...................................................................................................................................... 78 
Figure 3.1 - Diagram of how immunoblot can be used to isolate immune-reactive proteins. Proteins from 
either one- or two-dimensional SDS-PAGE separation gels are blotted (using electric current in the 
Western blot protocol) onto a nitrocellulose or PVDF membrane (proteins; Blue and Green in diagram 
above). A mixture of proteins not present in the original sample (usually milk; pale blue in diagram) is 
applied to the membrane to block any unbound sites on the membrane. Primary antibody (usually whole 
sera but sometimes purified fractions of immunoglobulin; red in diagram) is applied to the membrane, 
antibodies bind to any proteins on the membrane that they ‘recognise’ at this point – unbound 
antibodies are washed away. A secondary antibody (green) that has been conjugated to an enzyme is 
then applied to the membrane. The secondary antibody is usually selected to only bind to a single isotype 
of immunoglobulin (eg. Only IgG). After another wash, the bound secondary antibody is detected by 
either a colour-changing or chemiluminescent substrate (yellow star). In this manner immune reactive 
proteins (those recognised by antibodies present in the sera of convalescent laboratory animals or 
people) can be isolated. ............................................................................................................................. 85 
Figure 3.2 – Growth curves of C. burnetii in ACCM-2 media incubated at 37 °C in a microaerophilic 
atmosphere over a ten-day period at five different culture inoculation concentrations. All titres measured 
by real-time qPCR targeting the icd gene as described in Chapter 2. Figure shows that the maximum titre 
supported by this media is approximately 10
10
 copies/ml and that culturing for over 6 days with seeding 
concentrations above 10
5
 copies/ml leads to a reduction in qPCR signal. ............................................... 103 
Figure 3.3 - Transmission electron micrograph of the ACCM-2 grown C. burnetii – from the larger scale 
growth discussed in Section 3.2.1.2 and harvested at day 10 post-inoculation. 7900x magnification. 
Showing that the preparation contains very little contaminating material with the preparation consisting 
almost entirely of microorganisms. Representatives of the small- (SCV) and large cell variants (LCV) are 
indicated demonstrating the preparation contains a mixture of the two morphological forms of the 
organism. Scale bar 2 µm. ........................................................................................................................ 104 
xv 
 
Figure 3.4 – Transmission electron micrograph of the ACCM-2 grown C. burnetii at a higher 
magnification. 34,000x magnification. Large cell variant (LCV indicated with L) and small cell variant (SCV 
indicated with S) indicated, showing that the preparation consisted of organisms in both morphological 
forms. Scale bar 500 nm. .......................................................................................................................... 105 
Figure 3.5 - Immunofluorescent microscopy image of C. burnetii (bright green coccobacilli) stained with a 
diagnostic control convalescent goat sera (Veterinary Laboratory Agency) and detected with an anti-
goat IgG-FITC conjugated secondary antibody. An Evans blue counterstain (red) was also applied to the 
slide to provide an indication of the level of non-C. burnetii protein was present. The extremely low level 
of red staining from the Evans blue is an indication that the preparation was of a high purity and 
contained very little contaminating protein from the yolk sac inoculum. Magnification 400x. ............... 106 
Figure 3.6 – One-dimensional SDS-PAGE image of extracted C. burnetii protein run on a 12 % Bis-Tris gel 
in MOPS-SDS running buffer at 200 V for 50 m. The three lanes are 10 µl, 5 µl, and 2.5 µl of protein boiled 
in Laemmli buffer to ensure good band clarity. The figure shows that the extracted protein contained a 
wide range of proteins of different masses present in distinct species with little evidence of degradation 
(bands were sharply delineated with little smearing). ............................................................................. 107 
Figure 3.7 - Western blot of C. burnetii proteins (on the membrane) probed with the aerosol-exposed 
guinea pig sera (containing immune-reactive antibodies), that binding detected with anti-guinea pig IgG 
conjugate, and visualised with ECL prime substrate. Lane 1 is the transferred SeeBlue Plus2 Molecular 
Weight standard and lane 2 contains the MagicMark XP Standard.  Figure shows that the sera from all of 
the exposed guinea pigs reacted to some degree with the proteins present in the C. burnetii extract 
whereas the unexposed guinea pig (A1-7) did not react. The image also suggests that individuals A1-4 
and A1-6 reacted with a more proteins over a wider mass range than the other exposed animals. ....... 108 
Figure 3.8 - Linear Regression of protein quantitation standards and the resulting line equation used to 
calculate the protein quantities present in the C. burnetii extract. Line equation OD480 nm = 0.856–0.003 
µg BSA; S = 0.013; R
2
 = 94.8%; R2 (adj) = 94.5 %; P < 0.001. The derived line equation was used to 
determine the loading quantities of proteins for the first-dimension (isoelectric focussing) of the 2D SDS-
PAGE process to reduce the risk of under or overloading the gels. .......................................................... 109 
Figure 3.9 - Coomassie-stained 2D PAGE separation of C.  burnetii proteins across the wide pI range 3.0–
11.0 (non-linear). Isoelectric point ranges from pI = 3 at the left side of the image to pI = 11 at the right 
side of the image. Each stained spot represents a single, or small group of proteins of a specific size and 
isoelectric point. ....................................................................................................................................... 110 
Figure 3.10 - Coomassie-stained 2D PAGE separation of C.  burnetii proteins across the narrower (acidic) 
pI range 3.0–5.6 (non-linear). Isoelectric point ranges from pI = 3 at the left side of the image to pI = 5.6 
at the right side of the image. .................................................................................................................. 111 
Figure 3.11 - Coomassie-stained 2D PAGE separation of C.  burnetii proteins across the narrower (basic) 
pI range 7.0–11.0 (non-linear). Isoelectric point ranges from pI = 7 at the left side of the image to pI = 11 
at the right side of the image. .................................................................................................................. 112 
xvi 
 
Figure 3.12 – Western Blue® (BCIP/NBT)-stained antibody-probed Western blot of C.  burnetii proteins 
detected in wide pI range 3-11 (non-linear). Immunoreactive proteins probed with antibody (IgG) present 
in guinea pig sera (A1-4), the bound antibody was detected with anti-Guinea Pig IgG/alkaline 
phosphatase conjugate. The areas marked C1–C9 indicate the locations from where spots of the 
corresponding protein gel were excised for protein identification. .......................................................... 113 
Figure 3.13 – Western Blue® (BCIP/NBT)-stained antibody-probed Western blot of C.  burnetii proteins 
detected in lower, narrow pI range 3–5.6 (non-linear). Immunoreactive proteins probed with antibody 
(IgG) present in guinea pig sera (A1-4), the bound antibody was detected with anti-Guinea Pig 
IgG/alkaline phosphatase conjugate. The areas marked L1–L20 indicate the location from where spots of 
the corresponding protein gel were excised for protein identification. ................................................... 114 
Figure 3.14 – Western Blue® (BCIP/NBT)-stained antibody-probed Western blot of C.  burnetii proteins 
detected in higher, narrow pI range 7–11 (non-linear). Immunoreactive proteins probed with antibody 
(IgG) present in guinea pig sera (A1-4), the bound antibody was detected with anti-Guinea Pig 
IgG/alkaline phosphatase conjugate. The areas marked H1–H7 indicate the location from where spots of 
the corresponding protein gel were excised for protein identification. ................................................... 115 
Figure 3.15 - Output trace of the AKTA FPLC instrument during affinity purification of the guinea pig 
antisera. The blue trace shows protein concentration (arbitrary units) measured by UV, the two sample 
injection points are indicated by the pink vertical bars, the switch of the instrument from binding buffer 
to elution buffer is indicated by the change in conductivity shortly after 25 ml (green trace) and the 
eluted protein fraction identities are in red text from this point. ............................................................. 116 
Figure 3.16 – Left-hand pane - 1D PAGE analysis of affinity purified guinea pig IgG. Lanes 1-3 non-
reduced protein. Lanes 5-7 reduced protein. Lanes 1 and 5 are antisera, lanes 2 and 6 are purification 
column wash through, lanes 3 and 7 are the eluted, dialysed and concentrated IgG. In lane 7 the heavy 
(~50 kDa) and light (~23 kDa) chains of IgG can be clearly seen, in lane 3 the ~150 kDa single band of the 
un-reduced IgG is not easily visualised, this is likely due to lane-to-lane bleed of the reducing agents 
partly reducing the IgG. Right-hand pane – Antibody-probed Western Blots of C. burnetii protein 
detected with Western Blue® substrate showing no difference in activity between the un-treated antisera 
and the affinity-purified antibody. ........................................................................................................... 117 
Figure 3.17 – The left-hand pane is the Coomassie-stained 1D PAGE of the immunoprecipitation (IP) 
experiment protein samples. Lanes 1 and 2 are the Native C. burnetii protein material pre- and post- IP. 
Lanes 3 and 4 are the Denatured material pre- and post-IP. Lane 7 is the post-IP (Convalescent guinea pig 
IgG-captured) eluted native proteins. Lane 10 is the post-IP eluted denatured proteins. The right-hand 
panel is the residual protein remaining in the gel after Western blotting the same material with the 
exception that lanes 5 and 6 are the eluted native and denatured protein materials. The greater 
sensitivity of the silver staining procedure shows that a good range of protein species were eluted from 
the IP experiment. .................................................................................................................................... 119 
Figure 3.18 – Western-blot of the immunoprecipitation (IP) experiment protein samples probed with 
guinea pig convalescent sera (4427 1-4). Lanes 1 and 2 are the Native C. burnetii protein material pre- 
xvii 
 
and post- IP. Lanes 3 and 4 are the Denatured material pre- and post-IP. Lane 5 is the post-IP 
(Convalescent guinea pig IgG-captured) eluted native proteins. Lane 6 is the post-IP eluted denatured 
proteins. ................................................................................................................................................... 120 
Figure 4.1 - General layout of the Q-Exactive mass-spectrometer (MS) used in this work. The peptides 
enter the MS from the nano-scale liquid-chromatography separation (not shown) and are ionised at the 
electrospray ionisation source (ESI) – labelled NanoSpray source (lower right). The peptide ions then pass 
in the first MS – the quadrupole – which can be used to generate low-resolution/high mass range spectra 
and act as a mass filter for ions entering the C-Trap. In the C-trap, ions are accumulated before having 
their mass (actually their m/z which is later de-convoluted by a computer algorithm to discover ion mass) 
determined by the OrbiTrap mass-analyser or fragmented by collisions with nitrogen gas (in the HCD 
collision cell) before being measured in the OrbiTrap. The OrbiTrap is a much higher-resolution mass 
analyser and it is this accuracy that allows peptide sequence to be derived. Diagram adapted from 
Michalski et al. (2011). ............................................................................................................................. 126 
Figure 4.2 - Functional distribution of immunoreactive proteins. Showing the proportion of proteins in 
each functional grouping after the categories described previously (Samoilis et al., 2007; Skultety et al., 
2011). The legend order follows the pie segment order in a clockwise direction starting with “Energy 
Metabolism – electron transport” with a value of 17 %. Figure shows that the proteins identified were 
diverse in function and that the majority were not likely to be exposed on the surface of the organism – 
as one would expect for an intracellular pathogen. ................................................................................. 139 
  
xviii 
 
Abbreviations 
 
AGI – All-Glass Impinger  
ANCOVA – Analysis of Covariance 
BLAST – Basic Local Alignment Search Tool  
CMI – Cell-Mediated Immunity 
CTL – Cytotoxic T-lymphocytes 
DSTL – Defence Science and Technology Laboratory 
DTT - Dithiothreitol 
EDTA – Ethylenediaminetetraacetic acid 
ESI – Electrospray Ionisation FITC – Fluorescein Isothiocyanate  
HEPA – High Efficiency Particulate Air  
ICD – Isocitrate dehydrogenase 
IEF – Iso-electric focussing 
IFN - Interferon 
LC – Liquid Chromatography 
LCV – Large Cell Variant  
LDS – Lithium Dodecyl Sulphate 
LPS - Lipopolysaccharide 
MALDI – Matrix-assisted laser desorption/ionisation  
MGB – Minor-groove binding, non-fluorescing quencher 
MOPS – 3-(N-morphlino)propanesulphonic acid 
MS – mass spectrometer/mass spectrometry  
NCBI – National Center for Biotechnology Information 
NIAID – National Institute of Allergy and Infectious Diseases 
PAGE – Polyacrylamine Gel Electrophoresis 
PBMC – Peripheral Blood Mononuclear Cells 
PBS – Phosphase buffered saline 
PCR – Polymerase chain reaction 
xix 
 
PHE – Public Health England 
PMF – Peptide Mass Fingerprinting 
PTFE - Polytetrafluoroethylene  
PVDF – Polyvinylidene fluoride  
QFS – Q Fever Fatigue Syndrome 
qPCR – real-time quantitative polymerase chain reaction 
SCID – Severe Combined Immunodeficiency 
SCV – Small Cell Variant  
SDS – Sodium dodecyl sulphate  
SOD – Superoxide Dismutase 
SST – Serum Separation Tube 
TAE – Tris-acetate EDTA  
TOF – Time of flight  
TOF/TOF – a form of tandem mass spectrometry that uses two TOF MS instruments arranged 
back-to-back  
WCV – Whole Cell Vaccine  
xx 
 
Acknowledgements 
 
No work of scientific endeavour occurs in isolation and during this project I had useful training, 
advice, assistance and intellectual discussions with many inspirational and knowledgeable 
experts. I would therefore like to offer my specific thanks to the following individuals and 
teams. To Graham Hatch and the Biological Investigations Group for all of their assistance and 
expertise in the aerobiological elements of the project as well as the numerous procedures, 
measurements, monitoring, husbandry and necropsy of the protected species used in this 
work. The in vivo elements of this work were funded by the US NIAID under task order C19 
(DMID-03-39-N01-A1-30062) and by DSTL. I would like to thank Dr Isobel Norville and her team 
at DSTL for allowing me to perform the large scale culture and centrifugation of C. burnetii that 
was critical for producing enough protein to complete this project. Particular thanks should go 
to the PHE Porton electron microscopist, Howard Tolley, whose skill and knowledge made the 
images in Chapter 3 possible. Thanks go also to Drs Kevin Richards and Phil Nugent for passing 
on their technical knowledge in the art, and science, of protein preparation, separation and 
isoelectric focussing. I would like to offer especial thanks to Drs Haroun Shah and Min Fang of 
the Colindale Proteomics facility who practically ‘saved’ the mass spectrometry element of this 
project when other avenues for these analyses dried up and especially to Dr Simon Funnell 
who helped me make the initial contact with that team. I would also like to thank Dr Richard 
Hesp for the countless discussions regarding proteomics, immunoprecipitation and the joy and 
pain that is lipopolysaccharide. Thanks also to my supervisors Dr Julia Vipond, Professor 
Graham Mills and Sarah Fouch for their continual support, encouragement and feedback 
throughout all phases of this work. 
I would also like to offer my grateful thanks to the members of my own team who helped with 
the weighing of tissues, extraction of DNA from the animal study tissues and bloods, and the 
running of numerous qPCR assays. So, in order of length of time you have had to endure me as 
your “boss”, Mel, Gem, Debbie, and James – thanks guys! 
Finally, I would like to wholeheartedly thank my family and especially my wife Elizabeth for 
their constant support, encouragement and toleration of all that a research project and the 
writing of a thesis entail! I really could not have got this far without you.  
xxi 
 
Dedication 
 
For my friends, my family, Peter and my Lizzie.   
xxii 
 
Declaration 
 
I declare that whilst registered as a candidate for the Doctorate in Biomedical Science at the 
University of Portsmouth I have not been registered for any other research award. The results 
and conclusions embodied in this thesis are the work of the named candidate and have not 
been submitted for any other academic award. 
 
Word count: 55,003 
 
 
Kevin Raymond Bewley 
April 2015 
 
23 
  
1 Introduction 
1.1 History 
 
The first recorded outbreak of Q fever occurred in 1935 in a small number of patients who 
worked in an abattoir in Brisbane in the state of Queensland, Australia (Derrick, 1937). The key 
symptoms of the disease affecting the workers were fever with an accompanying headache, 
which Derrick described as “the outstanding symptom … severe and persistent” (Derrick, 1937, 
p. 298). The causative agent was initially unknown and the disease was thus named “query” or 
Q fever (Babudieri, 1959). Derrick was unable to isolate the causative agent, although he did 
successfully infect guinea pigs with blood from infected patients and demonstrate that the 
liver of the animals contained the infectious agent; he speculated that the disease was caused 
by a virus (Derrick, 1937).  
In the same year in the United States, and independently of Derrick, guinea pigs were found to 
develop a febrile illness after being fed on by ticks collected from Nine Mile Creek, Montana 
(G. E. Davis & Cox, 1938). The link that the two agents were closely related was made after a 
laboratory-acquired infection with a Montana isolate led to a scientist suffering from a disease 
resembling the Australian Q fever. It was found that guinea pigs that had recovered from 
disease caused by the isolate from the scientist were protected from infection with the 
Australian Q Fever agent (Dyer, 1939). 
The organism was eventually given the name Coxiella burnetii after Herald Cox (USA) and F. 
Macfarlane Burnet (Australia) in honour of their recognition that the Q fever agent was a new 
bacterial species (McDade, 1990; Philip, 1948). 
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1.2 The organism 
 
C. burnetii is an obligate intracellular, Gram-negative bacterium (approximately 0.2 x 1.0 µm) 
(Maurin & Raoult, 1999). As with other Gram-negative bacteria, the cell envelope consists of 
an inner membrane consisting of a phospholipid bilayer, a periplasmic space containing 
peptidoglycan, and an outer membrane into which is embedded numerous surface exposed 
molecules such as proteins associated with the secretion system, lipoproteins, and the 
lipopolysaccharide (LPS) as shown in Figure 1.1.  
  
Figure 1.1 - Diagram of a Gram-negative bacterial cell envelope. The cytoplasm (inside) of the organism is situated 
at the bottom of the figure. The components of each layer of are listed on the right of the figure. The 
lipopolysaccharide (LPS) that is particularly important in C. burnetii consists of the Lipid A and the “O” antigen 
side chains embedded in and protruding from the Outer Membrane. Diagram from B. D. Davis (1990a). 
 
The organism displays antigenic phase variation comparable to the rough-smooth variation 
seen in Enterobacteriaceae. In C. burnetii, phase variation has been demonstrated to be due to 
mutational variation in the LPS (Hackstadt, 1986, 1990; Hackstadt, Peacock, Hitchcock, & Cole, 
1985). Organisms displaying the phase I phenotype can be identified by the presence of a 
complete LPS on the cell surface, whereas organisms displaying the phase II phenotype have a 
truncated LPS that does not possess the O-antigen side chains. The O-antigen of phase I LPS 
has been shown to contain two sugar residues in the O-polysaccharide chain that are not 
found in other bacterial LPSs, these are virenose and dihydrohydroxystreptose (Toman, 
Skultety, Ftacek, & Hricovini, 1998). Organisms with the phase I phenotype are the infectious 
and virulent form found in nature. Organisms with the phase II phenotype are observed mostly 
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during repeated subculture in laboratory chick-embryo or cell culture systems (Hackstadt, 
1990); they possess a chemically simpler LPS (Amano & Williams, 1984) and several substantial 
deletions in the genome (Hoover, Culp, Vodkin, Williams, & Thompson, 2002; Vodkin & 
Williams, 1986). 
Until recently C. burnetii was regarded as an obligate intracellular organism meaning that most 
of the work to date studying the organism took place within living animal hosts. Host cell-free 
growth of the organism has been reported recently (Omsland et al., 2009), but the technique is 
only beginning to be exploited. Cell culture-based in vitro systems remain limited in the study 
of C. burnetii as the organism reverts to the avirulent phase II form (characterised by the loss 
of the phase I LPS phenotype) within a short period of time in these systems (Baca et al., 
1981). 
In addition to the phenomenon of phase variation, C. burnetii also exists in two morphological 
or developmental forms. The putative intracellular cycle is shown in Figure 1.2. The two 
morphological forms can be differentiated by their shape, size, peptidoglycan content, and 
their resistance to chemical and physical stress (Amano & Williams, 1984; McCaul & Williams, 
1981). The small cell variant (SCV) is 200 by 450 nm in size and electron-dense while the large 
cell variant is up to 2 µm long and more diffuse when viewed by electron microscopy (McCaul 
& Williams, 1981). The SCV is the extracellular form of the organism and has been shown to be 
highly stable in the environment and resistant to ultraviolet light, heat, desiccation, and 
osmotic and oxidative stress (Amano & Williams, 1984). The LCV is the metabolically active, 
replicative intracellular form of the organism and is much less resistant to physicochemical 
stress (McCaul & Williams, 1981). 
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Figure 1.2 - The putative developmental cycle of C. burnetii in eukaryotic cells. (1) The small cell variant (SCV) 
enters the cell and is transported to the endosome which becomes acidified (2). The SCV develop into the large 
cell variant (LCV) which begins to replicate. After the lysosome fuses with the endosome to form the 
phagolysosome (3) the LCV continue to replicate by binary fission. As bacterial numbers increase the LCV mature 
into the SCV (4) and are released from the cell (5). Diagram adapted from Arricau-Bouvery and Rodolakis (2005). 
  
1.3 The disease 
 
Disease caused by C. burnetii can take several forms and has been described as clinically 
polymorphic (Angelakis & Raoult, 2010). In man, presentation ranges from asymptomatic, 
through acute disease, up to life-threatening chronic illness. In the majority of cases, acute 
disease presents as a self-limiting febrile illness with half of cases also suffering from severe 
headaches (Tissot-Dupont, Vaillant, Rey, & Raoult, 2007). In more severe cases of acute 
disease, atypical pneumonia is often found (Tissot-Dupont et al., 2007). A small proportion of 
those suffering from symptomatic acute Q fever will be admitted to hospital (2-4 %) (Raoult, 
Marrie, & Mege, 2005; Tissot-Dupont et al., 2007). However, in the outbreak that began in 
2007 in the Netherlands, the hospitalisation rate was much higher, the figure being closer to 
20 % (van der Hoek et al., 2010). Progression to chronic disease develops in approximately 5 % 
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of those infected (Cutler, Bouzid, & Cutler, 2007), the vast majority of these cases will present 
as a bacterial culture-negative endocarditis (Cutler et al., 2007; Gami, Antonios, Thompson, 
Chaliki, & Ammash, 2004) often in those with predisposing heart-damage (Fournier et al., 
1998) or immunosuppression (Cutler et al., 2007). Without effective treatment Q fever 
endocarditis is generally fatal, however earlier diagnosis of cases coupled with more effective 
treatment strategies has brought the death rate down to below 5 % in some cases (Raoult et 
al., 1999).  
In addition to acute and chronic disease, two other clinical manifestations of Q fever are of 
note due to their less than satisfactory outcomes with current treatment strategies. These are 
Q fever during pregnancy and Q fever fatigue syndrome (QFS). Infection with C. burnetii during 
pregnancy leads to premature delivery in almost half of those affected and spontaneous 
abortion in over a quarter (Carcopino, Raoult, Bretelle, Boubli, & Stein, 2007). There have been 
few studies in this area, but there are indications that in those infected during the first 
trimester and treated with suboptimal drug regimes, the abortion rate is 100 % (Raoult, 
Fenollar, & Stein, 2002). This is compounded by the fact that the frontline bactericidal drugs 
for treatment (doxycycline and hydroxychloroquine) are contraindicated for use during 
pregnancy (Raoult et al., 2002). A bacteristatic regimen (co-trimoxazole) has therefore been 
proposed for use (Raoult et al., 2002) until delivery. Without satisfactory treatment during and 
after pregnancy there is also a high probability for infection to lead to chronic Q fever in the 
mother (70 % was reported in a group of pregnant women in France (Raoult et al., 2002)). 
Post-Q fever fatigue syndrome (QFS) was first reported in 1996 (Marmion, Shannon, 
Maddocks, Storm, & Penttila, 1996), but an association between Q fever and chronic fatigue 
had been observed as early as 1982 (Marmion et al., 1996). Between 10 % and 15 % of those 
who have acute Q fever will develop a chronic fatigue syndrome that can last between five and 
ten years, and in some cases even longer (Marmion et al., 2009). In some cases these patients 
have been found to have long-term persistence of C. burnetii cell components and 
lipopolysaccharide (LPS) associated with traces of genomic DNA (Marmion et al., 2009), which 
led the authors to propose that QFS may be immunologically-mediated rather than caused by 
the organism directly. The syndrome appears to be linked to a failure of cell-mediated 
immunity to control the response to the persisting antigens. This leads to the development of 
an elevated, but impaired, cell mediated and cytokine response characterised by high levels of 
IL-6 (Penttila et al., 1998). 
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1.4 Epidemiology 
 
Q fever is a zoonosis that has been described worldwide and C. burnetii infection has been 
detected throughout the entire animal kingdom (Babudieri, 1959; Maurin & Raoult, 1999) 
including wild and livestock mammals, and invertebrates such as ticks. Animals are often 
asymptomatic despite chronic infection. Although C. burnetii can be shed into the environment 
via bodily fluids, the majority of shedding occurs mainly via the birth products of domestic 
farm animals; over 1 x 109 bacteria per gram of placenta can be released from domestic 
ruminants during birth (Babudieri, 1959). However, outbreaks have also been reported 
associated with the birth products of domestic pets such as cats (Marrie & Raoult, 2002). 
Human infection primarily occurs via the inhalation of aerosols containing infected material 
(Maurin & Raoult, 1999).  
Figure 1.3 shows the transmission lifecycle for C. burnetii. It has been proposed that natural 
tick populations act as a reservoir for the organism through transovarial (eg. Egg, larvae, 
nymph, adult) transmission (Babudieri, 1959). Ticks then infect animals and birds either by 
feeding on them, or by the animals inhaling tick faeces which can contain heavy loads of C. 
burnetii (Babudieri, 1959). 
Over the past ten years, Q fever outbreaks have been reported in the Netherlands (Roest et 
al., 2011), Israel (Amitai et al., 2010), Bulgaria (Panaiotov et al., 2009), Germany (Gilsdorf et al., 
2008), Iraq (Faix et al., 2008), France (Tissot-Dupont et al., 2007), Slovenia (Grilc et al., 2007), 
Spain (Garcia-Clemente et al., 2007), the United States (Bamberg et al., 2007) , Croatia (Medic 
et al., 2005), Italy (Starnini et al., 2005), and the United Kingdom (van Woerden et al., 2004; 
Wallensten et al., 2010; Wilson et al., 2010).  
In humans, it is has been determined that a very small number of C. burnetii organisms are 
required to cause infection by inhalation. The evidence suggests that infection can occur after 
inhalation of as few as a single organism (Jones, Nicas, Hubbard, & Reingold, 2006). This fact, 
coupled with its ability to cause debilitating disease and the organism’s extraordinarily high 
level of resistance to various means of inactivation (Ransom & Huebner, 1951; G. H. Scott, 
McCaul, & Williams, 1989; G. H. Scott & Williams, 1990) have resulted in it being listed as a 
category B biological warfare and bioterrorism agent by the Centers for Disease Control 
(CDC)(Madariaga, Rezai, Trenholme, & Weinstein, 2003). 
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Figure 1.3 - Transmission cycle for infection of hosts by C. burnetii. Ixodid ticks act as a reservoir maintaining and 
spreading the microorganism through transovarial transmission. Ticks (Ixodid & Argasid) maintain the wildlife 
cycle throughout the world and spread the infection to wild and domesticated animals by feeding. Humans 
generally acquire the infection by inhalation of aerosols from domesticated animals during parturition through 
exposure to placental tissues, birth fluids, faeces, urine, and contaminated dust and bedding materials. However, 
infection via contact with contaminated food has been described. Diagram from Weiss, Williams, and Thompson 
(1991) 
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1.5 Immunity 
 
After entry into the body the major targets for C. burnetii are phagocytic cells of the 
monocyte/macrophage lineage, typically the alveolar macrophage that patrol the airways. The 
organism enters the macrophage via interaction with the αvβ3 integrin, situated on the cell 
surface (Capo et al., 1999; Raoult et al., 2005). As shown in Figure 1.2, once inside the 
macrophage the organisms are transported to an acidic phagolysosome where they escape 
killing by inhibition of a final phagosome maturation step – cathepsin D fusion (Ghigo et al., 
2002). Application of the cytokine, interferon-γ, was shown to remove this inhibition and 
restore the fusion step leading to killing of the organisms. This demonstrates that interferon-γ 
is an essential component of C. burnetii killing in cells (Ghigo et al., 2002). The role of 
interferon-γ induced cell death is illustrated in Figure 1.4. 
 
 
Figure 1.4 - Immune response to C. burnetii infection. Macrophages and dendritic cells (DC), once infected, 
present bacterial antigens to T lymphocytes. The production of interferon-γ (IFN-γ) by T lymphocytes and tumour 
necrosis factor (TNF) by various immune cells induce apoptosis (genetically-directed cell death) of infected 
macrophages and killing of C. burnetii. Diagram adapted from Capo and Mege (2012) 
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There are two primary components involved in the adaptive immune, or pathogen-specific, 
response to pathogens. These are generally referred to as the antibody-mediated and the cell-
mediated responses (Peakman & Vergani, 1997). 
Antibody-mediated immunity relies on antigen-specific B-lympohocytes producing specific 
antibodies (immunoglobulins) that can bind to the antigens on the surface of the invading 
pathogen and inhibit it through several mechanisms. These mechanisms include opsonising 
(coating) the bacterial surface and interfering with adhesion or entry into host cells, targeting 
bacteria for destruction by the complement system, and Fc-receptor cross-linking leading to 
either Fc-receptor-mediated cytokine release (enhanced inflammatory response) or inhibition 
of intracellular growth and enhanced microbial killing (Casadevall, 1998). However, antibody-
mediated immunity should not be considered a system separate and independent from the 
cell-mediated immune system because the B lymphocyte response to antigens depends upon 
cognate interactions between antigen-specific B lymphocytes and activated antigen-specific 
CD4+ T “helper” lymphocytes (Smith et al., 2000). B-lymphocytes antigens or epitopes (the part 
of an antigen actually recognised by the immune system) can either be conformational, that is 
they retain a three-dimensional shape such as a fully-folded protein structure (which may be 
non-linear and/or non-continuous) or they can be linear, that is they recognise short 
sequences of amino acids (called peptides) in a continuous manner (Peakman & Vergani, 
1997). 
There is substantial evidence that the antibody-mediated response is important in recovery 
from infection, and long-term protection from re-infection, with C. burnetii. Passive transfer of 
immune sera or purified antibody, specifically the immunoglobulin G (IgG) fraction, from mice 
immunised with whole cell vaccine (WCV) has been demonstrated to provide complete 
protection against C. burnetii challenge (by the intraperitoneal route) of immunologically naïve 
mice (Shannon, Cockrell, Takahashi, Stahl, & Heinzen, 2009; G. Zhang et al., 2007). Specifically, 
it seemed to be the IgG fraction that is the active component of sera necessary for this 
protection (G. Zhang et al., 2007). However, in severely combined immunodeficient (SCID) 
mice, while passive transfer of immune sera did protect against clinical disease and weight 
loss, the animals still developed levels of splenomegaly indiscernible from mice given non-
immune sera. This suggests that while antibody mediated immunity is important in protection 
from Q fever disease; it may not offer complete protection. 
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The cell-mediated immune system is that part of the immune system that relates 
predominantly to the actions of T-lymphocytes and their interactions with other cells. As 
discussed above, the cell-mediated immune response can involve T-lymphocytes, bearing the 
CD4+ glycoprotein marker, “helping” B-lymphocytes to produce antibody and/or CD4+ cell 
activation of macrophage to destroy phagocytosed organisms. In addition, it also involves CD8+ 
T-lymphocytes (cytotoxic T-cells) directly destroying infected host-cells (with the “help” of 
CD4+ lymphocytes) by either inducing cell suicide (apoptosis) or by releasing perforin granule 
contents near to the infected cell to disrupt its membrane(Kaufmann, 1999). The cell-mediated 
immune response recognises only linear epitopes (short peptides) presented on either MHC 
class I or II T-cell receptors to CD8+ or CD4+ T-lymphocytes respectively (Peakman & Vergani, 
1997). For the remains of this discussion, cellular response is considered to be all that 
described above with the exception of that part of the response that leads to antibody 
production. 
The cellular components of the immune system have been found to be important in the 
response to C. burnetii. Adoptive transfer of splenocytes, which contain a mixture of CD4+ and 
CD8+ T lymphocytes, B lymphocytes, myeloid cells (dendritic cells and macrophages), and 
natural killer cells, from mice immunised with WCV has been demonstrated to provide 
complete protection against C. burnetii challenge (by the intraperitoneal route) of 
immunologically naïve mice to a similar degree to that seen for immune sera and IgG (G. Zhang 
et al., 2007). When splenocytes or T-lymphocytes only were adoptively transferred to SCID 
mice however, the protection observed was far higher than for sera in terms of reduction in 
bacterial load and splenomegaly (G. Zhang et al., 2007). In intratracheally-challenged SCID 
mice it was demonstrated that reconstituting them with either CD4+ or CD8+ T-lymphocytes 
was sufficient to resolve infection but that CD8+ T-lymphocyte immunity was associated with 
fewer pathological changes in the lungs and lower burden of C. burnetii  in the spleen (Read, 
Erickson, & Harmsen, 2010). 
In summary, it can be seen that specific antibody alone is not sufficient to provide complete 
immunity to C. burnetii and that a competent cell mediated immune system is required to fully 
control infection. In the absence of antibody, it appears that T-lymphocytes alone are sufficient 
to protect against disease. However, the literature does suggest that protection is enhanced by 
both components working in synergy. This evidence suggests that a protective vaccine should 
seek to stimulate both the antibody- and cell-mediated arms of the immune system. 
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1.6 Vaccines 
 
The current vaccine licensed for human use, albeit only in Australia for those at occupational 
risk, is a formalin-killed whole-cell vaccine (WCV) produced by cultivating the organism in 
embryonated chick eggs (Marmion et al., 1990). This vaccine is reported to be effective in 
protecting those at risk from Q fever (Marmion et al., 1990). However, it is associated with 
severe local reactions in those with pre-existing immunity. The severity is such that pre-
screening of potential vaccinees for skin reactions (to a small quantity of vaccine) and blood 
antibody levels, has to be performed before vaccination takes place (Kermode, Yong, Hurley, & 
Marmion, 2003; Lawrence et al., 2003). In spite of this pre-screening, severe reactions are still 
reported in some individuals (Lawrence et al., 2003). This makes the vaccine less appropriate 
for general or widespread use, its use being limited to those in defined occupational risk 
groups such as abattoir workers.  
Alternative vaccines based on highly-purified preparations of the formalin-inactivated whole-
cell material known as chloroform:methanol residues (CMR) have been developed and shown 
to have similar levels of protection in some animal models (Waag et al., 2002; Williams & 
Cantrell, 1982) with potentially fewer side-effects. However, it has been demonstrated that 
although vaccination with CMR appeared to protect against disease upon challenge, it did not 
protect against splenomegaly, hepatomegaly, or lesions in the liver whereas vaccination with 
WCV did (Williams & Cantrell, 1982). Indeed, animals vaccinated with CMR showed significant 
splenomegaly and hepatomegaly when either challenged with live C. burnetii or injected with 
killed WCV vaccine. This is an indication that inadequate immunity against C. burnetii may lead 
to enhanced disease rather than partial protection. In addition, both WCV and CMR require 
the production of large quantities of virulent C. burnetii at high containment during their 
manufacture.  
Vaccines based on phase II organisms that, due to their avirulence could be a convenient 
vaccine, were briefly investigated but found to be non-protective (G. Zhang et al., 2007). 
Attempts to produce a vaccine based on recombinantly expressed immunodominant C. 
burnetii proteins also failed to elicit protection in a mouse model (Tyczka, Eberling, & Baljer, 
2005). There is still a significant amount of work required to develop an easy to manufacture, 
safe to administer, and effective vaccine against Q fever.  
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1.7 Towards a second-generation vaccine 
 
A subunit vaccine is a vaccine containing only the antigens from a pathogen necessary to elicit 
a protective immune response. Due to the minimal set of antigens present it is likely that 
vaccines of this type are safer and produce far fewer adverse reactions. To develop a sub-unit 
vaccine, it is first necessary to identify those antigens recognised by the immune system during 
recovery from disease that lead to protection from subsequent infection. 
Attempts to identify immunoreactive proteins in C. burnetii have been described in the 
literature. The most common approach involves extracting the proteins from cultured C. 
burnetii, separating them on a two-dimensional electrophoresis gel, producing a Western blot 
of those proteins and finally performing an immunoassay on the blot with serum (containing 
antibodies) from patients or laboratory animals who have recovered from infection. Only a 
subset of the blotted proteins will react with the antibodies in the sera, and those proteins can 
be identified by various means such as mass spectrometry. This approach was the one taken 
by Coleman et al. (2007), Sekeyova et al. (2009), Deringer, Chen, Samuel, and Brown (2011), 
and (Xiong, Wang, Wen, Graves, & Stenos, 2012) which are discussed in more detail below. 
Coleman et al. (2007) probed immunoblots made from two-dimensional polyacrylamide gels 
(2D-PAGE) of cell culture-grown C. burnetii Crazy strain with sera from two human patients 
who had recovered from acute Q fever. The regions of the 2D-PAGE were analysed by mass 
spectrometry (MALDI-TOF/TOF) to identify the proteins present in the gel fragments. In this 
work, a total of ten immunoreactive proteins were identified. However, it has been reported 
that almost half of all single 2D-PAGE protein spots can contain multiple proteins (Kosaihira et 
al., 2009). It is possible that some proteins identified by this method could actually be another, 
perhaps more readily ionised, protein present in the same spot rather than the true 
immunoreactive species. In addition, the Crazy strain of C. burnetii is essentially a high passage 
laboratory strain of the organism with a large 31.5 kb deletion in its genome – larger than the 
26 kb deletion leading to the avirulent phenotype of the phase II strain of Nine Mile (Hoover et 
al., 2002; A. Moos & Hackstadt, 1987). The presence of these potential shortcomings in this 
work might mean the results presented are not wholly representative of wild type phase I C. 
burnetii strains. 
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Sekeyova et al. (2009) used a similar approach to identify 29 antigenic proteins. In this work 
the protein source was Nine Mile strain C. burnetii that had been propagated in cell culture. 
The article fails to mention the passage number, which is important as it has been 
demonstrated that organisms passaged in this manner as few as eight times have different 
antigenic properties (Hotta et al., 2002). The 2D-PAGE-isolated proteins were identified by 
MALDI-TOF/TOF MS so therefore this work is subject to the same limitations as the work 
described by Coleman et al. (2007) above. However, this work did identify two proteins 
associated with the chronic endocarditic form of the disease in humans; OmpH (CBU_0612) 
and argR (CBU_0480) which may lead to some novel serodiagnostic developments for 
example, permitting prediction of acute cases likely to progress to chronic disease in the 
future. 
Deringer et al. (2011) once again took a similar approach. In this work the C. burnetii used was 
Nine Mile strain and both phase I (egg cultured) and phase II (cell cultured) organisms were 
used. The sera used to probe the 2D-PAGE immunoblots was raised in guinea pigs by 
subcutaneous vaccination with inactivated whole-cell organisms. The natural route of infection 
with C. burnetii, however, is via the inhalation of an aerosol of infectious organisms. The route 
of delivery and the use of inactivated organisms in this study, may have led to the sera having 
reactions with proteins that are not present in natural infections or to a lack of reactions to 
proteins that would be present in a natural infection. The mass spectrometry in the work was 
performed by both ESI-TOF/TOF and nano-LC-ESI-MS/MS and, as expected by the use of this 
more refined MS system, multiple proteins were detected in many of the 2D-PAGE spots 
analysed. However, no second method was performed to validate which of the proteins 
present in the multiple proteins spots were the immunoreactive species. 
Xiong et al. (2012) further developed the 2D-PAGE spot picking methodology by identifying 
immunoreactive spots against the Xinqiao strain of C. burnetii, with sera from mice that were 
infected intraperitoneally with phase I C. burnetii as well as human patient sera. The picked 
spots were identified by a mixture of peptide mass fingerprinting (PMF) and ESI-MS/MS. 
However, identified proteins were validated by expression of the proteins in recombinant 
Escherichia coli, spotting the proteins onto microarrays, and assessing the activity of 56 patient 
sera and 25 negative (for C. burnetii activity) human sera against the recombinant proteins. 
This procedure is ideal for identifying proteins that, in their native conformations, can be used 
as diagnostic antigens. However, it might have failed to validate reactions with proteins where 
a non-conformational or linear epitope, such as those presented to components of the cellular 
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immune system on MHC molecules, was being recognised by the antibodies in the isolation 
and identification elements of the work. 
A different approach to identifying immunoreactive proteins uses a microarray constructed 
from recombinant proteins representing all of the predicted open reading frames in the C. 
burnetii genome. The recombinant proteins were produced either by in vitro protein 
transcription-translation (IVTT) or recombinant E. coli expression. These microarrays were then 
probed with panels of human patient and vaccinee sera (Beare et al., 2008; Vigil et al., 2010). 
This approach has the advantage that any proteins that do react with the sera are validated 
with regards to their precise identity, unlike in the MS identity methods where multiple 
proteins could be the possible reactive species present in a spot. However, this method is likely 
to fail to detect some reactions where conformational epitopes rather than linear epitopes in 
the proteins are being recognised or where the folded protein hinders antibody access to the 
epitope in question. In addition, because recombinant techniques do not use the precise 
protein translation and post-translational machinery as native C. burnetii or have the native 
molecular chaperones to ensure correct folding and conformation some of the native reactions 
may also be missed. Finally, any post-translational modifications made to proteins by the 
protein processing machinery present in wild-type C. burnetii will not necessarily be made by 
in vitro or recombinant in vivo systems (based on expression in a different microorganism). 
Chen et al. (2009) further evolved the protein evaluation methodology used for microarrays by 
measuring, using ELISA, human patient sera reactions against recombinantly expressed C. 
burnetii proteins. In addition, these workers vaccinated transgenic mice (expressing a human 
HLA DR4 molecule) with WCV and measured cellular immune responses using the ELISPOT 
technique (IFN-γ/CD4+ T-cell recall response). By directly measuring the recall response in this 
manner, reactions with non-conformational epitopes would have been seen. Unfortunately, 
only eleven proteins were examined in this study which is only a very small proportion of the 
immunoreactive proteins described to date in the literature.  
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Wang, Xiong, Graves, Stenos, and Wen (2013) produced a protein microarray consisting of a E. 
coli-expressed subset of the C. burnetii proteome concentrating on gene products implicated 
in adhesion, invasion, intracellular trafficking, host modulation, detoxification, and other 
virulence functions. They then screened the proteins with sera from mice that had been 
intraperitoneally infected with phase I Xinqiao strain organisms and from human patients. This 
work identified sixteen proteins that were major immunoreactive species in mouse; a subset 
of seven of these proteins was also reactive in human sera. This work is subject to similar 
criticisms as the other microarray-based protein discovery articles. 
1.8 Aims 
 
In order to provide more information about the proteins that may be involved in immunity 
against C. burnetii infection and how they might contribute to a second generation Q fever 
vaccine, this thesis will attempt to achieve the following aims: 
• To generate convalescent sera in an animal model, seeking to closely mimic the route 
of natural infection and the clinical manifestations of acute disease in humans. 
• To develop methods to use antibodies from those animal sera to isolate immune-
reactive protein species in C. burnetii. 
• To identify those isolated proteins. 
• To critically assess those proteins in terms of their potential as elements of a sub-unit 
Q fever vaccine. 
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1.9 Roadmap 
 
The next three chapters of this thesis will describe the practical elements of this project. In 
Chapter 2 the assessment of the virulence of the stocks of C. burnetii is described as well as the 
development of an assay to determine bacterial load. This chapter also describes the selection 
of the animal model and the generation of the convalescent sera. Chapter 3 discusses the 
generation of the C. burnetii protein lysates and the isolation of immunoreactive protein-
containing gel fragments by two complementary methods. Chapter 4 describes the extraction 
of peptides from the gel fragments and their identification by mass spectrometry.  
In the final chapter of this thesis, Chapter 5, a critical assessment of the identified proteins 
with regards to their suitability as potential subunit vaccine candidate components is 
undertaken. 
 
39 
 
2 In vivo Experiments 
2.1 Introduction 
 
Coxiella burnetii is an obligate intracellular organism and because of this, until very recently, it 
has only been possible to study the organism within living animal hosts. Host cell-free growth 
of the organism has been recently reported (Omsland et al., 2009), but the technique has yet 
to be fully exploited. Cell culture-based in vitro systems remain limited in the study of C. 
burnetii due to the reversion of the organism to an avirulent phase II form (characterised by 
the loss of the phase I LPS phenotype) within a short period of time in these systems (Baca et 
al., 1981). In nature, C. burnetii has been detected throughout the animal kingdom (Babudieri, 
1959) including wild and domesticated mammals, and invertebrates such as ticks. Animals are 
often asymptomatic despite chronic infection. To generate representative immune-reactive 
sera for this project it was necessary to attempt to model the symptoms seen in acute human 
Q fever disease in humans in small laboratory animal species. The key features of human 
disease are that the major mode of infection is by the inhalation of contaminated aerosols 
(Angelakis & Raoult, 2010; Raoult et al., 2005); that the organism needs to be in the wild-type 
virulent phase I form (Angelakis & Raoult, 2010) and; the disease itself is characterised by a 
fever that may reach a plateau of 40 °C before returning to normal (Angelakis & Raoult, 2010). 
Further, relatively common disease features include pneumonia and hepatitis (Angelakis & 
Raoult, 2010).  
Of the small animal models reported in the literature, the mouse and guinea pig were the most 
appropriate, in terms of practicality, for a research project of this scope. 
 
2.1.1 Mouse models of acute Q fever 
Mice have been used to study C. burnetii (Perrin, 1942) since the discovery of the organism in 
1937 (Derrick, 1937). Generally, they are not reported to display overt febrile disease to the 
degree seen in man and it is often reported that there are minimal signs of infection in 
laboratory mice (Franti, Behymer, Goggin, & Wright, 1974; Perrin, 1942). As in other models, 
pneumonia is observed after intranasal and aerosol exposure but not after intraperitoneal 
injection (Franti et al., 1974; Perrin, 1942). The majority of reports suggest that splenomegaly 
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and change in weight, followed by confirmation of seroconversion, are the most reliable 
markers of infection in mice. In an evaluation of 47 strains of inbred laboratory mice, 33 were 
found to be resistant to infection with C. burnetii, 10 partially susceptible and 4 susceptible (G. 
H. Scott, Williams, & Stephenson, 1987). The A/J strain of mouse was found to have the 
highest mortality (70%), but could still be protected by vaccination with formalin-inactivated C. 
burnetii whole-cell vaccine (G. H. Scott et al., 1987). The BALB/c strain of mouse was also 
reliably infected and displayed some overt signs of illness, including ruffled fur and lethargy in 
all members of the group, but with no fever (G. H. Scott et al., 1987).  
In mouse models, as in humans, the male sex is associated with more severe signs of infection 
(Franti et al., 1974; Leone et al., 2004). One study established a protective role of 17β-
estradiol, the primary female sex hormone, (Leone et al., 2007) that could partially explain why 
males suffer more severe clinical disease than females despite similar seropositivity rates. The 
presence of 17β-estradiol was found to be correlated with lower bacterial loads and a lesser 
degree of granuloma formation (Leone et al., 2007). Recent studies using microarray analysis 
found that 86 % of the genes probed were differentially expressed in infected male and female 
mice (Textoris et al., 2010). Of those genes, 60 % were due to sex hormones. Perhaps 
surprisingly, many of the genes that appeared to play a role in protection of female mice from 
severe disease were involved in the circadian rhythm clock (Textoris et al., 2010). 
Mice have become the model of choice for research investigating the immunology of Q fever 
due to the availability of mouse strains with specific immunological lesions, coupled with the 
availability of reagents and antibodies for the characterisation of their immune responses 
(Andoh, Russell-Lodrigue, Zhang, & Samuel, 2005; Andoh et al., 2007; Kishimoto, Rozmiarek, & 
Larson, 1978; Ochoa-Reparaz, Sentissi, Trunkle, Riccardi, & Pascual, 2007). 
 
2.1.2 Guinea pig models of acute Q fever 
Guinea pigs were recognised early in the study of C. burnetii, as being an effective model for 
the disease course of Q fever in man (Lillie, 1942). With the exception of immunocompromised 
breeds of mouse, guinea pigs have been found to be consistently more susceptible to infection 
than mice (G. H. Scott, Burger, & Kishimoto, 1978). Early studies concentrated on 
intraperitoneal challenge as the route of infection (Handley, Paretsky, & Stueckemann, 1967; 
Heggers, Billups, Hinrichs, & Mallavia, 1975; Lillie, 1942; Paretsky, Downs, & Salmon, 1964; 
Paretsky & Stueckemann, 1970; Thompson & Paretsky, 1973). As in man, a pronounced fever 
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(with some strains resulting in temperatures of > 40 °C) is produced (Heggers et al., 1975; Lillie, 
1942; Paretsky et al., 1964). Granulomas are observed in the liver, spleen, and bone marrow 
(Heggers et al., 1975; Lillie, 1942). The animals also suffer from a marked weight loss (Paretsky 
et al., 1964). 
The model was later refined to use small particle aerosol delivery to replicate more realistically 
the natural route of infection (Kishimoto, Johnson, et al., 1978; La Scola, Lepidi, & Raoult, 
1997; Russell-Lodrigue, Zhang, McMurray, & Samuel, 2006). This route of infection is reported 
to lead to greater lung and less liver pathology than the intraperitoneal route (La Scola et al., 
1997). In addition to fever and weight loss, animals also display a clear pneumonia when 
exposed by this route (Russell-Lodrigue et al., 2006). As few as twenty organisms, determined 
by an optical density measurement method, were found to cause acute Q fever in this model 
(Russell-Lodrigue et al., 2006), which is comparable to the doses predicted to be infectious in 
humans by mathematical modelling (Brooke, Kretzschmar, Mutters, & Teunis, 2013) . 
In conclusion, while the mouse model has been used in many more studies than guinea pigs, it 
lacks several critical features of human infection. The lack of fever, fewer overt signs of disease 
and the lower susceptibility to infection in the mouse means that, of the small animal models 
for human acute Q fever, the guinea pig with organisms delivered via an inhaled aerosol can be 
regarded as the superior model. 
 
2.1.3 In vitro enumeration of Coxiella burnetii organisms 
The traditional method for counting or enumerating bacteria is to apply dilutions of a bacterial 
suspension to a solid growth media in Petri dishes, to allow the bacteria to grow to form visible 
colonies and to count those colonies. By back-calculation an estimate of the number of 
bacteria present in the original suspension can be made (B. D. Davis, 1990b). However, due to 
the obligate intracellular nature of C. burnetii (ie. it doesn’t grow in conventional culture 
media), enumeration of the organism is subject to many technical difficulties. Until recently, 
most studies performed estimation of median lethal or infectious dose endpoints in chick 
embryos (Riley, Campbell, & Patrick, 1964; Wike, Tallent, Peacock, & Ormsbee, 1972), mice 
(Schneider, Ehrlich, Yamashiroya, & Miller, 1966; Wike et al., 1972), immunocompromised 
mice (Andoh et al., 2003), guinea pigs (Wike et al., 1972) or plaque assays in primary chick 
embryo cell cultures (McDade & Gerone, 1970; Wike et al., 1972). The median endpoint 
estimation methods were not considered appropriate for this project because of ethical 
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considerations of using mice or guinea pigs as a means to enumerate organisms where 
adequate in vitro alternatives exist. The plaque assay methods all require primary cell cultures 
which are difficult to obtain as they must be derived from living animal tissues close to the 
point of use, in addition the results derived from these assays have been reported to be time-
consuming and difficult to reproduce (Baca & Paretsky, 1983; R. Ormsbee, Peacock, Gerloff, 
Tallent, & Wike, 1978).  
Real-time quantitative PCR (qPCR) has been proposed as an alternative to the median 
endpoint estimation in mice (Howe et al., 2009). In all polymerase-chain reaction (PCR)-based 
methods, a pair of synthetic oligonucleotides (primers) that hybridise (sequence-specific 
binding) to target DNA within a gene of interest, along with free nucleotides and a 
thermostable DNA polymerase are used to amplify the gene of interest. This is achieved by 
cycling the temperature through denaturation (separation of double-stranded DNA into single 
stranded DNA), annealing (cooling the reaction to a point where the primers bind to their 
specific sequences), and extension (heating the reaction to the optimum temperature for the 
polymerase, such that complementary DNA is produced by primer extension) – such that two 
complementary copies of the gene of interest are produced. PCR  is typically performed over 
30-40 cycles of the this temperature protocol resulting in exponential amplification of the gene 
of interest (Mackay, Mackay, Nissen, & Sloots, 2007). In the conventional form of PCR just 
described the assay is merely qualitative (presence or absence of the gene of interest), to 
make the assay quantitative two elements need to be added, namely; a fluorogenic probe and 
a quantitation standard. The fluorogenic probe used in the majority of C. burnetii studies is a 
TaqMan probe (a modified oligonucleotide), this has a fluorescent reporter at the 5’ 
(upstream) end of the probe and a quencher at the 3’ (downstream) end, this probe is 
designed so that is situated in the “path” of the extension of either the forward or reverse 
primer of a conventional PCR. In its native conformation the probe’s reporter signal is 
quenched by the quencher such that no signal is detected by the qPCR instrument. During 
amplification the polymerase that is extending DNA from a primer collides with the bound 
probe and through the action of a 5’ exonuclease activity, breaks up the probe such that the 
fluorescent reporter becomes free in the reaction solution – this can be detected by the qPCR 
instrument. During each cycle of the PCR, more and more reporter dye is freed in this manner 
giving an increasing fluorescent signal. The point at which this signal is detected (is detected 
above the background threshold) is referred to as the Ct value (Mackay et al., 2007). By 
performing parallel reactions with a sample of DNA containing a copy of the gene/region of 
interest for which the quantity is known, a standard curve can be generated of Ct value versus 
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quantity. By comparing Ct values of test/unknown samples with the standard curve the qPCR 
instrument can report quantities in terms of copies/ml of the target DNA (Mackay et al., 2007). 
In a study directly comparing qPCR endpoint estimation in CD-1 mice, the qPCR assay was 
found to give results not significantly different and with four times smaller measurement 
variation for purified organism preparations and in non-human primate (NHP) blood samples 
(Howe et al., 2009). The conclusion of the authors was that “Real-time PCR assays represent a 
significant improvement over the cumbersome bioassay, providing equal or better results in 
hours rather than weeks while avoiding the use of animal models.” (Howe et al., 2009, p. 131). 
Therefore, for this project, a qPCR assay was developed and used as the sole quantification 
assay. 
The literature describes over twenty different qPCR assays for C. burnetii (Brouqui, Rolain, 
Foucault, & Raoult, 2005; Howe et al., 2009; Jones, Hertwig, et al., 2011; Kersh et al., 2010; 
Klee et al., 2006; Loftis et al., 2006; Marmion et al., 2005b; Mediannikov et al., 2010; Muskens, 
van Engelen, van Maanen, Bartels, & Lam, 2011; Panning et al., 2008; Schneeberger et al., 
2010; Tilburg et al., 2010; G. Q. Zhang, To, Yamaguchi, Fukushi, & Hirai, 1997) fifteen of which 
target the IS1111 element of the C. burnetii genome (Hoover, Vodkin, & Williams, 1992) and a 
further two assays target the IS30a element (Brouqui et al., 2005; Mediannikov et al., 2010). 
These two regions are insertion sequences present in a variable number of copies in the 
genome. Due to the fact that there are between 7 and 110 copies of these genes per bacterial 
cell (Klee et al., 2006) and absent altogether in some clinical isolates (Marmion et al., 2005b) 
these targets are better suited to highly sensitive detection assays but be more likely to 
adversely affect the accuracy and precision of quantitation assays. Therefore, for this project a 
single-copy gene target was considered more desirable. 
Several single-target assays have been reported in the literature; the outer membrane protein 
gene (Com1) (Howe et al., 2009; Jones, Twomey, et al., 2011; Kersh et al., 2010; Marmion et 
al., 2005b), the isocitrate dehydrogenase gene (icd) (Klee et al., 2006), and the 16s rRNA gene 
(Marmion et al., 2005b). Of these, the Com1 gene has been suggested to be genus specific but 
the icd gene to be species specific for C. burnetii (Lee et al., 2004). In addition, the icd target 
has been given a more thorough validation by the analysis of 75 different C. burnetii isolates 
and 31 non-Coxiella micro-organisms in addition to the statistical determination of detection 
limits (Klee et al., 2006). However, the assay described uses the older TaqMan probe 
quenching technology utilizing the fluorescing quencher, TAMRA, at the 3’ end of the probe. 
Due to the fluorescing nature of the TAMRA quencher, background signal is higher reducing 
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the fidelity of the qPCR assay. In addition, the use of the minor-groove binding aspect of the 
non-fluorescing quencher molecule allows probes to be designed shorter – and are thus more 
specific (Afonina, Reed, Lusby, Shishkina, & Belousov, 2002). Therefore, a more modern assay 
using a minor-groove binding/non-fluorescing quencher would potentially offer improvements 
to the assay. 
 
2.1.4 Aims 
The aims of this chapter are listed below: 
• Develop a qPCR assay to detect and enumerate C. burnetii in tissue, blood and culture 
samples. 
• Assess which of the two available C. burnetii stocks are more virulent in the guinea pig 
model. 
• Perform an aerosol infection study to determine the most appropriate animal model 
for reproducing clinical disease and to generate convalescent anti-sera for subsequent 
work. 
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2.2 Materials and Methods 
 
2.2.1 Real-time quantitative PCR assay 
2.2.1.1 Primer and probe design 
The full genome sequences of the five available C. burnetii strains were downloaded from the 
nucleotide database at the National Centre for Biotechnology Information (NCBI). The nucleic 
acid sequence for the icd genes were extracted from each using the DNASTAR Lasergene v7 
software (Table 2.1). The sequences were then aligned in the DNASTAR MegAlign module 
using the ClustalW algorithm (Larkin et al., 2007). The resultant consensus sequence generated 
was used in the ABI Primer Express v3 software package to generate three primer and MGB 
probe sets. These primers and probes were subjected to Basic Local Alignment Search Tool 
(BLAST) analysis (Altschul et al., 1997) against the database; “all GenBank+EMBL+DDBJ+PDB 
sequences (but no EST, STS, GSS, environmental samples or phase 0, 1 or 2 HTGS sequences)” 
consisting of 14,201,828 sequences to search for similarities to published sequences to allow 
any cross-reacting sequences to be excluded prior to synthesis. 
Table 2.1 - C. burnetii nucleotide sequences used to produce nucleotide alignments of the icd gene and generate 
consensus sequence for qPCR primer and probe design. 
C. burnetii strain NCBI accession number Nucleotide range extracted 
for icd gene 
RSA 493 (Nine Mile) AE016828 1,142,958 to 1,144,244 
RSA 331 (Henzerling) NC_010117.1 1,225,446 to 1,226,729 
Dugway 5J108-111 NC_009727.1 1,274,417 to 1,275,703 
CbuG_Q212 NC_011527.1 784,854 to 786,140 
CbuK_Q154 NC_011528.1 1,015,839 to 1,017,125 
 
2.2.1.2 Quantitation control plasmid design 
To produce a piece of DNA capable of functioning as a quantitation control in a qPCR it was 
decided that a plasmid, containing a copy of the amplification target would be the most 
convenient and economical to produce. Therefore, a nucleotide sequence was designed in 
silico for synthesis and insertion into a plasmid vector using the DNASTAR EditSeq module. In 
addition to containing the three icd gene targets described above, the target sequences with 
approximately twenty nucleotides of flanking context sequence for several other C. burnetii 
assays was also inserted to create maximum future value of the control plasmid. The targets 
designed into the plasmid insert are shown in Table 2.2. 
46 
 
Table 2.2 - All qPCR targets that were designed into the pCox quantitative control plasmid synthetic insert. The 
icd1, icd2 and icd3 (icd – isocitrate dehydrogenase gene) targets were designed and validated within this project. 
Other targets were added to allow future utility of the control plasmid for quantitation (sod – superoxide 
dismutase gene, and 16s RNA) and for more sensitive detection of the variable/multi-copy target is1111 (an 
insertion sequence present in a variable number of copies in C. burnetii isolates). 
Target 
Sequence 
5’ – 3’ 
Reference 
sod Forward Primer tcttcaacaatgcagcacaacat Designed in-house  
(not this study) Reverse Primer tgaagccaattcgccagaa 
Probe 6FAM-
cattttattggcactgcatgagccctg – 
BHQ1 
icd1 Forward Primer ggagatgggattggcattga Designed in-house 
(this study) Reverse Primer cggcatcgaccacgtttt 
Probe (MGB) 6FAM - atcacgcccgtcatg – 
MGBNFQ 
icd2 Forward Primer gttcccagccaaggtgaaaa Designed in-house 
(this study) Reverse Primer gggtcggtcaggaacttctaaa 
Probe (MGB) 6FAM – atcaccgttaataaagc – 
MGBNFQ 
icd3 Forward Primer tgctccgggcgctaatt Designed in-house 
(this study) Reverse Primer tgtcccatgagtggcttcaa 
Probe (MGB) 6FAM – cgacaccgtcggtct – 
MGBNFQ 
is1111 Forward Primer aaaacggataaaaagagtctgtggtt (Schneeberger et al., 
2010) Reverse Primer ccacacaagcgcgattcat 
Probe 6FAM - aaagcactcattgagcgccgcg 
- TAMRA 
16s 
rRNA 
gene 
Forward Primer ggataacctggggaaactcg* (Marmion et al., 
2005b) Reverse Primer ggctcatcttatagcacgaggtc 
Probe 6FAM - cataatctctttggagcaa - 
TAMRA 
* This sequence differs from that published as the order of the 3’-terminus two bases was 
incorrect; published errata (Marmion et al., 2005a). 
 
In total, the synthetic insert consisted of 709 nucleotides; this was annotated in the DNASTAR 
MapDraw module to show where the targets occur including the exact location of the primers 
and probes. This sequence was synthesised by GeneArt and inserted into a pMK-T plasmid 
backbone. The plasmid control was given the name pCox. 
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2.2.1.3 Quantitation control plasmid linearisation 
The pCox plasmid DNA was re-constituted in 50 µl of molecular biology grade water (from here 
on called water) as per GeneArt’s instructions. In nature, the genomic DNA of C. burnetii is not 
found in a circular, supercoiled state such as that found in a plasmid, therefore the plasmid 
was linearised by restriction endonuclease digestion at the single KpnI site of the plasmid. By 
linearising the plasmid the supercoiled structure was broken down and the plasmid DNA 
becomes more representative of the C. burnetii genome. Ten 19 µl reactions were set up as 
shown in Table 2.3; a single negative control (undigested) was also set up by replacing the KpnI 
enzyme with water. To each of the ten remaining reactions was added approximately 100 ng 
(1 µl) of the pCox plasmid. The reactions were incubated at 37 °C for 2 h and the products 
electrophoresed on 7 cm square 1.0 % (w/v) Agarose/TAE buffer gels containing 0.5 µg/ml 
ethidium bromide at 100 V for 1 h. The gel was then visualised and photographed using an 
ultraviolet light (302 nm) transilluminator. 
Table 2.3 - Reaction constituents of restriction endonuclease reaction for linearisation of the pCox plasmid. 
Component Volume (µl) 
Kpn I – 10 units/µl (Promega R6341) 1 
Buffer J - 10X concentrate 2 
Acetylated BSA, 10 µg/µl 0.2 
Molecular Biology Grade water 15.8 
 
2.2.1.4 Purification and precipitation of linearised plasmid pCox 
All ten digestion reactions were pooled into one tube (~200 µl) and an equal volume of 
phenol:chloroform:Isoamylalcohol  (25:24:1) was added, the sample was then mixed by 
vortexing. 
A MaXtract High Density gel (QIAGen #129056) phase-separation tube was prepared by 
centrifuging at 16,000 x g for 5 min. The digestion reaction mixed with phenol:chloroform:IAA 
was added to the phase-separation tube and centrifuged at 16,000 x g for 10 min. The 
supernatant was aspirated and retained into a fresh 2 ml tube. To recover any residual plasmid 
DNA, 50 µl of phenol:chloroform:IAA  mixed with 50 µl water was added into the phase-
separation tube. This was centrifuged again at 16,000 x g for 10 min and supernatant was 
pooled with sample. The total sample size of the purified linear plasmid DNA was 250 µl. 
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To precipitate the DNA, a 1:10 volume of 3 M (pH = 5.2) sodium acetate salt (25 µl) was added 
to the sample and mixed by vortexing. The DNA was precipitated out of solution by adding 2.5 
volumes (687.5 µl) of molecular biology grade ethanol at -20 °C and mixed. Samples were 
stored at this point at -20 °C overnight.  
The precipitated linearised plasmid DNA was centrifuged at 16,000 x g for 30 min to pellet the 
precipitated DNA. The ethanol was aspirated and discarded, leaving the pellet. The pellet was 
washed in 70 % (v/v) aqueous ethanol and centrifuged at 16,000 x g for 5 min. The ethanol was 
aspirated and discarded; the pellet was then dried in a vacuum centrifuge at 60 °C for 5 min. 
The DNA was re-suspended in 25 µl of water. DNA concentration (absorbance at 260 nm) and 
purity (260/280nm ratio) were assessed spectrophotometrically using a NanoDrop ND-2000 
instrument zeroed on water. 
The plasmid DNA was diluted to 1 x 107 copies/µl in water and stored at -20 °C in single-use 30 
µl aliquots. This material was used as the standard calibrator for all qPCR assays performed 
throughout this project. 
 
2.2.1.5 Coxiella icd primer/probe evaluation 
An initial evaluation of the amplification of the three icd primer/probe sets was assessed by 
preparing a decimal dilution series of pCox from 1 x 107 copies/µl down to 1 x 101 copies/µl 
and performing real-time PCR reactions in duplicate with all three primer/probe sets.  
The reaction mix is shown in Table 2.4, three mixes were prepared, one for each of the three 
icd primer/probe sets. Into a PCR 96-well reaction plate, all the wells of two rows for each 
primer/probe set was loaded with 18 µl of appropriate reaction mix. The dilutions of pCox 
were added in duplicate to each of the three reaction mixes, 2 µl per well. The reaction plate 
was sealed with an optical sealer, loaded into an ABI 7500 Fast real-time PCR instrument and 
subjected to 95 °C for 20 s followed by 40 cycles of 95 °C for 3 s and 60 °C for 30 s. The 
instrument read the fluorescence (FAM dye filter) in all wells at the end of each 60 °C step. 
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Table 2.4 - Real-time PCR master-mix for icd assay (TaqMan chemistry). 
Component Volume (µl) 
(1 x rxn) 
2 x Mastermix concentrate  
(ABI TaqMan Fast PCR #4352042) 
10 
Water 5 
Sense primer (18 µM concentration) 1 
Anti-sense primer (18 µM concentration) 1 
Dual-labelled probe (5 µM concentration) 1 
 
Visual inspection of the graphical output of the amplification plots from the instrument and 
the cycle-threshold crossing (Ct) values were used to select the optimal primer/probe set. 
Briefly, steeper slopes and higher plateau of the qPCR fluorescent signal indicated higher 
amplification efficiency and lower Ct values for a given DNA concentration indicated greater 
sensitivity and efficiency. 
 
2.2.1.6 Sensitivity determination of primer/probe set icd2 
Probit analysis has been reported as a method of determining the detection limit of qPCR 
assays at a desired confidence level (Klee et al., 2006). To provide the data for this analysis 
pCox was diluted in the series; 200, 20, 10, 2, and 0.2 copies per reaction. Over three separate 
qPCR runs, using the mastermix and thermal parameters described previously, 10 reactions 
each of 200 and 20 copies/reaction, 20 reactions of 10 copies/reaction, and 30 reactions each 
of 2 and 0.2 copies/reaction were analyzed. The Probit analysis requires binary input data, 
therefore Ct values less than 40 were coded as a 1 (detected) and an ‘undetermined’ result as 
a 0 (not-detected). A Probit analysis was carried out using the MiniTab v16 software package 
assuming a Normal distribution. 
All qPCR measurements and analyses performed throughout the remains of this project were 
performed with the icd2 primer set. 
 
2.2.1.7 Efficiency determination of PCR 
The efficiency of a PCR reaction is how close to the theoretical exponential production of 
amplified target sequence a given assay’s performance is, an efficiency of one being an assay 
close to exponential and an efficiency of zero being an assay that does not amplify. 
Determination of qPCR efficiency has been described (Klee et al., 2006) and the method 
50 
 
replicated here. Briefly the number of copies of the pCox control were correlated in linear 
regression (MiniTab v16 software) with the output Ct values. The slope of the calculated 
regression line was used in the equation shown below to calculate the efficiency. 
 = 	10( ) − 1 
 
2.2.2 Virulence assessment of Coxiella burnetii stocks 
To investigate whether C. burnetii from stored stocks were virulent in an animal model, guinea 
pigs were infected by intraperitoneal injection with 1.5 x 107 copies/ml of the inocula 
described below (determined by qPCR). They were then monitored for disease symptoms. 
The two inocula assessed were: 
1. Coxiella burnetii, Nine Mile strain (EP2, GP1) – Spleen homogenate (produced in BIG study 
reference 4334). 
2. Coxiella burnetii, Nine Mile strain (EP2, GP1 EP1) – 30 % Egg yolk sack homogenate 
(produced in study – dstl BSC11-05). 
 
Male Dunkin-Hartley guinea pigs, four for each of the two inocula were used. Each animal was 
fitted with a subcutaneous implant for identification and temperature monitoring purposes 
(Animalcare identichip with Bio-Thermo #XID050). The animal group allocations are shown in 
Table 2.5. The animals’ weight, temperature, and general health were recorded twice daily for 
two days prior to inoculation and four times daily post inoculation. Any animals with a 
bodyweight loss of greater than 20 % or with severe disease symptoms were euthanized in 
accordance with the requirements of Home Office project licence 30/2423. 
Table 2.5 – Virulence assessment experiment: Guinea pig identities, group allocations and challenge material 
used during the virulence assessment experiment. Individual animal identities are of the form Vx-y; V=virulence 
assessment, x=group identifier; y=individual animal identifier. Eg. V2-3 is individual 3, in group 2 of the virulence 
experiment. 
Group 1 2 
Group ID V1-1, V1-2, V1-3, V1-4 V2-1, V2-2, V2-3, V2-4 
Challenge material 1 – Spleen Homogenate 2 – Yolk Sac Homogenate 
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At each euthanasia or at experiment end, autopsy was performed, spleens removed and 
weighed to assess whether splenomegaly could be used as a measure of disease severity, and 
blood was collected into EDTA-blood, heparin and serum-separation tubes. Spleens were 
homogenised using a GentleMACS homogeniser into 15 ml of PBS. DNA was extracted from 
200µl of the homogenates and a 1:10 dilution of each spleen homogenate (in PBS) and from 
200µl each of EDTA-blood, heparin-blood, and clotted serum from each animal. qPCR was 
performed on these DNA extracts. 
DNA Extractions on all blood and body fluids was performed using the QIAamp DNA Blood Mini 
Kit (QIAgen #51106) and DNA Extractions on all tissue and yolk sack homogenates was 
performed using the QIAamp DNA Mini Kit (#51306) as per the supplied protocols. 
Analysis of spleen weight and thus splenomegaly assessment was performed using MiniTab 
v16 software package using the t-test. 
 
2.2.3 Aerosol infection of guinea pigs and two strains of mouse 
The two primary purposes of this experiment were; to investigate whether bacteria from the 
egg yolk sack-grown C. burnetii working stock was able to produce and model human disease 
in guinea pigs and mice after small particle aerosol exposure, and to generate convalescent 
antisera for the identification of immune-reactive proteins in subsequent work.  
The challenge substance was the egg yolk sack grown Coxiella burnetii, Nile Mile strain from 
study DSTL-BSC-05, designated batch EP2 GP1 EP1. This material was previously identified as 
virulent in guinea pigs, via the intraperitoneal route (see Section 2.3.2). 
Seven Dunkin-Hartley guinea pigs and two strains of mice (7 x BALB/c and 7 x A/J), all male, 
were used in this experiment. Each animal was implanted with a subcutaneous identification 
and temperature monitoring chip (Animalcare identichip with Bio-Thermo #XID050). The 
animal group allocations are shown in Table 2.6. The animals’ weight, temperature, and 
general health were recorded twice daily for two days prior to aerosol challenge and four 
times each day post-challenge. Any animals with a bodyweight loss of greater than 20 % or 
with severe disease symptoms were euthanized in accordance with Home Office project 
licence 30/2423. 
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Table 2.6 – Aerosol Infection Experiment: Guinea pig and mouse identities with group allocations used during the 
aerosol infection experiment. Individual animal identities are of the form Ax-y; A=aerosol infection experiment, 
x=group identifier; y=individual animal identifier. Eg. A2-6 is individual 6, in group 2 of the aerosol exposure 
experiment. 
Group 1 2 3 
Group ID A1-1, A1-2,  
A1-3, A1-4,  
A1-5, A1-6 
A1-7 A2-1, A2-2,  
A2-3, A2-4,  
A2-5, A2-6 
A2-7 A3-1, A3-2,  
A3-3, A3-4,  
A3-5, A3-6 
A3-7 
Species Guinea pig Mouse (BALB/c) Mouse (A/J) 
Aerosol 
challenge 
C. burnetii None.  
 
Unexposed 
control 
C. burnetii None  
 
Unexposed 
control 
C. burnetii None 
 
Unexposed 
control 
 
Aerosol exposures were performed with the run parameters described in Table 2.7 using a 
Biaera (AeroMP) modified Henderson apparatus (Druett, 1969) contained within a flexible film 
isolator. A schematic of the system is shown in Figure 2.1. Animals were placed in restraining 
tubes, which were then inserted, nose only, into the sow (exposure section) of the Henderson 
apparatus. The apparatus is designed such that animals inspire a consistent small particle 
aerosol of the infectious agent and simultaneously the airflow is split so that air samples of the 
material being presented to the animals can be taken. DNA was extracted from the nebuliser 
and the air sampler after the exposures and quantitated by qPCR to determine titres and to 
back-calculate the inhaled dose.  
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Table 2.7 - Biaera (AeroMP) parameters for the aerosol exposure of animals to C. burnetii. Showing the 
nebulisation parameters, the flow rate and collection medium used in the aerosol sampler, and the exposure 
time. 
Chamber description 
Total system flow 25 l/min 
Aerosol Generators 
Type 6-jet Collison Nebuliser 
Flow 15 l/min 
Generator 1 C. burnetii homogenate 
Generator 2 Water 
Sampler 
Type All-glass impinger (AGI-30) 
Flow 6 l/min 
Collection medium PBS 
Humidity set point 65 % 
Run Cycle 
Run time 10 min 
Generator 1  ON 
Generator 2 OFF 
Sampler  ON 
Purge Cycle 
Run time 30 s 
Generator 1  OFF 
Generator 2 ON 
Sampler  OFF 
 
 
Figure 2.1 - The small animal configuration of the AeroMP-Henderson. The compressor, vacuum pump and 
AeroMP control unit are sited outside of the containment isolator. The required flow and electrical connections 
pass through the service panel into the flexible film isolator to connect to delivery system. Conditioned airflow 
from the AeroMP control unit enters the isolator through a single HEPA filter where it is mixed in the piccolo with 
the challenge aerosol from a Collison nebuliser. The challenge aerosol flows into the exposure chamber/sow. A 
sample of aerosol is collected via an impinger before returning to the AeroMP control unit through two HEPA 
filters. This airflow circuit allows the control of the relative pressure of the sow compared to the isolator.  
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At the end of the study, (days 15 and 21 post-exposure respectively) two blood samples of 2 ml 
volume were taken under terminal anaesthesia by cardiac puncture from guinea pigs and 
placed into EDTA and SST blood tubes. Any remaining blood was placed into a Heparin tube. 
For mice, the blood samples were taken as for guinea pig but were divided equally between 
paediatric EDTA and SST blood tubes. 
In addition, the following organs were harvested for qPCR analysis; spleen, kidney, liver, heart, 
lung and testicle. For the qPCR, approximately 1/3 of the total organ mass was removed from 
each organ. DNA was extracted and qPCR performed (as described in Sections 2.2.1.5 and 
2.2.2). 
All temperature and weight change data (calculated in Microsoft Excel as a percentage of the 
two days pre-challenge average weight of all seven animals) were plotted graphically. For the 
weight change data linear regression was performed in MiniTab v16 and, where the regression 
suggested there may be a difference in the rate of weight gain, an analysis of covariance 
(ANCOVA) was performed (MiniTab v16) to test the statistical significance of any observed 
differences. 
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2.3 Results 
 
2.3.1 Real-time quantitative PCR assay 
Figure 2.2 shows the nucleotide alignments used to generate the consensus sequence that was 
used during primer/probe design. In the figure it can be seen that the forward primer of icd2 
has a mismatch from the Q212 strain of C. burnetii, this was deemed unlikely to cause practical 
problems for the assay because the mismatch is more than seven nucleotides distant from the 
3’ end of the primer and also, the strain used throughout this work was the type strain 
(RSA493-Nine Mile). Similarly the mismatch in the icd1 forward primer was not deemed of 
concern due to it being from the Q212 strain, despite being closer to the 3’-end of the primer. 
However the mismatch in the icd1 probe, although being almost on the 5’-end, was against the 
strain used in this work. The icd3 primer/probe set had no mismatches to any of the 5 
sequences in the alignment. 
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Figure 2.2 - Nucleotide alignment of part of the icd gene of four strains of C. burnetii (Q212, Q194, Dugway, 
RSA331, and the type strain RSA493 – Nine Mile) showing the positions of the three primer/probe sets (coloured 
in the consensus sequence) designed for the real-time quantitative PCR assay (forward (fwd) primers in blue, 
probe oligonucleotides (prb) in red, and reverse (rev) primers in green). Mismatches from the consensus 
sequence are illustrated by a contrasting background colour.  
 
The BLAST results (not shown due to the size of the output) showed that all primers and 
probes were highly specific for the icd genes of C. burnetii sequences.  Where there were 
matches in the genomes of non-Coxiella organisms, no corresponding match (within a 
kilobase) was seen in the other two primers/probes for that assay and therefore no product 
would be amplified or detected for those sequences. 
The insert of the pCox control plasmid annotated with the positions of all the synthetic target 
sequences are shown in Figure 2.3.  
The linearisation of the pCox plasmid by KpnI restriction endonuclease digestion can be seen in 
the gel image (Figure 2.4). The purified and precipitated linearised plasmid spectrophotometry 
results and the derived concentration in copies/µl (sometimes called genomic equivalents (GE) 
in the literature) are also shown (Table 2.8 and calculations beneath it). 
Q212         1 ATGACGGAGTTAACCGGAGTATCCATCGTGACTTACCAACACATCAAAGTTCCCAGCGAAGGTGAAAAAA 
Q194         1 ATGACGGAGTTAACCGGAGTATCCATCGTGACTTACCAACACATCAAAGTTCCCAGCCAAGGTGAAAAAA 
Dugway       1 ATGACGGAGTTAACCGGAGTATCCATCGTGACTTACCAACACATCAAAGTTCCCAGCCAAGGTGAAAAAA 
RSA331       1 ATGACGGAGTTAACCGGAGTATCCATCGTGACTTACCAACACATCAAAGTTCCCAGCCAAGGTGAAAAAA 
RSA493       1 ATGACGGAGTTAACCGGAGTATCCATCGTGACTTACCAACACATCAAAGTTCCCAGCCAAGGTGAAAAAA 
consensus    1 ATGACGGAGTTAACCGGAGTATCCATCGTGACTTACCAACACATCAAAGTTCCCAGCcAAGGTGAAAAAA  
                                                         icd2 fwd 
Q212        71 TCACCGTTAATAAAGCCGTTTTAGAAGTTCCTGACCGACCCATTATTCCCTTTATCGAAGGAGATGGGAT 
Q194        71 TCACCGTTAATAAAGCCGTTTTAGAAGTTCCTGACCGACCCATTATTCCCTTTATCGAAGGAGATGGGAT 
Dugway      71 TCACCGTTAATAAAGCCGTTTTAGAAGTTCCTGACCGACCCATTATTCCCTTTATCGAAGGAGATGGGAT 
RSA331      71 TCACCGTTAATAAAGCCGTTTTAGAAGTTCCTGACCGACCCATTATTCCCTTTATCGAAGGAGATGGGAT 
RSA493      71 TCACCGTTAATAAAGCCGTTTTAGAAGTTCCTGACCGACCCATTATTCCCTTTATCGAAGGAGATGGGAT 
consensus   71 TCACCGTTAATAAAGCCGTTTTAGAAGTTCCTGACCGACCCATTATTCCCTTTATCGAAGGAGATGGGAT 
        icd2 prb    icd2 rev          icd1 fwd 
Q212       141 TGGTATTGATATCACGCCCGTCATGAAAAACGTGGTCGATGCCGCCGTGGAAAAATCCTACGCTGGAAAG 
Q194       141 TGGCATTGATATCACGCCCGTCATGAAAAACGTGGTCGATGCCGCCGTGGAAAAATCCTACGCTGGAAAG 
Dugway     141 TGGCATTGATATCACGCCCGTCATGAAAAACGTGGTCGATGCCGCCGTGGAAAAATCCTACGCTGGAAAG 
RSA331     141 TGGCATTGATATCACGCCCGTCATGAAAAACGTGGTCGATGCCGCCGTGGAAAAATCCTACGCTGGAAAG 
RSA493     141 TGGCATTGATATCGCGCCCGTCATGAAAAACGTGGTCGATGCCGCCGTGGAAAAATCCTACGCTGGAAAG 
consensus  141 TGGcATTGATATCaCGCCCGTCATGAAAAACGTGGTCGATGCCGCCGTGGAAAAATCCTACGCTGGAAAG  
              icd1 prb        icd1 rev 
     
nucleotides 211-980 not shown (not relevant to primer/probe placement) 
 
Q212       981 CGGCGGCATTGGCATTGCTCCGGGCGCTAATTTAAGCGACACCGTCGGTCTTTTTGAAGCCACTCATGGG 
Q194       981 CGGCGGCATTGGCATTGCTCCGGGCGCTAATTTAAGCGACACCGTCGGTCTTTTTGAAGCCACTCATGGG 
Dugway     981 CGGCGGCATTGGCATTGCTCCGGGCGCTAATTTAAGCGACACCGTCGGTCTTTTTGAAGCCACTCATGGG 
RSA331     981 CGGCGGCATTGGCATTGCTCCGGGCGCTAATTTAAGCGACACCGTCGGTCTTTTTGAAGCCACTCATGGG 
RSA493     981 CGGCGGCATTGGCATTGCTCCGGGCGCTAATTTAAGCGACACCGTCGGTCTTTTTGAAGCCACTCATGGG 
consensus  981 CGGCGGCATTGGCATTGCTCCGGGCGCTAATTTAAGCGACACCGTCGGTCTTTTTGAAGCCACTCATGGG 
     icd3 fwd         icd3 prb         icd3 rev 
Q212      1051 ACAGCGCCTAAATATGCGGGGCAAGATAAAGTCAATCCAGGCTCTCTAATTTTATCAGCAGAAATGATGC 
Q194      1051 ACAGCGCCTAAATATGCGGGGCAAGATAAAGTCAATCCAGGCTCTCTAATTTTATCAGCAGAAATGATGC 
Dugway    1051 ACAGCGCCTAAATATGCGGGGCAAGATAAAGTCAATCCAGGCTCTCTAATTTTATCAGCAGAAATGATGC 
RSA331    1051 ACAGCGCCTAAATATGCGGGGCAAGATAAAGTCAATCCAGGCTCTCTAATTTTATCAGCAGAAATGATGC 
RSA493    1051 ACAGCGCCTAAATATGCGGGGCAAGATAAAGTCAATCCAGGCTCTCTAATTTTATCAGCAGAAATGATGC 
consensus 1051 ACAGCGCCTAAATATGCGGGGCAAGATAAAGTCAATCCAGGCTCTCTAATTTTATCAGCAGAAATGATGC 
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The crude visual assessment of the amplification with each of the three icd primer/probe sets 
designed is shown in Figure 2.5. The icd2 set has steeper amplification curves that reach a 
higher plateau. The icd3 set is next in terms of steepness and height and the icd1 has a much 
less steep curve and does not appear to be exponential. The poor performance of the icd1 set 
is likely due to the mismatch (against the RSA493, Nine Mile strain) in the forward primer 
discussed earlier.  
Another measure of the crude quality of primer/probe sets is to compare the Ct values at 
which they detect a given quantity of target DNA. In Table 2.9 these data are shown and it can 
be seen that the icd2 assay consistently detects a given quantity of DNA (across a range of 
seven orders of magnitude) at a smaller Ct value than either the icd3 or icd1 assays. In 
agreement with the crude visual assessment, the icd2 assay is superior to the icd3 assay and 
the icd1 assay is inferior to both. 
The results of these crude assessments led to only the icd2 primer/probe set being evaluated 
further for use in this project. 
 Figure 2.3 - Annotated sequence of the pCox 
the figure) indicate the location of the 16s primer and probe set, green block arrows indicate the three 
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Figure 2.4 - Kpn I Restriction digest of plasmid pCox, after 2 hours. Electrophoresed on a 1.0 % (w/v) Agarose gel. 
Lanes 1 and 13; NEB 1 kb MW marker (#N3232), Lanes 2 – 11; 10 restriction reactions. Lane 12; Negative 
(undigested) control – showing uncut plasmid in supercoiled state. White box indicates the plasmid bands 
between 3 and 4 kb. The molecular weights (Lanes 1 and 13), in kilobases, of the MW marker starting from the 
bottom (smallest) are; 0.5, 1.0, 1.5, 2.0, 3.0 (bright), 4.0, 5.0, 6.0, 8.0. 
 
Table 2.8 – Quantification of DNA present used to make standard pCox plasmid for real-time PCR assay. 
Ultraviolet spectrophotometry was used to quantify linearised and purified pCox plasmid. The ratio of 
absorbance at 260 nm and 280 nm is used to assess the purity of DNA. A reading of 1.80 at 260/280 nm is 
generally accepted as pure. The ratio of absorbance at 260 nm and 230 nm is used as a secondary measure of 
purity. An acceptable reading at 260/230 is usually 2.00-2.20. If the readings are substantially lower, it is an 
indication of contaminants such as proteins present in the sample. 
pCox Replicate DNA concentration 
(ng/µl) 
260nm/280 nm 260nm/230 nm 
1 32.5 1.73 1.92 
2 32.0 1.80 1.98 
3 31.3 1.76 2.10 
 
The average amount of DNA from the triplicate readings is 31.9 ng/µl. 
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The number of genome copies/µl was derived from this value as follows: 
 31.9	/μ1000 = 3.19 × 10/ 3.19 × 10(3038	 !	 × 660) × 6.022 × 10$ = 9.6 × 10%	&!'/ 
 
Where 3,038 bp is the size of the pCox plasmid, 660 is the average molecular weight of a 
nucleotide base, and 6.022 x 1023 is Avogadro’s number. 
 
Thus, there was a total concentration of 9.6 x 109 copies/µl. 
 
Figure 2.5- Real-time PCR Amplification slopes of the three icd primer/probe sets. The steepest and highest 
slopes are icd2, the next steepest/highest are icd3, and the shallowest/lowest are icd1. The pairs of lines for each 
primer/probe set are for the decimal dilutions of pCox plasmid (1 x 10
7
 down to 1 x 10
1
 copies/µl). This illustrates 
that the icd2 primer/probe set amplifies the target with greater efficiency than either icd3 or icd1. 
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Table 2.9 – Real-time PCR assessment of relative sensitivity of the three primer/probe sets. The mean cycle at 
which fluorescent signal crosses the threshold (Ct) and standard deviation (SD) for seven concentrations of pCox 
plasmid for all three primer probe sets. This shows that the icd2 assay is consistently more sensitive than the icd1 
and icd3 assays, as evidenced by the small Ct values for a given target DNA concentration. 
Concentration 
of pCox 
(copies/µl) 
Primer/probe icd1 Primer/probe icd2 Primer/probe icd3 
Mean 
Ct 
SD Ct Mean 
Ct 
SD Ct Mean 
Ct 
SD Ct 
1 x 107 16.8 0.1 14.8 < 0.1 15.2 < 0.1 
1 x 106 19.5 < 0.1 17.2 < 0.1 17.7 < 0.1 
1 x 105 23 < 0.1 20.3 0.2 21.1 0.1 
1 x 104 26.4 0.1 24 0.1 24.5 < 0.1 
1 x 103 29.5 0.3 27.5 < 0.1 27.9 0.2 
1 x 102 32.8 < 0.1 30.5 0.8 31.3 0.1 
1 x 101 37 < 0.1 33.9 0.6 35.2 0.7 
 
2.3.1.1 Detection limit determination for the icd2 assay 
The Probit analysis output includes measures of the quality of the regression and an 
assessment of how well the chosen model fits the dataset being analysed. The regression 
output is shown in Table 2.10. The goodness of fit output is shown in Table 2.11. Both outputs 
show the Probit model to be valid for the dataset generated. From the Probit output table of 
percentiles (not shown due to size), the icd2 assay is predicted to detect 5.9 copies/reaction or 
more with a 95 % probability. 
                        
Table 2.10 – Limit of detection determination of the icd2 real-time PCR assay. The regression table from Probit 
analysis shows that the regression, and thus the analysis, is valid. 
Variable         Coefficient Standard Error Z P 
Constant 1.452 0.348 4.18 <0.001 
Copies/reaction -0.853 0.216 -3.85 <0.001* 
Natural response 0.000  
*The p-value for Copies/reaction is less than 0.05, indicating that the number of copies has a 
significant impact on whether or not a signal is detected (the Probit model is valid). 
 
 
Table 2.11 – Limit of detection determination of the icd2 real-time PCR assay. Goodness of fit output from Probit 
analysis shows that the chosen distribution (Normal) is a good fit for the dataset being analysed. 
Method Chi-Squared Degrees of Freedom P 
Pearson 0.000 3 1.000* 
Deviance 0.000 3 1.000* 
* The high p-values for the copies/reaction data indicate that the chosen distribution 
adequately fits the data. 
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2.3.1.2 Amplification efficiency for the icd2 assay 
The MiniTab v16 linear regression output for the efficiency determination is shown in Table 
2.12 with the corresponding fitted line plot Figure 2.6. The regression shows the correlation 
between number of copies input and the Ct value output by the assay to be high (adjusted R2 = 
99.7 %) and significant (P < 0.001). The resulting slope value from the calculated regression line 
allowed the calculation of the PCR efficiency. The efficiency of the assay was 1.0, which is 
consistent with highly efficient amplification of the target gene. 
 = 	10( $.() − 1 = 1.0 
Table 2.12 – Amplification efficiency determination of the icd2 real-time PCR assay. MiniTab linear regression 
output for the Quantity (Copies/µl) vs. Ct value. The ANOVA shows that the regression is highly significant (P < 
0.05) with strong correlation (R
2
 values close to 100 %). Therefore, the use of the calculated slope value from the 
regression to calculate the PCR efficiency of the assay is supported. The calculated value for the sloper (-3.281) 
used in the efficiency calculations is highlighted in bold in the table. 
Analysis of Variance/Linear Regression 
Source DF SS MS F P 
Regression 1 904.2 904.2 4820.5 <0.001 
Error 14 2.6 0.2  
Total 15 906.8  
S = 0.43;   R2 = 99.7 %   R2(adj) = 99.7 % 
The regression equation is: 
Ct = 37.18 - 3.281 log10(Copies/ul) 
 
 
 
Figure 2.6 - Amplification efficiency determination of the icd2 real-time PCR assay. The regression analysis fitted 
line plot of the quantity (copies/µl) vs. the output Ct value from the assay. This figure shows a close relationship 
between the input and output values of the assay and the calculated regression line. 
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2.3.2 Virulence assessment of Coxiella burnetii stocks 
The assessment of splenomegaly between the two groups (Table 2.5) of guinea pigs examined 
the differences between the weights of the guinea pigs spleens, removed at autopsy, 
expressed as a proportion of the weight of the individual guinea pig. This was to control for the 
differences in bodyweight between different individuals. The raw data suggested that the 
spleens of the Group 2 (yolk sac homogenate exposed) animals were heavier than those in 
Group 1 (spleen homogenate exposed) (Table 2.13). However, statistical analysis showed this 
to be a non-significant observation (Table 2.14). Therefore, there was no difference in 
splenomegaly between the two groups. 
Animals in Group 2, experienced a more pronounced weight loss, ranging from 15.3 % to over 
20 % (attained euthanasia criteria), than those in Group 1, ranging from 6.15 % to 13.87 % 
weight loss (Figure 2.7). The surviving animal in Group 2 (V2-4) began to regain bodyweight 
from day 7 but was still approximately 8 % below its initial weight at the end of the study. 
Animals in Group 1, all initially lost weight but had begun to slowly regain it by the end of the 
study (range day 6 to day 11). The initial mean weights of the two groups based on the pre-
exposure measurements were 1040 g for Group 1 and 1171 g for Group 2; t-test found this 
difference to be statistically significant (T = -2.50; P = 0.02). The weight loss results (Figure 2.7) 
and temperature results (Figure 2.8) show the Group 2 animals lost more weight and suffered 
a more pronounced fever despite their larger starting weights. It is likely, had the initial 
weights been closer to those of the Group 1 animals, that the observed differences in virulence 
would have been more substantial. 
All animals in Group 2 displayed a prominent febrile spike (~40 °C) with noticeably small 
variation at day 3 post-inoculation whereas those in Group 1 had lower overall febrile 
responses, wider variation in peak fever temperature (max 39.4 °C) and a much less defined 
peak that occurred later at approximately day 5 (Figure 2.8). 
Bacterial loads of C. burnetii in spleen and blood measured using qPCR revealed that only 
animals V2-1, V2-2, and V2-3 had C. burnetii DNA in their circulation at the time of euthanasia. 
These results also show that for this assay, blood samples with EDTA as anticoagulant gave the 
highest detection sensitivity (Figure 2.9).  
Bacterial load in the spleen was less in the animals of Group 1 than Group 2. The levels of C. 
burnetii DNA found in the spleen do not appear to correlate with the levels found in the blood. 
These results are shown in Figure 2.10.  
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2.3.2.1 Health/Clinical monitoring 
In Group 1, two animals (V1-1 and V1-3) demonstrated a decrease in water intake on day 5 
post-exposure before returning to health. Animal V1-4 demonstrated a decrease in water 
intake from day 5 until day 7 post-exposure. Animal V1-2 demonstrated a wider range of 
clinical signs from day 5 until day 11 post-exposure; these signs included reduced water 
intake/dehydration, wasp-waisted appearance, slow movement, discharge from both eyes, 
and ruffled fur.  
In Group 2, all animals demonstrated adverse clinical signs from day 3 post-exposure. Animal 
V2-4 was the least severely affected with reduced water intake/dehydration being the sole 
sign until day 6 when it regained its healthy appearance. Animals V2-1, V2-2, and V2-3 
demonstrated a wide range of adverse clinical observations until they were culled at days 9, 
10, and 8 respectively. The adverse signs included reduced water intake/dehydration, reduced 
food intake, wasp-waisted appearance, ruffled fur, slow movement, and eye discharge.  
From these observations the animals in Group 2 were clinically more unwell and the period 
from exposure to the appearance of adverse clinical signs was 2 days shorter. 
The results of this experiment are discussed further in section 2.4.1. 
 
Table 2.13 – Virulence Assessment Experiment: Weights of animals, spleens and spleens as a percentage of 
necropsy bodyweight for all animals by group suggesting that the spleen weights (and thus splenomegaly) are 
higher in the Group 2 animals. 
Group 1 - Spleen Homogenate (ip) Group 2 - Yolk Sack Homogenate (ip) 
  
Animal 
ID 
Spleen 
weight 
(g) 
Animal 
weight 
at 
necropsy 
(g) 
Spleen 
weight as a 
% of 
bodyweight 
Animal 
ID 
Spleen 
weight 
(g) 
Animal 
weight at 
necropsy 
(g) 
Spleen 
weight as a 
% of 
bodyweight 
V1-1 3.03 1133 0.27 V2-1 3.08 981 0.31 
V1-2 1.62 780 0.21 V2-2 2.27 920 0.25 
V1-3 2.23 827 0.27 V2-3 3.50 1007 0.35 
V1-4 1.64 1062 0.15 V2-4 2.57 1027 0.25 
mean 2.13 950.5 0.23 mean 2.86 983.8 0.29 
SD 0.67 173.26 0.06 SD 0.54 46.49 0.05 
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Table 2.14 - Virulence Assessment Experiment: Statistical analysis using t-test (assuming equal variances) of 
spleen weight as a percentage of bodyweight at necropsy. Showing that the observed greater spleen weight in 
Group 2 (egg yolk sack homogenate) is not significant (p>0.05) and therefore no difference in splenomegaly was 
observed in the experiment. 
Group N Mean StDev SE Mean 
1 – Spleen homogenate 4 0.225 0.057 0.029 
2 – Egg yolk sack 
homogenate 
4 0.290 0.049 0.024 
Difference = mu(1) – mu (2) 
Estimate for difference: -0.065 
95% CI for difference: (-0.157, 0.027) 
T-Test of difference = 0 (vs not =): T-Value = -1.72  P-Value = 0.14  DF = 6 
Both use Pooled StDev = 0.053 
 
 
Figure 2.7 – Virulence Assessment Experiment: Group mean guinea pig bodyweight change as a percentage of the 
average baseline weights for each group. This shows that the animals that received the yolk sac homogenate 
material, by intraperitoneal injection (ip), lost substantially more weight than those that received the spleen 
homogenate. Error bars ±1 Standard Error of the mean - black arrows signify the euthanasia points of animals V2-
3, V2-1, and V2-2 respectively. 
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Figure 2.8 - Virulence Assessment Experiment: Group mean guinea pig temperature for each group. Error bars ±1 
Standard Error of the mean – black arrows signify the euthanasia points of animals V2-3, V2-1, and V2-2 
respectively. Fever was defined as the average of the 32 pre-inoculation temperatures added to double the 
standard deviation (38.8 °C). This shows that the animals that were inoculated with yolk sac homogenate by 
intraperitoneal injection (ip) had a higher and more sharply defined fever ‘spike’ than those that received spleen 
homogenate. 
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Figure 2.9 - Virulence Assessment Experiment: Blood bacterial load of C. burnetii as determined by real-time 
qPCR. Three different blood sampling tubes; EDTA or Heparin as anticoagulant or separated serum, were used to 
assess which would give the best recovery of organisms for future work. Figure shows that no Coxiella DNA was 
detected in the blood of in any of the group 1 (spleen homogenate) animals or in V2-4 (the surviving animal from 
group 2 – yolk sack homogenate) and that EDTA as anticoagulant gave recovery approximately one order of 
magnitude higher than either heparin anticoagulant or separated serum collection tubes. 
 
 
Figure 2.10 - Virulence Assessment Experiment: Bacterial load of C. burnetii as determined by qPCR in the spleen 
of animals at necropsy. The spleens of group 1 (spleen homogenate) animals V1-2 and V1-4 contained low levels 
of C. burnetii relative to the spleens of group 2 (yolk sack homogenate). Animals V1-1, V1-3, V2-4 (only survivor in 
group 2) had no detectable C. burnetii DNA present in their spleens. 
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2.3.3 Aerosol infection of guinea pigs and two strains of mouse 
qPCR data for the titres of C. burnetii in the Collison nebuliser and the AGI-30 impinger (air 
samples) are shown in Table 2.15. From these values the Caero, that is the concentration of 
organisms in the generated aerosol, are derived by the following calculation: 
)*+,-. 	× '/0!	1&20	(20	0)'/0!	&3	4/5	(10	 6 0)	× '/0!	50	(10	0)⁄ 1000	(&145	4&0		5&	0)8
= )9. 
An estimate of the volume of the aerosol inspired by the animals was made using Guyton’s 
formula for laboratory animal breathing rates (Guyton, 1947) using the average pre-challenge 
bodyweight of each group of animals. To derive the accumulated or inspired volume, this 
figure was multiplied by the time (10 min) the animals were exposed to the aerosol: 
2.10 × ( &:3ℎ5	&	/0/		)<.=% =  4/5ℎ	4/5	(0/0) 
 
To calculate an estimate of the dose of organism each animal inhaled (Table 2.16) the Caero was 
multiplied by the inspired volume. Due to their smaller size, the mice received less inoculum 
but overall a dose of 1,000-7,800 organisms (copies) was predicted by the literature to be 
sufficient to infect laboratory animals. This was supported by the clinical data (temperature 
and bodyweight) presented below. 
Table 2.15 - qPCR titres of the bacterial culture material in the Collison nebuliser (generator 1 - Cnebuliser) samples 
taken prior to challenge of each group as well as the impinger samples (Cimpinger) and the derived Caero 
concentrations in copies/ml (derived from Cimpinger x 20 ml (the sample volume)/l/min (sample flow) x 10 
min(sampling time)/1000). 
Sample Copies/ml    
Cnebuliser 
Copies/ml 
Cimpinger 
Copies/ml 
Caero 
Guinea Pig – Group 1 1.10 x 107 1.30 x 104 4.54 x 100 
Mouse (BALB/c) – Group 2 1.10 x 107 3.20 x 104 1.68 x 101 
Mouse (A/J) – Group 3 6.30 x 106 1.10 x 104 5.02 x 100 
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Table 2.16 – Volume of infectious aerosol inspired by the animals in each group and the calculated inhaled dose 
(copies) of C. burnetii calculated from Caero x Inspired volume. The inhaled dose is an estimate of the number of 
organisms to which each animal was exposed. 
Animal Group (mean weight) Inspired 
volume (ml) 
Inhaled Dose 
(copies) 
Guinea Pig (356.8 g) – Group 1 1,724 7.8 x 103 
Mouse (BALB/c) (20.7 g) – Group 2 204.1 3.4 x 103 
Mouse (A/J) (21.0 g) – Group 3 206.3 1.0 x 103 
 
2.3.3.1 Health/Clinical monitoring 
In contrast to the intraperitoneally (ip) exposed animals in the virulence assessment 
experiment (Section 2.3.2.1), no animals (in any group) demonstrated any clinical signs of 
infection for the duration of this study. 
 
2.3.3.2 Body temperature measurements 
In guinea pigs, a clear febrile response can be seen from approximately 9 to 12 days post 
infection (Figure 2.11). Neither strain of mouse (BALB/c or A/J), demonstrated a clear pattern 
in the mouse temperature results (Figure 2.12 and Figure 2.13). From these data, it appears 
the mouse, at an inhaled dose in the 1.0 x 103 – 3.4 x 103 copies range, produces no 
measureable febrile response. 
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Figure 2.11 - Aerosol Infection Experiment: Guinea pig temperature measurements collected via subcutaneous 
implant post-challenge with C. burnetii aerosol. Fever was defined as the mean pre-challenge temperature 
measurements of all seven animals plus double the standard deviation. Shows exposed guinea pigs 
demonstrated a fever from day 9 lasting approximately 3 days relative to the unexposed animal. Error bars ±1 
SEM. 
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Figure 2.12 – Aerosol Infection Experiment: Mouse (BALB/c strain) temperature measurements collected via 
subcutaneous implant post-challenge with C. burnetii aerosol. Fever was defined as the mean pre-challenge 
temperature measurements of all seven animals plus double the standard deviation. No clear fever can be seen 
in the exposed mice relative to the unexposed. Error bars ±1 SEM. 
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Figure 2.13 – Aerosol Infection Experiment: Mouse (A/J strain) temperature measurements collected via 
subcutaneous implant post-challenge with C. burnetii aerosol. Fever was defined as the mean pre-challenge 
temperature measurements of all seven animals plus double the standard deviation. No clear fever can be seen 
in the exposed mice relative to the unexposed. Error bars ±1 SEM. 
 
2.3.3.3 Guinea pig weight change measurements 
The change in guinea pig weight (Figure 2.14) appears to show that the rate of weight gain is 
lower in the animals exposed to C. burnetii (trend line shown was generated by linear 
regression analysis in MiniTab v16). In contrast to the unexposed animal, from day seven to 
day ten the exposed animals failed to gain any weight. Statistical analysis of the rates of weight 
gain data by analysis of covariance (ANCOVA) in section 2.3.3.3.1 supported the hypothesis 
that the differences in weight gain, the rate indicated by the slopes of the regression lines, was 
significant. However, some of this observed rate change could be explained by the slightly 
higher pre-exposure weights of the negative animal (mean = 367.6 g) compared to the 
exposed animals (mean = 355.0 g) which is a significant difference as determined by t-test (T = 
-3.26; P = 0.012).   
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Figure 2.14 - Aerosol Infection Experiment: Guinea pig weight change post-challenge with C. burnetii aerosol. The 
linear regression line equations, R
2
-values and P-values are shown for each data set (MiniTab v16). Graph 
indicates that exposed guinea pigs gained weight at a slower rate relative to unexposed. Exposed guinea pigs 
failed to gain any weight from approximately day 8 until day 9, broadly coinciding with the observations of fever 
in Figure 2.11. Error bars ±1 SEM. 
 
2.3.3.3.1 Analysis of guinea pig weight change 
 
 
Table 2.17 – Aerosol Infection Experiment: Analysis of Covariance (ANCOVA) on guinea pig weight data. 
Demonstrating that the observed slower rate of weight gain in the animals exposed to C. burnetii versus the 
unexposed animals is statistically significant (P < 0.05). 
Source DF Seq SS Adj SS Adj MS F P 
Days post-inoc 1 19,907.5 14,695.9 14,695.9 626.2 < 0.001 
Exposed/Unexposed 1 1,789.5 25.6 25.5 1.1 0.295* 
Exposed/Unexposed 
* Days post-inoc 
1 990.6 990.6 990.6 42.21 < 0.001** 
Error 213 4,998.6 4,998.6 23.5  
Total 216 27,686.2  
S = 4.8; R2 = 82.0 %; R2(adj) = 81.7 % 
* - No support for the hypothesis that the intercepts are different (P > 0.05) 
** - Strong support for the hypothesis that the slopes are different (P < 0.05) 
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2.3.3.4 Mouse weight change measurements 
The changes in mouse weight shown for BALB/c strain (Figure 2.15) and A/J strain (Figure 2.16) 
appears to show that the rate of weight gain is lower in the animals exposed to C. burnetii 
(trend line shown was generated by linear regression analysis in MiniTab v16). This difference 
is not as marked as in the guinea pig and all mice continued to gain weight throughout the 
experiment. Statistical analysis of the rates of weight gain data by analysis of covariance 
(ANCOVA) (Table 2.18 and Table 2.19) supports the hypothesis that the differences in weight 
gain for BALB/c, the rate indicated by the slopes of the regression lines, was significant. 
However, in the A/J mice the ANCOVA statistical analysis (Table 2.19) suggests that the 
observed difference in the rate of weight gain was not significant (p = 0.063). However, in 
BALB/c mice, some of the observed rate change could be explained by the slightly higher pre-
exposure weights of the exposed animals (mean = 20.8 g) compared to the negative animal 
(mean = 20.1 g) which is a significant difference as determined by t-test (T = 3.80; P = 0.003). 
The pre-exposure weights of the A/J mice (exposed = 21.1 g; negative = 20.6 g) were not found 
to be different (T = 1.40; P = 0.185). 
 
Figure 2.15 - Aerosol Infection Experiment: Mouse (BALB/c strain) weight change post-exposure with C. burnetii 
aerosol. The linear regression line equations, R
2
-values and P-values are shown for each data set (MiniTab v16). 
Graph indicates there may be a small difference in weight gain between exposed and unexposed mice, the 
exposed mice gaining weight at a lower rate. Error bars ±1 SEM. 
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Figure 2.16 - Aerosol Infection Experiment: Mouse (A/J strain) weight change post-exposure with C. burnetii 
aerosol. The linear regression line equations, R2-values and P-values are shown for each data set (MiniTab v16). 
*It should be noted that the P-value for the regression of the unexposed A/J mice did not reach significance, 
likely due to the deviation from the predicted lines between days 6 and 10. Graph indicates there may be a small 
difference in weight gain between exposed and unexposed mice, the exposed mice gaining weight at a lower rate 
– this was not found to be statistically significant. Error bars ±1 SEM. 
 
2.3.3.4.1 Analysis of mouse weight change data 
Table 2.18 - Aerosol Infection Experiment: Analysis of Covariance (ANCOVA) on BALB/c mouse weight data. 
Demonstrating that the observed slower rate of weight gain in the animals exposed to C. burnetii versus the 
unexposed animals is statistically significant (P<0.05) 
Source DF Seq SS Adj SS Adj MS F P 
Days post-inoc 1 1,809.2 1,148.8   1,148.8   235.5   < 0.001 
Exposed/Unexposed 1 51.4 1.5     1.5     0.3   0.580* 
Exposed/Unexposed 
* Days post-inoc 
1 33.4 33.4    33.4     6.8   0.010** 
Error 213 1,038.8 1,038.8 4.9  
Total 216 2,932.8  
S = 2.2; R2 = 64.6 %; R2(adj) = 64.1 % 
* - No support for the hypothesis that the intercepts are different (P > 0.05) 
** - Strong support for the hypothesis that the slopes are different (P < 0.05) 
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Table 2.19 - Aerosol Infection Experiment: Analysis of covariance (ANCOVA) on A/J mouse weight data. 
Demonstrating that the observed slower rate of weight gain in the animals exposed to C. burnetii versus the 
unexposed animals is not statistically significant (P < 0.05) 
Source DF Seq SS Adj SS Adj MS F P 
Days post-inoc 1 110.2 134.9 134.9 13.2 <0.001 
Exposed/Unexposed 1 623.5 60.9 60.9 5.9 0.016* 
Exposed/Unexposed 
* Days post-inoc 
1 35.7 35.7 35.7 3.5 0.063** 
Error 213 2,180.9 2,180.9 10.2  
Total 216 2,950.3  
S = 3.2; R2 = 26.1 %; R2(adj) = 25.0 % 
* - Support for the hypothesis that the intercepts are different (P<0.05) 
** - No support for the hypothesis that the slopes are different (P>0.05) 
 
2.3.3.5 Bacterial load measurements in blood 
C. burnetii DNA was not detected in blood with either EDTA or heparin as anticoagulant, or 
from clotted serum in any of the guinea pigs. No C. burnetii DNA was detected in blood with 
EDTA anticoagulant, or from clotted serum in the BALB/c mice. Three mice in the A/J group 
had low levels of C. burnetii DNA (Table 2.20). These results indicate that serum-separation 
tubes may be a better collection vessel than EDTA anticoagulation tubes for qPCR analysis; this 
is in contrast to the findings of the intraperitoneal virulence experiment (Section 2.3.2) that 
suggested that EDTA collection tubes gave superior results in comparison to both clotted 
serum and heparin. In addition, the data indicate that the animals necropsied on the earlier 
date had higher levels of circulating bacteria. 
Table 2.20 - Aerosol Infection Experiment: Bacterial load measurements in the three mice (A/J) found at necropsy 
to have detectable C. burnetii in their blood. 
Individual (Necropsy date) EDTA (copies/ml) Clotted serum (copies/ml) 
A3-1 (15d post-exposure) 1950 6,750.0 
A3-4 (21d post-exposure) Undetected 1,875.0 
A3-6 (15d post-exposure) Undetected 7,500.0 
 
2.3.3.6 Bacterial load measurements in tissue 
The mean bacterial loads in the tissues of the guinea pigs on the two necropsy timepoints 
(Figure 2.17) were higher overall in the earlier necropsy than the later one for lung. In other 
tissues, no bacteria were detected in the later necropsy samples. Indicating that by day 21, the 
guinea pigs had cleared the infection. 
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Figure 2.18 and Figure 2.19 show the bacterial tissue loads for BALB/c and A/J mice 
respectively. In mice, in contrast to guinea pigs, high levels of C. burnetii were seen in several 
tissues (spleen, heart, liver, and lung) with lower levels seen in kidney and testes. The titres in 
kidney and testes appear to rise from the D+15 to the D+21 samples in BALB/c. In comparison 
to the guinea pig, these data suggest that the mice are somewhat persistently infected with no 
indication that they are effectively clearing the organism by day 21. 
 
Figure 2.17 - Aerosol Infection Experiment: C. burnetii bacterial loads (measured by qPCR) in guinea pig tissues at 
15 and 21 days post-exposure. Black bars indicate the animals autopsied (PM) at day 15 (d+15) post-exposure 
(p.e.), white bars those autopsied at day 21 post-exposure. Figure shows that by day 21 guinea pigs have cleared 
the infection from all tissues other than lung, consistent with an acute infection. Error bars +1 SEM. 
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Figure 2.18 - Aerosol Infection Experiment: Aerosol Infection Experiment: C. burnetii bacterial loads (measured by 
qPCR) in mouse (BALB/c) tissues at 15 and 21 days post-exposure. Black bars indicate the animals necropsied 
(PM) at day 15 (d+15) post-exposure (p.e.), white bars those necropsied at day 21 post-exposure. Figure shows 
that mice had not cleared the infection by day 21 relative to day 15 (levels in kidney and testes had actually 
increased), consistent with chronic infection of the mice. Error bars +1 SEM. 
 
Figure 2.19 - Aerosol Infection Experiment: C. burnetii bacterial loads (measured by qPCR) in mouse (A/J) tissues 
at 15 and 21 days post-exposure. Black bars indicate the animals necropsied (PM) at day 15 (d+15) post-exposure 
(p.e.), white bars those necropsied at day 21 post-exposure. Figure shows that mice had not cleared the infection 
by day 21 relative to day 15, consistent with chronic infection of the mice Error bars +1 SEM. 
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2.4 Summary of Results 
 
2.4.1 Virulence assessment of Coxiella burnetii stocks 
All animals in the virulence assessment by intraperitoneal inoculation experiment 
demonstrated signs of overt disease as evidenced by a loss of bodyweight and concurrent 
increase in body temperature. Therefore, both inocula (yolk sack homogenate and spleen 
homogenate) were considered virulent in guinea pigs by this route. 
Animals inoculated with egg yolk sack homogenate (Group 2; individuals V2-1 to V2-4) showed 
more severe disease than those inoculated with spleen homogenate (Group 1; individuals V1-1 
to V1-4). All animals in Group 1 survived the disease whereas all but one of the animals in 
Group 2 had to be euthanised due to the severity of symptoms. Peak fever occurred earlier 
and was higher in Group 2 relative to Group 1. Group 2 animals also demonstrated a higher 
number of adverse health observations. In addition, loss of bodyweight was more pronounced 
in Group 2 than Group 1; even the surviving animal in Group 2 lost a maximum of 15 % of its 
original bodyweight (at day 6) and was still 6 % below its original bodyweight at the end of the 
experiment (day 14). The initial weight assessments of the guinea pigs showed the Group 1 
animals to be 11 % lighter than Group 2. One might expect heavier animals to be more 
resistant to aspects of the disease such as weight loss; therefore if the initial weights had been 
comparable the difference in disease between the two inocula might have been more 
dramatic. However, the literature has not, to date, described the effect of guinea pig weight on 
their susceptibility to disease for C. burnetii. 
Bacterial load in the blood was found to be highest in the three animals that required 
euthanasia in Group 2. No C. burnetii was detected in the circulation of the animals of Group 1 
or the surviving animal in Group 2. DNA was extracted from blood with EDTA as the 
anticoagulant more efficiently than either blood with heparin as the anti-coagulant or clotted 
serum. C. burnetii was detected only in the spleens of the three animals that required 
euthanasia in Group 2. The detection of C. burnetii in the blood and spleens of the euthanized 
animals could be a reflection of the greater severity of the disease in those animals but also 
may be a reflection of their being euthanized and examined during the active phase of the 
infection, their being examined on days eight and nine. 
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Both Group 1 and Group 2 received the same number of C. burnetii as enumerated by real-
time qPCR. Real-time qPCR measures copies of pathogen DNA present and cannot determine 
viability; that is it counts both viable and non-viable organisms. This could mean that the 
proportions of viable to non-viable C. burnetii in the preparations are different. Alternatively, 
the C. burnetii grown in yolk sac could be more virulent due to its growth in a different species 
or differing proportions of virulent (phase I) and avirulent (phase II) organisms. Regardless, the 
egg yolk sack-grown material offers a higher level of virulent potential and was therefore a 
more suitable inoculum for the aerosol infection experiments. 
 
2.4.2 Aerosol infection of guinea pigs and two strains of mouse 
All guinea pigs in this study demonstrated overt signs of disease as evidenced by a lower rate 
of bodyweight gain and concurrent increase in body temperature. Therefore, the inoculum 
was virulent by the aerosol route at the dose used. Only the BALB/c mouse strain 
demonstrated bodyweight changes and they were subtle and only detectable by the use of 
statistical testing. In the A/J mice the differences in weight gain did not reach significance. 
However, in the A/J and BALB/c exposed mice a small ‘dip’ in weight gain is seen at days 6 and 
7 and 7 and 8 respectively, this could be an indicator of illness. It is, nevertheless, incredibly 
subtle but may be an indicator that higher aerosol doses of C. burnetii may give a more robust 
indicator of illness in the mouse model. Due to the small numbers of animals used in this study 
this finding would need further experiments to determine whether rate of weight gain could 
be a reliable marker of infection in mice. Neither mouse strain demonstrated a measureable 
febrile response. 
No significant bacterial blood load of C. burnetii was found in any of the study animals. This 
would be consistent with natural infections in humans with C. burnetii where bacteraemia is 
transient and confined to the febrile portion of disease. The bacterial load in the tissues of 
guinea pigs was undetectable in all but the lungs at day 21 post-infection. In contrast, both 
strains of mice had detectable C. burnetii in all tissues tested at day 21. This possibly indicates 
that in guinea pig the infection is being cleared, consistent with an acute infection; whereas in 
mice the infection may be of a more chronic nature. 
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The egg-yolk sack grown C. burnetii is clearly infectious in both guinea pig and mouse by the 
aerosol route. Clinical measurements were more pronounced in guinea pig than in mice but 
the guinea pigs did receive a substantially higher dose of organisms. However, while it has 
been reported that aerosol doses as high as 2.8 x 106 genomic equivalents (3 orders of 
magnitude greater than the doses used here) are required to produce signs of disease in A/J 
mice (weight loss of almost 20 % and ruffled fur) no febrile response is seen (Norville et al., 
2014). At a similar dose of 2 x106 organisms (OD) in guinea pigs the infection was fatal in 71 % 
of the animals within 10 days of infection. Therefore, it is unlikely the much smaller differences 
in inhaled dose seen here explain the observed differences in disease progression. Disease 
after aerosol infection of guinea pigs appears to have more features consistent with human 
acute Q fever than mouse. 
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2.5 Outcomes 
 
• A real-time quantitative PCR assay to detect and enumerate C. burnetii in tissue, blood 
and culture samples was designed, developed and implemented. The assay amplifies 
and detects the C. burnetii isocitrate-dehydrogenase (icd) gene.  
• Two C. burnetii stocks, one spleen homogenate from an infected guinea pig and one 
egg yolk sack grown stock, were assessed for clinical signs of virulence after 
intraperitoneal infection with 1.5 x 107copies/ml. Both stocks proved virulent in this 
experiment but the egg-yolk sack-grown stock to a substantially greater degree. The 
egg-grown stock was used for the successive aerosol-exposure experiment. 
• An aerosol infection experiment was performed to assess the signs of clinical infection 
in guinea pig and two strains of mouse that the literature had suggested may show 
some signs of infection. This experiment was also intended to generate convalescent 
anti-sera and antibodies that could be used later in this project to identify C. burnetii 
proteins that are immune-reactive. The aerosol infection succeeded in producing an 
acute, febrile disease in guinea pig. Terminal blood was harvested from all animals and 
the anti-sera harvested and stored. 
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3 Protein Isolation 
3.1 Introduction 
 
The lipopolysaccharide (LPS) situated on the bacterial cell surface of phase I C. burnetii has a 
large role to play in the protective effects of the inactivated whole cell vaccine and has been 
demonstrated, when administered alone, to be partially protective against mortality in a 
mouse model (Williams et al., 1990). However, the authors of that report stated that the LPS 
used was not pure and contained several C. burnetii proteins in addition to LPS. Therefore, the 
isolation and identification of immune-reactive proteins of C. burnetii remains important in the 
drive to create a successful sub-unit vaccine.  
Proteomic comparisons between virulent phase I and avirulent phase II organisms (Skultety et 
al., 2011) have identified that, in addition to a truncated LPS, phase II organisms have a 
restricted proteome. Comparisons have also found differences in the proteomes of the two 
morphological forms, the large- and small-cell variants (Coleman et al., 2007). Therefore, it is 
important that immune-reactive protein isolation is performed using phase I organisms that 
are present in a mixture of the two morphological forms. 
Immune reactive proteins are specfic proteins, present in the pathogen, that have been 
recognised by the host during infection, as evidenced by the presence of antibodies in the sera 
that bind to those proteins. Immune reactive proteins are generally isolated by using the 
immunoblot method using antibodies present in convalescent patient or animal serum to 
determine where, on a parallel protein separation gel, immune reactive proteins are situated. 
The proteins separated on the 2D-PAGE gels generally consist of whole-cell lysates of C. 
burnetii contaminated with varying amounts of host-cell protein from whatever biological 
system the organisms were cultivated in. The general scheme of how an immunoblot works to 
isolate those proteins from the organism that are immune reactive is shown below (Figure 
3.1). Several studies have sought to identify immune-reactive proteins associated with C. 
burnetii infection. The approaches include; using antibodies present in sera from mice infected 
with yolk sack-grown C. burnetii via the intraperitoneal route (Xiong et al., 2012), antibodies 
present in sera from guinea pigs immunised with inactivated whole cell vaccine (Deringer et 
al., 2011), antibodies present in sera from guinea pigs infected by the aerosol route and 
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antibodies present in the sera of human patients with cell-culture grown C. burnetii (Coleman 
et al., 2007), and sera from human patients with yolk sack (Chao et al., 2005) or Vero cell 
(Sekeyova et al., 2009) grown organisms. All of these approaches have used two-dimensional 
protein separations (2D PAGE) followed by immunoblots to isolate immune-reactive proteins 
which were then picked from parallel protein-separation gels and identified by mass 
spectrometry.  
Further approaches, identifying proteins by in vitro translation of proteins and analysis by 
microarray (Beare et al., 2008; Vigil et al., 2010; Wang et al., 2013) or ELISA/ELISPOT (Chen et 
al., 2009) have also been used to successfully identify immune-reactive proteins. In this 
microarray method, protein representing a single open-reading frame (ORF; a predicted 
protein) are synthesized and bound to a single spot on a glass slide, one spot for each 
protein/ORF. For C. burnetii this equates to approximately 2,000 ORF ‘spots’ (Beare et al., 
2006). To detect immune-reactive spots sera/antibody from a convalescent patient or animal 
is used as primary antibody and anti-immunoglobulin conjugate are used and detected in 
much the same was as that described for an immunoblot (Figure 3.1). Except that the identity 
of the protein/ORF in a microarray spot is already known, whereas in the 2D-
PAGE/Immunoblot method mass-spectrometry must be used to identify the isolated protein. 
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Figure 3.1 - Diagram of how immunoblot can be used to isolate immune-reactive proteins. Proteins from either 
one- or two-dimensional SDS-PAGE separation gels are blotted (using electric current in the Western blot 
protocol) onto a nitrocellulose or PVDF membrane (proteins; Blue and Green in diagram above). A mixture of 
proteins not present in the original sample (usually milk; pale blue in diagram) is applied to the membrane to 
block any unbound sites on the membrane. Primary antibody (usually whole sera but sometimes purified 
fractions of immunoglobulin; red in diagram) is applied to the membrane, antibodies bind to any proteins on the 
membrane that they ‘recognise’ at this point – unbound antibodies are washed away. A secondary antibody 
(green) that has been conjugated to an enzyme is then applied to the membrane. The secondary antibody is 
usually selected to only bind to a single isotype of immunoglobulin (eg. Only IgG). After another wash, the bound 
secondary antibody is detected by either a colour-changing or chemiluminescent substrate (yellow star). In this 
manner immune reactive proteins (those recognised by antibodies present in the sera of convalescent laboratory 
animals or people) can be isolated. 
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One problem with using egg yolk sack or cell-culture grown C. burnetii as the antigen for the 
2D PAGE is that, despite the best attempts at purification, some of the proteins from the host 
cells will remain. These residual proteins will form spots on the 2D PAGE which can hinder or 
make accurate harvesting of the reactive spots impossible. Axenic growth of C. burnetii in a 
complex culture media under microaerophilic conditions has recently been described 
(Omsland, Cockrell, Fischer, & Heinzen, 2008; Omsland et al., 2009). Furthermore, growth in 
this media has been demonstrated to maintain the virulent phase I phenotype for at least 5–8 
passages (Kersh, Oliver, Self, Fitzpatrick, & Massung, 2011). A great advantage of producing a 
protein preparation for 2D PAGE and immunoprobing using this method is that there would be 
no contaminating proteins/antigens from the host, in which the organisms are cultivated, 
present to interfere with spot isolation and no complex or hazardous purification, such as large 
volume high-speed centrifugation, of the live organisms required. 
 
3.1.1 Aims 
The aims of this chapter are: 
• To grow a stock of C. burnetii, free of host proteins, in the axenic media described by 
Omsland et al. (2009). This stock should be produced from a low passage stock of 
phase I material and contain a mixture of the two morphological forms (SCV and LCV) 
to maximise the probability that a comprehensive representation of the organism’s 
proteins are present in the preparation. 
• To isolate the proteins that are immunoreactive with the antibody (IgG fraction) 
present in the serum from the aerosol infected guinea pigs to permit downstream 
mass spectrometric identification. 
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3.2 Materials and Methods 
 
3.2.1 Growth of C. burnetii 
3.2.1.1 Optimisation of inoculation concentration 
To axenically culture C. burnetii, acidified citrate cysteine media (ACCM-2) was prepared as 
described in the literature (Omsland et al., 2009) and Appendix 1.  Bacterial inoculum stock 
was C. burnetii, Nine Mile strain (EP2, GP1 EP1) – 30% (w/v) egg yolk sack in PBS homogenate 
(produced in study – dstl BSC11-05). DNA was extracted from this material and its average titre 
estimated by three separate determinations in qPCR as described in Chapter 2, this titre was 
2.9 x 107 copies/ml. As this material was the first chick egg passage after a guinea pig passage, 
and was demonstrated in Chapter 2 to be pathogenic in animals, it was assumed it was in the 
virulent phase I form of the organism. 
Into the wells of six-well cell-culture plates (ThermoScientific/Nunc #140675) 2 ml of ACCM-2 
media was pipetted. The wells were then inoculated with C. burnetii such that there were five 
concentrations of organisms, from 1.0 x 102 copies/ml to 1.0 x 106 copies/ml in 101 increments. 
The plates were sealed into a 2.5 l gas-tight box with a microaerophilic atmosphere generating 
pack (Biomerieux GENbox microaer #96125) and the box placed in an incubator set at 37 °C. At 
intervals throughout the ten day experiment, the box was opened, samples taken for DNA 
extraction/qPCR analysis, a fresh gas pack added, and the box re-sealed and returned to the 
incubator. 
The qPCR analysis data was plotted graphically to determine which seeding concentration 
yielded the best growth of the organism. Optimal growth was determined to be that which, 
given the smallest inoculum concentration, gave the greatest increase over the ten day 
incubation. Seeding concentration is an important consideration due to the proportion of egg 
yolk sac-associated protein contaminating the final material. 
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3.2.1.2 Larger scale growth 
Ten 250 ml plastic sterile conical flasks were filled with 100 ml each of ACCM-2 media. Each 
flask was inoculated with C. burnetii (Nine Mile strain as described previously) such that the 
estimated titre in each flask was 1 x 104 copies/ml. This consisted of 35 µl of yolk sac 
homogenate per 100 ml flask. Each flask was sealed into an O-ring sealed, screw-capped BioJar 
containing a microaerophilic atmosphere generating pack. The BioJars were then incubated for 
nine days in a shaking incubator set at 37 °C and 75 rpm. 
Prior to harvest, a sample of the pooled cultured organisms was taken for DNA 
extraction/qPCR titration and other quality assessment measures. To harvest the bacteria the 
cultures were combined and centrifuged at 12,000 x g for 30 min to pellet the cells. The pellets 
were re-suspended in a small amount of the spent ACCM-2 media, combined and re-pelleted. 
All media was aspirated from the pellets and they were stored at -80 °C until lysis and protein 
extraction. The estimated titre of the culture at harvest was 1.1 x 109 copies/ml (using icd real-
time qPCR as described in Chapter 2). 
 
3.2.1.3 Quality assessments 
3.2.1.3.1 Electron microscopy 
To assess the quality of the cultured C. burnetii prior to cell lysis and protein extraction, 
agarose-embedding followed by transmission electron microscopy (TEM) of a sample of the 
material was undertaken. The organisms were fixed and inactivated by taking a 2 ml sample of 
the culture, centrifuging at 16,000 x g for 30 min and re-suspending the pellet in 2.5 % (w/v) 
glutaraldehyde in 0.1 M phosphate buffer (pH = 7.0). This material was then held at 4 °C for 24 
h prior to further processing. Cells were pelleted and re-suspended in 0.1 M phosphate buffer 
to wash away the fixative. Cells were once again pelleted and re-suspended in 1 % (w/v) 
osmium tetroxide in 0.1 M phosphate (pH = 7.0) buffer for 2 h at 4 °C. 
  
89 
 
Cells were pelleted; the osmium tetroxide discarded, the cells re-suspended in a drop of 2 % 
(w/v) agar (Oxoid No. 1) and allowed to cool. The solidified agar was cut into approximately 1 
mm3 cubes. The agar cubes were dehydrated using a graded ethanol series at room 
temperature; 30 % (v/v) 10 min, 50 % (v/v) 10 min, 70 % (v/v) 20 min, 90 % (v/v) 30 min, 100 % 
(v/v) for 2 x 30 min. 
Agar cubes were immersed in 100 % propylene oxide for 2 x 10 min changes. Araldite® Resin 
(50:50 v/v dodecenyl succinic anhydride hardener and Araldite® CY212, with 200 µl N-
benzyldimethylamine accelerator) was mixed 50:50 v/v with propylene oxide and the agar 
cubes immersed for 2 h at room temperature. The agar cubes were immersed in 100 % 
Araldite resin for approximately 24 h at room temperature before transfer of the cubes to 
embedding capsules (BEEM size 00), covering with fresh resin and allowing setting for a further 
24 h at room temperature. Resin was fully polymerised by holding the embedding capsules at 
60 °C for 72 h. 
Embedded material was sectioned using an ultramicrotome (Reichert-Jung Ultracut E) to a 
thickness of approximately 70 nm. The sections floated onto a water bath and were collected 
by raising an adhesive-coated electron microscopy (EM) grid from below; the grids were then 
dried on filter paper. Grids were immersed in 2 % (v/v) aqueous uranyl acetate stain solution 
for 2 h. Grids were washed in three changes of distilled water and immersed in 0.1 % (w/v) 
aqueous lead citrate stain solution for 30 min before three final washes in distilled water and 
drying on filter paper. Grids were examined using a Philips CM100 transmission electron 
microscope with a lanthanum hexaboride cathode (LaB6) electron source at 80 kV. 
 
3.2.1.3.2 Immunofluorescent microscopy 
To prepare antigen-coated slides; twelve well, PTFE-coated glass slides (Menzel-Glaser 
X2XER202W#) were spotted with approximately 25 µl per well volumes of ACCM-2 grown C. 
burnetii. The excess was aspirated from the edge of the well and the slides left to air-dry. Slides 
were then fixed by immersion in 8 % (w/v) formaldehyde in PBS for 10 min, and permeabilised 
in neat ice-cold (-20 °C) acetone for a further 10 min.  
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To each well of the slide, 20 µl of anti-C. burnetii (primary) antibody was added (Veterinary 
Laboratory Agency 3+ goat sera diluted 1:1000 (v/v) in PBS).  Slides were incubated in a 
humidified chamber for 40 - 60 min, and rinsed three times in PBS.  To each well of the slide, 
20 µl anti-species secondary antibody was added (Sigma F7367; Anti-goat IgG (whole-
molecule) FITC conjugate diluted 1:100 (v/v) in PBS) containing 2 µl Evans blue (Bio-Rad, 1 % 
stabilised solution #74911) as counterstain. Slides were incubated in a humidified chamber for 
40 - 60 min, and rinsed three times in PBS. 
To mount the slides, three drops of Vectashield Hardset (Vectorlabs H-1400) mountant was 
added to a glass coverslip. The inverted slide was then lowered onto the coverslip, avoiding 
bubble creation. The stained Coxiellae were visualised using an epi-fluorescent (UV) 
microscope, and images captured using a digital camera fitted with an eyepiece adapter (Best 
Scientific).  
 
3.2.2 Extraction of proteins from ACCM-2 grown C. burnetii 
The ACCM-2 grown C. burnetii pelleted organisms from Section 3.2.1.2 were weighed and 
found to contain approximately 165 mg (wet-pellet), this was re-suspended in PBS and divided 
equally between four 2 ml microcentrifuge tubes to yield approximately 41 mg/tube. This 
material was re-pelleted at 16,000 x g and the PBS discarded. 
The pellets were re-suspended in 1.0 ml each of Bug Buster master mix (containing Benzonase 
Nuclease and rLysozyme; Novagen #71456-3 ) containing 1x protease inhibitor cocktail (Roche 
cOmplete ULTRA, EDTA-free #05892953001) to lyse the bacterial cells, solubilise proteins and 
break down the nucleic acids. The lysis was allowed to continue for 2 h at room temperature 
before clarification by centrifugation at 16,000 x g for 20 min. The soluble protein fraction was 
then filtered through a 0.1 µm PVDF syringe filter (Millipore #SLVV033RS) to remove any 
residual infectious particles. 
Soluble C. burnetii protein was stored at -80 °C in small aliquots until required. 
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3.2.3 One dimensional protein separation and detection 
3.2.3.1 One dimensional protein separation 
To produce a denatured, reduced protein preparation suitable for one-dimensional (1D) PAGE, 
50 µl of soluble protein was mixed with 50 µl of 2x concentrated Laemmli (Laemmli, 1970) 
sample buffer (Sigma S3401-10VL). This mixture was heated in a heating block at 95 °C for 10 
min. 
The denatured, reduced proteins were loaded directly into an 1 mm thick, 8 cm square 12 % 
Bis-Tris Protein Gel (Life Technologies NuPage® Novex® NP0343BOX) submerged in MOPS SDS 
running buffer (Life Technologies NuPage® Novex® NP0001) at the anode and MOPS SDS 
running buffer containing antioxidant (Life Technologies NuPage® NP0005) at the cathode. The 
Bis-Tris gel system (M. Moos, Jr., Nguyen, & Liu, 1988) is a modification of the original SDS-
PAGE that runs at a neutral pH rather than the basic pH of the original method (Laemmli, 
1970). Into the first lane was loaded a pre-stained protein standard marker (Life Technologies 
SeeBlue® Plus2 LC5925). The gel was then electrophoresed at 200 V for 50 min. 
 
3.2.3.2 Coomassie staining of gels 
For general protein visualisation, where sensitivity to protein bands or spots containing more 
than 10 ng was sufficient, or where downstream mass spectrometry analysis was desired, 
Coomassie staining was used. After electrophoresis, gels were removed from their plastic 
cassettes and subjected to three, 5 min washes with deionised water on a rocking platform. 
The gels were then covered with 20 ml of Coomassie G-250 stain (Life Technologies 
SimplyBlue™ SafeStain LC6060) and rocked on the platform for 1 h at room temperature. The 
stain was discarded and the gel de-stained using deionised water for two, 1 h washes. 
Gel images were captured using a PC running the Bio-Rad QuantityOne software package 
attached to a self-contained dark-room gel-documentation system containing a digital camera 
(BioRad XR System #170-8170). 
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3.2.3.3 Silver staining of gels 
For greater sensitivity staining of protein gels (spot or band abundance as low as 0.25 ng), 
silver staining was used. A mass spectrometry compatible protocol, included in the reagent kit, 
was used (Pierce® silver stain kit; ThermoScientific #24612). After electrophoresis, gels were 
removed from their plastic cassettes and subjected to two, 5 min washes with deionised water 
on a rocking platform. The gels were then fixed with two, 15 min washes in 30 % (v/v) ethanol: 
10 % (v/v) acetic acid. Gels were washed with two; 5 min washes in 10 % (v/v) ethanol 
followed by two, 5 min washes in deionised water.  
Gels were sensitised for 1 min in sensitiser working solution and washed for two, 1 min washes 
in deionised water. The gel was stained for 5 min in stain working solution followed by two, 20 
s washes in deionised water. The stain was developed in developer working solution until the 
bands had a good intensity (less than 3 min) and the developing stopped by two, 10 min 
washes in 5 % (v/v) acetic acid. 
 
3.2.3.4 Western blotting 
To produce membranes with bound C. burnetii proteins, a Western Blot (Towbin, Staehelin, & 
Gordon, 1979) was performed. This was achieved using an iBlot® semi-dry blotting system (Life 
Technologies IB1001UK) using a PVDF mini transfer stack (Life Technologies iBlot® IB4010-02). 
The pre-run PAGE gel was removed from the cassette, trimmed and floated off into deionised 
water. The iBlot anode stack was inserted into the iBlot device. The gel was carefully laid onto 
the PVDF membrane without introducing air-bubbles. An iBlot filter paper, wetted with 
deionised water, was carefully laid on top of the gel and the de-bubbling roller used to remove 
any residual air bubbles. The cathode stack was then place on the stack and the lid of the iBlot 
(fitted with a cathode sponge) closed. The transfer itself was performed by running 
programme preset P3 (20 V for 7 min). After transfer, the membranes were used either 
immediately for antibody probing or stored. 
For storage, the membranes were air-dried and placed into 50 ml screw-capped Falcon tubes 
and kept at -20 °C. Before use, frozen membranes were warmed to room temperature and re-
wetted with methanol for 10 s, thoroughly rinsed with deionised water and used as freshly-
transferred membranes. 
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3.2.3.5 Antibody probing of transferred proteins 
Blocking of unoccupied protein binding sites on the membranes was achieved by incubating 
them in polypropylene tubes on a roller containing 30 ml of 5 % (w/v) non-fat milk (Milk; Sigma 
M7049-1BTL) diluted in PBS containing 0.05 % (v/v) Tween-20 buffer (PBS-T; Thermo 
Scientific™ Pierce™ 20X PBS Tween™ 20 PI-28352) (5 % Milk/PBS-T) at room temperature for 1 
- 2 h, or overnight at 8 °C. 
After blocking, the membranes were incubated with 5ml of primary antibody diluted (generally 
at 1:1000) in 5 % Milk/PBS-T for 1 h at room temperature on a roller. Membranes were 
washed three times for 5 min in PBS-T (without milk). 
Membranes were probed with secondary antibody diluted 1:3000 in 5 % Milk/PBS-T for 1 h at 
room temperature. The conjugate used was dependent upon the detection method used 
downstream (see below). For ECL detection, anti-guinea pig IgG (whole molecule)-peroxidase 
produced in goat (Sigma A7289) was used and for BCIP/NBT detection and anti-guinea pig IgG 
(whole molecule)-alkaline phosphatase produced in goat (Sigma A5062) was used. After 
incubation, membranes were washed three times for 5 min in PBS-T. 
Horseradish peroxidase-conjugated secondary antibody was detected using enhanced 
chemiluminescence (Amersham ECL Prime Western Blotting Detection Reagent RPN 2232); 
reagents A and B were mixed 50:50 v/v, applied to the membranes and incubated in the dark 
at room temperature for 5 min. The ECL mixture was aspirated from the membranes and the 
membranes blotted dry. Visualisation and imaging was performed using a gel documentation 
system (BioRad XRS System #170-8071). 
Alkaline phosphatase-conjugated secondary antibodies were detected using 5-bromo-4-
chloro-3-indolyl-phosphate (BCIP) and nitro blue tetrazolium (NBT) (Western Blue® substrate; 
Promega S3841). Approximately 5 ml were applied to the membranes and the reaction 
allowed to proceed at room temperature until protein spots/bands were clearly visible and the 
background had just began to take up stain. The reaction was stopped by washing the 
substrate away with deionised water. Visualisation and imaging was performed using a gel 
documentation system (BioRad XR System #170-8170). 
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3.2.3.6 Confirmation of antibody activity in convalescent sera 
To confirm the reactivity of the antibodies present in the convalescent guinea pig sera from 
the aerosol-exposure experiment with the C. burnetii proteins, a 1D PAGE was performed with 
the C. burnetii proteins described in Section 3.2.2 and the proteins blotted onto a membrane 
as described above (Sections 3.2.3.1 and 3.2.3.4). The membrane was cut into strips and the 
sera from each guinea pig used to probe a single strip (Section 3.2.3.5). 
 
3.2.4 Two-dimensional protein separation and immune-reactive protein isolation 
Prior to two-dimensional (2D) PAGE, protein samples requires relatively accurate 
quantification as well as a more thorough clean-up procedure to ensure no substances (ionic 
detergents or salts) that will interfere with the isoelectric focusing (IEF) process are present. 
 
3.2.4.1 Protein quantitation 
The C. burnetii protein prepared in Section 3.2.2 was quantitated using the 2-D Quant Kit (GE 
Healthcare 80-6483-56) by the following procedure. A standard curve was prepared in 1.5 ml 
microcentrifuge tubes from the 2 mg/ml bovine sera albumin (BSA) supplied with the kit; 0, 10, 
20, 30, 40, 50 µg. Two microcentrifuge tubes were also set up with 10 µl each of the C. burnetii 
protein. To all tubes, 500 µl of precipitant (containing trichloroacetic acid) was added, the 
tubes vortex-mixed and incubated at room temperature for 3 min. To all tubes, 500 µl of co-
precipitant (containing deoxycholic acid) was added, the tubes vortex-mixed and the proteins 
pelleted by centrifugation at 10,000 x g for 5 min. 
The supernatants were decanted to waste and the tubes re-centrifuged at 10,000 x g for a 
brief pulse. Any residual supernatant was removed with a micropipette. To all tubes, 100 µl of 
copper solution and 400 µl of deionised water were added and the tubes vortex-mixed to 
dissolve the precipitated protein. To all tubes, 1 ml of working colour reagent (100 parts of 
colour reagent A mixed with 1 part colour reagent B) was added and mixed by inversion, the 
tubes were then incubated for 15 min at room temperature. 
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The absorbance of all samples and the standard curve were read in triplicate on a NanoDrop 
spectrophotometer (ND-2000) using 10 mm disposable plastic cuvettes at wavelength 480 nm 
using deionised water as a reference. The standard curve data were subjected to linear 
regression analysis in MiniTab v16, the regression equation re-arranged and used to calculate 
the quantity of protein in the extracted C. burnetii protein preparation. 
 
3.2.4.2 Protein purification 
Prior to first-dimension separation of proteins according to charge by isoelectric focussing, the 
proteins from the C. burnetii lysis material prepared in Section 3.2.2 were subjected to a 
precipitation-based purification to remove contaminants such as salt that could give the 
material a high conductivity or charged detergents that could interfere with the separation. 
This purification was performed using the 2-D Clean-Up Kit (GE Healthcare 80-6484-51). For 7 
cm pI = 3–11 NL IEF separations 17 µl (41 µg) and pI = 3–5.6 NL and pI = 7–11 NL separations 
25 µl (60 µg) per strip were used. 
The required number of µg of lysed C. burnetii material was pipetted into 1.5 ml 
microcentrifuge tubes. To each tube, 300 µl precipitant was added and the tubes vortex-
mixed, the samples were then incubated on ice (4 °C) for 30 min. To each tube, 300 µl of co-
precipitant was added and the contents vortex-mixed. The tubes were centrifuged at 12,000 x 
g at 4 °C for 10 min. The supernatant was removed and discarded, the tubes were then pulse 
centrifuged at the same speed and temperature as above. Residual supernatant was removed 
and discarded using a fine micropipette. Onto the pellets, 40 µl of co-precipitant was carefully 
layered so as to not disturb the pellet. The tubes were then incubated on ice for 5 min. The 
tubes were centrifuged at 12,000 x g at 4 °C for 10 min and the supernatant discarded using a 
micropipette. 
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Onto each pellet was pipetted 25 µl of deionised water and the tubes vortex-mixed for 30–60 s 
to disperse the pellet. Pre-chilled wash buffer (-20 °C) was added to each tube, 1 ml per tube 
containing 5 µl of wash additive and vortex-mixed. The tubes were then incubated in a freezer 
at -20 °C for 1 h with vortex-mixing every 15 min. Protein was pelleted by centrifuging the 
tubes at 16,000 x g at 4 °C for 10 min and the supernatant discarded. The pellets were allowed 
to air-dry for 5 min in a rack with the lids open at room temperature. Pellets were re-
suspended in 125 µl of IPG strip rehydration solution (GE Healthcare 17-6003-19) by repeated 
pipetting. The re-suspended, purified proteins were then stored at -80 °C until just prior to IEF 
strip rehydration. 
 
3.2.4.3 Isoelectric focusing of C. burnetii proteins 
For first dimension separation of proteins according to their charge or isoelectric point (pI), 
isoelectric focusing (IEF) was performed. An Ettan IPGPhor II instrument using 7 cm Immobiline 
DryStrip gels which consist of a pre-formed pH gradient immobilized into a poly-acrylamide gel 
on a stiff plastic backing was used. To the thawed purified proteins suspended in rehydration 
solution, the immobilised pH gradient (IPG) buffer containing carrier ampholytes (GE 
Healthcare pI 3 - 11NL 17-6004-40, pI 7 - 11NL 17-6004-39, pI 3 - 5.6NL 17-6002-02) with the 
appropriate pI interval to the strip being run, was added to a final concentration of 1 % (v/v). 
Into the IPG strip holder of the IPGPhor, 125 µl of the protein preparation was pipetted. The 
protective backing was removed from the IPGstrip (GE Healthcare pI 3 - 11NL 17-6003-73, pI 7 
- 11NL 17-6003-68, pI 3 - 5.6NL 17-6003-53), and the strip placed, gel side down, onto the 
protein solution. The strip was then overlaid with cover fluid (GE Healthcare 17-1335-01) and 
the lid placed on top. The rehydration was left overnight in the IPGPhor at room temperature. 
After rehydration, the IPG strips were removed from the strip holders and thoroughly washed 
with deionised water. The strip holders were washed and dried to remove all traces of cover 
fluid. Two filter paper electrode bridges were cut and placed into the strip holders and either 
both soaked with deionised water for acidic pI range (pI 3-3.5NL) or the anode with deionised 
water and the cathode with rehydration solution for basic pI ranges (pI 3-11NL and pI 7-11NL). 
The rehydrated IPG strip was carefully placed, gel side down, such that the electrode bridges 
made contact with each end of the gel, the strip holder filled with cover fluid and the lid placed 
on top. The lid of the IPGPhor was closed and the IEF programme, appropriate to the strip, run. 
The parameters used are presented below (Table 3.1). After IEF, the strips were washed with 
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deionised water and either used immediately for second dimension separation or stored in 
petri dishes sealed with Parafilm® M (Sigma-Aldrich P7793) at -20 °C. 
Table 3.1 – For first dimension separation of C. burnetii proteins by isoelectric point the IPG Strip running 
conditions here were used for focussing the 7 cm Immobiline DryStrips on the Ettan IPGPhor II Isoelectric 
focussing instrument. Temperature was held at 20 °C and current was capped at 50 µA/strip. 
pI Interval Step voltage mode Voltage (V) Time (h:min) 
3.0 – 11.0 NL 1. Step and Hold 300 1:00 
2. Gradient 1,000 0:30 
3. Gradient 5,000 1:20 
4. Step and Hold 5,000 0:25 
3.0 - 5.6 NL 1. Step and Hold 300 1:00 
2. Gradient 1,000 0:30 
3. Gradient 5,000 1:30 
4. Step and Hold 5,000 0:36 
7.0 – 11.0 NL 1. Step and Hold 300 1:00 
2. Gradient 1,000 1:00 
3. Gradient 5,000 1:30 
4. Step and Hold 5,000 0:55 
  
3.2.4.4 Second dimension protein separation 
For second dimension separation of the pI-separated proteins according to their size, 
polyacrylamide gel electrophoresis (PAGE) was performed. Lithium dodecyl sulphate buffer (4X 
NuPAGE® LDS sample buffer; Life Technologies NP0008) was diluted to 1x with deionised 
water. The proteins in the IPG strips were reduced in immunoassay reagent troughs in 1X LDS 
sample buffer containing 1:10 sample reducing agent (NuPAGE® sample reducing agent 10X; 
Life Technologies NP0009) at room temperature for 15 min with gentle rocking. The reducing 
buffer was decanted off and replaced with alkylating buffer consisting of 1X LDS sample buffer 
containing 125 mM iodoacetamide (Sigma I1149) at room temperature for 15 min with gentle 
rocking. The alkylating buffer was decanted off and discarded.  
The plastic backing strip of the IPG strip was trimmed to 7 cm and the strip carefully inserted 
into the IPG well of the PAGE gel (NuPAGE® Novex® 4–12 % Bis-Tris ZOOM® protein gel, 1 mm 
thick; Life Technologies NP0330BOX). Approximately 400 µl of molten 0.5 % (w/v) agarose 
(VWR Electran® 438795A) in MOPS-SDS running buffer (NuPAGE® MOPS SDS running buffer; 
Life Technologies NP0001) were pipetted into the well containing the IPG strip and allowed to 
set. 
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The gel was loaded into the electrophoresis unit with MOPS SDS running buffer at the anode 
and MOPS SDS running buffer containing antioxidant (Life Technologies NuPage® NP0005) at 
the cathode. Into the molecular weight lane, a pre-stained protein standard marker (Life 
Technologies SeeBlue® Plus2 LC5925) was loaded. The gel was then electrophoresed at 200 V 
for 45 min. 
Gels were stained and visualised using either Coomassie or silver protocols as described 
previously (Sections 3.2.3.2 and 3.2.3.3). Western blots and antibody probing of membranes 
were performed as described previously (Sections 3.2.3.4 and 3.2.3.5). 
 
3.2.4.5 Isolation of immune-reactive protein spots 
Parallel 2D PAGE gels were prepared of the C. burnetii proteins for three pI ranges; 3–11, 3–
5.6, and 7–11. One gel from each pair was used to produce a Western Blot, probed with guinea 
pig sera from the aerosol-exposure experiment group one, subject four (4427 1-4), and 
detected with Western Blue® (NCIP/NBT) substrate as described previously (Section 3.2.3.5). 
The other gel was stained with Coomassie (Section 3.2.3.2); despite the use of a mass 
spectrometric-compatible protocol, silver staining was avoided because it is less compatible 
with down-stream mass spectrometry analysis than Coomassie. 
The stained Western blot membrane was placed on a lightbox and the Coomassie-stained 
protein gel placed in a petri dish on top of this. The protein gel was moved until the two gels 
were aligned using the molecular weight markers and the larger spot-features as a guide. 
Protein spots that visibly corresponded to spots on the Western blot membrane were carefully 
excised using sterile, trimmed, 1 ml micropipette tips or, for larger regions of interest, with a 
disposable scalpel. In some cases it could not be ascertained which protein spot corresponded 
to an individual spot on the Western blot membrane, in those cases no spot was collected. This 
is why some spots visible on the membrane in the results section have no corresponding cut 
spot. 
The spots and regions that were cut were collected into labelled 500 µl microcentrifuge tubes 
and stored at -80 °C prior to further processing. 
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3.2.5 Immunoprecipitation of immune-reactive proteins 
A single spot picked from a 2D PAGE gel may well contain numerous protein species and there 
is no convenient method for identifying which of the identities corresponds to the immune-
reactive protein species detected on the sera-probed Western blot. Due to this, a second 
method was used to produce a second dataset of protein identities generated by using the 
guinea pig sera to ‘capture’ the immune-reactive proteins by Immunoprecipitation as 
described below. The captured proteins were then eluted, and identified by tandem mass 
spectrometry in the next chapter. 
 
3.2.5.1 Antibody affinity purification 
Immunoprecipitation (IP) requires an affinity purified class G immunoglobulin (IgG) antibody to 
use as the capture antibody. This was prepared from 500 µl of guinea pig sera as follows.  
A 1 ml recombinant Protein A (1 ml) column (HiTrap™ rProtein A FF GE Healthcare #17-5079-
02) was fitted to an AKTA fast protein liquid chromatography (FPLC) instrument. The flow rate 
of the instrument was set to 1 ml/min. The column was flushed to remove any residual storage 
buffer with 5 ml of binding buffer (Appendix 1). The column was regenerated with 5 ml of 
Elution Buffer (Appendix 1) and finally equilibrated with 10 ml of binding buffer. 
The guinea pig antisera (4427 1-4) was made up to 5 ml with binding buffer and filtered 
through a 0.45 µm syringe filter. This was then injected into a 5ml loading loop on the FPLC 
instrument. Due to the precious nature of the antisera, the syringe was washed with binding 
buffer and the contents injected onto the column. The column was then washed with 15 ml of 
binding buffer. 
Finally, the bound IgG was eluted by washing 5 ml of elution buffer through the column. 
Fractions (7 x 1 ml) were collected into tubes each containing 200 μl of 1 M Tris-HCl, pH 9.0 to 
rapidly neutralise the low pH of the elution buffer and minimise damage to the purified 
antibodies. 
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3.2.5.2 Dialysis and concentration of affinity purified antibody 
To buffer-exchange the antibodies into a buffer compatible with IP, the pooled fractions (four 
and five) containing the eluted, affinity-purified IgG (approximately 2.5 ml) were dialysed 
against phosphate buffered saline (PBS) in a Slide-A-Lyzer dialysis cassette (Thermo #66380 - 
10,000 MWCO). Three dialyses were performed, two stirred 500 ml volumes at room temp for 
2 h each, followed by a third overnight at 8 °C. 
The dialysed antibody was concentrated using a centrifugal concentrator (VivaSpin500 
Sartorious #VS0121; 30K MWCO) by first washing the storage buffer off the column with 500 µl 
PBS for 10 min at 15,000 x g. The purified antibody was loaded onto the column 500 µl at a 
time and concentrated for 10 min at 15,000 x g until all of the antibody had been loaded and 
concentrated, and the final volume was approximately 50 µl. The concentrated antibody was 
quantitated by measuring the absorbance at 280 nm (NanoDrop ND-2000 spectrophotometer) 
using PBS as a blank. 
 
3.2.5.3 Purity and activity check of affinity purified antibody 
Non-reducing and reducing 1D PAGE was performed on the neat guinea pig sera, the column 
wash through, and the eluted, dialysed and concentrated IgG. To reduce the samples they 
were heated to 95 °C for 10 min in the presence of 50 mM dithiothreitol (DTT; Life 
Technologies P2325). 
In addition, to assess there was no activity loss during processing of the IgG, two Western blot 
strips of C. burnetii protein were probed as described above (Section 3.2.3.5) one with the pre-
treated guinea pig sera (4427 1-4) and the other with the purified, concentrated IgG. 
 
3.2.5.4 Preparation of proteins for immunoprecipitation 
For capture of the proteins recognised by the antibodies by their conformation, the native 
epitopes, 0.5 mg of C. burnetii protein was buffer-exchanged into the IP lysis/wash buffer 
supplied with the Pierce™ Crosslink Magnetic IP (Thermo #8805) kit. The buffer-exchange was 
carried out by performing three, 1 ml concentrations into IP lysis/wash buffer in a 5 kDa 
MWCO centrifugal concentrator (Sartorius Vivaspin 2; VS0211) at 20 °C and 4,000 x g. 
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The majority of proteins isolated so far in this chapter using the 2D PAGE spot picking method, 
were all denatured and reduced and consisted of predominantly linear epitopes. To produce a 
denatured protein preparation, 0.5 mg of C. burnetii protein was made to 1 % (v/v) sodium 
dodecyl sulphate with 10 % (v/v) stock solution (Life Technologies 24730-020) and 10 mM 
dithiothreitol (DTT; Life Technologies P2325) and heated to 95 °C for 15 min. This mixture was 
then alkylated by the addition of iodoacetamide (IAA; Sigma I1149) to a final concentration of 
50 mM and incubated in the dark at room temperature for 45 min. To remove the substances 
that would interfere with the IP reaction, the denatured, reduced, and alkylated proteins were 
buffer-exchanged into IP lysis/wash buffer as described above for the native proteins. 
 
3.2.5.5 Immunoprecipitation of C. burnetii immune-reactive proteins 
Immunoprecipitation was performed using a Pierce™ Crosslink Magnetic IP (Thermo #8805) 
kit. For each immunoprecipitation experiment, antibody was bound to protein A/G magnetic 
beads by pipetting 50 μL of the magnetic beads into a 2.0 ml microcentrifuge tube. The tubes 
were placed in a magnetic stand and the storage buffer discarded. The beads were twice 
washed for 1 min in 500 µl of modified coupling buffer (MCB – consisting of 100 µl of 20X 
coupling buffer and 100 µl mL of IP lysis/wash buffer made up to 2 ml with deionised water) on 
a rotating platform followed by magnetic collection and discarding of the supernatant. The 
affinity-purified guinea pig IgG was diluted to a final volume of 200 µl of MCB containing 20 µg 
of antibody. To bind antibody to the beads, the diluted antibody solution was added to the 
beads and the tubes incubated on a rocking platform for 30 min at room temperature – 
vortexing every 10 min during incubation. The beads were collected with a magnetic stand and 
the supernatant discarded. 
The beads were washed with 100 μl of MCB, vortexed, magnetically collected and the 
supernatant discarded. This was repeated with a 300 µl volume of MCB twice more to remove 
any unbound antibody. 
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Antibody was cross-linked to the magnetic beads using disuccinimidyl suberate (DSS). The DSS 
was diluted to 0.25 mM in dimethylformamide (DMF). The cross-linking buffer consisted of 100 
µl coupling buffer containing 20 µM DSS. The cross-linking buffer was added to the beads, 
vortexed and incubated for 30 min at room temperature on a rocking platform. The beads 
were collected in a magnetic stand and the cross-linking solution discarded. To remove any 
non-crosslinked antibody and stop the cross-linking reaction, 100 µl volumes of elution buffer 
were added to the beads and mixed for 5 min at room temperature before magnetically 
collection and discarding the supernatant. This was performed twice. The beads were finally 
given two, 200 µl washes in 8 °C IP lysis/wash buffer. 
The native or denatured protein preparations (Section 3.2.5.4) were added to tubes containing 
cross-linked magnetic beads and incubated for 1 h at room temperature followed by overnight 
incubation at 8 °C on a rotating mixer. The beads were collected and the unbound proteins 
removed and retained. The beads were washed twice with 500 µl of IP lysis/wash buffer and 
once with 500 µl of deionised water. Bound proteins were eluted by adding 100 μL of elution 
buffer to each tube followed by incubate for 5 min at room temperature on a rotating 
platform. The beads were magnetically collected, the supernatant containing the eluted 
proteins removed, and the pH neutralised with 10 µl of neutralisation buffer. The elution step 
was repeated twice and the supernatants pooled. 
The eluted proteins were immediately purified and concentrated by precipitation using a 2-D 
Clean-Up Kit (GE Healthcare 80-6484-51) described previously (Section 3.2.4.2). The 
precipitated protein was denatured and reduced by re-suspended in 1x Laemmli buffer, 
heating to 95 °C for 10 min and subjecting to 1D PAGE as described previously (Section 3.2.3). 
Western blots were also performed and the blots probed with guinea pig antisera. 
The eluted protein lanes from the Coomassie-stained gel were cut into 7 x sections (each 
approximately 1 cm x 0.5 cm) and stored at -20 °C for mass spectrometric analysis in the next 
chapter. 
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3.3 Results 
 
3.3.1 Growth of C. burnetii 
3.3.1.1 Optimisation of inoculation concentration 
The growth curves for different C. burnetii seeding concentrations (Figure 3.2) show that for 
inoculation concentrations in the range 1 x 102 to 1 x 104 copies/ml, growth was exponential. 
For the two highest titres (1 x 105 and 1 x 106 copies/ml), growth was initially exponential until 
day five post-inoculation, where the titre reaches a plateau and begins to fall. The optimal 
inoculation concentration was determined to be 1 x 104 copies/ml because the endpoint titre 
at day ten post-inoculation is almost as high as the peak titre observed for higher inoculation 
concentrations but without the associated fall in titre at the end. 
 
Figure 3.2 – Growth curves of C. burnetii in ACCM-2 media incubated at 37 °C in a microaerophilic atmosphere 
over a ten-day period at five different culture inoculation concentrations. All titres measured by real-time qPCR 
targeting the icd gene as described in Chapter 2. Figure shows that the maximum titre supported by this media is 
approximately 10
10
 copies/ml and that culturing for over 6 days with seeding concentrations above 10
5
 copies/ml 
leads to a reduction in qPCR signal.  
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3.3.1.2 Quality assessments 
3.3.1.2.1 Electron microscopy 
The electron micrographs of the ACCM-2 grown C. burnetii (Figure 3.3 and Figure 3.4) show 
that the material (larger scale growth; Section 3.2.1.2) consists almost exclusively of bacterial 
material with little to no contaminating matter. The micrographs show a mixture of 
morphological forms, the smaller electron-dense particles are likely to be the SCV and the 
larger more diffuse particles with visible structural detail (electron dense chromatin in the core 
and a double-walled plasma membrane) the LCV. 
 
Figure 3.3 - Transmission electron micrograph of the ACCM-2 grown C. burnetii – from the larger scale growth 
discussed in Section 3.2.1.2 and harvested at day 10 post-inoculation. 7900x magnification. Showing that the 
preparation contains very little contaminating material with the preparation consisting almost entirely of 
microorganisms. Representatives of the small- (SCV) and large cell variants (LCV) are indicated demonstrating the 
preparation contains a mixture of the two morphological forms of the organism. Scale bar 2 µm. 
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Figure 3.4 – Transmission electron micrograph of the ACCM-2 grown C. burnetii at a higher magnification. 34,000x 
magnification. Large cell variant (LCV indicated with L) and small cell variant (SCV indicated with S) indicated, 
showing that the preparation consisted of organisms in both morphological forms. Scale bar 500 nm. 
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3.3.1.2.2 Immunofluorescent UV light microscopy 
The immunofluorescent microscopy image of the ACCM-2 grown C. burnetii (Figure 3.5) shows 
that the material consists almost exclusively of bacterial material (stained as bright green 
coccobacilli) with little to no contaminating matter. The Evans blue counterstain has stained 
very little material and this material is likely to be the dried proteinaceous residue from the 
ACCM-2 media (bacterial cells were not washed before drying onto the slides as it was found 
that without some quantity of salt and protein in the buffer, Coxiellae did not adhere to the 
glass). If there was a large amount of contaminating protein present one would expect to see 
evidence of extensive red counterstaining from the Evans blue. 
 
 
Figure 3.5 - Immunofluorescent microscopy image of C. burnetii (bright green coccobacilli) stained with a 
diagnostic control convalescent goat sera (Veterinary Laboratory Agency) and detected with an anti-goat IgG-FITC 
conjugated secondary antibody. An Evans blue counterstain (red) was also applied to the slide to provide an 
indication of the level of non-C. burnetii protein was present. The extremely low level of red staining from the 
Evans blue is an indication that the preparation was of a high purity and contained very little contaminating 
protein from the yolk sac inoculum. Magnification 400x. 
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3.3.2 One dimensional protein separation 
3.3.2.1 Basic assessment of protein extraction 
The initial assessment of the C. burnetii protein extraction process was performed by running 
three lanes of the reduced, denatured protein; 10 µl, 5 µl, 2.5 µl. The gel image (Figure 3.6) 
shows a range of many well-defined bands from approximately 100 kDa down to smaller than 
19 kDa. This is an indication that the BugBuster extraction process is successfully extracting a 
mixture of proteins from the organism. 
 
Figure 3.6 – One-dimensional SDS-PAGE image of extracted C. burnetii protein run on a 12 % Bis-Tris gel in MOPS-
SDS running buffer at 200 V for 50 m. The three lanes are 10 µl, 5 µl, and 2.5 µl of protein boiled in Laemmli 
buffer to ensure good band clarity. The figure shows that the extracted protein contained a wide range of 
proteins of different masses present in distinct species with little evidence of degradation (bands were sharply 
delineated with little smearing). 
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3.3.2.2 Confirmation of antibody activity in convalescent sera 
The Western blots of C. burnetii proteins (on the membranes) probed with guinea pig sera (IgG 
fraction only detected by the conjugate) from the aerosol-exposure experiment show that the 
negative animal (4427 V1-7) had no response to the proteins present in the protein 
preparation (Figure 3.7). The faint band seen at ~40 kDa is likely to be bleed-through from the 
MW marker in the adjacent lane. Guinea pigs A1-1 to A1-6 all showed good responses to a 
wide range of proteins present in the preparation. The quality of the response in animals 1-4 
and 1-6 is subjectively better in that the bands detected are sharper and more well-defined 
with more bands detected in the 19–60 kDa range; these two animals were autopsied at day 
15 post-exposure whereas the others were autopsied at day 21 post-exposure. 
 
Figure 3.7 - Western blot of C. burnetii proteins (on the membrane) probed with the aerosol-exposed guinea pig 
sera (containing immune-reactive antibodies), that binding detected with anti-guinea pig IgG conjugate, and 
visualised with ECL prime substrate. Lane 1 is the transferred SeeBlue Plus2 Molecular Weight standard and lane 
2 contains the MagicMark XP Standard.  Figure shows that the sera from all of the exposed guinea pigs reacted to 
some degree with the proteins present in the C. burnetii extract whereas the unexposed guinea pig (A1-7) did not 
react. The image also suggests that individuals A1-4 and A1-6 reacted with a more proteins over a wider mass 
range than the other exposed animals. 
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3.3.3 Two-dimensional protein separation and immune-reactive protein isolation 
3.3.3.1 Protein quantitation 
The standard curve generated during the protein assay (Figure 3.8) yielded the line equation: 
>?	480	0	 = 0.856 − 0.003 × μ	BSA 
 
To calculate the quantity of protein present in the C. burnetii protein preparation this was re-
arranged to the form: 
μ	EFG	 = 	>?	480	0 − 0.8560.003  
The two samples of the C. burnetii extract gave protein quantities of 21 and 26 µg in the 10 µl 
tested. For the purposes of the 2D PAGE the mean value of 2.4 µg/µl was used. 
 
Figure 3.8 - Linear Regression of protein quantitation standards and the resulting line equation used to calculate 
the protein quantities present in the C. burnetii extract. Line equation OD480 nm = 0.856–0.003 µg BSA; S = 0.013; 
R
2
 = 94.8%; R2 (adj) = 94.5 %; P < 0.001. The derived line equation was used to determine the loading quantities 
of proteins for the first-dimension (isoelectric focussing) of the 2D SDS-PAGE process to reduce the risk of under 
or overloading the gels. 
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3.3.3.2 Two-dimensional protein separation 
Protein separations in two-dimensions over the three pI ranges chosen showed a satisfactory 
range of spots in terms of both molecular weight and pI (Figure 3.9, Figure 3.10, and Figure 
3.11). There appears to be a slight bias towards the number of spots in the low pI (3–5.6) range 
compared to the higher (7–11) range. 
 
Figure 3.9 - Coomassie-stained 2D PAGE separation of C.  burnetii proteins across the wide pI range 3.0–11.0 
(non-linear). Isoelectric point ranges from pI = 3 at the left side of the image to pI = 11 at the right side of the 
image. Each stained spot represents a single, or small group of proteins of a specific size and isoelectric point. 
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Figure 3.10 - Coomassie-stained 2D PAGE separation of C.  burnetii proteins across the narrower (acidic) pI range 
3.0–5.6 (non-linear). Isoelectric point ranges from pI = 3 at the left side of the image to pI = 5.6 at the right side of 
the image. 
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Figure 3.11 - Coomassie-stained 2D PAGE separation of C.  burnetii proteins across the narrower (basic) pI range 
7.0–11.0 (non-linear). Isoelectric point ranges from pI = 7 at the left side of the image to pI = 11 at the right side of 
the image. 
 
3.3.3.3 Immune-probing of 2D PAGE Western Blots and protein spot excision 
Western blot membranes that were probed with guinea pig sera (4427 A1-4) were used to 
identify spots or regions on the Coomassie stained 2D PAGE gels that contained immune-
reactive proteins. The locations and assigned identities of the cut proteins are indicated on the 
images of the blots below (Figure 3.12, Figure 3.13, and Figure 3.14). 
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Figure 3.12 – Western Blue® (BCIP/NBT)-stained antibody-probed Western blot of C.  burnetii proteins detected 
in wide pI range 3-11 (non-linear). Immunoreactive proteins probed with antibody (IgG) present in guinea pig 
sera (A1-4), the bound antibody was detected with anti-Guinea Pig IgG/alkaline phosphatase conjugate. The 
areas marked C1–C9 indicate the locations from where spots of the corresponding protein gel were excised for 
protein identification. 
114 
 
 
Figure 3.13 – Western Blue® (BCIP/NBT)-stained antibody-probed Western blot of C.  burnetii proteins detected 
in lower, narrow pI range 3–5.6 (non-linear). Immunoreactive proteins probed with antibody (IgG) present in 
guinea pig sera (A1-4), the bound antibody was detected with anti-Guinea Pig IgG/alkaline phosphatase 
conjugate. The areas marked L1–L20 indicate the location from where spots of the corresponding protein gel 
were excised for protein identification. 
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Figure 3.14 – Western Blue® (BCIP/NBT)-stained antibody-probed Western blot of C.  burnetii proteins detected 
in higher, narrow pI range 7–11 (non-linear). Immunoreactive proteins probed with antibody (IgG) present in 
guinea pig sera (A1-4), the bound antibody was detected with anti-Guinea Pig IgG/alkaline phosphatase 
conjugate. The areas marked H1–H7 indicate the location from where spots of the corresponding protein gel 
were excised for protein identification. 
  
 3.3.4 Imm
3.3.4.1 Antibody affinity purification
The output of the FPLC instrument is shown below (
four and five contain the bulk of the eluted IgG. The concen
produced yielded a mean quantity of 2.9 µg/µl (A
The purity and activity assessment (
serum proteins were washed from the column in
affinity purified antibody contained almost pure IgG (heavy and light IgG chains in the reduced 
gel image). In addition, the antibody
IgG to be indiscernible f
Figure 3.15 - 
blue trace shows protein concentrati
indicated by the pink vertical bars, the switch of the instrument from binding buffer to elution buffer is indicated 
by the change in conductivity shortly after 25 ml (green trace) an
text from this point.
 
unoprecipitation of immune
Output trace of the AKTA FPLC instrument during affinity purification of the guinea pig antisera. The 
 
rom the untreated antisera from which it was derived.
on (arbitrary units) measure
-reactive proteins
 
Figure 3.16
-probed Western blots show the acti
Figure 
280 nm = 3.945).
) show that the majority of the non
 the flow
d by UV, the two sample injection points are 
d the eluted protein fraction identities are in red 
 
3.15). It can be seen that fractions 
trated antibody preparation 
 
-through (lanes 2 and 6) and the 
vity of the purified 
 
116
-antibody 
 
 
117 
 
 
Figure 3.16 – Left-hand pane - 1D PAGE analysis of affinity purified guinea pig IgG. Lanes 1-3 non-reduced protein. 
Lanes 5-7 reduced protein. Lanes 1 and 5 are antisera, lanes 2 and 6 are purification column wash through, lanes 
3 and 7 are the eluted, dialysed and concentrated IgG. In lane 7 the heavy (~50 kDa) and light (~23 kDa) chains of 
IgG can be clearly seen, in lane 3 the ~150 kDa single band of the un-reduced IgG is not easily visualised, this is 
likely due to lane-to-lane bleed of the reducing agents partly reducing the IgG. 
Right-hand pane – Antibody-probed Western Blots of C. burnetii protein detected with Western Blue® substrate 
showing no difference in activity between the un-treated antisera and the affinity-purified antibody. 
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3.3.4.2 Immunoprecipitation 
The protein results of the immunoprecipitation (IP) experiment (Figure 3.17) do not show any 
obvious loss of protein in the post-IP lanes. However, the eluted proteins from both the native 
and denatured protein samples contain a good range of sizes of protein species. Some of these 
proteins are present at low abundance, evidenced by the fact that they are only visible on the 
more sensitive silver-stained gels.  
Immunoprobing the Western-blot membrane with the IgG present in guinea pig sera (4427 A1-
4) shows reactions with proteins present in all lanes (Figure 3.18). This is further confirmation 
that the IP experiment did not remove all of the immune-reactive proteins from the post-IP 
samples. Although as the protein mixture is applied (as specified in the protocol) in an excess 
relative to the amount of antibody bound to the magnetic beads, this is unsurprising. 
Reactions with the eluted protein lanes demonstrate that the proteins that were 
immunoprecipitated were immune-reactive species. Many of the protein species bands from 
the highly-sensitive silver-stained gel were not detected on the immunoblot; this is likely due 
to the low abundance of these proteins rather than their lack of immunogenicity. However, it 
is possible that some of the native proteins, due to their denatured and reduced state here, 
would not be recognised by their corresponding antibody. 
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Figure 3.17 – The left-hand pane is the Coomassie-stained 1D PAGE of the immunoprecipitation (IP) experiment 
protein samples. Lanes 1 and 2 are the Native C. burnetii protein material pre- and post- IP. Lanes 3 and 4 are the 
Denatured material pre- and post-IP. Lane 7 is the post-IP (Convalescent guinea pig IgG-captured) eluted native 
proteins. Lane 10 is the post-IP eluted denatured proteins. 
The right-hand panel is the residual protein remaining in the gel after Western blotting the same material with 
the exception that lanes 5 and 6 are the eluted native and denatured protein materials. The inherent inefficiency 
of the blotting procedure (which leaves a proportion of proteins in the gel) coupled with the greater sensitivity of 
the silver staining procedure demonstrates that a good range of protein species were eluted from the IP 
experiment. 
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Figure 3.18 – Western-blot of the immunoprecipitation (IP) experiment protein samples probed with guinea pig 
convalescent sera (4427 1-4). Lanes 1 and 2 are the Native C. burnetii protein material pre- and post- IP. Lanes 3 
and 4 are the Denatured material pre- and post-IP. Lane 5 is the post-IP (Convalescent guinea pig IgG-captured) 
eluted native proteins. Lane 6 is the post-IP eluted denatured proteins. 
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3.4 Summary of Results 
 
In the C. burnetii axenic growth experiments, the reason for the drop in titre at the end of the 
growth curve, for the higher titre inoculations, is difficult to interpret. In a normal growth 
curve, this phenomenon could be explained by organisms dying due to the accumulation of 
toxic metabolites in the media or the nutrients being exhausted. Given that the qPCR amplifies 
and quantitates the organism’s DNA, the viability status of the organisms should not affect the 
titre. It is unlikely that this observation is due to the DNA being degraded to a point where the 
qPCR assay would detect a fall in titre of this magnitude due to the small size of the 
amplification target. It is possible that the Coxiellae are switching from the large cell variant 
(LCV) to the small cell variant (SCV) morphological form as the nutrients in the media become 
limiting, or toxic metabolites have built up to inhibitory levels. This would mean that the small 
and dense SCV, which are believed to be more chemically resistant than the larger LCV 
(Ransom & Huebner, 1951), are more resistant to the extraction of their DNA and thus, the 
DNA is not available for qPCR amplification. For the purposes of this project it was desirable to 
have a protein preparation that contained organisms in both morphological states to more 
comprehensively represent the organism’s range of proteins. Therefore, these two doses were 
avoided when preforming the larger-scale growth used in the protein extraction experiments. 
The electron microscopy images demonstrate that a mixture of morphological types were 
present in the final material produced (the large scale grown stock in Figure 3.3). 
The initial one-dimensional protein separations and Western blots showed that the extracted 
proteins contained a satisfactory range of protein species and that the guinea pig sera from 
the aerosol-infection experiments reacted strongly with a restricted subset of the protein 
bands. This demonstrated that the antisera could be used to select only those proteins 
recognised by the guinea pig immune-system during infection, organism clearance and 
recovery.  
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The two-dimensional (2D) protein separations further supported the observations from the 
one-dimensional work by yielding a wide range of protein species in terms of both size and 
charge (pI). The Western blot analysis of the 2D-separated proteins again demonstrated that 
only a subset of the proteins present reacted with the sera from the guinea pigs. Sections of 
the 2D PAGE gels corresponding to reactive areas on the immunoblots were excised and 
stored for further analysis (Chapter 4). 
A single spot or region cut from a 2D PAGE gel may contain more than one protein species, and 
there is no convenient method for identifying which protein in the mixture is the one being 
identified on the immunoblots. The use of immunoprecipitation (IP), using purified IgG from 
the guinea pig sera, to capture proteins from a denatured and reduced preparation should 
allow the generation of a second, more definitive, dataset to help validate the data from the 
spot-picking experiments. In addition, the proteins blotted from 2D PAGE gels, by nature of the 
procedure, have been denatured, reduced and alkylated before exposure to the antibody. 
Therefore, any antibodies recognising larger, conformational epitopes will fail to react with the 
linearised proteins found on these gels. In an attempt to capture these proteins, IP was also 
used to capture proteins from an untreated protein preparation. The entire protein gel lanes 
containing the proteins eluted during IP were cut into sections and stored for further analysis 
(Chapter 4). The use of IP for the detection of immune-reactive proteins in C. burnetii has not 
been reported in the literature. 
  
123 
 
3.5 Outcomes 
 
• A protein preparation was made from a host-protein free preparation of C. burnetii 
grown in axenic media that was only a single passage distant from the egg-grown 
organisms (EP2) and therefore likely to be of the virulent, phase I phenotype. 
• The protein preparation was demonstrated to have a wide range of proteins in terms 
of size and charge.  
• A subset of these proteins was demonstrated to react with sera from animals that 
have been infected by a representative route, suffered from febrile illness, and 
recovered. 
• A novel approach to immune-reactive protein discovery, immunoprecipitation, was 
employed with purified guinea pig IgG to capture both native and denatured immune-
reactive proteins. 
• The immune reactive proteins from both 2D PAGE and IP were excised from gels and 
stored for further protein identification. 
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4 Protein Identification 
4.1 Introduction 
 
In the previous chapter, a protein preparation was made from low-passage, axenically-grown 
C. burnetii. This protein preparation was demonstrated to contain a wide range of proteins in 
terms of size and charge and a subset of these proteins reacted with sera from animals that 
had been infected with, and recovered from, C. burnetii infection. Finally, PAGE gel fragments 
containing regions corresponding to reactive areas on immunoblots from 2D gels or immune-
reactive protein mixtures captured using convalescent guinea pig IgG were stored for down-
stream protein identification. In this chapter, those proteins will be subject to identification 
and further analysis. 
Until the 1990s the only way to identify a protein was to prepare a substantial amount at a 
high level of purity and sequence it by a process known as Edman degradation (Edman, 1949; 
Edman & Begg, 1967). Mass spectrometry at that time was limited to the analysis of small 
molecules due to the harsh ion sources available. However, the introduction of ‘soft’ ionisation 
techniques such as matrix-assisted laser desorption ionisation (MALDI) (Karas & Hillenkamp, 
1988) and electrospray ionisation (ESI) (Fenn, Mann, Meng, Wong, & Whitehouse, 1989) made 
analysis of intact proteins and peptides by mass spectrometry possible. 
Mass spectrometry is now a routine procedure in microbial diagnostics for the identification of 
bacterial clinical isolates; indeed systems are commercially available to perform this analysis 
such as the Bruker Biotyper. In the standard identification experiment, bacterial colonies are 
directly applied to a target plate, coated with matrix and analysed by a MALDI ion-source 
coupled to a time-of-flight mass spectrometer (MALDI-TOF). The mass spectra are then directly 
compared with a database of spectra which in most cases facilitates rapid identification of the 
organism in the colony. The technology is generally capable of identifying isolates to the 
species and, in some cases, the subspecies level (Kliem & Sauer, 2012). 
The simplest method for identifying single proteins is peptide mass fingerprinting (PMF). In this 
technique the isolated protein to be identified is first digested into a series of peptides with a 
protease that has a known cleavage pattern. The enzyme used for this is generally trypsin 
which cleaves proteins at lysine and arginine residues except those adjacent to proline (Olsen, 
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Ong, & Mann, 2004).  The peptide mixture is then analysed by MALDI-TOF to generate a list of 
peptide masses contained in the sample. The masses of the peptides, the peptide mass 
fingerprints, are then compared with a database of in silico digested proteins to identify the 
protein being analysed (Mann, Hojrup, & Roepstorff, 1993; Pappin, Hojrup, & Bleasby, 1993). 
The disadvantage of this form of identification is that it is possible, especially when analysing 
protein mixtures, that relying only on peptide mass data can lead to a lack of a database match 
or mismatching with a similar profile of an erroneous protein. 
A further refinement in the analysis of peptides derived from the tryptic digestion of proteins 
is the use of tandem mass spectrometry. A tandem mass spectrometer (MS/MS or MSn) is a 
pair of mass spectrometers arranged such that the output of one is directly coupled to the 
input of another, often with an additional collision cell for performing fragmentation of 
peptides (see diagram and explanation of general functions in Figure 4.1). A typical modern 
instrument simplifies the digested peptide mixture by separation based on hydrophobicity 
using nano-scale high-performance liquid chromatography (nanoLC) followed by analysis in a 
tandem mass spectrometer. As well as measuring the masses of the individual peptides, the 
instrument also fragments those peptides and measures the masses of each of the fragments. 
In this manner it is possible to generate sequence information approaching the quality of de 
novo sequence data on each of the peptides (Scigelova & Makarov, 2006). The peptide 
sequence ‘tags’ produced by this method are then searched against a database to give very 
accurate predictions of the proteins from which the peptides were cleaved. 
Previous efforts using mass spectrometry to identify immunoreactive proteins of C. burnetii 
used MALDI-TOF/TOF (Coleman et al., 2007; Sekeyova et al., 2009; Xiong et al., 2012) and 
nanoLC-ESI-MS/MS (Deringer et al., 2011; Xiong et al., 2012). These workers all successfully 
used the position of immunoblot reactive spots to select and analyse gel regions in 2D-PAGE 
gels to identify many proteins. The nanoLC-ESI-based tandem MS method is generally 
recognised as a more successful method of identifying proteins in complex mixtures (X. Zhang, 
Scalf, Berggren, Westphall, & Smith, 2006), this means that some of the previously published 
MALDI-TOF/TOF data may contain spurious identities or only identify the most abundant 
protein in each spot. In addition, spot picks from 2D-PAGE, as can be seen in the data 
presented in Appendix 3, generally contain many different proteins. Therefore, it is impossible, 
in many cases, to definitively identify which protein in the mixture is the immunoreactive 
species. It is probable, therefore, that there are likely to be unidentified and misidentified 
proteins in at least some of the previous reports.  
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In vitro translation of proteins/predicted open-reading frames (ORFs) followed by either; 
probing the synthetic proteins with sera/antibody of microarray or ELISA to identify immune-
reactive proteins, or using the ELISPOT assay to determine which synthetic proteins will elicit a 
recall response (IFN-γ production) in splenocytes or peripheral blood monocytes have also 
been used to successfully identify immune reactive proteins of C. burnetii (Beare et al., 2008; 
Chen et al., 2009; Vigil et al., 2010). The identified proteins will be considered later in this 
project but the methods they described cannot be applied to the 2D-PAGE and 
immunoprecipitation-derived protein isolates produced using the methods described in 
Chapter 3 so they are not discussed further at this point. 
 
 
Figure 4.1 - General layout of the Q-Exactive mass-spectrometer (MS) used in this work. The peptides enter the 
MS from the nano-scale liquid-chromatography separation (not shown) and are ionised at the electrospray 
ionisation source (ESI) – labelled NanoSpray source (lower right). The peptide ions then pass in the first MS – the 
quadrupole – which can be used to generate low-resolution/high mass range spectra and act as a mass filter for 
ions entering the C-Trap. In the C-trap, ions are accumulated before having their mass (actually their m/z which is 
later de-convoluted by a computer algorithm to discover ion mass) determined by the OrbiTrap mass-analyser or 
fragmented by collisions with nitrogen gas (in the HCD collision cell) before being measured in the OrbiTrap. The 
OrbiTrap is a much higher-resolution mass analyser and it is this accuracy that allows peptide sequence to be 
derived. Diagram adapted from Michalski et al. (2011). 
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4.1.1 Aims 
The aims of this chapter are: 
• To identify the proteins contained in the 2D-PAGE spots that corresponded to reactive 
areas on the immunoblots. 
• To identify the proteins contained in the gel slices of immunoreactive proteins 
captured by the convalescent guinea pig IgG by immunoprecipitation. 
• To present the identified proteins according to their predicted function. 
• To use in silico predictive tools to gather more information about the identified 
proteins. 
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4.2 Materials and Methods 
 
4.2.1 In gel tryptic digestion of proteins 
Excised gel spots or regions from Coomassie-stained polyacrylamide gels (Chapter 3) were first 
de-stained and the proteins contained in the gel, reduced and alkylated. These proteins were 
then digested or cleaved into peptides with trypsin followed by passive elution using the 
procedure described below based on a published protocol (Rosenfeld, Capdevielle, Guillemot, 
& Ferrara, 1992). 
Destaining buffer, consisting of 25 mM ammonium bicarbonate (Fisher Scientific #10207183) 
in 50% (v/v) aqueous acetonitrile (Fisher Scientific #10080000) and digestion buffer, consisting 
of 25 mM aqueous ammonium bicarbonate were prepared in advance of the procedure and 
stored at 8 °C. Trypsin enzyme (Trypsin Gold, Mass spectrometry grade; Promega V5280) was 
re-suspended in 50 mM acetic acid to produce a 1 µg/µl stock. This stock was divided into 10 µl 
aliquots and stored at -80 °C. For each digestion, a fresh vial of trypsin was thawed. To 
minimise missed-cleavage artefacts during analysis of the mass spectrometric data 
downstream, freeze-thawed enzyme was never used for this work. 
Each gel piece was incubated with 500 µl of destaining buffer for 30 min at 37 °C in a shaking 
incubator set at 300 rpm. The destaining solution was carefully aspirated from around the gel 
piece and discarded. This step was repeated until all of the blue colouring from the gel had 
been removed. The gel pieces were then dehydrated by incubating twice with 500 µl of 
acetonitrile for 10 min, after the second incubation the acetonitrile was removed and the gel 
pieces allowed to air-dry (caps open) at room temperature for 10 min. 
The proteins were reduced by adding 50 µl of 10 mM dithiothreitol (DTT; Life Technologies 
P2325) diluted in 25 mM ammonium bicarbonate to each gel piece and heating to 60 °C for 30 
min. After incubation, the excess solution was discarded. To alkylate the proteins, the gel 
pieces were suspended in 50 µl of 55 mM of iodoacetamine (Sigma I1149) diluted in 25 mM 
ammonium bicarbonate and incubated at room temperature in the dark for 45 min. The 
alkylation buffer was removed and the gel pieces subjected to three, 5 min washes with 500 µl 
digestion buffer. The gel pieces were then dehydrated by incubating twice with 500 µl of 
acetonitrile for 10 min, after the second incubation the acetonitrile was removed and the gel 
pieces allowed to air-dry (caps open) at room temperature for 10 min. 
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Trypsin was thawed and diluted in 25 mM ammonium bicarbonate to a working concentration 
of 10 ng/µl. To each gel piece, 75 µl of working trypsin solution was added and the tubes 
incubated overnight at 37 °C at 300 rpm in a shaking incubator.  
Peptides were extracted by centrifuging the gel pieces at 10,000 x g for 5 min and aspirating 
off and storing the digested peptide/trypsin solution in individual tubes. The tubes were then 
incubated at 37 °C for 1 h with 100 µl of 0.1 % (v/v) aqueous trifluoroacetic acid (Fisher 
Scientific #10311725). The gel pieces were again centrifuged at 10,000 x g for 5 min, the 
trifluoroacetic acid aspirated off and combined and mixed with the retained trypsinised 
peptide solution. 
The extracted peptides were frozen at -80 °C until required for mass spectrometric analysis. 
 
4.2.2 Mass spectrometry analysis 
Tryptic peptide mixtures from the in-gel trypsin digestion were separated using nanoflow 
reversed phase liquid chromatography (RPLC) and analysed using a tandem mass spectrometer 
(nLC-MS/MS). Online chromatography was performed with the Thermo Easy nLC 1000 ultra-
high pressure HPLC system (Thermo Fisher Scientific Ltd.) coupled to the Q Exactive mass 
spectrometer (Thermo Fisher Scientific Ltd.). The instrument was controlled by the Xcalibur 
software (Q Exactive Plus 2.3, ThermoFisher Scientific Ltd.).  
For chromatographic separation, buffer A (0.1 % (v/v) aqueous formic acid) and buffer B (0.1 % 
(v/v) formic acid in acetonitrile) were used as mobile phases for gradient separation. Each 
sample (10 μl) was loaded onto a reversed phase Nano Trap Column (Acclaim PepMap 100, 
100 µm i.d. x 2 cm long, C18, 5µm, 100 Å) and further separated on an C18 reversed-phase 
nanocolumn (Acclaim PepMap100, 75 μm i.d. × 15 cm long, C18, 3 μm, 100 Å; ThermoFisher 
Scientific Ltd.) with a linear gradient of 4 – 75 % buffer B at a flow rate of 300  nl/min over 30 
min, then to 95 % B over 1 min and held at 95% B for 7 min (see Table 4.1). Due to loading, 
lead-in and washing steps, the total time for the nLC-MS/MS runs was 53 min. 
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Table 4.1 - NanoLC parameters used to feed the electrospray ionisation (ESI) component of the tandem mass 
spectrometer. Buffer A (default) consisted of 0.1 % (v/v) aqueous formic acid and buffer B of 0.1 % (v/v) formic 
acid in acetonitrile. 
Time (min) Duration (min) Flow rate (nl/min) % buffer B (in A) 
0.00 0.00 300 4 
30.00 30.00 300 75 
31.00 1.00 300 95 
38.00 7.00 300 95 
 
General mass spectrometric conditions were set as follows: spray voltage at 1.6 kV, capillary 
temperature at 260 °C, S-lens RE level at 50. Nitrogen was used as collision gas, but no sheath 
or auxiliary gases were applied.  
For data acquisition, the instrument was operated in positive ion mode and a data-dependent 
‘top 20’ method was used. Full scans (300–2,000 amu) were acquired at a resolution of 70,000 
at m/z = 200 with maximum ion injection time (IIT) of 100 ms. MS/MS was performed by 
higher-energy collisional dissociation (HCD) fragmentation using collision-induced dissociation 
(CID). Resolution for HCD spectra was set to 17,500 at m/z = 200 amu with maximum IIT of 50 
ms. Normalized collision energy was set as 27 %. The ‘underfill ratio’, specifying the minimum 
percentage of the target ion value likely to be reached at maximum fill time was defined as 1.0 
%. Default dynamic exclusion of 15.0 s was selected to prevent an ion from triggering a 
subsequent data-dependent scan after it has already triggered a data-dependent scan.   
 
4.2.3 Database searching and protein identification 
MS data were generated in the form of .RAW files (ThermoFinnigan file format), which contain 
all of the spectra detected from the LC-MS/MS analysis for each sample. Spectra acquired 
were searched against the non-redundant Uniprot protein database (http://www.uniprot.org – 
containing 8,955 C. burnetii protein sequences including randomly generated peptide decoys 
(TDA) to reduce the false discovery rate) using Proteome Discoverer™ (Version 1.4, Thermo 
Scientific). The search parameters used were: Enzyme: trypsin; Fixed (or static) Modifications: 
carbamidomethylation of cysteine; Variable Modifications: oxidation of methionine; Missed 
Cleavage Sites: 2; peptide mass tolerance ± 10 ppm. The search results were filtered using 
Scaffold (Version 4, Proteome Software, USA) to minimise the number of false positives, as 
indicated by a false discovery rate (FDR) of < 2 %. Protein identifications were accepted with at 
least two unique, exclusive identified peptides. 
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4.2.4 Organisation of identified proteins 
The lists of identified proteins were compared to the five published reports of proteins 
discovered by 2D-PAGE followed by immunoblotting, spot-picking and mass spectrometry 
(Coleman et al., 2007; Deringer et al., 2011; Sekeyova et al., 2009; Skultety et al., 2011; Xiong 
et al., 2012) and the four reports of proteins discovered using microarray and ELISA/ELISPOT 
and in vitro translated open-reading frames of the C. burnetii genome (Beare et al., 2008; Chen 
et al., 2009; Vigil et al., 2010; Wang et al., 2013). This comparison yielded three groups of 
identified proteins; those that were present in both 2D-PAGE picked spots and in the 
immunoprecipitated proteins, those that were present only in in the immunoprecipitated 
proteins, and those present only in 2D-PAGE picked spots. These were further sub-divided into 
two groups each; those previously described in one or more of the seven published reports 
and those that were unique to this work. 
 
4.2.5 Protein functional characterisation 
Functional annotation of all identified proteins was based on the cellular process information 
from the COG database (Tatusov, Galperin, Natale, & Koonin, 2000), the UniProt server 
(UniProt, 2015), and the InterPro domains and functional sites database (Hunter et al., 2009). 
The proteins were then assigned to 20 functional categories based on the criteria used in two 
published C. burnetii proteomics articles (Samoilis, Psaroulaki, Vougas, Tselentis, & Tsiotis, 
2007; Skultety et al., 2011). 
Proteins identified that had not been previously reported in the literature were subjected to 
further characterisation by a range of tools to ascertain their size and isoelectric point using 
the “Compute pI/Mw tool” on the ExPASy server (Gasteiger et al., 2005), their predicted 
subcellular localisation with PSORTb v3.0.2 (Yu et al., 2010) and SOSUIGramN (Imai et al., 2008), 
their predicted non-classical secretion probability with SecretomeP v2.0 (Bendtsen, Kiemer, 
Fausboll, & Brunak, 2005), the presence of predicted signal peptides using SignalP v4.1 
(Bendtsen, Nielsen, von Heijne, & Brunak, 2004), the presence of predicted integral beta-
barrels using BOMP (Berven, Flikka, Jensen, & Eidhammer, 2004), the presence of predicted 
lipoproteins using Lipo (Berven et al., 2006) and LipoP v1.0 (Juncker et al., 2003), and the 
presence of predicted transmembrane regions using TMHMM v2.0 (Krogh, Larsson, von Heijne, 
& Sonnhammer, 2001). Table 4.2 shows the internet locations of these tools. 
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Table 4.2 - Tools used to predict subcellular localisation and functionality of identified C. burnetii proteins. 
Tool name  
(and version where applicable) 
Uniform resource locator (URL) of server hosting the tool 
Compute pI/Mw tool web.expasy.org/compute_pi/ 
PSORTb v3.0.2 www.psortb.org/psortb/ 
SOSUIGramN harrier.nagahama-i-
bio.ac.jp/sosui/sosuigramn_submit.html 
SecretomeP v2.0 www.cbs.dtu.dk/services/SecretomeP/ 
SignalP v4.1 www.cbs.dtu.dk/services/SignalP/ 
BOMP services.cbu.uib.no/tools/bomp 
Lipo services.cbu.uib.no/tools/lipo 
LipoP v1.0 www.cbs.dtu.dk/services/LipoP/ 
TMHMM v2.0 www.cbs.dtu.dk/services/TMHMM/ 
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4.3 Results 
 
4.3.1 Protein identification 
Due to the fact that an immunoreactive spot picked from a 2D-PAGE gel can contain several 
proteins, proteins that were identified by spot picks alone have been excluded from the tables 
presented in this chapter but can be found in the full listings in Appendix 3. Proteins identified 
in spot picks and captured by the guinea pig convalescent IgG during the immunoprecipitation 
(IP) experiments and proteins identified only by IP are presented. Proteins that were identified 
by 2D-PAGE spot picks and validated as immunoreactive by IP and previously identified in the 
literature are presented (Table 4.3) and those that were identified as immunoreactive by IP 
only and previously identified in the literature are presented (Table 4.5). 
Table 4.3 - Proteins identified by both 2D-PAGE spot picks and immunoprecipitation methods that have 
previously been reported in the literature. 
Locus Tag Functional Classification 
Protein Name 
Regions/Spots 
Containing 
Published 
Translation – Protein Biosynthesis 
CBU_0236 Protein Translation Elongation Factor Tu (EF-Tu) C5; L10, L11-L13, L19; 
H7 
adfg 
Amino acid biosynthesis and metabolism 
CBU_0503 Glutamine synthetase  L12, L13, L19; H7, H7 g 
Energy metabolism – electron transport 
CBU_1200 Isocitrate dehydrogenase [NADP]  L13; H3, H6 a 
CBU_1241 Malate dehydrogenase  C1-C5; L1, L6, L7, L10-
L12, L14, L15, L19; H3-
H7 
fg 
CBU_1396 Succinyl-CoA synthetase alpha chain  C1, C2, C3, C4; L14, 
L15, L17; H5 
f 
Posttranslational modification, degradation, protein turnover, chaperones 
CBU_0215 Peptidase, C40 family/NlpC-P60 family protein C2, C5; L13, L16, L17, 
L19; H3, H4, H6, H7 
f 
CBU_0309 Chaperone protein htpG C1, C7, C8; L5-L10, L18, 
L19, L21, L22; H2- H4 
d 
CBU_0737 Trigger factor, ppiase  L19; H3, H4, H7 ag 
CBU_1290 Chaperone protein dnaK C1, C5, C7-C9; L2-L13, 
L15, L16, L18-L22; H2-
H4 
dfg 
CBU_1718 60 kDa chaperonin GROEL C1-C5, C7-C9; L1-L22; 
H2-7 
adfgh 
CBU_1719 10 kDa chaperonin GROES L7-L9 de 
Fatty acid, lipid and phospholipid biosynthesis and metabolism 
CBU_0497 3-oxoacyl-[acyl-carrier-protein] synthase  L21, H7 ag 
Lipopolysaccharide biosynthesis and metabolism 
CBU_0479 3-deoxy-manno-octulosonate cytidylyltransferase  L15, L20; H6 d 
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Table 4.3 - (continued) - Proteins identified by 2D-PAGE spot picks and by immunoprecipitation methods that 
have previously been reported in the literature. 
Locus Tag Functional Classification 
Protein Name 
Regions/Spots 
Containing 
Published 
Cell envelope biosynthesis 
CBU_0307 Outer membrane protein C1-C6, C8, C9; L14, L15, 
L17, L19, L21, L22; H1-
H7 
bdf 
CBU_0311 Outer membrane porin P1 C4, C6; H1, H3-H5, H7 c 
CBU_0891 Hypothetical exported membrane associated 
protein 
C5; L10-L12, L19; H6 bce 
CBU_0937 Hypothetical exported protein H7 df 
Protein and peptide secretion and trafficking 
CBU_0092 Tol system periplasmic component YbgF C1-C4; L13-L15; H3, 
H5 
defg 
CBU_0482 Arginine-binding protein C6; H1 f 
CBU_1519 Protein translocase subunit secB H6, H7 h 
Pathogenicity and pathogenesis 
CBU_0952 AdaA (acute disease antigen) H1 adg 
Detoxication and resistance 
CBU_1706 Thioredoxin peroxidase  C1, C5; L10-L13, L15, 
L19, L20; H6 
df 
Published key: a = Coleman et al. (2007); b = Beare et al. (2008); c = Chen et al. (2009);  
d = Sekeyova et al. (2009); e = Vigil et al. (2010); f = Deringer et al. (2011); g = Xiong et al. (2012);  
and, h = Wang et al. (2013). 
 
Table 4.4 - Proteins identified by immunoprecipitation method (and not seen in 2D-PAGE spots) that have 
previously been reported in the literature. 
Locus Tag Functional Classification 
Protein Name 
Published 
DNA metabolism – Replication, recombination and repair 
CBU_0271 Single-strand DNA binding protein d 
DNA – mediated transformation (Competence) 
CBU_1910 Outer membrane protein (Com1) defgh 
Energy metabolism – electron transport 
CBU_1943 ATP synthase alpha chain  af 
CBU_1945 ATP synthase beta chain  dg 
Lipopolysaccharide biosynthesis and metabolism 
CBU_1778 Fructose-bisphosphate aldolase  g 
Protein and peptide secretion and trafficking 
CBU_0147 Protein translocase subunit secA h 
Multi-biosynthetic pathways 
CBU_0628 Inorganic pyrophosphatase  dg 
CBU_1783 Glyceraldehyde 3-phosphate dehydrogenase  d 
CBU_1789 Gluconolactonase  d 
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Table 4.4 – (continued) Proteins identified by immunoprecipitation method (and not seen in 2D-PAGE spots) that 
have previously been reported in the literature. 
Locus Tag Functional Classification 
Protein Name 
Published 
Cell envelope biosynthesis 
CBU_0545 LemA protein be 
Protein and peptide secretion and trafficking 
CBU_1143 Protein translocase subunit YajC be 
Pathogenicity and pathogenesis 
CBU_0612 Outer membrane protein OmpH bcdeg 
Detoxication and resistance 
CBU_0963 Thioredoxin peroxidase  a 
Poorly characterised 
CBU_1768 Hypothetical exported protein e 
Published key: a = Coleman et al. (2007); b = Beare et al. (2008); c = Chen et al. (2009);  
d = Sekeyova et al. (2009); e = Vigil et al. (2010); f = Deringer et al. (2011); g = Xiong et al. (2012);  
and, h = Wang et al. (2013). 
 
Novel proteins that have not been described as immune-reactive in the literature previously as 
isolated by 2D-PAGE spot picks and validated by immunoprecipitation (IP) are presented (Table 
4.5) as well as those isolated by IP only Table 4.6. 
Table 4.5 – Novel proteins identified by 2D-PAGE spot picks and by immunoprecipitation methods that have not 
been previously reported as immunoreactive in the literature; the calculated molecular weight (MW) in Daltons 
(Da) and the estimated average isoelectric point (pI) are shown for each protein. 
ID Functional Classification 
Protein Name 
Spot locations MW 
(Da) 
pI 
DNA metabolism – Replication, recombination and repair 
CBU_1337 DNA polymerase III alpha subunit  L20 128,481 5.7 
Transcription 
CBU_0232 DNA-directed RNA polymerase beta' chain  H2 157,104 7.6 
CBU_0852 Polyribonucleotide nucleotidyltransferase/ 
Polynucleotide adenylyltransferase  
L6, L8, L9, L21, 
L22, H2,  
76,331 5.4 
Nucleotide and nucleoside biosynthesis and metabolism 
CBU_0326 Phosphoribosylamine-glycine ligase  L11, L13, L19, 
H3, H4, H6, H7, 
C5 
47,631 6.1 
CBU_0897 Amidophosphoribosyltransferase  H3, H4 55,936 6.0 
CBU_1384 Uridylate kinase  H1, C6 26,362 9.1 
Regulatory function 
CBU_1579 Trp repressor binding protein H5, H6, H7 21,156 7.0 
Translation – Protein Biosynthesis 
CBU_1475 Aspartyl/glutamyl-tRNA(Asn/Gln) 
amidotransferase subunit B  
H2, L16, L17, 
L21, H3, H4, H7, 
C1, C2, C3 
53,454 5.4 
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Table 4.5 – (continued) Novel proteins identified by 2D-PAGE spot picks and by immunoprecipitation methods 
that have not been previously reported as immunoreactive in the literature; the calculated molecular weight 
(MW) in Daltons (Da) and the estimated average isoelectric point (pI) are shown for each protein. 
Amino acid biosynthesis and metabolism 
CBU_0517 Aspartate aminotransferase/ 
Succinyldiaminopimelate aminotransferase  
L12, L13, H3, H4, 
H6, H7, L19, C5 
46,419 6.4 
Energy metabolism – electron transport 
CBU_0270 Short-chain alcohol dehydrogenase  L10, L11, L13, 
L19, H7, C5 
44,875 5.8 
CBU_0629 Proline dehydrogenase/Delta-1-pyrroline-5-
carboxylate dehydrogenase  
H2 116,423 6.3 
CBU_0974 Acetyl-CoA acetyltransferase  H6, H7 42,243 7.7 
CBU_1088 
Bifunctional NAD(P)H-hydrate repair enzyme 
Nnr L16, L17, H7 51,699 5.7 
CBU_1116 Alanine dehydrogenase  H6 39,472 6.1 
CBU_1193 Thioredoxin reductase  H5, C2, C3, C4 34,620 5.9 
CBU_1296 ATP-NAD kinase  
L15, H5, C1, C2, 
C4 32,892 5.3 
CBU_1397 Succinyl-CoA synthetase beta chain  
L10, L11, L12, 
L13, L19, H3, H4, 
H6, H7 42,333 5.5 
CBU_1400 Succinate dehydrogenase iron-sulfur protein  C6 27,792 8.2 
CBU_1401 Succinate dehydrogenase flavoprotein subunit  
H2, L21, L22, H3, 
H4 65,438 6.7 
CBU_1720 Aconitate hydratase  H2, L22, H4 101,389 5.8 
Intermediary metabolism and other metabolic pathways 
CBU_0638 Dihydrolipoamide acetyltransferase component 
of pyruvate dehydrogenase complex  
L2, L10, L11, L12, 
L13, L19, H3, H4, 
H6, H7, C5 
40,846 5.2 
CBU_0640 Pyruvate dehydrogenase E1 component alpha 
subunit  
L10, L11, L12, 
L13, L19, H3, H4, 
H6, H7, C1 
41,138 5.3 
CBU_0962 Short chain dehydrogenase H1, H5, H6, H7 25,567 6.9 
Posttranslational modification, degradation, protein turnover, chaperones 
CBU_0073 Xaa-Pro aminopeptidase  H2, L21 68,185 5.6 
CBU_0094 ClpB protein H2, L22 96,769 5.5 
CBU_0338 Membrane alanine aminopeptidase  H2, L22, H4 103,023 6.1 
Cell division, chromosome partitioning 
CBU_1352 Cell division protein ftsH  L15 71,610 6.2 
Protein and peptide secretion and trafficking 
CBU_1648 DotA protein H4, C8 86,867 5.4 
CBU_1652 IcmX protein H3, C3 41,352 6.0 
Adaptation to atypical conditions – response to starvation 
CBU_1275 Starvation sensing protein rspA L10, L19, H2, H3, 
H4, H6, H7, C5 
45,431 5.7 
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Table 4.6 – Novel proteins identified by immunoprecipitation method that have not been previously reported as 
immunoreactive in the literature; the calculated molecular weight (MW) in Daltons and the estimated average 
isoelectric point (pI) are shown for each. 
ID Functional Classification 
Protein Name 
MW 
(Da) 
pI 
DNA metabolism – Replication, recombination and repair 
CBU_0297 Exodeoxyribonuclease III  30,453 9.2 
CBU_0916 Endonuclease/Exonuclease/phosphatase family protein 29,568 9.2 
CBU_1183 Glycine-rich RNA-binding protein 13,149 9.6 
CBU_1235 Oligoribonuclease  21,012 5.7 
DNA – medicated transformation (Competance) 
CBU_0532 COME operon protein 1 13,493 10.5 
CBU_0758 Lipoprotein, ComL family 30,899 9.6 
Transcription 
CBU_2086 Transcription termination factor rho 46,814 6.3 
Nucleotide and nucleoside biosynthesis and metabolism 
CBU_0043 Xanthosine triphosphate pyrophosphatase  21,777 4.7 
CBU_0296 Orotate phosphoribosyltransferase  24,190 6.4 
CBU_0531 Orotidine 5'-phosphate decarboxylase  25,849 7.6 
CBU_0631 Phosphoribosylformylglycinamidine synthase  146,552 6.3 
CBU_0796 Adenosine 5'-monophosphoramidase /  
Guanosine 5'-monophosphoramidase 
12,481 6.3 
CBU_1830 Ribose-phosphate pyrophosphokinase  35,221 5.8 
Translation – protein biosynthesis 
CBU_0234 SSU ribosomal protein S7P 21,291 10.3 
CBU_0445 SSU ribosomal protein S16P 20,726 9.9 
CBU_0808 Valyl-tRNA synthetase  106,648 8.6 
CBU_0851 SSU ribosomal protein S15P 10,316 10.4 
CBU_1325 Bacterial Protein Translation Initiation Factor 3 (IF-3) 19,456 9.9 
CBU_1383 Ribosome Recycling Factor (RRF) 20,945 6.4 
CBU_1473 Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit C  11,102 4.7 
CBU_1594 GatB/Yqey domain protein 16,744 6.0 
CBU_1841 Peptidyl-tRNA hydrolase  20,771 9.0 
Amino acid biosynthesis and metabolism 
CBU_1970 Diaminopimelate epimerase  30,071 6.1 
Energy metabolism – electron transport 
CBU_0075 2-polyprenyl-6-methoxyphenol hydroxylase  45,231 9.7 
CBU_2087 Thioredoxin 12,613 4.9 
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Table 4.6 (continued) – Novel proteins identified by immunoprecipitation method that have not been previously 
reported as immunoreactive in the literature; the calculated molecular weight (MW) in Daltons and the 
estimated average isoelectric point (pI) are shown for each. 
ID Functional Classification 
Protein Name 
MW 
(Da) 
pI 
Intermediary metabolism and other metabolic pathways 
CBU_0502 DNase, TatD family  28,627 5.9 
CBU_0288 Phosphopantetheine adenylyltransferase  17,967 6.2 
CBU_0928 Pyridoxamine 5'-phosphate oxidase  23,636 6.3 
Posttranslational modification, degradation, protein turnover, chaperones 
CBU_0738 ATP-dependent endopeptidase clp proteolytic subunit clpP  21,602 6.1 
CBU_2012 ATP-dependent endopeptidase hsl ATP-binding subunit hslU 52,123 5.5 
Lipopolysaccharide biosynthesis and metabolism 
CBU_2092 Phosphoenolpyruvate carboxykinase [ATP]  56,809 5.8 
Protein and peptide secretion and trafficking 
CBU_0091 Peptidoglycan-associated lipoprotein OmpA-like 21,357 9.5 
CBU_0155 Type 4 pili biogenesis protein pilB (nuleotide-binding protein) 57,831 8.6 
Pathogenicity and pathogenesis 
CBU_1136 Enhanced entry protein enhC, tetratricopeptide repeat family 117,740 9.3 
Detoxication and Resistance 
CBU_0943 Rhodanese-related sulfurtransferases 16,593 8.7 
CBU_1708 Superoxide dismutase  22,274 6.2 
Adaptation to atypical condition – response to starvation 
CBU_1916 Universal stress protein A 15,779 6.6 
Poorly characterised 
CBU_0114 Protein yajQ 18,184 7.9 
CBU_0510 Hypothetical protein 11,275 5.5 
CBU_0656 Hypothetical transcriptional regulatory protein 12,103 4.9 
CBU_2009 Hypothetical protein 50,169 9.1 
 
4.3.2 Functional grouping of proteins 
The proportions of proteins in each functional group are shown in Figure 4.2. Over 50 % of the 
proteins are involved in the 5 categories of energy metabolism; posttranslational modification, 
degradation, protein turnover, chaperones; translation – protein biosynthesis; nucleotide and 
nucleoside biosynthesis and metabolism; and protein and peptide secretion and trafficking. 
Approximately 25 % fall into the 4 categories of DNA metabolism – replication, recombination 
and repair; intermediary metabolism and other metabolic pathways; cell envelope 
biosynthesis; and the poorly characterised/hypothetical proteins. The remaining 11 categories 
account for the final 25 % of the discovered proteins. 
  
139 
 
 
Figure 4.2 - Functional distribution of immunoreactive proteins. Showing the proportion of proteins in each 
functional grouping after the categories described previously (Samoilis et al., 2007; Skultety et al., 2011). The 
legend order follows the pie segment order in a clockwise direction starting with “Energy Metabolism – electron 
transport” with a value of 17 %. Figure shows that the proteins identified were diverse in function and that the 
majority were not likely to be exposed on the surface of the organism – as one would expect for an intracellular 
pathogen. 
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4.3.3 Further characterisation of unpublished proteins 
All proteins in shown in Table 4.5 and Table 4.6 that were predicted to be located in a 
subcellular location other than the cytoplasm or to have predicted features of interest are 
shown in Table 4.7.  
Table 4.7 – Novel identified proteins (previously unpublished) that have predicted notable features and/or non-
cytoplasmic locations. Predictions of transmembrane regions using TMHMM2.0, lipoproteins using Lipo and 
LipoP, secretion using SecretomeP2.0, signal peptides using SignalP4.1 and beta-barrel outer membrane regions 
using BOMP. Of particular interest for possible antibody-mediated vaccine targets are CBU_0091, CBU_1648, and 
CBU_1652 as inhibition of those features has been shown in the literature to inhibit bacteria replication. The two 
hypothetical proteins are also worthy of future study due to their, as yet, unknown functions. 
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CBU_0075 2-polyprenyl-6-methoxyphenol 
hydroxylase 
+ - - - - C C 
CBU_0091 Peptidoglycan-associated 
lipoprotein OmpA-like 
- + + - - OM OM 
CBU_0094 ClpB protein - - + - - C C 
CBU_0338 Membrane alanine 
aminopeptidase 
- - - - - C OM 
CBU_0510 Hypothetical protein - - + - - ukn C 
CBU_0532 COME operon protein 1 - + - + - C OM 
CBU_0631 Phosphoribosylformylglycinamidin
e synthase 
- - - - - IM C 
CBU_0758 Lipoprotein, ComL family - + - - - OM C 
CBU_0962 Short chain dehydrogenase - - - - - E C 
CBU_1136 Enhanced entry protein enhC, 
tetratricopeptide repeat family 
- - + + 1 E ukn 
CBU_1193 Thioredoxin reductase - - - - - C P 
CBU_1352 Cell division protein ftsH + + - - - IM IM 
CBU_1400 Succinate dehydrogenase iron-
sulfur protein 
- - - - - IM ukn 
CBU_1401 Succinate dehydrogenase 
flavoprotein subunit 
- - - - - IM ukn 
CBU_1579 Trp repressor binding protein - - + - - ukn C 
CBU_1648 DotA protein + + - + 1 IM IM 
CBU_1652 IcmX protein - + + + - ukn P 
CBU_1708 Superoxide dismutase - - + - - P C 
CBU_2009 Hypothetical protein + - + - - ukn IM 
Key: C = Cytoplasmic; IM = Inner/Cytoplasmic Membrane; P = Periplasmic; OM = Outer Membrane; E = 
Extracellular; ukn = unknown 
 
  
141 
 
4.4 Summary of Results 
 
In this chapter, 71 novel immune reactive proteins previously undescribed in the literature 
were described. In addition, 36 immunoreactive C. burnetii proteins that have previously been 
described in the literature were also identified. As those articles (see tables in Section 4.3 for 
individual references) set out with the aim of discovering immunoreactive proteins of C. 
burnetii this finding was not unexpected. In fact, this result validates the processes and 
methods used within Chapters 2, 3 and 4 of this thesis. 
Polyclonal IgG antibody that had been affinity-purified from the sera of a guinea pig that had 
been infected with C. burnetii by the aerosol route, experienced clinical disease comparable to 
human acute Q fever (Chapter 2) and recovered was used as a capture antibody in IP 
experiments. These experiments isolated and identified a total of 71 previously undescribed 
proteins. Of these 71 proteins, 30 were also identified in spots picked from 2D-PAGE gels 
corresponding to immunoreactive regions on immunoblots the remaining 41 were only 
present in IP captured materials. 
Many of the proteins that were picked from 2D-PAGE spots were present in several spots of 
differing isoelectric points, and in some cases molecular weight. This could be an indication 
that those proteins are subject to a degree of post-translational modification. The proteins 
described in this chapter were functionally diverse, with no obvious bias towards any 
particular functional group.  
The proportions of proteins in the various functional groups as defined by Samoilis et al. (2007) 
and later refined by Skultety et al. (2011) did not agree with the findings of some previous 
work where the majority of immunoreactive proteins discovered tended to fall into the 
category of surface expressed proteins (Deringer et al., 2011). However, that article and others 
identified many immunoreactive proteins involved in diverse functional groups such as energy 
metabolism, nucleic acid metabolism, protein processing etc. (Beare et al., 2008; Coleman et 
al., 2007; Deringer et al., 2011; Xiong et al., 2012). The corroboration of these findings suggests 
that immune recognition of proteins that are not surface exposed is a true phenomenon in C. 
burnetii infection. This is perhaps not surprising due to the intracellular lifecycle of C. burnetii 
whereupon during processing in the host’s antigen-presenting cells any of the organism’s 
proteins, not just those located on the surface of the organism, could be presented to the CD4+ 
T-cells during immune recognition. 
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There were 19 novel immunoreactive proteins that had notable features or a predicted non-
cytoplasmic location. The implications of these features will be discussed further in the final 
chapter of this thesis. 
 
4.5 Outcomes 
 
• Proteins contained in the 2D-PAGE spots and captured by IP were identified by 
nanoLC-ESI-MS/MS and were were sorted into groups based on whether they had 
been previously described in the literature, whether they were detected in both 2D-
PAGE immunoreactive spots and IP, IP-only, or in 2D-PAGE spots only. 
• In total, 107 immune-reactive proteins were identified in this thesis. Of those, 71 were 
novel and previously unpublished, the remaining 36 were found to be described in one 
or more previously published articles. 
• Functional groupings were assigned to the proteins based on criteria previously 
described in the literature. The identified proteins have a diverse range of functions 
with no particular bias towards any particular function. 
• In silico predictive tools were used to gather more information about the identified 
proteins in terms of their subcellular locations and other structural features. These 
proteins will be discussed further in the next chapter.  
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5 Critical Discussion & Reflection 
 
The first chapter of this thesis gave an overview of the various clinical manifestations that can 
result after infection with C. burnetii, including acute Q fever, caused by Coxiella burnetii as 
well as its ability to cause large and unpredictable outbreaks of disease. The current vaccine 
was also discussed, including an outline of the problems with its use that have made it 
unsuitable for use in the general population. It is also not licensed for human use other than 
for abattoir workers in Australia. A summary of the need for an effective vaccine to stimulate 
both the humoral and cell-mediated arms of the immune system was included. Work on 
alternative vaccines was reviewed and the need for further work to identify elements of the 
organism that are important in immunity and protection against infection that could be used in 
a sub-unit vaccine was discussed. Finally, a critical review of the studies published to date and 
their shortcomings was described leading to the aims of this work. Chapters 2, 3 and 4 of this 
thesis described the work undertaken in this project to isolate and identify immune reactive 
proteins of C. burnetii that could be useful elements of a second-generation vaccine. 
In Chapter 2 of this thesis, the problems associated with enumeration of C. burnetii and the 
design and implementation of a quantitative real-time PCR assay (qPCR) to support all 
bacterial enumeration within this thesis were described. There are known shortcomings to 
using qPCR to enumerate live organisms. Generally speaking the assay actually enumerates the 
numbers of copies of the genome present in a sample. The assay does not, without substantial 
and difficult to implement modifications such as the use of propidium monoazide (PMA) (van 
Frankenhuyzen, Trevors, Lee, Flemming, & Habash, 2011), distinguish between viable and non-
viable organisms. One problem that is likely to affect the implementation of PMA-qPCR with C. 
burnetii is the fact that the organism is intracellular and PMA relies on non-viable organisms 
having damaged membranes; thus the PMA needs to cross multiple cellular membranes 
before reaching the C. burnetii membrane. This would likely require gentle lysis steps to free 
the Coxiellae prior to PMA treatment. Therefore, in this project, the reported values are likely 
to be overestimates of the number of viable organisms present in the samples. However, most 
recent published articles have used qPCR for C. burnetii analysis without a PMA modification 
which means the data in this thesis are comparable with that work.  
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The second chapter also described the initial virulence assessments of the C. burnetii stocks 
available and the attempts to model acute clinical Q fever in small laboratory animal species. 
The inter-species comparison supported the findings of the literature discussed in the 
introduction in that guinea pigs demonstrated disease symptoms with a greater similarity to 
human acute Q fever than either mouse strain. The mice did receive a smaller dose than the 
guinea pigs due to their smaller size and resultant smaller inspiratory volume. In a related 
study performed in our laboratory using an inhaled dose 1000x greater than that used in 
Chapter 2, the clinical signs of disease in mice were more pronounced. In that study, the mice 
lost up to 15 % of their bodyweight and showed signs such as ruffled fur not seen in this study, 
however, no febrile response was seen even at this high dose (Norville et al., 2014). However, 
the inhaled dose of 106 GE used in that study is likely to be far greater than that seen in natural 
infections of humans and the doses used in Chapter 2 more representative of a natural 
infection. Furthermore, the tissue distributions of C. burnetii found at necropsy in Chapter 2 
show that while the guinea pig has reduced the bacterial load to undetectable levels in all 
tissues other than the lung, the mouse tissues contained almost 1,000 copies/mg of C. burnetii. 
This suggests that while the guinea pig experienced disease consistent with acute infection, 
the disease pattern in mice had more in common with chronic disease. In BALB/c mice the 
levels of bacterial load in the tissues can be seen increasing from day 15 to day 21 post 
infection in heart, kidney and testes, implying an on-going infectious process in this species. In 
further support of this, bacterial load measurements of terminal bloods demonstrated the 
presence of more than 103 GE/ml of C. burnetii in three mice in the A/J group (50 %). A key 
output from this chapter was the production of convalescent guinea pig sera containing 
antibodies that the animals produced in response to infection that were used in Chapter 3 to 
isolate the immune reactive proteins. 
The growth of C. burnetii in axenic media was described in Chapter 3 followed by the 
extraction of soluble proteins and the subsequent isolation of immune-reactive proteins using 
two methods. The use of axenic media to produce a host-protein-free bacterial protein 
preparation in this chapter is the first time this technology has been applied to the isolation of 
immune reactive proteins of C. burnetii; all previous published studies either used chick egg or 
cell-culture grown organisms. The protein yield from axenic growth was considerably smaller 
than other methods, but it produced a cleaner protein preparation and reduced the use of 
protected animal species which is an important ethical consideration. Immunoprecipitation 
was used to capture immune reactive proteins in an attempt to overcome the problems 
associated with the isolation of proteins from 2D PAGE; those primarily being the presence of 
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multiple proteins in each spot and poor representation of hydrophobic and very basic proteins 
(Rabilloud, 2009).  
The digestion of isolated proteins into peptides and their identification by nanoscale liquid-
chromatography electro-spray ionization tandem mass spectrometry (nLC-ESI-MS/MS) was 
described in Chapter 4. All proteins isolated by immunoprecipitation (IP) were considered to 
be true identifications, proteins isolated from 2D-PAGE that were also in the IP results were 
considered validated identifications, but proteins in only the 2D-PAGE spot results were 
considered to be merely present in the spot but unlikely to be the immunoreactive species. 
The 2D-PAGE-only proteins were not included in the totals of immunoreactive proteins. This 
process identified a total of 107 immune reactive proteins; 36 of which had been previously 
described in the literature and 71 that were previously undescribed. The fact that a substantial 
proportion of the proteins discovered in this thesis were also discovered in previous studies is 
reassuring as to the suitability of the methods used to isolate and identify them here. In 
addition, their presence in the results here supports the hypothesis that axenic grown 
organisms are not likely to be substantially different from chick egg or cell-culture produced 
organisms. The proteins that were identified in previous publications will not be discussed 
further here, as that discussion can be found within the cited articles. 
The identified proteins fall into a diverse range of functional groups, only a small proportion of 
which are surface exposed. It is unlikely that these, non-surface located, proteins are critical in 
the antibody-mediated humoral immune response directly but, they indicate elements of the 
organism that are being processed and presented by the host immune system. It is possible, 
that these proteins are important in the cell-mediated immune response to C. burnetii.  
Approximately 35 % of the proteins identified are likely to be surface associated; those 
associated with protein conformation, secretion machinery, cell envelope biosynthesis, cell 
surface DNA competence, LPS biosynthesis, pathogenicity, and response to atypical conditions. 
In addition, the 5 % of hypothetical or poorly characterised proteins cannot be overlooked in 
terms of their importance in immunity. 
As discussed in Chapter 1, the primary problem with the current Q fever vaccine is not one of 
efficacy. Rather the problems that a second generation vaccine should seek to overcome are; 
production that does not require the use of live embryonated eggs, production to be at ACDP 
containment level 2 (CL2) or lower, safe enough to administer that pre-screening of recipients 
is no longer required, and to be well-defined in terms of its constituents. It is likely that a 
subunit vaccine would be the optimal way to achieve those goals as the main alternative, live-
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attenuated vaccines, have historically either failed to give adequate protection in the cases of 
phase II avirulent vaccines (R. A. Ormsbee, Bell, Lackman, & Tallent, 1964), or in the case of the 
M-44 strain, inadequately attenuated and showing evidence of persistence in the host 
(Freylikhman, Tokarevich, Suvorov, Vorobiova, & Totolian, 2003). In addition, live attenuated 
vaccines are often inappropriate in immunocompromised hosts. 
A subunit vaccine is essentially a formulation containing only antigens that are essential for the 
stimulation of a protective immune response (Liljeqvist & Stahl, 1999). In the case of proteins, 
the use of recombinant technologies means that single proteins can be produced in non-
pathogenic hosts at a high level of purity. This strategy has been proven with the Hepatitis B 
surface antigen vaccine that is highly immunogenic and well-tolerated, in which the protein is 
recombinantly expressed in the yeast, Saccharomyces cerevisiae (Keating & Noble, 2003). 
The evidence suggests that protective immunity against Q fever requires both humoral and 
cell-mediated acquired immune responses (G. Zhang & Samuel, 2004). The majority of the 
humoral or antibody response to Q fever disease or formalin-inactivated whole cell vaccine 
(WCV) is directed against the lipopolysaccharide (LPS) component of the bacterial cell wall. 
When used as a vaccine, phase I LPS alone has been shown to be highly protective (G. Zhang et 
al., 2007). Therefore, any effective vaccine against Q fever is likely to need to generate 
immunity against the LPS. 
The main problem with lipopolysaccharides is that developing vaccines against these 
components is difficult and immunity, due to its T-cell independent nature, is often short-lived 
(Weintraub, 2003). This problem is usually solved by conjugating the polysaccharide to a 
protein carrier such as tetanus toxoid; this helps to convert the immune response to a T-cell 
dependent one that is much more protective and long-lasting. This strategy is the basis of the 
successful Haemophilus influenzae b (Reynolds & Vidor, 2014), meningococcal C (Borrow, 
Abad, Trotter, van der Klis, & Vazquez, 2013; Findlow, 2013), and pneumococcal vaccines 
(Borrow, 2013). 
The polysaccharide conjugate strategy has also been successfully applied to highly-pathogenic 
bacteria such as Burkholderia pseudomallei using capsular polysaccharide isolated from 
avirulent derivatives of the pathogenic bacteria (A. E. Scott et al., 2014). Unfortunately, no 
avirulent C. burnetii organisms with a phase I phenotype are currently available, the LPS is too 
complex for chemical synthesis and the LPS biosynthesis pathway is not wholly elucidated 
(Narasaki, Mertens, & Samuel, 2011), hampering recombinant LPS production in another 
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organism. Therefore, LPS for the conjugation procedure would require organisms to be 
produced at CL3. However, an alternative strategy has been reported that uses a synthetically-
produced peptide mimic of the LPS, discovered by phase display, to generate T-cell dependent 
immunity against the phase I LPS (Peng, Zhang, Mitchell, & Zhang, 2012). Immunisation with 
this mimic conferred significant protection in mice against C. burnetii infection, but it still fell 
short of the protection elicited by WCV. However, this mimic was against a single epitope 
situated on the LPS and the authors suggested that a search for further unidentified epitopes 
of the phase I LPS could yield a pool of peptide mimics that would elicit greater protection. 
Furthermore, it is also possible that some of the additional protection elicited by WCV could be 
directed against protein epitopes. In fact, as LPS-only vaccines have been demonstrated to 
always fall short of the protection afforded by WCV (G. Zhang et al., 2007) it is likely that the 
difference is due to protein epitopes. An important factor to note is that a vaccine eliciting a 
specific phase I antibody response would be useful from a diagnostic standpoint, because 
antibody against phase I in the absence of antibody against phase II has not previously been 
described (Scola, 2002), allowing vaccinees to be readily distinguished from acute or 
convalescent cases. 
Since proteins that are intracellular are unlikely to be available to interact with humoral 
antibodies in a manner that neutralizes the organism, in terms of humoral immunity, it is likely 
that only proteins that are surface-exposed, membrane-associated or secreted will be 
protective. It is likely that many surface-exposed proteins are not involved in immunity as it is 
known that at least parts of the bacterial cell surface are shielded from the immune system by 
the LPS itself (Shannon, Howe, & Heinzen, 2005).  
From the list of proteins presented in Table 4.7, several could play possible roles in immunity. 
CBU0091 is described as OmpA-like, is predicted to be situated on the outer membrane and be 
secreted. In addition, another OmpA molecule (CBU1260) has been reported as the first C. 
burnetii invasin, antibodies against which were demonstrated to inhibit bacterial 
internalization into cells (Martinez, Cantet, Fava, Norville, & Bonazzi, 2014). CBU1648 (DotA) 
and CBU1652 (IcmX) are both constituents of the type IV secretion system of C. burnetii and 
are essential for replication within cells (Martinez et al., 2014). It is possible, therefore, that 
antibodies binding to these proteins could inhibit the organism.  Finally, both CBU0510 and 
CBU2009 are hypothetical proteins with predicted secretory functions. Therefore, although the 
function of these proteins is unknown they are worthy of further investigation in terms of their 
protective ability. 
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Prioritising antigens targeted by antibody responses has been suggested to be an efficient 
strategy to identify cell-mediated vaccine targets (Chen et al., 2011). The role of CD4+ T-cells 
appears critical for this protection (Andoh et al., 2007; Chen et al., 2011). This has been 
demonstrated by attaining substantial protection against disease by immunising mice with a 
pool of 7 peptides, although none of the 7 protected when administered individually (Xiong et 
al., 2014). Since CD4+ cells receive short peptides presented on MHC class II molecules from 
antigen-presenting cells such as phagocytic macrophages, any protein, not just surface-
associated ones, can be processed to produce T-cell antigens. Due to this, it is not possible to 
confidently identify any particular proteins among the results presented in Chapter 4 as likely 
to contain T-cell epitopes. However, the lists provide a short-list, relative to the 2,000 open 
reading frames in C. burnetii, for further screening to identify these epitopes. This approach 
will be discussed in the further work section of this chapter. 
 Protection by immunisation with recombinant proteins of C. burnetii has been somewhat 
unsuccessful to date. In one study, a mixture of eight proteins was found to elicit no protection 
against subsequent challenge (Tyczka et al., 2005). It is possible that the failure of this 
approach was due to incorrect folding or conformation of the proteins. In another study, 
proteins P1 (CBU0311) and GroEL (CBU1718) were found to be much more protective when 
presented as a fusion protein than as single proteins (Li et al., 2005). The results presented in 
Chapter 4 and many of the 2D PAGE spots presented in Appendix 3 show that GroEL is often 
found associated with a large proportion of other proteins, it is possible that the presence of 
this chaperonin plays an important role in the maintenance of the structural integrity of other 
proteins and is therefore an important constituent in any subunit vaccine. 
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5.1 Summary 
 
In summary, it is suggested that the foundation of any successful Q fever vaccine should be the 
development of protective immunity against the phase I LPS. Due to the current lack of 
knowledge about the biosynthesis of the LPS it is not possible to produce this synthetically or 
recombinantly at present. However, should an appropriate LPS molecule or a subset of LPS 
polysaccharides be made available in the future, this would also make a highly desirable 
conjugate vaccine candidate. Experiments using phage display to develop peptide mimics of 
epitopes on the LPS and successfully elicit a degree of protection against infection in a mouse 
model have demonstrated that this technology provides a route to producing well-defined 
vaccine subunits against this component of the organism. In addition, peptide mimics can be 
conjugated to protein carriers such as tetanus toxoid to increase their immunogenicity and 
ensure long-lived protective immunity in a manner that a purified LPS may fail to do.  
Proteins identified in this work, and those that have been predicted (or known to be present 
on the cell surface) may elicit antibodies that can neutralize or hinder bacterial attachment or 
entry into host cells. It is therefore desirable to produce these proteins recombinantly in a 
bacterial expression system such as Escherichia coli, to raise antibody in laboratory animals 
against these proteins and to assess their ability to hinder bacterial infectivity and growth both 
in vitro and in vivo. By expressing these proteins in fusion with the 60 kDa chaperonin (GroEL), 
or indeed one of the other chaperonin proteins described in Chapter 4, it is possible that the 
folding, presentation and immunogenicity of these proteins will be enhanced. 
Finally, the importance of a robust cell-mediated response to bacterial proteins cannot be 
overlooked. The proteins identified in this study may indicate some of those proteins that are 
presented on MHC class II to CD4+ cells. It is therefore important to produce these proteins 
recombinantly and assess their ability to stimulate T-cells from convalescent subjects to 
produce interferon γ. A strategy for this is discussed further in Section 5.2. 
In conclusion, this project evaluated three animal models for their ability to closely mimic the 
natural infection seen in humans. It used sera and IgG from the most clinically appropriate 
model, the guinea pig, to isolate and identify proteins to which these animals had produced 
immune reactions to. These proteins were discussed in terms of how they might contribute to 
a sub-unit vaccine against Q fever disease and made recommendations for how this work 
could inform future research in this topic. 
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5.2 Further work  
 
There are three elements that are important to develop an effective, safe, and well-defined 
vaccine against Q fever. The work required to achieve those elements is outlined below. 
 
5.2.1 Towards a robust anti-LPS response 
The work published by Peng et al. (2012) demonstrated that, although the single peptide 
mimic of the C. burnetii LPS afforded some degree of protection that there are as yet 
unidentified protective epitopes on the LPS. The first arm of the further work should be to 
build upon this strategy to generate a panel of mimics distributed over the LPS molecule. To 
achieve this, a panel of anti-LPS monoclonal antibodies are required, which would be assessed 
for their ability to offer protection against disease (i.e. neutralizing activity) before being used 
to ‘pan’ phage display libraries to find their associated mimics.  
 
5.2.2 Neutralizing antibodies 
As discussed above, proteins that have been found to be immune reactive in this and previous 
studies needs to be assessed for their ability to hinder bacterial attachment, entry and 
replication in in vitro and later in vivo experiments. These proteins would ideally be expressed 
in a bacterial expression system such as E. coli with small modifications to target them for 
secretion and His-tagging them to facilitate convenient isolation and purification. Antibody 
raised in laboratory animals against these proteins would then be first screened in cell culture 
systems to assess their ability to hinder bacterial entry. Successful antibodies would then be 
tested in vivo by passive transfer to assess if this inhibitory effect holds true in a living system. 
Finally, the proteins corresponding to successfully neutralizing antibodies would be assessed in 
a vaccination/challenge model to assess protective efficacy. 
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5.2.3 Cell-mediated immunity 
It is clear that the proteins involved in this element of the immune response against C. burnetii 
infection are the least well understood. It is known however, that a successful vaccine must 
elicit a robust CMI response to fully protect against infection and disease. To identify which 
proteins are important for CMI one would isolate the splenocytes from convalescent 
laboratory animals and stimulate them with either recombinant proteins or overlapping 
peptide pools and determine which proteins elicited a robust interferon γ response. This assay 
is usually performed in an ELISPOT format. However, while reagents are freely available to 
perform this assay on mice, the data presented in Chapter 2 and throughout the literature 
suggest that the mouse may not be a very representative model in which to do this (Deringer 
et al., 2011). In the absence of reagents to perform these recall-response experiments in 
guinea pig, a suitable alternative would be human patients.  
The discovery of T-cell epitopes would therefore require ethical approval and clinician 
engagement to harvest peripheral blood mononuclear cells (PBMC) from the blood of 
convalescent, but non-chronic, patients. The exclusion of chronic patients is important because 
their T-cell response is known to be insufficient to clear the infection. These PBMCs would 
then be stimulated in IFN-γ ELISPOT format with recombinant proteins or overlapping peptide 
pools corresponding to the short list of immunoreactive proteins identified in this and previous 
works. Those proteins corresponding to the highest stimulation responses could then be 
assessed further in animal protection experiments. However, it might be more efficient in 
terms of ethical approvals and data quality to focus on developing reagents to facilitate these 
recall assays on material derived from guinea pig. 
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5.3 Related professional activities 
 
During the completion of this project and the writing of this thesis I undertook a number of 
other professional activities related to my work on C. burnetii. These are discussed here 
further and are provided as evidence of my ongoing research and dissemination activities 
within this field of research. 
In Appendix 4 a copy of the poster I presented at the 26th Meeting of the American Society of 
Rickettsiology hosted in in Portland, Maine from the 15th – 18th June 2013. This work arose as a 
side observation of the C. burnetii antigen produced in ACCM-2 media described in Chapter 3. I 
had noticed that the purity of the antigen preparation was such that no purification, other 
than a brief wash in PBS, was required to generate immunofluorescence slides suitable for 
diagnostic testing. In a previous project I had worked on, I had produced slides such as this for 
diagnostic purposes and I recalled that phase I antigen could be converted by a relatively 
straightforward chemical procedure (Schramek, Brezina, & Urvolgyi, 1972). The conversion 
process involves chemically reducing the sugars of the O-antigen on the bacterial surface such 
that only the lipid A and inner core elements of the LPS molecule remain – effectively making 
the preparation phenotypically phase II LPS. The poster was well received at the meeting and 
generated interest from several workers interested in diagnostics. The method certainly 
provides a safer, more rapid and defined method than those used currently for the production 
of diagnostic slides (growth in embryonated hen eggs followed by multi-stage purification). I 
intend to submit applications for a small amount of funding to further characterize the method 
and validate the slides for diagnostic purposes in the near future. 
In Appendix 5 is a reprint of a published review I authored on the current state of animal 
models for Q fever (Bewley, 2013). It is an earlier draft, with a different focus, of the text that 
later became parts of the introductions in this thesis found in Chapters 1 and 2. Despite being 
involved with several publications during my career this was the first time I had published as a 
single author and also the first time I had experienced the task of dealing with multiple rounds 
of rejection and referee’s comments to address. I learned a lot about persistence and flexibility 
during the process leading to the ultimate publication of this article and I am pleased with the 
final text. In particular the referees urged me to make recommendations, the original article 
being mainly a descriptive exercise, and I feel the final article benefits from this input. 
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In Appendix 6 is a reprint of an article in which I was heavily involved (Norville et al., 2014). 
This was the first published piece of work that included bacterial loads generated by an earlier 
revision of the real-time quantitative PCR assays described in Chapter 2. The use of A/J mice in 
this work is a direct result of the findings presented in Chapter 2 of this thesis. It also highlights 
the importance of using a high dose of organisms in the mouse model, 3 orders of magnitude 
greater than described in this thesis, to generate clinically observable symptoms in this model. 
I was pleased to be able to contribute to and be associated with this work which demonstrated 
that the inhaled liposome-encapsulated ciprofloxacin had therapeutic benefits even relative to 
the current recommended therapeutic, doxycycline. 
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5.4 Critical Reflection  
 
To reflect upon the work described in this thesis I will use a structured model as described by 
Gibbs (1988). In this approach one is encouraged to follow a sequence of six guided reflection 
points; starting with a description of the events, working through ones feelings broadly and 
then more critically, eventually leading to an action plan. This follows below: 
5.4.1 Description 
Throughout most of this project, work proceeded more-or-less to the plan I had initially set out 
with. I had been put into contact with the mass-spectrometry department at a university and 
they had agreed that I could attend their facility and perform the protein identification, along 
with some novel liquid-phase isoelectric focusing experiments to complement that which I had 
performed in IPG strips. However, when I came to try and go and analyse my isolated proteins 
I found the contact difficult to ‘pin down’. I eventually discussed this with my Scientific Leader 
who helped me make contact with the mass-spectrometry/proteomics team at the PHE 
Colindale site.  Ultimately, this proved to ‘save’ my project as all the analyses progressed 
smoothly from that point. 
5.4.2 Feelings 
At the time, I felt I was being given the ‘run around’ by the original contact. On the telephone 
he was always enthusiastic and keen to help out, but when it came to the crunch he ultimately 
let me down. Since the mass-spectrometry was such a pivotal element of this project I became 
particularly down-hearted about this and for a while lost my way somewhat with the work as I 
couldn’t see beyond somehow getting this contact to cooperate. When my SL helped me make 
contact with the PHE proteomics team I was initially skeptical that they would also let me 
down but in the end I found them incredibly helpful and accommodating and their advice 
invaluable. 
5.4.3 Evaluation 
It was unfortunate that I got so bogged down when I could not get the original contact to 
cooperate and that I got into a position where I couldn’t see a way forward to progress the 
project.  
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Ultimately however, the alternative contact with PHE proteomics actually gave me access to a 
much more accurate instrument. 
5.4.4 Analysis 
This incident demonstrates to me that while it is good to be self-sufficient I should not be 
averse to seeking out advice from colleagues and discussing with them the problems that I am 
experiencing with my work. It also illustrates that I have a tendency to occasionally hit a 
problem and concentrate on overcoming the problem via a direct approach rather than 
evaluating alternative approaches to circumvent the obstruction. 
5.4.5 Conclusions 
If I had discussed the issue I was experiencing earlier with my colleagues and especially the 
scientific leaders within my own work area I would have been able to overcome this problem 
much more rapidly. In addition, if I had thought about the problem more I would have realized 
that the original contact had some barrier to assisting with my work and I should have sought 
alternative facilities elsewhere sooner. If I had remained objective and not developed such an 
emotional attachment to the problem I probably would have seen this sooner. 
5.4.6 Action plan 
When my work appears to have hit a ‘road block’ in future I should seek to recognize the need 
to remain objective and to consider alternative options. I should discuss the problems I am 
experiencing with my managers and SLs as an easy solution may be apparent to them. 
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Appendix One –Formulations and Stock Solutions 
 
Table A1-1 - Running buffer for agarose gel electrophoresis of DNA. 
Buffer Stock solution 
TAE (electrophoresis) 50 x concentration  
242 g Tris base 
57.1 ml glacial acetic acid 
100 ml of 0.5 M EDTA (pH 8.0) 
Make up to 1 l 
Diluted 1:50 v/v in deionised water to give 1x TAE just prior 
to use 
 
Table A1-2 - Media for the axenic growth of C. burnetii. 
ACIDIFIED CITRATE CYSTEINE MEDIUM-2 (ACCM-2) 
Component Chemical Formula Manufacturer 
(Catalogue N
o
) 
Quantity 
(per l) 
Citric acid C6H8O7 Sigma (C0759) 2,568 mg 
Sodium citrate Na3C6H5O7.2H2O Sigma (S4641) 4,740 mg 
Potassium phosphate KH2PO4 Sigma (#60218) 500 mg 
Magnesium 
chloride(hexahydrate) 
MgCl2.6H2O Calbiochem 
(#442611) 
200 mg 
Calcium chloride CaCl2.2H2O Sigma (C5080) 13.2 mg 
Iron sulphate (Heptahydrate) FeSO4.7H2O Fisher (S93248) 2.78 mg 
Sodium chloride NaCl Sigma (S9625) 7,280 mg 
L-Cysteine C3H7NO2S.HCl.H2O Sigma (C6852) 263.4 mg 
Bacto Neopeptone n/a BD (#211681) 100 mg 
Casamino acids n/a Fisher (BP1424-100) 2,500 mg 
Methyl-b-Cyclodextrin n/a Sigma (C4555) 1,000 mg 
RPMI media containing 
GlutaMax 
n/a Invitrogen (#61870) 125 ml 
Deionized H2O n/a Laboratory supply 875 ml 
pH adjusted to to 4.75 with 6 N NaOH. 
Finally, sterile filter through 0.45 µm filter (do not autoclave). 
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Table A1-3 - Buffers used in affinity purification of IgG from guinea pig sera on rProtein A column. 
Buffer name Composition Production 
Binding Buffer 20 mM Sodium Phosphate 
buffer pH = 7.0 
5.77 ml of 1M Na2HPO4 added to 4.23 
ml of 1 M NaH2PO4 and made up to 
100 ml with deionised water to get 
0.1 M (100 mM). This was given a 
further diluted (1:5) in deionised 
water to yield 20 mM. 
Elution Buffer 100 mM Glycine-HCl buffer 
pH = 2.5 
5.55 g of glycine dissolved in 350 ml 
of deionised water. The pH corrected 
with HCl to pH = 2.5 and the volume 
made up to 500 ml. 
Buffers filtered through a 0.45 µm nitrocellulose filter before use. 
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Appendix Two – Ethical Statement 
 
All animal work described in this thesis was conducted in compliance with the UK Home Office 
Animals (Scientific Procedures) Act 1986 with licensed individuals performing all practical 
techniques (procedures). The work was covered by project licence PPL 30/2423 entitled 
‘Protection against novel and dangerous microbial infections’. 
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Appendix Three – Comprehensive listing of 2D-PAGE picked protein spots 
 
Table A3-1 - Proteins identified by 2D-PAGE spot picks from the pI range 3.0–5.6 NL 
Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
L1 
60 kDa chaperonin GROEL CBU_1718 58,284.10 31 62.00% adfg 
Malate dehydrogenase  CBU_1241 35,479.90 2 6.10% fg 
L2 
60 kDa chaperonin GROEL CBU_1718 58,284.10 34 57.20% adfg 
Chaperone protein dnaK CBU_1290 70,756.30 5 7.32% dfg 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex  CBU_0638 40,846.80 2 5.56%  
L3 
60 kDa chaperonin GROEL CBU_1718 58,284.10 43 69.00% adfg 
Chaperone protein dnaK CBU_1290 70,756.30 11 17.70% dfg 
L4 
60 kDa chaperonin GROEL CBU_1718 58,284.10 48 75.90% adfg 
Chaperone protein dnaK CBU_1290 70,756.30 14 25.90% dfg 
L5 
60 kDa chaperonin GROEL CBU_1718 58,284.10 42 73.00% adfg 
Chaperone protein htpG CBU_0309 75,450.40 11 19.20% d 
Chaperone protein dnaK CBU_1290 70,756.30 11 17.20% dfg 
Glutamine-dependent NAD(+) synthetase  CBU_0858 60,233.50 2 3.32% f 
SSU ribosomal protein S1P CBU_0528 62,120.60 2 2.72% df 
L6 
Chaperone protein dnaK CBU_1290 70,756.3 28 33.20% dfg 
60 kDa chaperonin GROEL CBU_1718 58,284.1 27 48.40% adfg 
Protein Translation Elongation Factor G (EF-G) CBU_0235 77,760.9 10 13.70% df 
Chaperone protein htpG CBU_0309 75,450.4 5 6.40% d 
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Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
L6 
Polyribonucleotide nucleotidyltransferase/Polynucleotide adenylyltransferase  CBU_0852 76,331.6 5 6.18%  
ribosomal protein L7/L12  CBU_0229 4,223.7 2 25.70% aefg 
Thioredoxin CBU_2087 12,197.7 2 17.60%  
Malate dehydrogenase  CBU_1241 35,479.9 2 5.79% fg 
AMP-binding domain protein  no LT 62,459.2 2 3.23%  
Transketolase  CBU_1784 74,446.7 2 2.38%  
L7 
Chaperone protein dnaK CBU_1290 70,756.30 37 51.20% dfg 
60 kDa chaperonin GROEL CBU_1718 58,284.10 25 44.20% adfg 
Protein Translation Elongation Factor G (EF-G) CBU_0235 77,760.90 6 8.44% df 
Chaperone protein htpG CBU_0309 75,450.40 6 7.93% d 
10 kDa chaperonin GROES CBU_1719 14,089.40 3 20.50% de 
Malate dehydrogenase  CBU_1241 35,479.90 2 6.10% fg 
L8 
Chaperone protein dnaK CBU_1290 70,756.30 43 54.10% dfg 
60 kDa chaperonin GROEL CBU_1718 58,284.10 25 50.70% adfg 
Chaperone protein htpG CBU_0309 75,450.40 20 30.50% d 
Polyribonucleotide nucleotidyltransferase  / Polynucleotide adenylyltransferase  CBU_0852 76,331.60 4 5.32%  
10 kDa chaperonin GROES CBU_1719 14,089.40 3 29.10% de 
Transketolase  CBU_1784 74,446.70 2 2.83%  
L9 
Chaperone protein dnaK CBU_1290 70,756.30 38 45.30% dfg 
Chaperone protein htpG CBU_0309 75,450.40 31 43.60% d 
60 kDa chaperonin GROEL CBU_1718 58,284.10 23 43.50% adfg 
Transketolase  CBU_1784 74,446.70 6 9.67%  
Polyribonucleotide nucleotidyltransferase  / Polynucleotide adenylyltransferase  CBU_0852 76,331.60 6 8.05%  
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Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
L9 
Oligopeptidase A  CBU_0039 78,247.00 5 7.68%  
ribosomal protein L7/L12  CBU_0229 4,223.70 2 25.70% aefg 
10 kDa chaperonin GROES CBU_1719 14,089.40 2 15.00% de 
L10 
 
60 kDa chaperonin GROEL CBU_1718 58,284.10 19 41.50% adfg 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 14 32.50% g 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex  CBU_0638 40,846.80 13 33.10%  
peptide chain release factor 2  CBU_0428a 32,502.10 11 27.30%  
Chaperone protein dnaK CBU_1290 70,756.30 11 21.20% dfg 
Thioredoxin peroxidase  CBU_1706 21,850.00 8 31.50% df 
Hypothetical exported membrane associated protein CBU_0891 34,369.90 8 23.40% bce 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 7 16.10% adfg 
N utilization substance protein A CBU_1433 56,333.20 7 13.30% d 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 5 14.90%  
Malate dehydrogenase  CBU_1241 35,479.90 5 14.60% fg 
ATP synthase beta chain  CBU_1945 52,961.60 4 7.66% dg 
Starvation sensing protein rspA CBU_1275 45,432.00 3 7.71%  
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 3 7.14%  
Chaperone protein htpG CBU_0309 75,450.40 2 5.79% d 
Succinyl-CoA synthetase beta chain  CBU_1397 42,349.70 2 5.64%  
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,290.20 2 5.09% d 
Acriflavin resistance plasma membrane protein CBU_0804 110,034.00 2 1.88%  
L11  
60 kDa chaperonin GROEL CBU_1718 58,284.10 19 37.30% adfg 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 15 34.40% g 
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Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
L11 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex  CBU_0638 40,846.80 13 33.10%  
Chaperone protein dnaK CBU_1290 70,756.30 9 15.20% dfg 
Thioredoxin peroxidase  CBU_1706 21,850.00 8 31.50% df 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 8 16.40% adfg 
Hypothetical exported membrane associated protein CBU_0891 34,369.90 6 20.50% bce 
peptide chain release factor 2 CBU_0428a 32,502.10 6 15.20%  
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 5 14.90%  
Malate dehydrogenase  CBU_1241 35,479.90 5 14.60% fg 
Phosphoribosylamine--glycine ligase  CBU_0326 46,193.90 3 7.31%  
Succinyl-CoA synthetase beta chain  CBU_1397 42,349.70 2 5.64%  
S-adenosylmethionine synthetase  CBU_2030 42,777.50 2 4.58% g 
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 2 4.19%  
ATP synthase beta chain  CBU_1945 52,961.60 2 3.11% dg 
Acriflavin resistance plasma membrane protein CBU_0804 110,034.00 2 1.88%  
L12 
  
60 kDa chaperonin GROEL CBU_1718 58,284.10 21 37.10% adfg 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex  CBU_0638 40,846.80 15 37.00%  
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 11 30.60% g 
Chaperone protein dnaK CBU_1290 70,756.30 11 18.80% dfg 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 8 23.60%  
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 8 21.40% adfg 
Thioredoxin peroxidase  CBU_1706 21,850.00 6 24.50% df 
Malate dehydrogenase  CBU_1241 35,479.90 5 14.60% fg 
Hypothetical exported membrane associated protein CBU_0891 34,369.90 4 13.80% bce 
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ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
L12 
Succinyl-CoA synthetase beta chain  CBU_1397 42,349.70 3 8.21%  
peptide chain release factor 2 CBU_0428a 32,502.10 2 6.23%  
Glutamine synthetase  CBU_0503 39,616.00 2 4.74% g 
Aspartate aminotransferase/Succinyldiaminopimelate aminotransferase  CBU_0517 42,835.70 2 4.06%  
L13 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 18 42.80% adfg 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 16 35.30% g 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 10 30.40%  
60 kDa chaperonin GROEL CBU_1718 58,284.10 10 16.50% adfg 
Peptidase, C40 family / NlpC-P60 family protein CBU_0215 60,213.50 7 13.00% f 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex  CBU_0638 40,846.80 6 15.60%  
Aspartate aminotransferase/Succinyldiaminopimelate aminotransferase  CBU_0517 42,835.70 6 12.70%  
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 5 11.80%  
S-adenosylmethionine synthetase  CBU_2030 42,777.50 5 11.50% g 
Chaperone protein dnaK CBU_1290 70,756.30 5 6.10% dfg 
Succinyl-CoA synthetase beta chain  CBU_1397 42,349.70 4 10.50%  
Thioredoxin peroxidase  CBU_1706 21,850.00 3 14.00% df 
2-amino-3-ketobutyrate coenzyme A ligase  CBU_0111 43,335.30 3 7.83%  
Phosphoribosylamine--glycine ligase  CBU_0326 46,193.90 3 6.84%  
Tol system periplasmic component YbgF CBU_0092 34,261.30 2 5.90% defg 
Glutamine synthetase  CBU_0503 39,616.00 2 4.18% g 
Isocitrate dehydrogenase [NADP]  CBU_1200 46,638.90 2 3.75% a 
L14  
Tol system periplasmic component YbgF CBU_0092 34,261.30 13 26.90% defg 
(2R)-phospho-3-sulfolactate synthase  CBU_1954 33,331.80 9 29.30% g 
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Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
L14 
Succinyl-CoA synthetase alpha chain  CBU_1396 30,666.50 6 22.80% f 
Protein Translation Elongation Factor Ts (EF-Ts) CBU_1385 31,819.50 6 20.30% f 
Dihydrodipicolinate synthase  CBU_1222 31,613.70 6 19.00%  
Malonyl-CoA-[acyl-carrier-protein] transacylase  CBU_0494 33,930.20 4 10.20%  
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 3 9.64% g 
Malate dehydrogenase  CBU_1241 35,479.90 3 8.84% fg 
Outer membrane protein CBU_0307 24,901.80 2 8.23% bdf 
3-hydroxyisobutyrate dehydrogenase  CBU_0926 31,669.20 2 8.08%  
GrpE protein CBU_1293 22,952.30 2 7.35%  
3-oxoacyl-[acyl-carrier-protein] synthase III  CBU_0493 34,664.10 2 5.64%  
Pyruvate dehydrogenase E1 component beta subunit  CBU_0639 35,478.10 2 5.52%  
Ornithine cyclodeaminase  CBU_1727 37,915.70 2 5.36%  
Ribose-phosphate pyrophosphokinase  CBU_1830 35,221.90 2 4.70%  
60 kDa chaperonin GROEL CBU_1718 58,284.10 2 4.35% adfg 
L15 
60 kDa chaperonin GROEL CBU_1718 58,284.10 23 41.30% adfg 
Malate dehydrogenase  CBU_1241 35,479.90 11 20.70% fg 
Dihydrodipicolinate synthase  CBU_1222 31,613.70 9 27.00%  
Tol system periplasmic component YbgF CBU_0092 34,261.30 9 23.30% defg 
Chaperone protein dnaK CBU_1290 70,756.30 9 13.70% dfg 
(2R)-phospho-3-sulfolactate synthase  CBU_1954 33,331.80 7 23.40% g 
Succinyl-CoA synthetase alpha chain  CBU_1396 30,666.50 5 17.30% f 
Protein Translation Elongation Factor Ts (EF-Ts) CBU_1385 31,819.50 5 15.50% f 
ATP-NAD kinase  CBU_1296 32,834.80 4 16.10%  
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ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
L15 
Thioredoxin peroxidase  CBU_1706 21,850.00 3 14.50% df 
3-deoxy-manno-octulosonate cytidylyltransferase  CBU_0479 28,497.50 3 13.40% d 
Magnesium and cobalt efflux protein corC CBU_0565 32,382.50 3 9.89%  
Electron transfer flavoprotein alpha-subunit CBU_1117 34,072.40 3 8.60%  
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,290.20 3 8.08% d 
Malonyl-CoA-[acyl-carrier-protein] transacylase  CBU_0494 33,930.20 3 7.99%  
Ornithine cyclodeaminase  CBU_1727 37,915.70 3 7.14%  
Outer membrane protein CBU_0307 24,901.80 2 8.23% bdf 
Agmatinase  CBU_0720 28,066.80 2 7.36%  
Acid phosphatase surE  CBU_1671 32,299.20 2 6.48%  
cystathionine beta-lyase no LT 34,304.70 2 6.01%  
Ribose-phosphate pyrophosphokinase  CBU_1830 35,221.90 2 4.70%  
Cell division protein ftsH  CBU_1352 72,005.20 2 2.62%  
Acriflavin resistance plasma membrane protein CBU_0804 110,034.00 2 2.37%  
L16  
ATP-dependent endopeptidase hsl ATP-binding subunit hslU CBU_2012 50,183.50 25 50.10%  
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 19 45.50%  
60 kDa chaperonin GROEL CBU_1718 58,284.10 16 33.30% adfg 
Sugar kinase CBU_1088 51,758.20 13 28.90%  
Peptidase, M20A family CBU_0103 52,900.00 13 26.90% f 
Peptidase, C40 family/NlpC-P60 family protein CBU_0215 60,213.50 7 13.20% f 
Succinate-semialdehyde dehydrogenase [NADP+]  CBU_1204 50,064.30 6 13.10%  
Glycerol kinase  CBU_0932 56,873.10 6 11.30% f 
Seryl-tRNA synthetase  CBU_1188 48,148.90 5 13.50%  
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L16 
Chaperone protein dnaK CBU_1290 70,756.30 4 6.40% dfg 
Glutamyl-tRNA synthetase  CBU_1488 52,693.10 3 5.81%  
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 2 6.61% g 
Dihydrolipoamide dehydrogenase  CBU_0463 51,213.70 2 4.01%  
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex  CBU_0462 47,974.70 2 3.90%  
Cysteinyl-tRNA synthetase  CBU_1487 52,854.50 2 3.71%  
L17  
ATP-dependent endopeptidase hsl ATP-binding subunit hslU CBU_2012 50,183.50 25 47.70%  
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 13 28.30%  
60 kDa chaperonin GROEL CBU_1718 58,284.10 8 17.00% adfg 
Sugar kinase CBU_1088 51,758.20 8 15.60%  
Peptidase, M20A family CBU_0103 52,900.00 7 15.20% f 
Transcription termination factor rho CBU_2086 46,815.70 5 13.40%  
Chlorohydrolase/deaminase family protein CBU_0521 49,561.30 5 11.50%  
S-adenosylmethionine synthetase  CBU_2030 42,777.50 4 9.67% g 
Fumarate hydratase  CBU_1096 49,851.70 4 8.93%  
GrpE protein CBU_1293 22,952.30 3 13.20%  
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 3 9.09% g 
ATP synthase beta chain  CBU_1945 52,961.60 3 6.63% dg 
Chain F, 2.50 Angstrom Resolution Structure Of 3-Phosphoshikimate 1- 
Carboxyvinyltransferase (Aroa) From Coxiella Burnetii In Complex With 
Phosphoenolpyruvate 
3ROI_A 46,408.60 3 6.39%  
Cysteinyl-tRNA synthetase  CBU_1487 52,854.50 3 5.46%  
Glycerol kinase  CBU_0932 56,873.10 3 5.45% f 
Outer membrane protein CBU_0307 24,901.80 2 8.23% bdf 
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L17 
Succinyl-CoA synthetase alpha chain  CBU_1396 30,666.50 2 7.14% f 
Seryl-tRNA synthetase  CBU_1188 48,148.90 2 5.91%  
Succinate-semialdehyde dehydrogenase [NADP+]  CBU_1204 50,064.30 2 4.59%  
Peptidase, C40 family / NlpC-P60 family protein CBU_0215 60,213.50 2 4.14% f 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex  CBU_0462 47,974.70 2 3.90%  
L-serine dehydratase  CBU_0194 48,860.50 2 3.74%  
L18  
Chaperone protein htpG CBU_0309 75,450.40 34 39.50% d 
60 kDa chaperonin GROEL CBU_1718 58,284.10 18 30.10% adfg 
Chaperone protein dnaK CBU_1290 70,756.30 11 14.30% dfg 
Transketolase  CBU_1784 74,446.70 6 7.29%  
Oligopeptidase A  CBU_0039 78,247.00 6 7.09%  
NADH-quinone oxidoreductase chain N  CBU_1435 53,422.70 2 5.39%  
SSU ribosomal protein S1P CBU_0528 62,120.60 2 3.27% df 
L19  
60 kDa chaperonin GROEL CBU_1718 58,284.10 20 46.60% adfg 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 14 34.30% adfg 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 12 32.00% g 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 8 23.90%  
Chaperone protein htpG CBU_0309 75,450.40 8 15.90% d 
Succinyl-CoA synthetase beta chain  CBU_1397 42,391.70 7 17.70%  
Chaperone protein dnaK CBU_1290 70,756.30 7 13.40% dfg 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex  CBU_0638 40,846.80 6 15.60%  
Malate dehydrogenase  CBU_1241 35,479.90 5 14.00% fg 
Aspartate aminotransferase/Succinyldiaminopimelate aminotransferase  CBU_0517 46,393.00 5 12.80%  
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L19 
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 5 12.10%  
Hypothetical exported membrane associated protein CBU_0891 34,369.90 4 17.60% bce 
Trigger factor, ppiase  CBU_0737 50,247.80 4 10.40% ag 
Glutamine synthetase  CBU_0503 39,616.00 4 9.19% g 
Starvation sensing protein rspA CBU_1275 45,432.00 3 7.71%  
S-adenosylmethionine synthetase  CBU_2030 42,777.50 3 7.63% g 
Polyribonucleotide nucleotidyltransferase/Polynucleotide adenylyltransferase  CBU_0852 76,331.60 3 6.47%  
Phosphoglycerate kinase  CBU_1782 42,363.70 3 6.14%  
ribosomal protein L7/L12 CBU_0229 4,223.70 2 25.70% aefg 
Outer membrane protein CBU_0307 24,901.80 2 8.23% bdf 
Thioredoxin peroxidase  CBU_1706 21,850.00 2 7.50% df 
2-amino-3-ketobutyrate coenzyme A ligase  CBU_0111 43,335.30 2 5.05%  
Phosphoribosylamine--glycine ligase  CBU_0326 46,193.90 2 4.95%  
SSU ribosomal protein S1P CBU_0528 62,120.60 2 4.54% df 
Citrate synthase  CBU_1410 48,652.00 2 4.42%  
Peptidase, C40 family/NlpC-P60 family protein CBU_0215 60,213.50 2 3.95% f 
L20 
  
60 kDa chaperonin GROEL CBU_1718 58,284.10 14 23.60% adfg 
3-deoxy-manno-octulosonate cytidylyltransferase  CBU_0479 28,497.50 8 24.10% d 
3'(2'),5'-bisphosphate nucleotidase/Myo-inositol 1-(4-)phosphatase  CBU_0599 30,505.20 7 20.70%  
Chaperone protein dnaK CBU_1290 70,756.30 6 8.08% dfg 
Thioredoxin peroxidase  CBU_1706 21,850.00 5 19.00% df 
Agmatinase  CBU_0720 28,066.80 2 5.43%  
Carboxymethylenebutenolidase  CBU_1119 30,798.60 2 3.66%  
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L20 DNA polymerase III alpha subunit  CBU_1337 128,484.50 2 1.57%  
L21  
60 kDa chaperonin GROEL CBU_1718 58,284.10 40 71.70% adfg 
Succinate dehydrogenase flavoprotein subunit  CBU_1401 65,440.70 24 33.00%  
SSU ribosomal protein S1P CBU_0528 62,120.60 19 35.80% df 
Prolyl-tRNA synthetase  CBU_0081 63,298.00 16 26.40%  
Chaperone protein dnaK CBU_1290 70,756.30 12 21.30% dfg 
Aspartyl-tRNA synthetase  CBU_1565 68,962.70 12 21.30%  
IcmE protein CBU_1627 106,004.80 12 11.50% e 
Glutamine-dependent NAD(+) synthetase  CBU_0858 60,233.50 10 19.00% f 
Methionyl-tRNA synthetase  CBU_1695 62,245.60 10 15.90%  
Xaa-Pro aminopeptidase  CBU_0073 68,205.70 10 15.00%  
Arginyl-tRNA synthetase  CBU_2008 66,709.40 9 15.40%  
NAD-dependent malic enzyme  CBU_0823 63,394.00 9 14.20%  
N utilization substance protein A CBU_1433 56,333.20 7 18.10% d 
Chaperone protein htpG CBU_0309 75,450.40 7 12.80% d 
GTP-binding protein TypA/BipA CBU_0884 67,272.60 5 9.97%  
Outer membrane protein CBU_0307 24,901.80 3 10.80% bdf 
3-oxoacyl-[acyl-carrier-protein] synthase  CBU_0497 44,076.30 3 9.42% ag 
Phosphoenolpyruvate carboxykinase [ATP]  CBU_2092 56,799.90 3 6.96%  
Transcription termination factor rho CBU_2086 46,815.70 2 5.74%  
Citrate synthase  CBU_1410 48,652.00 2 4.65%  
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 2 4.61%  
GMP synthase [glutamine-hydrolyzing]  CBU_1341 58,955.30 2 2.85%  
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L21 Polyribonucleotide nucleotidyltransferase/Polynucleotide adenylyltransferase  CBU_0852 76,331.60 2 2.59%  
L22 
Chaperone protein dnaK CBU_1290 70,756.30 37 44.50% dfg 
IcmE protein CBU_1627 106,004.80 26 24.90% e 
Polyribonucleotide nucleotidyltransferase/Polynucleotide adenylyltransferase  CBU_0852 76,331.60 24 36.40%  
60 kDa chaperonin GROEL CBU_1718 58,284.10 22 48.70% adfg 
Chaperone protein htpG CBU_0309 75,450.40 10 16.00% d 
Transketolase  CBU_1784 74,446.70 7 9.08%  
Oligopeptidase A  CBU_0039 78,247.00 5 6.06%  
ClpB protein CBU_0094 96,772.00 5 5.94%  
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,290.20 4 10.20% d 
Succinate dehydrogenase flavoprotein subunit  CBU_1401 65,440.70 4 6.30%  
Aconitate hydratase  CBU_1720 101,391.80 4 3.82%  
SSU ribosomal protein S1P CBU_0528 62,120.60 3 8.17% df 
Membrane alanine aminopeptidase  CBU_0338 100,513.30 3 3.30%  
Hypothetical cytosolic protein CBU_1303 10,787.00 2 14.70%  
Outer membrane protein CBU_0307 24,901.80 2 7.36% bdf 
Protein Translation Elongation Factor G (EF-G) CBU_0235 77,760.90 2 2.86% df 
Pyruvate dehydrogenase E1 component  CBU_0461 99,741.80 2 2.15%  
Published key: a = Coleman et al. (2007); b = Beare et al. (2008); c = Chen et al. (2009); d = Sekeyova et al. (2009);  
e = Vigil et al. (2010); f = Deringer et al. (2011); and, g = Xiong et al. (2012). 
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Table A3-2 - Proteins identified by 2D-PAGE spot picks from the pI range 3.0–11.0 NL 
Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
C1 
60 kDa chaperonin GROEL CBU_1718 58,284.10 19 31.30% adfg 
Malate dehydrogenase  CBU_1241 35,479.90 10 23.20% fg 
Dihydrodipicolinate synthase  CBU_1222 31,613.70 9 27.00% 
 
Magnesium and cobalt efflux protein corC CBU_0565 31,846.70 9 26.20% 
 
Chaperone protein dnaK CBU_1290 70,756.30 8 11.10% dfg 
Tol system periplasmic component YbgF CBU_0092 34,261.30 7 18.00% defg 
(2R)-phospho-3-sulfolactate synthase  CBU_1954 33,331.80 6 19.30% g 
Succinyl-CoA synthetase alpha chain  CBU_1396 30,666.50 5 18.70% f 
Protein Translation Elongation Factor Ts (EF-Ts) CBU_1385 31,819.50 5 16.60% f 
Outer membrane protein CBU_0307 24,901.80 5 16.50% bdf 
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,237.10 5 15.60% d 
Uroporphyrin-III C-methyltransferase  CBU_2080 35,264.20 4 13.60% 
 
Electron transfer flavoprotein alpha-subunit CBU_1117 34,125.50 4 13.10% 
 
Thioredoxin peroxidase  CBU_1706 21,850.00 3 12.00% df 
Ornithine cyclodeaminase  CBU_1727 37,915.70 3 9.23% 
 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 3 8.97% 
 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 3 6.08% 
 
ATP-NAD kinase  CBU_1296 32,834.80 2 7.36% 
 
Outer membrane protein CBU_1910 27,625.50 2 7.14% defg 
Agmatinase  CBU_0720 32,330.10 2 6.48% 
 
Cystathionine beta-lyase No LT 34,304.70 2 6.01% 
 
Malonyl-CoA-[acyl-carrier-protein] transacylase  CBU_0494 33,930.20 2 5.75% 
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C1 Chaperone protein htpG CBU_0309 75,448.40 2 3.20% d 
C2 
Tol system periplasmic component YbgF CBU_0092 34,261.30 12 28.90% defg 
Succinyl-CoA synthetase alpha chain  CBU_1396 30,666.50 11 45.20% f 
Dihydrodipicolinate synthase  CBU_1222 31,613.70 10 30.80% 
 
(2R)-phospho-3-sulfolactate synthase  CBU_1954 33,331.80 9 27.20% g 
Methylisocitrate lyase  CBU_0771 31,759.90 8 28.60% 
 
Protein Translation Elongation Factor Ts (EF-Ts) CBU_1385 31,819.50 7 23.00% f 
60 kDa chaperonin GROEL CBU_1718 58,284.10 6 11.60% adfg 
Outer membrane protein CBU_0307 24,901.80 5 19.50% bdf 
3-hydroxyisobutyrate dehydrogenase  CBU_0926 31,669.20 5 15.80% 
 
Malate dehydrogenase  CBU_1241 35,479.90 5 14.30% fg 
Hydroxymethylglutaryl-CoA lyase  CBU_0520 32,342.20 5 12.70% 
 
Peptidase, C40 family / NlpC-P60 family protein CBU_0215 60,163.50 4 7.71% f 
3-oxoacyl-[acyl-carrier-protein] synthase III  CBU_0493 34,664.10 3 13.20% 
 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 3 10.70% g 
ATP-NAD kinase  CBU_1296 32,834.80 3 10.00% 
 
Magnesium and cobalt efflux protein corC CBU_0565 31,846.70 3 9.32% 
 
Ornithine cyclodeaminase  CBU_1727 37,915.70 3 9.23% 
 
Ribose-phosphate pyrophosphokinase  CBU_1830 35,221.90 3 7.52% 
 
Carboxymethylenebutenolidase  CBU_1119 26,482.30 2 9.28% 
 
2-dehydro-3-deoxyphosphooctonate aldolase  CBU_1675 30,538.00 2 7.86% 
 
Uroporphyrin-III C-methyltransferase  CBU_2080 35,264.20 2 7.26% 
 
Outer membrane protein CBU_1910 27,625.50 2 7.14% defg 
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C2 
Cystathionine beta-lyase No LT 34,304.70 2 6.01% 
 
Amidinotransferase family protein CBU_0279 31,905.60 2 5.82% 
 
Malonyl-CoA-[acyl-carrier-protein] transacylase  CBU_0494 33,930.20 2 5.75% 
 
Riboflavin kinase  / FMN adenylyltransferase  CBU_0391 36,477.20 2 5.31% b 
Thioredoxin reductase  CBU_1193 34,621.10 2 5.00% 
 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 2 4.19% 
 
C3 
Tol system periplasmic component YbgF CBU_0092 34,261.30 9 23.60% defg 
Protein Translation Elongation Factor Ts (EF-Ts) CBU_1385 31,819.50 7 23.60% f 
DNA-directed RNA polymerase alpha chain  CBU_0263 35,556.90 7 18.70% df 
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,237.10 7 16.20% d 
Ribose-phosphate pyrophosphokinase  CBU_1830 35,221.90 6 14.40% 
 
Dihydrodipicolinate synthase  CBU_1222 31,613.70 5 17.00% 
 
3-hydroxyisobutyryl-CoA hydrolase  CBU_1856 42,086.00 5 11.90% 
 
Succinyl-CoA synthetase alpha chain  CBU_1396 30,666.50 4 14.60% f 
(2R)-phospho-3-sulfolactate synthase  CBU_1954 33,331.80 4 12.40% g 
Hydroxymethylglutaryl-CoA lyase  CBU_0520 32,342.20 4 11.70% 
 
Malate dehydrogenase  CBU_1241 35,479.90 4 11.30% fg 
Thioredoxin reductase  CBU_1193 34,621.10 4 11.20% 
 
Pyruvate dehydrogenase E1 component beta subunit  CBU_0639 35,478.10 4 10.70% 
 
Outer membrane protein CBU_0307 24,901.80 3 12.10% bdf 
Carboxymethylenebutenolidase  CBU_1119 26,482.30 3 11.40% 
 
Methylisocitrate lyase  CBU_0771 31,759.90 3 10.30% 
 
Malonyl-CoA-[acyl-carrier-protein] transacylase  CBU_0494 33,930.20 3 9.27% 
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C3 
Ornithine cyclodeaminase  CBU_1727 37,915.70 3 9.23% 
 
IcmX protein CBU_1652 41,354.00 2 5.32% 
 
Thiamine-monophosphate kinase  CBU_1415 34,836.50 2 5.31% 
 
60 kDa chaperonin GROEL CBU_1718 58,284.10 2 3.62% adfg 
Riboflavin kinase  / FMN adenylyltransferase  CBU_0391 36,477.20 2 2.81% b 
C4 
Protein Translation Elongation Factor Ts (EF-Ts) CBU_1385 31,819.50 9 32.40% f 
Tol system periplasmic component YbgF CBU_0092 34,261.30 7 18.00% defg 
Methylisocitrate lyase  CBU_0771 31,759.90 6 23.40% 
 
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,237.10 6 15.90% d 
Ribose-phosphate pyrophosphokinase  CBU_1830 35,221.90 6 13.80% 
 
Succinyl-CoA synthetase alpha chain  CBU_1396 30,666.50 5 18.70% f 
Dihydrodipicolinate synthase  CBU_1222 31,613.70 5 15.90% 
 
Hydroxymethylglutaryl-CoA lyase  CBU_0520 32,342.20 5 15.40% 
 
Pyruvate dehydrogenase E1 component beta subunit  CBU_0639 35,478.10 5 13.20% 
 
Outer membrane protein CBU_0307 24,901.80 4 15.60% bdf 
Thioredoxin reductase  CBU_1193 34,621.10 4 11.20% 
 
3-oxoacyl-[acyl-carrier-protein] synthase III  CBU_0493 34,664.10 3 13.20% 
 
Uroporphyrin-III C-methyltransferase  CBU_2080 35,264.20 3 11.00% 
 
ATP-NAD kinase  CBU_1296 32,834.80 3 10.00% 
 
Amidinotransferase family protein CBU_0279 31,905.60 3 9.45% 
 
ATP synthase gamma chain  CBU_1944 32,596.40 3 9.34% 
 
60 kDa chaperonin GROEL CBU_1718 58,284.10 3 6.16% adfg 
Outer membrane porin P1 CBU_0311 25,422.10 2 9.62% c 
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C4 
Carboxymethylenebutenolidase  CBU_1119 26,482.30 2 7.59% 
 
2-dehydro-3-deoxyphosphooctonate aldolase  CBU_1675 30,538.00 2 7.14% 
 
Malate dehydrogenase  CBU_1241 35,479.90 2 6.10% fg 
Malonyl-CoA-[acyl-carrier-protein] transacylase  CBU_0494 33,930.20 2 5.75% 
 
Methylenetetrahydrofolate dehydrogenase (NADP+)/  
   Methenyltetrahydrofolate cyclohydrolase  
CBU_0312 30,834.50 2 5.65% 
 
Riboflavin kinase  / FMN adenylyltransferase  CBU_0391 36,477.20 2 5.31% b 
C5 
60 kDa chaperonin GROEL CBU_1718 58,284.10 20 29.70% adfg 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase 
complex  
CBU_0638 40,828.80 14 38.10% 
 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 13 33.30% g 
Chaperone protein dnaK CBU_1290 70,756.30 10 18.00% dfg 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 9 19.40% adfg 
Peptide chain release factor 2 CBU_0428a 32,502.10 8 22.10% 
 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 7 22.30% 
 
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 7 17.50% 
 
S-adenosylmethionine synthetase  CBU_2030 42,777.50 7 17.00% g 
Phosphoribosylamine--glycine ligase  CBU_0326 46,193.90 6 15.60% 
 
Peptidase, C40 family/NlpC-P60 family protein CBU_0215 60,163.50 6 11.70% f 
Phosphoglycerate kinase  CBU_1782 42,363.70 5 11.30% 
 
Aspartate aminotransferase  / Succinyldiaminopimelate aminotransferase  CBU_0517 42,835.70 5 11.20% 
 
N utilization substance protein A CBU_1433 56,275.10 5 9.74% d 
Thioredoxin peroxidase  CBU_1706 21,850.00 4 17.50% df 
Hypothetical exported membrane associated protein CBU_0891 34,369.90 4 15.10% bce 
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C5 
2-amino-3-ketobutyrate coenzyme A ligase  CBU_0111 43,335.30 4 11.10% 
 
Adenosylhomocysteinase  CBU_2031 48,379.30 4 8.53% 
 
ATP synthase beta chain  CBU_1945 52,961.60 4 7.87% dg 
Outer membrane protein CBU_0307 24,901.80 3 12.10% bdf 
Malate dehydrogenase  CBU_1241 35,479.90 3 8.84% fg 
Succinyl-CoA synthetase beta chain  CBU_1397 42,333.70 3 8.46% 
 
Starvation sensing protein rspA CBU_1275 45,432.00 3 7.21% 
 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 2 4.40% 
 
C6 
Succinate dehydrogenase iron-sulfur protein  CBU_1400 27,793.30 10 37.90% 
 
Outer membrane protein CBU_0307 24,901.80 8 39.40% bdf 
Uridylate kinase  CBU_1384 26,362.20 8 27.20% 
 
Cytidylate kinase  CBU_0527 26,456.20 7 27.40% 
 
Outer membrane protein CBU_1910 27,625.50 6 17.90% defg 
3-hydroxyacyl CoA dehydrogenase  CBU_0847 26,941.10 5 15.70% 
 
Arginine-binding protein CBU_0482 29,631.90 5 14.90% f 
Hypothetical exported protein CBU_0395 24,494.10 4 18.00% 
 
Dimethyladenosine transferase  CBU_1982 29,751.30 4 15.50% 
 
Outer membrane porin P1 CBU_0311 25,422.10 3 14.20% c 
Hypothetical protein CBU_1291 21,626.50 3 13.20% 
 
Uracil-DNA glycosylase  CBU_0988 25,667.20 3 12.70% 
 
Hypothetical cytosolic protein CBU_2091 25,646.60 3 12.30% 
 
3-oxoacyl-[acyl-carrier protein] reductase  CBU_0495 26,316.10 3 10.40% f 
Short chain dehydrogenase CBU_1513 28,250.10 3 10.10% e 
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C6 
Hypothetical protein CBU_0632 11,885.10 2 18.20% d 
Acyl-CoA hydrolase  CBU_1269 18,657.60 2 9.82% 
 
Glycerophosphoryl diester phosphodiesterase  CBU_0642 27,513.10 2 7.79% 
 
Hypothetical cytosolic protein CBU_1960 27,040.80 2 7.05% 
 
OmpA-like transmembrane domain protein CBU_1260 26,254.30 2 4.44% df 
C7 
60 kDa chaperonin GROEL CBU_1718 58,284.10 49 84.80% adfg 
Chaperone protein dnaK CBU_1290 70,756.30 19 36.30% dfg 
SSU ribosomal protein S1P CBU_0528 62,120.60 7 11.80% df 
Chaperone protein htpG CBU_0309 75,448.40 5 10.80% d 
C8 
Chaperone protein dnaK CBU_1290 70,756.30 42 51.40% dfg 
60 kDa chaperonin GROEL CBU_1718 58,284.10 27 67.20% adfg 
Chaperone protein htpG CBU_0309 75,448.40 11 20.00% d 
Protein Translation Elongation Factor G (EF-G) CBU_0235 77,760.90 7 11.40% df 
Polyribonucleotide nucleotidyltransferase/Polynucleotide adenylyltransferase  CBU_0852 76,331.70 6 9.20% 
 
Outer membrane protein CBU_0307 24,901.80 3 12.10% bdf 
Transketolase  CBU_1784 74,446.70 2 2.83% 
 
DotA protein CBU_1648 86,901.00 2 2.33% 
 
C9 
  
60 kDa chaperonin GROEL CBU_1718 58,284.10 22 52.20% adfg 
Chaperone protein dnaK CBU_1290 70,756.30 19 27.90% dfg 
Outer membrane protein CBU_0307 24,901.80 4 16.00% bdf 
ASMA CBU_0939 54,976.00 2 3.39% 
 
Published key: a = Coleman et al. (2007); b = Beare et al. (2008); c = Chen et al. (2009); d = Sekeyova et al. (2009);  
e = Vigil et al. (2010); f = Deringer et al. (2011); and, g = Xiong et al. (2012). 
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Table A3-3 - Proteins identified by 2D-PAGE spot picks from the pI range 7.0–11.0 NL 
Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
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References 
H1 
Outer membrane protein CBU_1910 27,625.50 7 23.40% defg 
Arginine-binding protein CBU_0482 29,631.90 6 22.70% f 
Uridylate kinase  CBU_1384 26,362.20 5 21.00% 
 
Outer membrane protein CBU_0307 24,901.80 5 18.60% bdf 
Uracil-DNA glycosylase  CBU_0988 25,667.20 4 17.00% 
 
Stringent starvation protein A CBU_1747 24,416.20 3 14.80% 
 
Hypothetical protein CBU_1291 21,626.50 2 13.70% 
 
Short chain dehydrogenase CBU_0962 25,540.40 2 12.50% 
 
Hypothetical exported protein CBU_0952 20,385.50 2 11.80% adg 
Hypothetical exported protein CBU_0395 24,494.10 2 10.10% 
 
Outer membrane porin P1 CBU_0311 25,422.10 2 9.62% c 
Cytidylate kinase  CBU_0527 26,456.20 2 8.86% 
 
Hypothetical cytosolic protein CBU_2091 25,646.60 2 8.33% 
 
H2 
60 kDa chaperonin GROEL CBU_1718 57,286.80 23 41.20% adfg 
Chaperone protein dnaK CBU_1290 70,756.30 18 28.80% dfg 
Chaperone protein htpG CBU_0309 75,450.40 8 13.70% d 
ClpB protein CBU_0094 96,772.00 7 8.27% 
 
Pyruvate dehydrogenase E1 component  CBU_0461 99,741.80 7 7.13% 
 
Polyribonucleotide nucleotidyltransferase/Polynucleotide adenylyltransferase  CBU_0852 76,258.60 6 8.19% 
 
Aconitate hydratase  CBU_1720 101,340.90 6 6.87% 
 
DNA-directed RNA polymerase beta' chain  CBU_0232 157,106.50 6 4.53% 
 
Succinate dehydrogenase flavoprotein subunit  CBU_1401 65,440.70 5 8.01% 
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H2 
Membrane alanine aminopeptidase  CBU_0338 100,513.30 5 5.24% 
 
Proline dehydrogenase/Delta-1-pyrroline-5-carboxylate dehydrogenase  CBU_0629 116,412.80 5 4.49% 
 
Outer membrane protein CBU_0307 24,901.80 4 15.20% bdf 
ATP synthase alpha chain  CBU_1943 56,845.50 4 8.74% af 
Transketolase  CBU_1784 74,446.70 4 4.91% 
 
Pyridine nucleotide-disulfide oxidoreductase family CBU_0586 131,704.40 4 3.34% 
 
Starvation sensing protein rspA CBU_1275 45,432.00 3 7.71% 
 
Dihydrolipoamide dehydrogenase  CBU_0463 51,228.70 3 6.96% 
 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 3 6.71% 
 
Carbamoyl-phosphate synthase large chain  CBU_1281 118,542.10 3 3.63% 
 
ATP synthase B chain  CBU_1941 17,410.60 2 12.20% 
 
Xaa-Pro aminopeptidase  CBU_0073 66,945.20 2 3.18% 
 
DNA-directed RNA polymerase beta chain  CBU_0231 153,661.20 2 1.38% 
 
H3 
60 kDa chaperonin GROEL CBU_1718 58,284.10 34 49.80% adfg 
Succinate dehydrogenase flavoprotein subunit  CBU_1401 65,439.70 12 20.60% 
 
Glutamine-dependent NAD(+) synthetase  CBU_0858 60,233.50 11 16.20% f 
ATP synthase alpha chain  CBU_1943 56,845.50 10 19.80% af 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase 
complex  
CBU_0462 47,974.70 10 18.60% 
 
N utilization substance protein A CBU_1433 56,333.20 10 17.50% d 
Prolyl-tRNA synthetase  CBU_0081 63,590.50 10 14.50% 
 
Arginyl-tRNA synthetase  CBU_2008 66,777.10 9 13.00% 
 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 8 23.40% g 
2-amino-3-ketobutyrate coenzyme A ligase  CBU_0111 43,335.30 7 19.90% 
 
  
   
191 
Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
H3 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 7 14.70% 
 
Chaperone protein dnaK CBU_1290 70,756.30 7 13.30% dfg 
Xaa-Pro aminopeptidase  CBU_0073 67,006.20 7 9.88% 
 
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,237.10 6 15.90% d 
Amidophosphoribosyltransferase  CBU_0897 56,048.00 6 11.70% 
 
Methionyl-tRNA synthetase  CBU_1695 62,245.60 6 9.89% 
 
NAD-dependent malic enzyme  CBU_0823 63,394.00 6 9.73% 
 
Outer membrane protein CBU_0307 24,901.80 5 19.50% bdf 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase 
complex  
CBU_0638 40,846.80 5 13.20% 
 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit A  CBU_1474 52,564.50 5 12.80% 
 
Serine hydroxymethyltransferase  CBU_1419 45,779.30 5 9.79% 
 
Bacterial Peptide Chain Release Factor 3 (RF-3) CBU_0811 59,479.40 5 9.71% 
 
Peptidase, C40 family / NlpC-P60 family protein CBU_0215 60,213.50 5 9.59% f 
Phosphoenolpyruvate carboxykinase [ATP]  CBU_2092 56,808.10 5 9.28% 
 
SSU ribosomal protein S1P CBU_0528 62,120.60 5 8.71% df 
Methylcrotonyl-CoA carboxylase carboxyl transferase subunit  CBU_0975 61,059.20 5 6.68% 
 
IcmE protein CBU_1627 106,004.80 5 4.84% e 
Tol system periplasmic component YbgF CBU_0092 34,261.30 4 11.80% defg 
Phosphoribosylamine--glycine ligase  CBU_0326 46,193.90 4 11.10% 
 
IcmX protein CBU_1652 41,354.00 4 10.10% 
 
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 4 9.85% 
 
Pyruvate kinase  CBU_1781 53,152.30 4 9.71% 
 
ATP synthase beta chain  CBU_1945 50,435.50 4 9.33% dg 
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H3 
Enolase  CBU_1674 46,628.20 4 8.64% 
 
Chlorohydrolase/deaminase family protein CBU_0521 49,561.30 4 7.54% 
 
GMP synthase [glutamine-hydrolyzing]  CBU_1341 58,955.30 4 6.45% 
 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 3 10.10% 
 
Transcription termination factor rho CBU_2086 46,815.70 3 8.61% 
 
Malate dehydrogenase  CBU_1241 35,479.90 3 8.54% fg 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 3 7.81% adfg 
Isocitrate dehydrogenase [NADP]  CBU_1200 46,636.80 3 7.26% a 
Starvation sensing protein rspA CBU_1275 45,432.00 3 7.21% 
 
Dihydrolipoamide succinyltransferase component (E2) of 2-oxoglutarate 
dehydrogenase complex  
CBU_1398 45,496.20 3 6.97% befg 
Dihydrolipoamide dehydrogenase  CBU_0463 51,228.70 3 6.96% 
 
Citrate synthase  CBU_1410 48,652.00 3 6.74% 
 
Glutamyl-tRNA synthetase  CBU_1488 52,749.00 3 5.81% 
 
Succinate-semialdehyde dehydrogenase [NADP+]  CBU_1204 50,089.40 3 5.68% 
 
Transketolase  CBU_1784 74,507.80 3 4.32% 
 
Outer membrane porin P1 CBU_0311 25,422.10 2 9.62% c 
GrpE protein CBU_1293 22,952.30 2 8.33% 
 
Succinyl-CoA synthetase beta chain  CBU_1397 42,391.70 2 6.15% 
 
Ornithine cyclodeaminase  CBU_1727 37,915.70 2 5.36% 
 
Aspartate aminotransferase/Succinyldiaminopimelate aminotransferase  CBU_0517 46,393.00 2 4.73% 
 
Hypothetical protein CBU_2009 50,128.40 2 4.05% 
 
Peptidase, M20A family CBU_0103 52,900.00 2 3.96% f 
ABC transporter ATP-binding protein CBU_1770 48,969.70 2 3.88% d 
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H3 
Trigger factor, ppiase  CBU_0737 50,247.80 2 3.85% ag 
Cysteinyl-tRNA synthetase  CBU_1487 53,024.80 2 3.68% 
 
Phosphoglycerate mutase  CBU_1536 57,512.00 2 3.28% 
 
Chaperone protein htpG CBU_0309 75,450.40 2 3.20% d 
Aspartyl-tRNA synthetase  CBU_1565 66,790.90 2 3.05% 
 
H4 
Chaperone protein dnaK CBU_1290 70,756.30 40 53.20% dfg 
60 kDa chaperonin GROEL CBU_1718 58,284.10 32 62.10% adfg 
Polyribonucleotide nucleotidyltransferase/Polynucleotide adenylyltransferase  CBU_0852 76,331.60 25 42.10% 
 
Chaperone protein htpG CBU_0309 75,450.40 21 39.20% d 
Oligopeptidase A  CBU_0039 78,247.00 11 17.10% 
 
Transketolase  CBU_1784 74,507.80 11 17.00% 
 
ATP synthase alpha chain  CBU_1943 56,845.50 9 21.70% af 
Succinate dehydrogenase flavoprotein subunit  CBU_1401 65,439.70 8 16.50% 
 
ClpB protein CBU_0094 96,772.00 8 10.40% 
 
Succinyl-CoA synthetase beta chain  CBU_1397 42,391.70 7 24.10% 
 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 7 23.40% adfg 
Trigger factor, ppiase  CBU_0737 50,247.80 6 16.30% ag 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 6 15.50% 
 
Glutamine-dependent NAD(+) synthetase  CBU_0858 60,233.50 6 14.40% f 
Phosphoenolpyruvate carboxykinase [ATP]  CBU_2092 56,808.10 6 14.10% 
 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase 
complex  
CBU_0462 47,974.70 6 11.90% 
 
IcmE protein CBU_1627 106,004.80 6 6.19% e 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase CBU_0638 40,846.80 5 16.10% 
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complex  
H4 
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,237.10 5 15.30% d 
N utilization substance protein A CBU_1433 56,333.20 5 14.50% d 
Dihydrolipoamide dehydrogenase  CBU_0463 51,228.70 5 12.70% 
 
ATP synthase beta chain  CBU_1945 50,435.50 4 9.54% dg 
Peptidase, C40 family/NlpC-P60 family protein CBU_0215 60,213.50 4 8.46% f 
Amidophosphoribosyltransferase  CBU_0897 56,048.00 4 7.71% 
 
Xaa-Pro aminopeptidase  CBU_0073 67,006.20 4 7.20% 
 
Protein Translation Elongation Factor G (EF-G) CBU_0235 77,760.90 4 6.72% df 
Outer membrane protein CBU_0307 24,901.80 3 14.30% bdf 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 3 10.50% g 
Starvation sensing protein rspA CBU_1275 45,432.00 3 9.20% 
 
Pyruvate kinase  CBU_1781 53,152.30 3 7.23% 
 
Citrate synthase  CBU_1410 48,652.00 3 7.21% 
 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit A  CBU_1474 52,564.50 3 6.42% 
 
SSU ribosomal protein S1P CBU_0528 62,120.60 3 6.35% df 
Membrane alanine aminopeptidase  CBU_0338 103,038.20 3 3.44% 
 
Aconitate hydratase  CBU_1720 101,375.80 3 3.16% 
 
Hypothetical protein CBU_0632 11,885.10 2 24.20% d 
Outer membrane porin P1 CBU_0311 25,422.10 2 9.62% c 
ATP synthase gamma chain  CBU_1944 32,614.40 2 9.34% 
 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 2 7.88% 
 
Aspartate aminotransferase/Succinyldiaminopimelate aminotransferase  CBU_0517 46,393.00 2 6.86% 
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H4 
Malate dehydrogenase  CBU_1241 35,479.90 2 6.10% fg 
Adenosylhomocysteinase  CBU_2031 48,379.30 2 5.99% 
 
Phosphoribosylamine--glycine ligase  CBU_0326 46,193.90 2 5.66% 
 
Hypothetical protein CBU_2009 50,128.40 2 5.63% 
 
Fumarate hydratase  CBU_1096 49,851.70 2 5.45% 
 
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 2 5.42% 
 
Transcription termination factor rho CBU_2086 46,815.70 2 5.26% 
 
Succinate-semialdehyde dehydrogenase [NADP+]  CBU_1204 50,089.40 2 4.80% 
 
Prolyl-tRNA synthetase  CBU_0081 63,590.50 2 4.24% 
 
Serine hydroxymethyltransferase  CBU_1419 45,801.30 2 4.06% 
 
GTP-binding protein TypA/BipA CBU_0884 67,286.70 2 3.82% 
 
DotA protein CBU_1648 86,901.00 2 2.33% 
 
H5 
Protein Translation Elongation Factor Ts (EF-Ts) CBU_1385 31,819.50 9 33.10% f 
Dihydrodipicolinate synthase  CBU_1222 31,613.70 9 27.00% 
 
Methionyl-tRNA formyltransferase  CBU_1997 34,288.80 8 29.60% 
 
Hydroxymethylglutaryl-CoA lyase  CBU_0520 32,328.00 7 23.70% 
 
Tol system periplasmic component YbgF CBU_0092 34,261.30 7 22.30% defg 
ATP synthase gamma chain  CBU_1944 32,596.40 6 26.00% 
 
Outer membrane protein CBU_0307 24,901.80 6 22.50% bdf 
Peptide methionine sulfoxide reductase msrA/msrB  CBU_1306 32,799.20 6 20.80% 
 
Malate dehydrogenase  CBU_1241 35,479.90 6 17.10% fg 
Trp repressor binding protein CBU_1579 21,156.80 5 26.40% 
 
Stringent starvation protein A CBU_1747 24,416.20 5 23.00% 
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H5 
ATP-NAD kinase  CBU_1296 32,834.80 5 22.70% 
 
Succinyl-CoA synthetase alpha chain  CBU_1396 30,666.50 5 20.40% f 
Methylisocitrate lyase  CBU_0771 31,759.90 5 18.30% 
 
Thioredoxin reductase  CBU_1193 34,621.10 5 16.90% 
 
Riboflavin kinase/FMN adenylyltransferase  CBU_0391 36,477.20 5 15.90% b 
60 kDa chaperonin GROEL CBU_1718 58,284.10 5 14.70% adfg 
Magnesium and cobalt efflux protein corC CBU_0565 32,444.50 5 13.80% 
 
(2R)-phospho-3-sulfolactate synthase  CBU_1954 33,331.80 4 15.20% g 
Cystathionine beta-lyase no LT 34,304.70 4 15.20% 
 
Pyruvate dehydrogenase E1 component beta subunit  CBU_0639 35,478.10 4 11.70% 
 
Aspartate carbamoyltransferase  CBU_2095 34,973.20 4 11.60% 
 
Coproporphyrinogen III oxidase  CBU_1729 37,198.90 4 10.80% 
 
Ribose-phosphate pyrophosphokinase  CBU_1830 35,221.90 4 8.78% 
 
3-hydroxyisobutyrate dehydrogenase  CBU_0926 31,669.20 3 12.80% 
 
Curved DNA-binding protein CBU_1123 34,936.20 3 10.50% 
 
Short chain dehydrogenase  CBU_1276 29,148.60 3 9.33% 
 
4-hydroxythreonine-4-phosphate dehydrogenase  CBU_1981 32,675.40 3 9.12% 
 
6,7-dimethyl-8-ribityllumazine synthase  CBU_0648 16,600.90 2 16.60% d 
Queuosine biosynthesis protein queD CBU_1883 21,808.60 2 12.00% 
 
Hypothetical exported protein CBU_0952 20,385.50 2 11.80% adg 
Outer membrane porin P1 CBU_0311 25,422.10 2 9.62% c 
Short chain dehydrogenase CBU_0962 25,540.40 2 8.62% 
 
Uroporphyrin-III C-methyltransferase  CBU_2080 35,264.20 2 8.20% 
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H5 
Methylenetetrahydrofolate dehydrogenase (NADP+)/Methenyltetrahydrofolate 
cyclohydrolase  
CBU_0312 30,834.50 2 7.42% 
 
3-oxoacyl-[acyl-carrier-protein] synthase III  CBU_0493 34,688.20 2 7.21% 
 
Triosephosphate isomerase  CBU_1450 28,171.50 2 7.06% 
 
Anhydro-N-acetylmuramyl-tripeptide amidase  CBU_0379 30,184.50 2 7.00% 
 
Ornithine cyclodeaminase  CBU_1727 37,915.70 2 6.85% 
 
Acid phosphatase surE  CBU_1671 32,299.20 2 6.48% 
 
2-dehydro-3-deoxygluconokinase  CBU_1223 34,513.60 2 6.47% 
 
H6 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 14 37.70% g 
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 12 30.50% 
 
Adenosylhomocysteinase  CBU_2031 48,379.30 12 28.80% 
 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 11 29.20% adfg 
60 kDa chaperonin GROEL CBU_1718 58,284.10 11 25.40% adfg 
Isocitrate dehydrogenase [NADP]  CBU_1200 46,636.80 10 25.80% a 
Succinyl-CoA synthetase beta chain  CBU_1397 42,391.70 9 25.60% 
 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase 
complex  
CBU_0638 40,846.80 9 23.30% 
 
Phosphoribosylamine--glycine ligase  CBU_0326 46,193.90 9 22.90% 
 
Leucine dehydrogenase  CBU_0641 40,052.40 8 26.40% 
 
Hypothetical exported membrane associated protein CBU_0891 34,369.90 8 25.00% bce 
Starvation sensing protein rspA CBU_1275 45,432.00 8 20.90% 
 
2-amino-3-ketobutyrate coenzyme A ligase  CBU_0111 43,335.30 8 19.70% 
 
Citrate synthase  CBU_1410 48,652.00 8 18.10% 
 
S-adenosylmethionine synthetase  CBU_2030 42,777.50 7 17.80% g 
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H6 
Histidyl-tRNA synthetase  CBU_1248 47,811.30 7 16.40% 
 
Peptidase, C40 family/NlpC-P60 family protein CBU_0215 60,213.50 7 14.10% f 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 6 18.50% 
 
Acetyl-CoA acetyltransferase  CBU_0974 42,186.60 6 17.80% 
 
Nucleotide-sugar aminotransferase CBU_0696 43,350.80 6 16.70% 
 
Phosphoglycerate kinase  CBU_1782 42,363.70 6 15.30% 
 
Aspartate aminotransferase/Succinyldiaminopimelate aminotransferase  CBU_0517 46,393.00 6 14.70% 
 
Pyrophosphate--fructose 6-phosphate 1-phosphotransferase  CBU_1273 46,083.60 6 13.80% 
 
Trp repressor binding protein CBU_1579 21,156.80 5 24.40% 
 
Stringent starvation protein A CBU_1747 24,416.20 5 23.00% 
 
Outer membrane protein CBU_0307 24,901.80 5 16.00% bdf 
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,237.10 5 15.90% d 
Tryptophanyl-tRNA synthetase  CBU_2049 40,662.50 5 13.50% 
 
Malate dehydrogenase  CBU_1241 35,479.90 4 11.90% fg 
Cystathionine gamma-lyase  CBU_2025 42,701.90 4 10.30% 
 
Glutamine synthetase  CBU_0503 39,616.00 4 9.47% g 
TolB protein CBU_0090 47,829.40 4 8.70% 
 
Thioredoxin peroxidase  CBU_1706 21,850.00 3 13.00% df 
Phosphoserine aminotransferase  CBU_0525 40,647.10 3 9.72% 
 
NAD dependent epimerase/dehydratase family CBU_0829 36,657.40 3 9.09% 
 
Glycine dehydrogenase [decarboxylating]  CBU_1714 48,465.90 3 7.62% 
 
Queuine tRNA-ribosyltransferase  CBU_1072 42,632.10 3 7.27% 
 
Glutamate--cysteine ligase  CBU_1874 48,959.80 3 6.44% 
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H6 
Protein translocase subunit secB CBU_1519 18,376.50 2 13.70% 
 
Queuosine biosynthesis protein queD CBU_1883 21,808.60 2 12.00% 
 
Hypothetical exported protein CBU_0952 20,385.50 2 11.80% adg 
3-deoxy-manno-octulosonate cytidylyltransferase  CBU_0479 28,497.50 2 8.70% d 
Short chain dehydrogenase CBU_0962 25,540.40 2 8.62% 
 
ATP synthase gamma chain  CBU_1944 32,596.40 2 7.61% 
 
Cytidylate kinase  CBU_0527 26,456.20 2 7.59% 
 
(2R)-phospho-3-sulfolactate synthase  CBU_1954 33,331.80 2 7.59% g 
peptide chain release factor 2 CBU_0428a 32,502.10 2 6.57% 
 
2-methylcitrate synthase  CBU_0772 41,575.00 2 6.45% 
 
Isovaleryl-CoA dehydrogenase  CBU_0973 42,331.50 2 5.94% 
 
DNA polymerase III, beta chain  CBU_0002 41,765.50 2 5.42% 
 
Ornithine cyclodeaminase  CBU_1727 37,915.70 2 5.36% 
 
Alanine dehydrogenase  CBU_1116 39,439.20 2 5.15% 
 
dTDP-4-dehydro-6-deoxy-D-glucose 4-aminotransferase  CBU_0697 43,546.10 2 4.92% 
 
H7 
60 kDa chaperonin GROEL CBU_1718 58,284.10 14 33.70% adfg 
ATP-dependent endopeptidase hsl ATP-binding subunit hslU CBU_2012 50,183.50 14 30.20% 
 
ATP synthase beta chain  CBU_1945 50,435.50 13 32.50% dg 
Succinate-semialdehyde dehydrogenase [NADP+]  CBU_1204 50,089.40 13 31.70% 
 
Transcription termination factor rho CBU_2086 46,815.70 12 27.30% 
 
Seryl-tRNA synthetase  CBU_1188 48,148.90 11 26.50% 
 
Chlorohydrolase/deaminase family protein CBU_0521 49,561.30 11 23.70% 
 
Adenosylhomocysteinase  CBU_2031 48,379.30 10 25.10% 
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H7 
Cysteinyl-tRNA synthetase  CBU_1487 53,024.80 10 19.00% 
 
Short-chain alcohol dehydrogenase  CBU_0270 44,876.10 9 26.10% 
 
Phosphoribosylamine--glycine ligase  CBU_0326 46,193.90 9 22.90% 
 
Glutamyl-tRNA synthetase  CBU_1488 52,749.00 9 21.30% 
 
Fumarate hydratase  CBU_1096 49,851.70 9 19.80% 
 
Serine hydroxymethyltransferase  CBU_1419 45,801.30 9 18.60% 
 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B  CBU_1475 53,425.30 8 19.70% 
 
Citrate synthase  CBU_1410 48,652.00 8 18.10% 
 
Dihydrolipoamide dehydrogenase  CBU_0463 51,228.70 8 16.90% 
 
Peptidase, M20A family CBU_0103 52,900.00 8 16.90% f 
Outer membrane protein CBU_0307 24,901.80 7 26.00% bdf 
Enolase  CBU_1674 46,628.20 7 19.40% 
 
Adenylosuccinate synthetase  CBU_0998 47,972.60 7 15.60% 
 
Glycerol kinase  CBU_0932 55,389.20 7 13.20% f 
Succinyl-CoA synthetase beta chain  CBU_1397 42,391.70 6 19.00% 
 
Hypothetical protein CBU_1751 48,992.50 6 14.80% 
 
Chain F, 2.50 Angstrom Resolution Structure Of 3-Phosphoshikimate 1- 
Carboxyvinyltransferase (Aroa) From Coxiella Burnetii In Complex With 
Phosphoenolpyruvate 
3ROI_A 46,476.80 6 14.40% 
 
Peptidase, C40 family/NlpC-P60 family protein CBU_0215 60,213.50 6 12.40% f 
3-oxoacyl-[acyl-carrier-protein] synthase  CBU_0497 44,076.30 5 13.30% ag 
Trigger factor, ppiase  CBU_0737 50,247.80 5 12.20% ag 
Trp repressor binding protein CBU_1579 21,156.80 4 20.30% 
 
Stringent starvation protein A CBU_1747 24,416.20 4 17.70% 
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H7 
Pyruvate dehydrogenase E1 component alpha subunit  CBU_0640 41,108.40 4 12.80% 
 
Protein Translation Elongation Factor Tu (EF-TU) CBU_0236 43,525.70 4 12.10% adfg 
Glyceraldehyde 3-phosphate dehydrogenase  CBU_1783 36,237.10 4 12.00% d 
Leucine dehydrogenase  CBU_0641 40,052.40 4 11.50% 
 
Ornithine cyclodeaminase  CBU_1727 37,915.70 4 11.00% 
 
Dihydrolipoamide succinyltransferase component (E2) of 2-oxoglutarate 
dehydrogenase complex  
CBU_1398 45,496.20 4 9.20% befg 
Peptidase, M16 family CBU_1902 51,958.60 4 8.71% 
 
ABC transporter ATP-binding protein CBU_1770 48,969.70 4 8.68% d 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase 
complex  
CBU_0462 47,974.70 4 8.26% 
 
Glutamate--cysteine ligase  CBU_1874 48,959.80 4 6.90% 
 
Protein translocase subunit secB CBU_1519 18,376.50 3 19.30% 
 
Phosphoserine aminotransferase  CBU_0525 40,647.10 3 10.00% 
 
Nucleotide-sugar aminotransferase CBU_0696 43,350.80 3 8.85% 
 
Acetyl-CoA acetyltransferase  CBU_0974 42,186.60 3 8.38% 
 
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase 
complex  
CBU_0638 40,846.80 3 8.20% 
 
Hypothetical protein CBU_2009 50,128.40 3 7.66% 
 
Histidyl-tRNA synthetase  CBU_1248 47,811.30 3 7.60% 
 
Glutamine synthetase  CBU_0503 39,616.00 3 6.96% g 
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit A  CBU_1474 52,564.50 3 6.63% 
 
Outer membrane porin P1 CBU_0311 25,422.10 2 9.62% c 
Short chain dehydrogenase CBU_0962 25,540.40 2 8.62% 
 
ATP synthase gamma chain  CBU_1944 32,596.40 2 7.96% 
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Spot 
ID 
Protein name Locus tag 
Protein Mr 
(Da) 
Exclusive 
unique 
peptide 
count 
Sequence 
coverage 
References 
H7 
Aspartate aminotransferase/Succinyldiaminopimelate aminotransferase  CBU_0517 46,393.00 2 6.86% 
 
NAD dependent epimerase/dehydratase family CBU_0829 36,657.40 2 6.67% 
 
Fructose-bisphosphate aldolase  CBU_1778 39,532.80 2 6.61% g 
2-methylcitrate synthase  CBU_0772 41,605.10 2 6.40% 
 
Malate dehydrogenase  CBU_1241 35,479.90 2 6.10% fg 
NADH-quinone oxidoreductase chain F  CBU_1443 46,487.30 2 5.69% 
 
Biotin carboxylase  CBU_1726 49,264.60 2 5.58% 
 
Glycine dehydrogenase [decarboxylating]  CBU_1714 48,465.90 2 5.16% 
 
Starvation sensing protein rspA CBU_1275 45,432.00 2 4.98% 
 
Microcin-processing peptidase 2 (TldD) CBU_1467 50,700.40 2 4.82% 
 
Hypothetical exported protein CBU_0937 53,386.20 2 4.55% df 
Pyruvate kinase  CBU_1781 53,152.30 2 4.55% 
 
Tryptophanyl-tRNA synthetase  CBU_2049 40,662.50 2 4.49% 
 
tRNA(Ile)-lysidine synthetase TilS CBU_1509 51,265.40 2 4.23% 
 
Sugar kinase CBU_1088 51,758.20 2 4.10% 
 
Homoserine dehydrogenase CBU_1836 46,486.20 2 4.07% 
 
2-methylcitrate dehydratase/2-methylisocitrate dehydratase  CBU_0912 53,354.00 2 4.01% 
 
Published key: a = Coleman et al. (2007); b = Beare et al. (2008); c = Chen et al. (2009); d = Sekeyova et al. (2009);  
e = Vigil et al. (2010); f = Deringer et al. (2011); and, g = Xiong et al. (2012). 
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Axenically grown Coxiella burnetii as a diagnostic 
antigen
Bewley, K. R., Pitman, J. K., Atkinson, D. J., Charlwood, M., Vipond, J.
Public Health England, Porton Down, Salisbury, Wiltshire, SP4 0JG. UK. 
E-mail: kevin.bewley@phe.gov.uk; Telephone: +44(0)1980 619838
INTRODUCTION
Coxiella burnetii is a BSL-3 agent and is the causative agent of Q fever. Infection can take several forms and 
in man disease can range from asymptomatic, through acute, to life-threatening chronic illness. In the 
majority of cases, acute disease presents as a self-limiting febrile illness. In more severe cases, atypical 
pneumonia is found. A small proportion of those suffering from symptomatic acute Q fever will be admitted to 
hospital (2-4%). Chronic disease develops in approximately 5% of those infected.
Up until very recently C. burnetii was regarded as an obligate intracellular bacterial pathogen that could only 
be produced inside living cells. As a result of this, diagnostic antigen for ELISA and Immunofluorescence 
Assay (IFA) is currently produced by cultivating the organism in the yolk sacs of live embryonated hen eggs 
(Figure 1). The yolk sacs are harvested, homogenised, and processed via several clean-up steps ending 
with formalin inactivation, to produce a diagnostic antigen. The production of antigen by this method is 
hazardous, produces large amounts of waste that must be made safe, uses living animals, and in spite of the 
clean-up, produces an antigen that often contains residual chick/egg protein species.
RESULTS
 Antigen free from any visible impurities, with little aggregation (Figure 3). 
The material also contains a mixture of the Small- and Large- morphological forms of the 
organism (SCV and LCV).
Pre-
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 Immunofluorescence slides produced (figure 4) and tested with sera.
Good bright fluorescence of Coxiellae of both phases and absence of non-specific reactions 
with the added Vero-E6 cells. IgM results not shown but comparable to figure 4 image D.
Figure. 1 – Conventional method of antigen production
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METHODS
 Antigen was produced by cultivating phase I C. burnetii organisms in the acidified citrate 
cysteine medium (ACCM) of Omsland et al. (2011) for 8 days at 37°C in a sealed box with a 
microaerophillic atmosphere-producing pack. Growth was monitored by daily sampling and 
titration using in-house quantitative PCR assay to amplify part of the icd gene.
 Antigen was harvested by centrifugation and the pellet re-suspended in PBS containing formalin. 
After inactivation, the antigen was subjected to embedding in epoxy resin for transmission 
electron microscopy (Figure 3).
 To produce phase II antigen, this preparation was subjected to potassium periodate reduction by 
the method of Schramek et al. (1972).
 IFA slides were produced by mixing the phase I or phase II antigen with bovine serum albumin 
(BSA) and spotting into the wells of Teflon-coated 15 well slides. 
 A further batch of slides was produced as above but with the addition of Vero E6 cells to the 
A B
C D
Figure. 3 – Transmission electron micrographs of C. burnetii antigen (ACCM-2 grown)
A - 14,000x view of embedded section showing that preparation consists of only Coxiellae
B - 60,500x view showing mixture of morphological types of the organism.
AIM
To assess if antigen produced from axenically grown C. burnetii is a suitable alternative to that 
produced in embryonated hen eggs for diagnostic immunoassay.
CONCLUSIONS
 Growth in ACCM-2 produces antigen in less time and with less ‘hands-on’ work than conventional 
methods
 Less handling steps at BSL-3 increases laboratory worker safety significantly
 Removing the need for embryonated hen eggs has both positive ethical effect as well as increasing 
uniformity and consistency of the final product
 Clean-up after ACCM-2 growth is simple as there are no residual egg protein contaminants to be 
removed
 Slides produced are easier to read (focusing and confirmation of negatives) if Vero-E6 cells are added to 
the antigen prior to spotting
 Anti-ovalbumin reactions, common with conventionally-produced antigen, are unlikely to be an issue with 
antigen produced by this method (to be confirmed in further experiments)
 Further testing with this antigen in ELISA format and against a panel of clinical samples is warranted.
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antigen/BSA mixture prior to spotting out. This was to assess whether the presence of cells on 
the slides would permit easier focussing on the slide spots than antigen alone.
 Slides were tested with serum positive for the presence of Coxiella IgG and IgM, and detected 
with a secondary antibody conjugated to FITC (in a buffer containing Evan’s Blue).
RESULTS
 A 4-5 log increase in C. burnetii produced in only 8 days (Figure 2)
.
Figure. 2 – Growth curve of C. burnetii in ACCM-2 (by quantitate PCR icd gene)
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Figure. 4 – IFA images of produced slides (x400)
A – Phase II antigen with positive antiserum - IgG (no Vero E6 cells in preparation)
B – Phase I antigen with negative antiserum  - IgG (Vero E6 cells in preparation) 
C – Phase II antigen with positive antiserum  - IgG (Vero E6 cells in preparation)
D – Phase I antigen with positive antiserum  - IgG (Vero E6 cells in preparation)
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Coxiella burnetii is the causative agent of human Q fever. Infec-
tion can take several forms and has been described as clinically 
polymorphic.6 In humans, presentation ranges from asymptom-
atic, through acute disease, to chronic illness. In the majority 
of cases, acute disease presents as a self-limiting febrile illness, 
with half of cases also having severe headaches.88 In severe cases 
of acute disease, atypical pneumonia is often found.88 A small 
proportion (2% to 4%) of subjects with symptomatic acute Q fe-
ver are admitted to hospital.70,88 Chronic disease may develop in 
approximately 5% of those infected;16 the vast majority of these 
cases will present as a bacterial culture-negative endocarditis16,22 
often in those with predisposing heart-damage19 or immunosup-
pression.16 Without effective treatment, Q fever endocarditis is 
generally fatal, but early diagnosis coupled with novel treatment 
strategies has brought the death rate down to less than 5%.69 The 
2009 outbreak in the Netherlands involved 2357 human cases, of 
which more than 400 required hospitalization.90 The animal cost 
in the Netherlands was far higher, with more than 50,000 preg-
nant goats culled in an attempt to control the epidemic.82
Two other clinical manifestations of Q fever are worthy of men-
tion owing to their less-than-satisfactory outcomes with current 
treatment strategies. These are Q fever during pregnancy and Q 
fever fatigue syndrome. C. burnetii infection during pregnancy re-
sults in premature delivery in almost half of those affected and 
spontaneous abortion in more than a quarter.14 There have been 
few studies in this area, but there are indications that among those 
infected during the first trimester and treated suboptimally, the 
abortion rate is 100%.68 This effect is compounded by the fact that 
the frontline bactericidal drugs for treatment (doxycycline and hy-
droxychloroquine) are contraindicated for use during pregnancy.68 
A bacteriostatic regimen (cotrimoxazole) has therefore been pro-
posed for use68 until delivery. Without satisfactory treatment dur-
ing and after pregnancy, there is also a high probability for infection 
to lead to chronic Q fever: an incidence of 70% was reported in a 
group of pregnant women in France.68
Post-Q fever fatigue syndrome was first reported in 1996,52 but 
an association between Q fever and chronic fatigue had been ob-
served as early as 1982.52 Between 10% and 15% of those who 
have had acute Q fever develop a chronic fatigue syndrome that 
can last between 5 and 10 y—and even longer in some cases.53 
Some of these patients have been found to have long-term per-
sistence of C. burnetii cell components and LPS associated with 
traces of genomic DNA,53 suggesting that Q fever fatigue syn-
drome may be immunologically mediated rather than caused by 
the organism directly.
Q fever is a zoonosis that has been described worldwide,56 and 
human outbreaks are often associated with contact with the birth 
products of farm animals.56 However, outbreaks associated with 
the birth products of domestic cats have also been reported.54 Hu-
man infection primarily occurs via the inhalation of infectious 
aerosols.56 Over the past 10 y, outbreaks have been reported in 
the Netherlands,71 Slovenia,26 the United Kingdom,91,97,99 Israel,2 
Iraq,18 the United States,11 Germany,24 Bulgaria,63 Croatia,58 Spain,23 
Italy,83 and France.88
A very small number of C. burnetii organisms can cause infec-
tion by inhalation. Infection has been predicted to be possible af-
ter exposure to only a single organism.33 This low dosage, coupled 
with the organism’s ability to cause debilitating disease and high 
levels of resistance to various means of inactivation67,77,78 have 
resulted in it being listed as a category B biologic warfare and 
bioterrorism agent by the Centers for Disease Control.49
Prevention of Q fever in man can be achieved by vaccination; the 
only vaccine available for general use is Q-Vax, which was licensed 
in Australia in 1989.51 This vaccine consists of formalin-inactivated 
Overview
Animal Models of Q Fever (Coxiella burnetii)
Kevin R Bewley
Q fever, caused by the pathogen Coxiella burnetii, is an acute disease that can progress to become a serious chronic illness. The 
organism leads an obligate, intracellular lifecycle, during which it multiplies in the phagolytic compartments of the phagocytic 
cells of the immune system of its hosts. This characteristic makes study of the organism particularly difficult and is perhaps one 
of the reasons why, more than 70 y after its discovery, much remains unknown about the organism and its pathogenesis. A variety 
of animal species have been used to study both the acute and chronic forms of the disease. Although none of the models perfectly 
mimics the disease process in humans, each opens a window onto an important aspect of the pathology of the disease. We have 
learned that immunosuppression, overexpression of IL10, or physical damage to the heart muscle in mice and guinea pigs can 
induce disease that is similar to the chronic disease seen in humans, suggesting that this aspect of disease may eventually be fully 
understood. Models using species from mice to nonhuman primates have been used to evaluate and characterize vaccines to protect 
against the disease and may ultimately yield safer, less expensive vaccines.
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problem in comparing models of C. burnetii infection is related to 
the organism’s intracellular nature, which complicates attempts 
to count the organisms used for infection. The literature reflects 
this difficulty in the fact that there are many different methods 
used (including plaque assay in primary cell cultures, median 
infectious doses in chick eggs or mice, and median lethal dose in 
SCID mice) and no way to directly compare them.
Host Range
In nature, C. burnetii has been detected in species throughout 
the animal kingdom,9 including wild and livestock mammals as 
well as invertebrates, such as ticks. Animals are often asymptom-
atic despite chronic infection. Although C. burnetii can be shed 
into the environment via bodily fluids, the majority of shedding 
occurs via the birth products of domestic farm animals; more than 
109 bacteria can be released per gram of placenta from domestic 
ruminants during birth.9
A great deal of information is still missing regarding the im-
mune response to the infection in humans and animal models. Of 
particular importance in understanding the pathogenesis of dis-
ease is elucidating the composition and production of cytokines 
in response to infection. Unfortunately, modern technologies such 
as multiplex bead arrays and mRNA expression microarrays have 
only recently been applied to the field of Coxiella research. The 
only comprehensive description of cytokine response in the litera-
ture is in a mouse model, in which levels of IL6, TNFα, IL12, IFNγ, 
IL3, IL4, IL10, G-GCF, MIP1α, and RANTES were examined.73 The 
authors suggested that the levels of some cytokines differed de-
pending on the genogroup of the Coxiella strain used, thus adding 
weight to the argument that disease progression isn’t a wholly a 
host-dependent feature. However, without similar descriptions of 
the cytokine profiles in human patients and other animal models, 
useful comparisons are difficult to make.
The remainder of this review will focus on the main small 
animal models of acute Q fever (mouse and guinea pig), chronic 
Q fever, and ‘special cases’ of Q fever, such as disease during 
pregnancy and in immunocompromised hosts (Table 1). In ad-
dition, an overview of nonhuman primate models that have 
been used to investigate both the pathology of acute Q fever and 
evaluate the protection afforded by various vaccine candidates 
will be provided.
Small Animal Models of Acute Q Fever
Mice. Mice have been used to study C. burnetii since the dis-
covery of the organism.66 Generally, mice do not display overt fe-
brile disease to the degree seen in humans; in fact, often there are 
minimal signs of infection in laboratory mice.20,66 As in other mod-
els, pneumonia occurs after intranasal or aerosol exposure but 
not after intraperitoneal injection.20,66 Most reports suggest that 
splenomegaly and weight change, followed by confirmation of 
seroconversion, are the most reliable markers of infection in mice. 
In an evaluation of 47 strains of inbred laboratory mice, 33 were 
found to be resistant to infection with C. burnetii, 10 were partially 
susceptible, and 4 were susceptible.79 The A/J strain of mouse 
was found to have the highest mortality (70%) but could still be 
protected by vaccination with formalin-inactivated C. burnetii 
whole cells.79 The BALB/c strain of mouse was reliably infected 
and displayed overt signs of illness, including ruffled fur and 
lethargy in all members of the group, but with no mortality.79
C. burnetii whole cells, produced in chick embryos. Its use has 
been associated with severe local reactions in those with preex-
isting immunity. As a precaution, prevaccination screening (his-
tory, skin test, and serology) must therefore be performed prior 
to administration.35 Despite this safeguard, severe local reactions 
to vaccination are reported.44 The vaccine is also hazardous to 
produce, with the organism requiring culture in chick-embryos at 
biosafety level 3 prior to inactivation.51 There is, therefore, a need 
for a vaccine that is safer to produce and safer to use and that 
does not require prevaccination screening.
The organism displays antigenic phase variation often paral-
leled with the rough-smooth variation seen in Enterobacteriace-
ae. In C. burnetii, phase variation has been demonstrated to be 
due to differences in LPS. Phase I has been shown to contain a 
unique disaccharide galactosaminuronyl glucosamine and 9 un-
identified components in addition to the components of phase 
II LPS.1 Organisms with the phase I phenotype are the infec-
tious and virulent form found in the environment. Organisms 
with the phase II phenotype are observed only during repeated 
subculture in laboratory chick embryo or cell culture systems;27 
they have a chemically simpler LPS1 and several deletions in the 
genome.32,92 Phagocytosis of phase I, but not phase II, organisms 
by macrophages involves an interaction between the bacterial 
LPS and Toll-like receptor 4. This mechanism also stimulates F-
actin reorganization of the host cells and stimulates the release 
of type 1 cytokines including IFNγ and TNF.30 This interaction 
appears important in the initial priming of the immune response 
and could provide an explanation for the limited protection of 
vaccines based on potential virulence genes (omp1, HspB, Pmm, 
Fbp, Orf 410, Crc, CbMip, MucZ, P28) singly and in combinations 
but containing no LPS.47,89,102
In addition to its antigenic phase variation, C. burnetii occurs in 
2 morphologic forms, a large-cell variant and a small-cell variant. 
These forms differ antigenically due to differences in the proteins 
expressed on their surface. It has been suggested that the resis-
tance of C. burnetii to host defense mechanisms may be enhanced 
by antigenic differences between the different developmental 
forms.57,94 The small-cell morphologic form is highly resistant to 
destruction by chemical and environmental factors and is likely 
the transmissible form of the pathogen.15,67 After infection, which 
generally occurs by inhalation of the small-cell form, the organ-
isms are taken up by host alveolar macrophages.81 Morphogene-
sis from the small-cell to large-cell form then occurs, the large-cell 
variant being the replicative form of the organism.15 These or-
ganisms then replicate within parasitophorous vacuoles.50 As the 
organisms enter the stationary phase of their growth within the 
cell, they condense back into the small-cell form.15 During replica-
tion within the host cell, the organism subverts cellular processes 
though active mechanisms to avoid and modify the host immune 
response.50 C. burnetii possesses a type IV secretion system, and 
the proteins that cause this subversion are likely delivered to the 
host cell by this machinery.50,93
Because C. burnetii is an obligate intracellular organism, it has 
only been possible to study the organism within living animal 
hosts. Host-cell–free growth of the organism has been reported 
recently,62 but the technique has yet to be exploited fully. Cell-
culture–based in vitro systems remain limited in the study of C. 
burnetii, given that the organism soon reverts to the avirulent (at 
least in immunocompetent hosts) phase II form (characterized by 
the loss of the phase I LPS phenotype) in these systems.10 A key 
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and serum creatine phosphokinase all were elevated.29 The animals 
also demonstrated marked weight loss.64
The model was later refined to use aerosol delivery, to bet-
ter replicate the natural mode of infection.39,43,74 This method of 
delivery causes greater lung changes and less pronounced liver 
changes than does the intraperitoneal route.43 In addition to fever 
and weight loss, guinea pigs display a marked pneumonia when 
exposed by this route.74 As few as 20 organisms can cause acute Q 
fever in this model.74 Among the small animal models for acute Q 
fever, the guinea pig model with aerosol delivery of the organism 
can be regarded as the model of choice.
Small Animal Models of Chronic Q fever
Mice. In a model of C. burnetii infection during pregnancy us-
ing BALB/cJ mice, a large accumulation of organisms in the pla-
centa was present,12 mimicking findings in domestic livestock.9 
Infection was associated with clinical signs including high levels 
of abortion, still birth, and perinatal death. The birthrate fell to 
7.1% in infected mice, compared with 100% in the control group.12 
Another study investigating Q fever in pregnant BALB/c mice 
had similar findings but also reported endocarditis in 20% of the 
mice.85 This pattern is consistent with the observation that Q fever 
in pregnancy can lead to chronic infection in humans (as many as 
12 of 14 women infected in the first 2 trimesters in one report68). 
The current recommended therapy for women infected during 
pregnancy is treatment with cotrimoxazole until delivery.14 In a 
study of women treated with cotrimoxazole, although the out-
come of pregnancy was good, the mother still became chronically 
infected in 2 of 4 cases.68 The pregnant mouse model could be a 
useful and important tool, by allowing detailed examination of 
the pathology of Q fever in pregnancy as well as investigation of 
different antimicrobial therapies.
Using cyclophosphamide to immunosuppress the BALB/cJ 
strain of mouse revealed that intraperitoneal infection could lead 
to Q fever endocarditis without the need to predamage the heart,8 
as had been required in a rabbit model.27 There was no report 
of focal calcification in the heart in the BALB/cJ mouse model, 
as would be expected in human chronic Q fever endocarditis. 
However, the mortality rate was very high (53%) and was associ-
ated with C. burnetii antigen deposition.8 This model is perhaps 
In mouse models, as in humans, the male sex is associated 
with more severe signs of infection.20,46 One study established 
a protective role of 17β-estradiol45 that could partially explain 
why males experience more severe clinical disease than females 
despite similar seropositivity rates. The presence of 17β-estradiol 
was correlated with lower bacterial loads and less granuloma 
formation.45 Recent studies using microarray analysis found that 
86% of the genes probed were differentially expressed in infected 
male and female mice.86 Of those genes, 60% were due to sex hor-
mones. Perhaps surprisingly, many of the genes that appeared to 
play a role in protection of female mice from severe disease were 
involved in the circadian rhythm clock.86
For experiments requiring the titration of C. burnetii infectivity 
(generally presented as a median infectious dose), an assay consist-
ing of mouse infection followed by testing for seroconversion has 
been recognized as less labor-intensive and more economical than 
is the guinea pig assay. The titers given were reported as being rea-
sonably comparable between the mouse and guinea pig assays.75
The mouse model, predominantly using intraperitoneal ex-
posure, has also been used extensively to evaluate the efficacy 
of vaccines to protect against Q fever.17,89,98,101 These models have 
consistently found that the phase I formalin-inactivated whole-
cell vaccine (similar to the commercially available vaccine) is 
more effective at protection than are various chloroform:methanol 
extracts of C. burnetii, the phase II antigen-based vaccines,101 and 
a range of recombinant antigens.89 Mice have become the model 
of choice for research investigating the immunology of Q fever, 
because of the availability of mouse strains with specific immu-
nologic lesions, coupled with the availability of reagents and anti-
bodies for the characterization of their immune responses.4,5,40,61
Guinea pigs. Guinea pigs were recognized early in the study of C. 
burnetii as being an effective model for the disease course of Q fever 
in humans.48 With the exception of immunocompromised strains, 
guinea pigs are more susceptible to infection than are mice.76 Early 
studies concentrated on intraperitoneal challenge as the route of 
infection.28,29,48,64,65,87 As in humans, pronounced fever (with some 
strains achieving temperatures greater than 40 °C) is produced.29,48,64 
Granulomas occur in the liver, spleen, and bone marrow.29,48 Bio-
chemical changes include increases in liver glycogenolysis and 
lipogenesis;64,65 biochemical markers in the blood including glucose, 
serum ALP, serum AST, serum α-hydroxybutyrate dehydrogenase, 
Table 1. Summary of use of animal models for Q fever
Species Route
Study focus (reference citation numbers)
Pathology (acute)
Pathology 
(special or chronic)
Virulence 
assessment
Vaccine 
development
Adverse reaction 
to vaccine
Guinea pig Intraperitoneal 28, 48, 64, 65 42 34, 73 39 7, 72
Aerosol 37, 43, 74 34, 76
Mouse Intraperitoneal 5, 20, 45, 46, 55, 66, 
79, 80, 86
12, 84 73 17, 21, 89, 98,  
100, 101
Aerosol 36, 55, 66, 85
Immunocompromised and  
 genetically manipulated mice
Intraperitoneal 3, 4, 8, 40, 41, 
53, 59, 61
73
Aerosol 85 41
Nonhuman primates Aerosol 25, 95 38, 96
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pneumonia were seen from day 5 increasing in severity until day 
12.25 Serologically, the antibody response to phase II antigens rose 
first and reached higher titers than did the later phase I antibody 
response. The authors concluded that the disease in these primates 
closely resembled the acute Q fever seen in humans.
In the early 1980s, this model was used to evaluate a formalin-
inactivated C. burnetii whole-cell vaccine.38 The vaccine protected 
the majority of macaques, but some of those vaccinated devel-
oped clinical signs of illness after challenge. In the unvaccinated 
group, similar clinical symptoms to those found in the earlier 
study were described and included anorexia, depression, and fe-
ver.25 The vaccine study38 reported similar increases in ALP, AST, 
and total bilirubin to those of the previous work.25 In infected 
animals, interstitial pneumonia was noted in radiographs and 
during pathologic examination.38 In the group of macaques that 
were vaccinated, even those that displayed clinical signs had no 
changes in ALP, AST, total bilirubin, radiographs, or pathology.38 
Plasma fibrinogen was elevated in control and vaccinated ani-
mals that had an elevated temperature.38 Vaccinated macaques 
displayed a shorter duration of bacteremia (2 d rather than 7 d) 
that also was of a smaller magnitude.38 These results confirm the 
utility of the cynomolgus macaque model in assessing the protec-
tion afforded by vaccination.
A later study compared rhesus (Macaca mulatta) and cynomol-
gus macaques as models using aerosol challenge.95 As in previ-
ous reports,25,38 pulmonary radiologic changes were seen in most 
animals95 and more pronounced in cynomolgus macaques. More 
rhesus macaques were bacteremic and for longer periods than 
were cynomolgus macaques.95 Bacteremia was assessed only by 
whether samples of blood from macaques infected mice, and 
no attempt was made to quantify the levels of bacteria present 
in the circulation (for example, by real-time quantitative PCR 
analysis).95 Typical antibody responses, as described previously, 
developed in both species of macaques, but duration of fever was 
slightly longer in rhesus macaques.95 Clinical features of disease 
(decreases in ALP and total bilirubin concentration) were similar 
to those described in human cases of acute Q fever but contrasted 
with previous reports,25,38,95 but no explanation of this difference 
was offered. However, serum AST and fibrinogen levels were 
elevated in both macaque species, as in human disease and in the 
previously described primate models. In addition, LDH (another 
marker of liver disease) was significantly higher in infected ma-
caques, which also had elevated AST values, providing further 
evidence of liver involvement. The comparison of the rhesus and 
cynomolgus models did not include pathologic examinations or 
necropsy, thus preventing comparison between these and previ-
ous models in regard to the presence of liver granulomas or other 
specific liver pathology.95 The authors suggested that both rhesus 
and cynomolgus macaques would be suitable models for studies 
of vaccine efficacy but favored cynomolgus macaques because of 
the more significant radiologic findings and the more human-like 
changes in lactate dehydrogenase and AST in that species.95
The cynomolgus model with aerosol exposure was used 
in 2002 to compare the formalin-inactivated whole-cell vac-
cine that was licensed for use in humans in Australia with a 
chloroform:methanol residue of C. burnetii.96 In contrast to the 
previous study,38 vaccinated macaques exhibited signs of illness 
when challenged 6 mo after vaccination.96 However, the disease 
in vaccinated animals was of shorter duration and lower severity 
than that in unvaccinated controls.96 Levels of ALP raised, as in 
a model of acute Q fever endocarditis, rather than of the chronic 
form of the disease seen in humans. Chronic Q fever infection 
was established in another model using mice with severe com-
bined immunodeficiency, in which all infected mice eventually 
died, with a mean time to death of 33 d.3 In this model, endocardi-
tis was associated with focal calcification in the heart, as occurs in 
human chronic disease.3 However, in a report by another group, 
an aerosol exposure model using SCID mice was not lethal85—the 
fact that this experiment was terminated at 14 d postexposure 
probably explains this disparity between the reports.
Chronic infection with C. burnetii was achieved by using mice 
genetically modified to overproduce the cytokine IL10,59 which is 
associated with eliciting an antibody-mediated (Th2) immune re-
sponse. This chronic infection was characterized by high levels of 
antibody, impaired granuloma formation, and a sustained C. bur-
netii burden in the tissues.59 These features, including an increased 
level of IL10, are similar to those reported in human chronic Q 
fever.31 This model provides clues about the host immunologic re-
sponse that leads to some subjects becoming chronically infected 
and affords a model in which the pathology of the disease can be 
studied and treatment and prophylaxis options assessed.
Guinea Pigs. Although not strictly a manifestation of chronic 
C. burnetii infection, a common side effect of repeated vaccina-
tion is severe local skin reactions, including sterile abscess for-
mation.35 This adverse response has led to the requirement for 
prevaccination screening on potential vaccine recipients to test 
for preexisting immunity and reactivity.35 It is desirable to assess 
new vaccines for hypersensitivity and other adverse reactions in 
an animal model during vaccine development. The initial model 
required injection of the vaccine under test into the footpads of 
Hartley guinea pigs.7 This model replicated the hypersensitivity 
reactions well but would have affected mobility of the animals 
in the case of severe reactions. A refinement of the model using 
hairless guinea pigs inoculated subcutaneously72 was found to be 
as effective for assessing vaccine reactions but was more humane 
than was the Hartley model.
For assessing the most common of the chronic diseases, en-
docarditis, a model has been proposed that uses electrocoagula-
tion of the native aortic valve prior to exposure to C. burnetii.42 
In this model, approximately half of the guinea pigs with previ-
ously damaged heart valves developed endocarditis, with a cor-
responding high level of mortality. The authors noted, however, 
that this model is one of acute C. burnetii endocarditis rather than 
of the chronic endocarditis seen in humans. However, this model 
could still be useful in assessing prophylaxis in those with preex-
isting heart conditions during outbreaks.
Nonhuman Primate Models of Q Fever
Although Q fever affects many large animals, such as domestic 
ruminants, most development of large animal models has focused 
on nonhuman primates. In the late 1970s, cynomolgus macaques 
(Macaca fascicularis) were exposed to aerosols of C. burnetii.25 These 
primates displayed clinical signs of acute disease similar to those 
seen in humans, including anorexia, depression, and fever.25 The 
duration of fever was 5 d, and a bacteremia was detected between 
days 7 and 14.25 Hematology and clinical chemistry analyses 
showed significant increases in plasma ALP, AST, plasma fibrin-
ogen, and total bilirubin.25 Pathology examinations at necropsy 
revealed signs of subacute hepatitis, supporting the observations 
regarding bilirubin and AST observations.25 Radiologically, signs of 
cm12000130.indd   472 12/3/2013   3:21:09 PM
Animal models of Q fever
473
infected with C. burnetii, the epididymis has been reported to 
show interstitial and perivascular infiltration by lymphocytes.48
In mouse models using intraperitoneal and respiratory expo-
sure, features similar to those seen in guinea pigs are reported; 
however, lesions tend to be more widespread in mice than in 
guinea pigs.66 The spleen typically has the most striking lesions 
in mouse models of C. burnetii infection. Primarily found in the 
red pulp, these lesions are nodular or patchy and are granuloma-
tous in nature, consisting mainly of mononuclear cells and. Liver 
contains similar lesions, although they are less numerous than 
are those in spleen.66 Unlike in the guinea pig, the epididymis has 
not been identified as a tissue of interest in mice with C. burnet-
ti.66 In direct comparisons of guinea pigs and mice that have been 
exposed through various routes, interstitial pneumonia has been 
noted in multiple animals of both species, although in one study,76 
all guinea pigs developed pneumonia, whereas mice demonstrat-
ed some interstrain variation in regard to this lesion. In addition, 
the comparison study76 noted mild lymphocytic myocarditis, in 
contrast to earlier work.66
Recent work compared the histopathologic features of SCID 
mice with those of CB17 and A/J mice.3 In this work, consistent 
with other studies using immunocompetent mice, focal granulo-
mas were seen in spleen and liver. In addition, minimal intersti-
tial pneumonitis and an absence of heart or kidney involvement 
occurred in immunocompetent mice. In SCID mice, all of these 
lesions were abundantly present, with the addition of marked 
macrophage infiltration, glomerulonephritis, and pericarditis fea-
turing focal calcification of the epicardium and endocardium.3 
A much less severely immunocompromised mouse model uses 
mice overexpressing IL10 to interfere with macrophage activa-
tion, mirroring the observation that human patients with chronic 
Q fever sufferers overexpress this cytokine.13 In the IL10 overex-
pression model compared with the SCID mouse model, fewer 
granulomas are present, and those that do form are larger, often 
merging with the surrounding lymphoid tissue in the spleen. This 
effect is coupled with less pronounced splenomegaly in the IL10-
overexpressing mice. These features are “reminiscent” of chronic 
infection in humans.59
The histopathology of nonhuman primate models has been 
described only cursorily, although it is clear that these animals 
also develop moderate to severe interstitial pneumonia and mild 
to moderate multifocal granulomatous hepatitis.25,38,95 These data 
likely are rarer due to the need to perform a serial-euthanasia ex-
periment to obtain them and the associated expense of perform-
ing this type of study in primates.
Candidate Vaccines
The vaccine currently licensed for human use is a formalin-
killed whole-cell product.51 It is effective in protecting those at 
risk from Q fever.51 However, it is associated with severe local 
reactions to such an extent that potential vaccinees must be pre-
screened in regard to adverse skin reactions (to a small quantity 
of vaccine) and blood antibody levels44 in an effort to avoid these 
reactions. Despite prescreening, severe reactions do still occur in 
some subjects,44 thus making the vaccine less appropriate for gen-
eral use and limited to those in defined risk groups. Alternative 
vaccines based on chloroform:methanol residues of the formalin-
inactivated whole-cell material have been developed and shown 
to have similar levels of protection in some animal models96,98 
with potentially fewer side effects. However, vaccination with 
previous studies,25,38,96 but, in contrast to previous studies, AST 
and bilirubin values were not increased.96 The study demonstrat-
ed that the chloroform:methanol residue vaccine gave equivalent 
protection to that of the whole-cell vaccine.96 Additional studies 
to assess whether chloroform:methanol residue-based vaccines 
effectively immunize subjects without the need for prescreening 
for adverse reactions could be the first step toward licensure of a 
less expensive, safer Q fever vaccine.
Identification of Virulence Determinants
The virulence determinants of C. burnetii strains have not yet 
been determined fully. Early in the study of Q fever, it was believed 
that different strains were responsible for acute compared with 
chronic disease presentations. Differences in the abilities of differ-
ent strains to elicit a febrile response in the guinea pig model are 
well described, with acute strains (for example, Nine Mile) induc-
ing a greater febrile response than do chronic strains (for example, 
Priscilla);60,73 however, vaccines based on either a chronic or acute 
strain cross-protected against challenge from the other strain type.60 
Acute strains such as Nine Mile have been used to induce endo-
carditis in guinea pigs,42 rabbits,27 and immunosuppressed mice.8 A 
comparison of chronic and acute strains in mouse and guinea pig 
models revealed that chronic strains infected hosts as well as did 
acute strains but subsequent signs of infection were less severe.34 
Differences in pathology and virulence between chronic and acute 
strains have been reported,73,85 with acute strains proving more 
virulent in the mouse model used. Perhaps the more aggressive 
systemic reaction to the acute strains allows the host to more ef-
fectively clear the infection, whereas the milder response to chronic 
strains leads to ineffective clearance and allows the organism to 
efficiently colonize the host, particularly those with preexisting 
heart defects and immunodeficiency. Clearly, although the strain of 
C. burnetii may be part of the explanation of disease development, 
host factors including sex, age, the presence of heart damage, and 
immune status all have roles to play.
Histopathologic Features
Intraperitoneal and respiratory inoculation of guinea pigs with 
C. burnetii has been described in detail in several articles.43,48,74 
All of the organs examined (heart, lung, liver, spleen, kidney) 
develop specific pathomorphologic changes, although kidney 
involvement is present in some48 but not other43 reports. Liver and 
spleen typically have damage manifesting as multifocal granulo-
mas consisting of mononuclear aggregates, composed mainly of 
lymphocytes and macrophages. These focal granulomas are seen 
throughout the liver lobes and red pulp of the spleen but are lon-
ger lasting in liver. The lungs demonstrate mononuclear cell in-
filtration into the alveoli. Lung involvement is more pronounced 
in respiratory exposure models than in those involving intraperi-
toneal routes.43,74 The heart typically contains foci consisting of 
interstitial mononuclear cell infiltrates within the myocardium. 
No valvular involvement is described, except in the guinea pigs 
whose cardiac valves had previously been electrocoagulated.42 
In those animals, endocarditis was associated with a valvular 
inflammatory infiltrate that was composed mainly of macrophag-
es of lymphocytes.42 When changes were described, the kidney 
showed occasional mineralization of the kidney tubules;74 other 
reports mentioned focal lymphocyte infiltration of the pelvic mu-
cosa and fat.43,48 Although the testes typically have been described 
as displaying only minor degenerative changes in guinea pigs 
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much that is not known about C. burnetii. The models described 
in this review are crucial tools in solving the mysteries of this 
organism.
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chloroform:methanol residues that appeared to protect against 
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to be nonprotective,101 as were recombinant vaccines based on 
immunodominant proteins of C. burnetii.89 Considerable work 
remains in the effort to produce an easy-to-manufacture, safe-to-
administer, effective vaccine against Q fever.
Summary
Several animal models have been described for the study of Q 
fever and its causative organism, C. burnetii. Although cell culture 
and other in vitro systems are useful in the study of C. burnetii, 
vast amounts of new knowledge cannot be gained without the 
use of robust animal models. These models have proven useful in 
the study of the complex pathogenesis of the broad-spectrum of 
clinical disease caused by C. burnetii. In addition, animal models 
continue to help define the correlates of protection from infection 
that an effective vaccine needs to achieve.
In terms of the similarity to acute disease seen in humans, cyno-
molgus macaque model with aerosol exposure provides an excel-
lent model of C. burnetii disease in humans. However, this model 
is expensive in terms of animal use, husbandry, and space and, 
in many cases, might be difficult to justify on ethical grounds. 
In addition, the work on primates predates technologies such as 
multiplex bead arrays and microarrays, so it suffers from a lack 
of data on cytokine responses. The guinea pig aerosol exposure 
model is a much more convenient model. The clinical features 
of C. burnetii infection in guinea pigs are highly similar to those 
seen in human acute infections, in contrast to the lack of clinical 
signs in other models (for example, mice). In addition, the model 
involving electrocoagulation of the aortic valve is a shows prom-
ise for the study of chronic Q fever and endocarditis. Application 
of the IL10 overexpression concept, which was very successful in 
mice,59 would be particularly interesting to evaluate in the guinea 
pig model. More effective use of the guinea pig aerosol models 
is impeded by the lack of tools to effectively dissect the immune 
response to infection. There are many more tools and reagents 
for monitoring the expression of immune system molecules in 
mice than in guinea pigs. This discrepancy is illustrated by direct 
comparisons between the 2 models: for mice, data on circulat-
ing cytokines are given (several interleukins, IFNγ, TNFα, and so 
forth), but no comparative data from guinea pigs are given.73 For 
the guinea pig model to be maximally beneficial, species-specific 
tools such as whole-genome microarrays and reagents to measure 
levels of key immune system markers need to be developed. Fi-
nally, to derive the full benefit from data on the cytokine profiles 
of infected animals, corresponding data need to be collected from 
human patients.
Although an effective vaccine is available currently, there is 
great scope for improvement in terms of ease of production and 
the requirement for prevaccination skin and blood testing. For a 
pathogen that was first described more than 70 y ago, there is still 
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Efficacy of Liposome-Encapsulated Ciprofloxacin in a Murine Model
of Q Fever
I. H. Norville,a G. J. Hatch,b K. R. Bewley,b D. J. Atkinson,a K. A. Hamblin,a J. D. Blanchard,d S. J. Armstrong,a J. K. Pitman,b E. Rayner,b
G. Hall,b J. Vipond,b T. P. Atkinsa,c
Defence Science and Technology Laboratory, Porton Down, Salisbury, United Kingdoma; Public Health England, Porton Down, Salisbury, United Kingdomb; College of Life
and Environmental Sciences, University of Exeter, Exeter, United Kingdomc; Aradigm Corporation, Hayward, California, USAd
Encapsulation of antibiotics may improve treatment of intracellular infections by prolonging antibiotic release and improving
antibiotic uptake into cells. In this study, liposome-encapsulated ciprofloxacin for inhalation (CFI) was evaluated as a postexpo-
sure therapeutic for the treatment of Coxiella burnetii, the causative agent of Q fever. Intranasal treatment of male A/Jola (A/J)
mice with CFI (50 mg/kg of body weight) once daily for 7 days protected mice against weight loss and clinical signs following an
aerosol challenge with C. burnetii. In comparison, mice treated twice daily with oral ciprofloxacin or doxycycline (50 mg/kg) or
phosphate-buffered saline (PBS) lost 15 to 20% body weight and exhibited ruffled fur, arched backs, and dehydration. Mice were
culled at day 14 postchallenge. The weights and bacterial burdens of organs were determined. Mice treated with CFI exhibited
reduced splenomegaly and reduced bacterial numbers in the lungs and spleen compared to mice treated with oral ciprofloxacin
or doxycycline. When a single dose of CFI was administered, it provided better protection against body weight loss than 7 days of
treatment with oral doxycycline, the current antibiotic of choice to treat Q fever. These data suggest that CFI has potential as a
superior antibiotic to treat Q fever.
Coxiella burnetii is a Gram-negative intracellular bacterium andthe etiological agent of the disease Q fever. Q fever is prevalent
throughout the world, with the exception of New Zealand, and is
a zoonosis that typically presents as an acute, self-limiting febrile
disease or atypical pneumonia in humans (1). In addition, there
are several recent reports of outbreaks among military personnel
serving in Iraq and Afghanistan, and C. burnetii is listed as a cate-
gory B agent by the Centers for Disease Control and Prevention
(CDC) (2–4). Recovery from acute disease usually occurs
within 2 weeks and can be accelerated by treatment twice daily
with oral doxycycline. However, delays in diagnosis of acute Q
fever or an incorrect diagnosis often result in ineffective or
inappropriate antibiotic treatment (5). C. burnetii can also cause
a chronic form of disease which is a severe, and sometimes life-
threatening, manifestation, often characterized by endocarditis or
hepatitis (6). Chronic infections are treated with a combination of
doxycycline and chloroquine for at least 18 months and up to 4
years (7). A recent fatal case of Q fever was caused by a doxycy-
cline-resistant strain, and cases presenting with endocarditis are
associated with frequent relapses, despite antibiotic treatment (8,
9).
Encapsulation of antibiotics in delivery vesicles, such as lipo-
somes, has been shown to enhance drug availability and activity
and reduce toxicity in general (10), and antibiotics delivered by
inhalation particularly display these characteristics (11). Cipro-
floxacin is a broad-spectrum fluoroquinolone that demonstrates
in vitro bactericidal effects against several respiratory pathogens,
including C. burnetii, Mycobacterium tuberculosis, and Neisseria
meningitidis (12–14). However, oral or intravenous delivery of
ciprofloxacin results in a suboptimal pharmacokinetic profile in
the lower respiratory tract, and emergence of antibiotic resistance
makes treatment problematic (15–17). Formulations of lipo-
some-encapsulated ciprofloxacin have been developed and
shown to improve antibiotic efficacy in Francisella tularensis,
Mycobacteriumavium, and Streptococcus pneumoniae in vivomod-
els (18–21).
The liposome-encapsulated ciprofloxacin tested in this study,
ciprofloxacin for inhalation (CFI), is an advanced formulation
specifically designed for inhalation that has already been shown to
be highly efficacious in vivo against several intracellular patho-
gens, specifically F. tularensis LVS and Schu S4 strains (22) and
Yersinia pestis CO92 strain (K. A. Hamblin, J. D. Blanchard, C.
Davies, and S. V. Harding, presented at the 19th Congress of the
International Society of Aerosols in Medicine, April 2013, Chapel
Hill, NC) in mouse models of lung infection.
In this study, we report for the first time the evaluation of
antibiotic efficacy in an aerosol murine model of Q fever. The
efficacy of CFI, ciprofloxacin, and doxycycline as postexposure
therapeutics were compared, and single-dose pharmacokinetic
profiles were determined.
MATERIALS AND METHODS
Bacteria.C. burnetii strain Nine Mile was grown axenically in ACCM-2 in
250-ml Erlenmeyer flasks containing 100 ml medium (23). Cultures were
incubated at 37°C, shaking at 75 rpm for 6 days, with a GENbox microaer
atmosphere generator (bioMérieux, France) to displace oxygen. Bacteria
were harvested by centrifugation at 10,000  g at 21°C for 20 min and
resuspended in sterile phosphate-buffered saline (PBS) at a concentration
of approximately 1 109 genome equivalents (GE)/ml. All manipulations
of C. burnetii were carried out in a class III microbiological safety cabinet
complying with the 2000 European standard EN 12469 (24). Using the
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criteria within the “Proposed Framework for the Oversight of Dual Use
Life Sciences Research: Strategies for Minimizing the Potential Misuse of
Research Information” (25) by the National Science Advisory Board for
Biosecurity (NSABB), this research does not fall into any of the categories
for dual-use research of concern.
Bacterial enumeration. C. burnetii was enumerated using real-time
PCR (RT-PCR) targeting the sod gene using the forward primer TCTTC
AACAATGCAGCACAACAT and reverse primer TGAAGCCAATTCGC
CAGAA. The probe sequence was CATTTTATTGGCACTGCATGAGCC
CTG, and the probe was covalently labeled at the 5= end with the reporter
dye 6-carboxyfluorescein (FAM) and at the 3= end with the quencher dye
black hole quencher 1 (BHQ-1). Chromosomal DNA was extracted by
addition using Qiagen QIAmp DNA minikit/blood mini/tissue depend-
ing on the sample type. Real-time PCR mixtures comprised 2l template
DNA, forward primer (900 nM), reverse primer (900 nM), probe (250
nM) and ABI Fast TaqMan mastermix. PCR cycling conditions comprised
3 min at 95°C, 30 s at 60°C, followed by 50 two-step cycles, with 1 cycle
consisting of 15 s at 95°C and 30 s at 60°C. For each PCR, a control of
linearized synthetic plasmid that contains a single copy of the target was
included. The synthetic plasmid was quantitated after linearization and
purification using a ND-2500 NanoDrop spectrophotometer. For each
reaction, a standard curve of the synthetic plasmid was run in duplicate in
the range 1 107 GE/ml to 1 102 GE/ml. Plasmid concentration of 1
101 GE/ml in triplicate is used as a lower-limit check in every assay. The
lower limit of detection for this assay is 2.5 103 GE/ml culture or 4.4
101 GE/mg spleen or 2.2 101 GE/mg lung/liver/testes.
Mice. Groups of age-matched male A/Jola (A/J) mice (Charles River)
were housed on a 12-h day-night light cycle, with food and water available
ad libitum in an Advisory Committee on Dangerous Pathogens (ACDP)
(United Kingdom) level 3 flexible-film isolator, complying with the 2000
European Standard EN 12469 (24), and allowed to acclimatize before
challenge. All procedures were conducted under a project license ap-
proved by internal ethical review, and in accordance with both the Animal
(Scientific Procedures) Act (1986) (26) and the 1989 Codes of Practice for
the Housing and Care of Animals used in Scientific Procedures (27).
Antimicrobial agents. Ciprofloxacin (Bayer, Newbury, United King-
dom) or doxycycline hyclate (Sigma-Aldrich, United Kingdom) were dis-
solved in distilled water to a working concentration of 25 mg/ml or 40
mg/ml, respectively. Ciprofloxacin for inhalation (CFI) was provided by
Aradigm Corporation (Hayward, CA, USA) and diluted in PBS to a work-
ing concentration of 25 mg/ml. All antibiotics were prepared freshly each
day prior to dosing.
Infection of mice and antibiotic efficacy studies. Mice were chal-
lenged with an aerosol produced from 10-ml suspension of C. burnetii at
a concentration of 2.3 109 GE/ml (study 1), 6 109 GE/ml (study 2), or
1  1010 GE/ml (study 3) using the AeroMP-Henderson apparatus. The
challenge aerosol was generated using a six-jet Collison nebulizer (BGI,
Waltham, MA) operating at 15 liters/min. The aerosol was mixed with
conditioned air in the spray tube and delivered via a head-only exposure
chamber. Samples of the aerosol were taken using an AGI-30 (Ace Glass
Inc., USA) at 6 liters/min containing PBS and an aerodynamic particle
sizer (TSI Instruments, Ltd., Bucks, United Kingdom); these processes
were controlled and monitored using the AeroMP management platform
(Biaera Technologies, LLC, Frederick, MD). A back titration of the aerosol
samples taken at the time of challenge was performed using RT-PCR as
described above. Direct bacterial enumeration was used to calculate the
presented dose using a derived respiratory minute volume of 19.9 ml
estimated using the average weight of the animals (28).
For study 1, groups of six infected mice were observed, and clinical
signs (piloerection, arched back, dehydration, eyes shut, wasp-waisted
appearance, immobile, and death) and weight were evaluated twice daily.
Mice were culled on days 3, 4, 5, 6, 7, 8, 9, 11, and 13 postchallenge (p.c.),
and the lungs, spleen, liver, testes, and blood were aseptically removed.
Organs were weighed and homogenized using a Precellys24 homogenizer,
and bacteria were enumerated using RT-PCR as described above. Anti-
body titers were determined using Q fever phase I IgG and phase II IgM
Novalisa kits (Novatec, Germany).
For study 2, groups of 10 infected mice were treated from 24 h p.c. for
7 consecutive days with 40 l of a 25-mg/ml ciprofloxacin (50 mg/kg of
body weight) solution administered orally via pipette twice daily (12-h
intervals) or as 40 l of a 25-mg/ml solution of CFI (50 mg/kg) delivered
once daily (24-h intervals) by intranasal (i.n.) instillation using a pipette.
Control mice received PBS orally twice daily for 7 days postchallenge. At
day 14 p.c., mice were culled, and the lungs and spleens were aseptically
removed. The lungs and spleens were weighed, and half the organ was
placed in 10% neutral buffered formalin for histological analysis. The
remaining organ was homogenized using a Precellys24 instrument, and
bacteria were enumerated using RT-PCR as described above. Mice were
monitored as discussed above for study 1.
For study 3, groups of 20 infected mice were treated from 24 h p.c. for
1, 3, or 7 consecutive days with 25 l of a 40-mg/ml (50-mg/kg) doxycy-
cline solution administered orally via pipette twice daily (12-h intervals)
to mimic treatment of human Q fever or as CFI delivered once daily (24-h
intervals) by i.n. instillation (as described above for study 2). Control mice
received PBS orally twice daily for the same number of days postchallenge as
the respective treatment groups. At day 7 or 14 postchallenge, 10 mice from
each treatment group were culled, and the lungs and spleens were aseptically
removed and weighed. Mice were monitored as described above for study 1,
and the organs were processed as described above for study 2.
Pharmacokinetic studies. Ciprofloxacin was administered to mice
(n 30) by the oral route at a dose of 50 mg/kg. Groups of three mice were
culled at 10 min, 20 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 4 h, 8 h, and 24 h
after dosing.
Doxycycline was administered to mice (n 30) by the oral route at a
dose of 50 mg/kg. Groups of three mice were culled at 10 min, 20 min, 30
min, 45 min, 1 h, 2 h, 4 h, 8 h, 16 h, and 24 h after dosing.
CFI was administered to mice (n 30) by the i.n. route at a dose of 50
mg/kg. Groups of three mice were culled at 1 min, 15 min, 30 min, 2 h, 4
h, 8 h, 12 h, 16 h, 20 h, and 24 h after dosing.
Lungs and blood samples were collected from all animals immediately
postmortem. All blood samples were heparinized and centrifuged to sep-
arate the plasma fraction from the whole blood. Samples were immedi-
ately frozen and stored at 80°C until further analysis. Three untreated
control mice were included with each antibiotic group.
Histopathology. Samples of lung and spleen were processed and embed-
ded in paraffin wax. Sections were cut at 5 to 6 m and stained with hema-
toxylin and eosin. Microscopic lesions in lung and spleen were assessed and
recorded as within normal limits (whereC. burnetii-associated lesions were
not detected) or minimal, mild, moderate, and marked where C. burnetii-
associated lesions were detected. The slides were assessed independently
by two pathologists in a blind manner (unaware of the treatment).
Determination of antibiotic concentrations in plasma and lung tis-
sues by liquid chromatography-mass spectrometry (LC-MS). Lung
samples were weighed and mixed with 3 the volume of 0.1% (vol/vol)
aqueous formic acid. Tissue was homogenized in a Precellys24-Dual bead
homogenizer using 2.8-mm beads for two 20-s cycles at 5,000 rpm. The
lung homogenate was mixed with an equal volume of 1-g/ml internal
standard solution (ciprofloxacin-d8 hydrochloride hydrate or demeclo-
cycline hydrochloride hydrate; Fluka, United Kingdom), and 2 volumes of
dichloromethane were added. The plasma samples were mixed with an
equal volume of internal standard solution and 3 volumes of acetonitrile.
Following centrifugation, the supernatant was removed and reduced in
volume to remove the acetonitrile using a centrifugal evaporator (Gene-
vac Ltd., Ipswich, United Kingdom) and injected onto the LC-MS system
consisting of an Agilent 1100 binary pump (Agilent Technologies UK
Ltd., Wokingham, United Kingdom), CTC PAL injector (Presearch Ltd.,
Basingstoke, United Kingdom), Sciex API3000 LC-MS (AB Sciex, War-
rington, United Kingdom) using an ACE-3–C18HL 20- by 2.1-mm col-
umn (Hichrom, Theale, United Kingdom) and a gradient mobile phase.
Mobile-phase solvent A consisted of 0.1% (vol/vol) aqueous formic acid
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in water, and mobile-phase solvent B consisted of 0.1% (vol/vol) aqueous
formic acid in acetonitrile. The initial mobile-phase composition was 95%
solvent A and 5% solvent B. For ciprofloxacin analysis, the gradient was
increased from 1 to 4 min to 95% solvent B, maintained for 1 min, then
decreased back to 5% solvent B, and maintained for 3 min. For doxycy-
cline analysis, the gradient was increased from 1 to 8 min to 55% solvent B,
maintained for 1 min, then decreased back to 5% solvent B, and main-
tained for 3 min. The solvents were pumped at a flow rate of 250 l/min.
The LC-MS system was controlled by Analyst software (AB Sciex, United
Kingdom). Calibration curves were prepared in naive mouse plasma or
lung tissue samples, using reference standards ciprofloxacin (98%;
Fluka, United Kingdom) and doxycycline hyclate (98%; Sigma-Al-
drich) and consisted of 11 points from 1 ng/ml to 20,000 ng/ml. All cali-
bration curves had r of0.99 and were fitted using linear regression with
1/x2 weighting.
Pharmacokinetic calculations. The pharmacokinetic parameters ter-
minal half-life (t1/2), rate of clearance (CL), maximum concentration
(Cmax), time of maximum concentration (Tmax), and area under the con-
centration-time curve (AUC) were determined by noncompartmental
pharmacokinetic analysis using WinNonlin Phoenix (v6.1; Pharsight
Corp., USA) on mean concentration data. The relative bioavailability of
oral ciprofloxacin and i.n. ciprofloxacin quantified in lung homogenate
was calculated using an equation adapted from Rowland and Tozer (29),
with the error associated with the relative bioavailability equation adapted
from Taylor (30).
Statistical analysis. All statistical analysis was performed using SPSS
v18.0 (IBM). All graphs were produced using Graphpad Prism v5. Anal-
ysis of mouse body weight loss compared to controls was carried out using
a parametric univariate model of variance and Bonferroni’s post test. Bac-
terial burden data were first transformed by log10 and then analyzed using
a univariate linear model and Bonferroni’s post test. Organ weight (as a
percentage of body weight) was first transformed by square root function
and then analyzed using a univariate linear model and Bonferroni’s post
test. The validity of the univariate model approach (general linear model
[GLM]) was tested by Levene’s test for unequal variance. Statistical signif-
icance was indicated as follows: , P 0.05; , P 0.01; , P 0.001.
RESULTS
Study 1 (development of amurinemodel of Q fever). In order to
establish a model suitable for antibiotic efficacy studies, mice were
challenged by the aerosol route with a mean presented dose of 5
106 GE of C. burnetii. Infected mice showed clinical signs between
5 and 9 days after challenge, exhibiting ruffled coats, arched backs,
and a wasp-waisted appearance. In addition, weight loss was ap-
parent in all animals from day 5 postchallenge, with peak weight
loss observed between days 7 and 8. In order to characterize the
pathogenesis of disease over time, groups of six mice were culled at
FIG 1 Efficacy of ciprofloxacin or CFI against C. burnetii in vivo (n  10).
Mean percentage change in body weight of mice infected with 2.8 106 GE of
C. burnetii per ml and treated with free ciprofloxacin (by oral administration)
or CFI (by i.n. administration) for 7 days postchallenge.
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multiple time points after challenge, and the organs were har-
vested. During the 13-day course of this experiment, no signifi-
cant changes in organ weight in uninfected mice were observed
(sampled at 0, 7, and 13 days; P  0.981 for the spleen and P 
0.795 for the lung). In contrast, the weights of both the spleen and
the lung (but not liver and testes) from infected mice increased
over time (P 0.001) (Table 1), with the difference in the spleen
weight becoming statistically significant at day 8 postinfection
FIG 2 Weight and bacterial colonization of lungs and spleen at day 14 p.c. (n 10). (A) Weight of lungs and spleens from mice challenged with 2.8 106 GE
of C. burnetii per ml and treated with PBS, free ciprofloxacin, or CFI for 7 days. (B) Bacterial colonization of lungs and spleens from mice challenged with 2.8
106 GE of C. burnetii/ml and treated with PBS, free ciprofloxacin, or CFI for 7 days. Values are means standard errors (error bars). Values that are significantly
different from the value for the ciprofloxacin control are indicated by asterisks as follows: , P 0.05; , P 0.001.
FIG 3 Hematoxylin-and-eosin-stained spleen and lung tissues from mice at day 14 p.c. (A) Lung from a mouse treated with PBS for 7 days. Moderate
granulomatous alveolitis is present. (B) Lung from a mouse treated with CFI for 7 days. Moderate granulomatous alveolitis is present. (C) Spleen from a mouse
treated with PBS for 7 days. The sites of moderate, multifocal, granulomatous lesions are indicated by black arrows. (D) Spleen from a mouse treated with CFI
for 7 days. The sites of minimal granulomatous lesions are indicated by black arrows. Bar, 200 m.
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(P  0.001) and the difference in the lung weight becoming sta-
tistically significant at 5 days (P 0.033). C. burnetii was isolated
from all tissues postchallenge, with consistently high levels of bac-
teria (105 to 106 GE/ml) in the lungs. The bacterial burden in the
spleen, liver, testes, and blood increased throughout the course of
infection (Table 1). In addition, all infected mice culled at day 13
had developed antibodies to C. burnetii phase I and II antigens
(phase I IgG titers of 1:200; phase II IgM titers from 1:200 to
1:1,600).
Study 2 (in vivo efficacy of free ciprofloxacin and CFI). The
efficacy of ciprofloxacin or CFI for the treatment of mice infected
with C. burnetii was determined (Fig. 1). Mice were challenged
with a mean presented dose of 2.8 106 GE and treated with free
ciprofloxacin or PBS lost almost 20% body weight by day 7 post-
challenge (p.c.) and exhibited clinical signs such as piloerection
and arched backs from days 4 to 9 p.c. In contrast, mice treated
with CFI were significantly protected against weight loss from day
4 p.c. (P 0.001) and showed no clinical signs of disease.
Infection of mice with C. burnetii significantly increased the
weight of the spleen and lungs (P 0.001; data not shown). Treat-
ment with CFI significantly moderated lung and spleen weight
increases compared to treatment with ciprofloxacin or PBS (con-
trols) at day 14 p.c. (P 0.05 for the lung;P 0.001 for the spleen;
Fig. 2A). In addition, while mice treated with PBS were colonized
with approximately 105 to 106 GE/ml or 104 to 105 GE/ml in the
lungs or spleen, respectively, treatment with CFI reduced bacterial
numbers by 10- to 100-fold, which was significant in the lungs
(P 0.001; Fig. 2B).
On histological examination, in the lungs of all challenged an-
imals, focal or diffuse granulomatous alveolitis was observed, and
the severity of alveolitis was similar in treated and PBS control
groups (Fig. 3A and B). In the spleen, multifocal granulomatous
foci were observed in mice treated with free ciprofloxacin or in
PBS control groups (Fig. 3C), but reduced severity or absence of
lesions was observed following treatment with CFI (Fig. 3D).
Study 3 (in vivo efficacy of doxycycline andCFI).Doxycycline
is the standard antibiotic of choice to treat Q fever. Thus, the
efficacy of 1 day, 3 days, and 7 days of doxycycline or CFI treat-
ment postchallenge of mice challenged with a mean presented
dose of 7  106 GE of C. burnetii was determined (Fig. 4). Mice
treated with PBS lost 15% body weight by day 7 p.c., and 80% of
the mice exhibited clinical signs such as piloerection at least once
during the postchallenge period. Mice treated with doxycycline
for 1 day, 3 days, or 7 days also lost 13 to 15% body weight; how-
ever, there was a delay in initiation of weight loss of 1, 3, or 7 days,
respectively, compared to PBS-treated control mice. In all doxy-
cycline treatment groups, 70% of mice exhibited clinical signs that
correlated with peak weight loss. In contrast, mice treated with
CFI had significantly reduced weight loss from day 8 p.c. com-
pared to the corresponding doxycycline treatment regime (Fig. 4A
and B) (P 0.001). In addition, from day 12 to day 14 p.c., mice
treated with a single dose of CFI had significantly reduced weight
loss compared to mice treated with doxycycline for 1, 3, or 7 days
(P  0.01). The proportion of mice treated with CFI presenting
with clinical signs ranged from 50% (1 day of CFI treatment) to
0% (7 days of CFI treatment).
Treatment with CFI for 7 days significantly moderated lung
weight increases compared to treatment with doxycycline for 7
days at day 14 p.c. (P  0.01; Fig. 5A). Spleen weight gain of
CFI-treated mice was significantly moderated compared to PBS-
treated control mice (P 0.05), but not doxycycline-treated mice.
In addition, mice treated with CFI for 7 days had significantly
reduced bacterial numbers in the lungs and spleen compared to
mice treated with doxycycline for 7 days (P 0.001; Fig. 5B).
On histopathological examination, in the lungs of all chal-
lenged animals, focal or diffuse granulomatous alveolitis was ob-
served, with no differences observed between control and treated
animals (Fig. 6A and B). In the spleen, multifocal granulomatous
foci were observed in mice in the PBS control group, and lesion
severity was reduced in mice receiving CFI, but not in mice receiv-
ing doxycycline (Fig. 6C and D).
Pharmacokinetic profile. In order to determine drug concen-
trations in treated mice, ciprofloxacin, doxycycline, and CFI were
administered to naive animals. Animals were culled at set time
points over a 24-h period, and lungs and plasma samples were
collected postmortem. The concentration of ciprofloxacin after
oral administration decreased rapidly over time in both the lungs
and plasma, with terminal half-lives of 1.3 and 0.8 h, respectively
(Fig. 7). Pharmacokinetic parameters are shown in Table 2. In
contrast, mice receiving i.n. CFI had 100-fold-greater concentra-
tion of drug in the lung, with an extended terminal half-life of 4.1
h. In addition, the Cmax of CFI in the lung was higher than that of
oral doxycycline. Importantly, the AUC in the lung following CFI
administration was almost 3 orders of magnitude greater than the
AUC following the same dose of oral ciprofloxacin, resulting both
from the superior Cmax and the duration in the lung. The relative
bioavailability of oral ciprofloxacin in the lung compared to i.n.
CFI is 0.0014; in contrast, the relative bioavailability of oral cipro-
floxacin in the plasma compared to i.n. CFI is 0.363.
FIG 4 Efficacy of doxycycline or CFI againstC. burnetii in vivo (n 10) versus
PBS-treated control mice. Mean percentage change in body weight of mice
infected with 7  107 GE of C. burnetii/ml and treated with CFI (A) (by i.n.
administration) or free doxycycline (Dox) (B) (by oral administration) for 1
day, 3 days, or 7 days postchallenge.
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DISCUSSION
The recommended antibiotic used in the treatment of Q fever is
doxycycline, a bacteriostatic tetracycline used to treat several re-
spiratory diseases, including pneumonic plague and anthrax (31).
Antibiotic activity againstC. burnetii can be determined in embry-
onated eggs, tissue culture, animal models, and more recently in
axenic media (23, 32). The susceptibility of C. burnetii, in vitro, to
doxycycline has been determined with a MIC ranging from 0.05 to
FIG 5 Weight and bacterial colonization of lungs and spleen at day 14 p.c. (n 10). (A) Weight of lungs and spleens from mice challenged with 7 106 GE of
C. burnetii/ml and treated with doxycycline or CFI for 7 days. (B) Bacterial colonization of lungs and spleen from mice challenged with 9.68  107 GE of C.
burnetii/ml and treated with doxycycline or CFI for 7 days. Values are means  standard errors. Values that are significantly different from the value for the
doxycycline control are indicated by asterisks as follows: , P 0.01; , P 0.001.
FIG 6 Hematoxylin-and-eosin-stained spleen and lung tissues from mice at day 14 p.c. (A) Lung from a mouse treated with PBS for 7 days. Mild granulomatous
alveolitis is present. (B) Lung from a mouse treated with CFI for 7 days. Mild granulomatous alveolitis is present. (C) Spleen from a mouse treated with PBS for
7 days. Mild granulomatous lesions are present (indicated by white arrows). (D) Spleen from a mouse treated with CFI for 7 days. Mild granulomatous lesions
are present (indicated by white arrows). Bars, 200 m.
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2 g/ml (14, 33). Treatment of chronic Q fever endocarditis with
doxycycline alone resulted in 50% mortality and frequent re-
lapse and requires the addition of alkalinization agents, such as
hydroxychloroquine (7, 34). In addition, at least one doxycycline-
resistant C. burnetii strain has been isolated from a patient who
died following unsuccessful antibiotic treatment (6). Although
ciprofloxacin is not commonly used to treat acute Q fever, it has
been used to successfully treat Q fever endocarditis (35, 36). In
vitro, the MIC of ciprofloxacin is slightly higher than the MIC of
doxycycline (1 to 4g/ml), and resistance to fluoroquinolones has
been observed in some clinical isolates of C. burnetii (14, 33, 36).
To date, there is only one report evaluating antibiotic treatment in
an animal model of Q fever (37). Therefore, the development of
novel methods to overcome resistance and improve treatment of
Q fever is desirable.
In order to assess the efficacy of novel antibiotics against C.
burnetii in vivo, an aerosol model of Q fever was established. There
are several reported animal models of C. burnetii infection, using
invertebrates, mice, guinea pigs, and nonhuman primates (38,
39). A/J mice have been previously shown to be the most suscep-
tible immunocompetent mouse strain, and the aerosol route of
infection is of relevance to the majority of human Q fever cases
(40). The model is nonlethal, and therefore, five alternative pa-
rameters were used in order to monitor progression of disease,
namely, weight loss, clinical signs, organ weight, bacterial burden,
and histopathology. Weight loss and clinical signs were used as key
indicators of disease severity, as all infected mice showed signifi-
cant weight loss and reproducible clinical signs, such as piloerec-
tion and arched backs. These signs resolve, in the absence of treat-
ment, within 14 days of infection, which is a similar length of time
to resolution of acute disease in human Q fever cases (32). The
lungs and spleen were selected for monitoring, as both exhibited a
significant increase in weight and high levels of bacteria through-
out the course of C. burnetii infection. In addition, these organs
are of particular relevance, as the lungs are the foci of infection
following an aerosol challenge, and the spleen may provide an
indication of the extent of dissemination of the bacteria during a
systemic infection.
Using this murine model, we report for the first time that doxy-
cycline acts to delay the onset of body weight loss, reduce clinical
signs, and reduce pathology associated with Q fever. However,
following the cessation of doxycycline treatment, infected mice
still succumb to infection. This is unlikely to be due to toxicity of
oral doxycycline and instead may be due to relapse of infection
due to suboptimal antibiotic treatment. A possible reason for this
is that A/J mice are deficient in C5 complement and subsequently
may not be able to clear the infection. Alternatively, this could be
attributed to the antibiotic mechanism of action, with doxycycline
having a bacteriostatic mode of action that may also explain why
relapse is often observed in Q fever patients, in particular associ-
ated with cessation of the antibiotic regime (7). We have also
confirmed that, when given by the oral route, ciprofloxacin is not
an appropriate treatment for acute Q fever. However, we have
identified a novel, encapsulated formulation of ciprofloxacin, spe-
cifically designed for inhalation that enables pulmonary delivery
into the lung, which significantly improves efficacy in a mouse
model of C. burnetii infection. Mice treated with CFI exhibit sig-
nificantly reduced, rather than delayed, body weight loss through-
FIG 7 Profiles of the drug concentration in the plasma (A) or lungs (B) of
mice (n  3 per time point) after i.n. administration of CFI or oral adminis-
tration of ciprofloxacin or doxycycline. All compounds were given at a dose of
50 mg/kg. Values are means standard errors.
TABLE 2 Pharmacokinetic parameters in mice for intranasal CFI or oral ciprofloxacin or doxycyclinea
Antibiotic Formulation Route Sampling site
Terminal
half-life (h)
Clearance (g/h/kg
or liter/h/kg)b Cmax (g/ml) Tmax (h) AUC0–t (g · h/ml)
c
Doxycycline PBS vehicle Oral Lung 3.6 1,015 6.4 2 43.6
Plasma 3.5 2.1 3.4 2 21.3
Ciprofloxacin PBS vehicle Oral Lung 0.8 14,500 3.0 0.17 4.9
Plasma 1.3 25.4 1.4 0.5 2.4
CFI i.n. Lung 4.1 131 483 2 3,461
Plasma 2.2 8.5 1.7 0.017 6.5
a All antibiotic doses were 50 mg/kg. Values are means for three individual animals per time point.
b Clearance is shown in grams/hour/kilogram for the lung and in liters/hour/kilogram for plasma.
c AUC0 –t, area under the concentration-time curve from 0 h to the last measurable concentration.
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out the course of the study compared to mice treated with doxy-
cycline or with PBS (control).
Other in vivo studies have demonstrated the broad-spectrum
antibiotic activity of CFI. It is highly efficacious against several
intracellular pathogens, specifically F. tularensis LVS and Schu S4
strains (22) and Y. pestis CO92 strain (K. A. Hamblin, J. D. Blan-
chard, C. Davies, and S. V. Harding, presented at the 19th Con-
gress of the International Society of Aerosols in Medicine, April
2013, Chapel Hill, NC), with only a single dose being needed to
provide full protection against all three pathogens in mouse mod-
els of lung infection. This formulation is also very efficacious
against the extracellular pathogen Pseudomonas aeruginosa and
has completed multiple phase 2 clinical trials for infection in cystic
fibrosis and non-cystic fibrosis bronchiectasis patients (41, 42).
Encapsulation of drugs in liposomes has been shown to be
effective for the pulmonary delivery of various therapeutic agents,
including antibiotics (11, 19, 43, 44). Liposomes are taken up by
phagocytic cells, improving delivery of antibiotics into the pri-
mary site of infection for facultative intracellular pathogens, such
as C. burnetii (45). In vivo, C. burnetii multiplies in monocytes
within an acidic vacuole, and most antibiotics, including doxycy-
cline and ciprofloxacin, exhibit reduced activity in such a low-pH
environment (46, 47). Encapsulation of antibiotics enhances in-
tracellular uptake and subsequent accumulation to higher thera-
peutic levels within the intracellular site of infection. Inhaled lipo-
somally encapsulated antibiotics can be a particularly attractive
means to provide high sustained concentrations at the sites of
action within the respiratory tract, reducing local side effects and
systemic exposure and providing more convenient therapy such
as once-daily dosing (11) and smaller number of total doses ad-
ministered for prophylaxis or treatment as shown in this paper
and previous studies with CFI (22).
As shown in this study, in addition to improving uptake into
cells, encapsulation of ciprofloxacin allows effective delivery by
the i.n. route, resulting in high initial concentrations of antibiotic
in the lungs. This is demonstrated by theCmax for CFI in the lungs,
which is 100-fold higher than for free ciprofloxacin or doxycy-
cline. Previous studies have also shown that free ciprofloxacin is
ineffective when delivered by the i.n. or aerosol route, whereas
liposome-encapsulated ciprofloxacin, which is specifically devel-
oped for inhalational delivery, has been shown to be efficacious at
50 mg/kg (19, 21). This is because unencapsulated ciprofloxacin is
rapidly absorbed and cleared from the lungs (19, 21). The en-
hanced therapeutic efficacy of CFI can therefore be partly attrib-
uted to the increased initial retained dose of antibiotic in the lungs
(21). This property is particularly important for the treatment of
diseases such as Q fever, where the initial site of infection is the
lung. We have shown that treatment with CFI also improves the
overall exposure within the lungs over a 24-h period, as demon-
strated by the increased area under the curve (AUC) (~1,000-fold)
compared to free ciprofloxacin. Delivery of ciprofloxacin in a li-
posome results in a sustained release of antibiotics, indicated by a
prolonged half-life both in the lungs and in plasma. In addition,
the bioavailability of ciprofloxacin in the lungs was improved by
99.9% when delivered in the encapsulated formulation compared
to oral ciprofloxacin.
We also evaluated the effect of length of antibiotic treatment
on outcome of disease. The length of treatment with doxycycline
correlates with a delay in body weight loss and clinical signs. How-
ever, the length of treatment with CFI correlates with overall prog-
nosis of disease, with mice receiving 7 days treatment exhibiting
minimal weight loss and no clinical signs. This result, taken to-
gether with the use of a single daily dose of CFI compared to a
twice-daily dose of doxycycline, indicates that fewer doses of CFI
may be required to treat Q fever. The CDC currently recommends
100 mg of doxycycline, given orally, twice daily for 14 days for
treating acute Q fever. The efficacy of doxycycline has been corre-
lated with the AUC pharmacokinetic parameter (48). Published
average human AUCs for plasma following 100-mg oral dose of
doxycycline range from 13 to 40 mg · h/liter (49). The selected
doxycycline dose in the AJ mouse model, 50 mg/kg, results in an
average plasma AUC within this range (21.3 mg · h/liter). The
differences observed in organ weight and bacterial burden be-
tween doxycycline- and CFI-treated mice were less marked. Both
antibiotics did not significantly reduce lung or spleen organ
weight compared to the PBS-treated control mice; in fact,
treatment with doxycycline appeared to increase bacterial
numbers within organs compared to the PBS-treated control
mice. This finding may be due to using RT-PCR to detect re-
sidual bacterial DNA in the organs. An alternative method to
enumerate viable bacteria would be to plate organ homoge-
nates onto ACCM-2 agarose (23).
In conclusion, our study demonstrates that liposome encapsu-
lation of ciprofloxacin allows effective pulmonary delivery and
improves efficacy of an alternative antibiotic against C. burnetii
infection. Furthermore, we report that treatment of infected mice
with encapsulated ciprofloxacin shows significant improvements
over doxycycline, the current treatment for Q fever. We have de-
veloped an animal model suitable for testing novel antibiotic ther-
apies, which will allow evaluation and progression of next-gener-
ation antimicrobial treatments against Q fever.
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